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PRELUDE 
 
 
 
The first step towards the discovery of the double helical structure of DNA by Watson and Crick has its 
origins in the end of S.XIX, when Friedrich Miescher, interested in the substructure of the cell, studied the 
identification of proteins in the nucleus. He was able to isolate nuclei from human leukocytes. Furthermore, 
by means of chemistry and biology, Miescher could analyse the purified nuclei with the chemical tools 
available then: digestion by proteases, elemental analysis and solubility tests, obtaining what he defined as:  
In the experiment with the weakly alkaline fluids, I obtained, by neutralization of the solutions, precipitates 
which were insoluble in water, acetic acid, very dilute hydrochloric acid, or sodium chloride solutions; 
consequently, they could not belong to any of the known albuminoid substances. Where did this substance 
come from?1 
The elemental composition of the new substance, which he named nuclein, included carbon, oxygen, 
hydrogen and nitrogen, elements commonly found in organic compounds, but also phosphorus. It was not 
until 1889 when Richard Altmann, one of the students of Miescher, defined nuclein as nucleic acid. The 
discovery of nucleic acids using chemical methods to unravel the mysteries of the cell can be considered as 
the origin of chemical biology in the contemporary era. Despite several outstanding findings related to the 
new substance, including the discovery of their components (phosphate, sugar and the four bases), the way 
they are connected through the phosphate group, forming a polymeric chain of nucleotide subunits, the 
isolation of DNA and RNA and the X-Ray studies of chromosomes and DNA, it was not until 1953 when 
Francis Crick and James Watson reported the first accurate model of DNA’s molecular structure. They 
received the Nobel Prize in Physiology or Medicine in 1962 together with Maurice Wilkins "for their 
discoveries concerning the molecular structure of nucleic acids and its significance for information transfer 
in living material".  
But the history of DNA did not end with Watson and Crick resolving its three dimensional structure. The 
story was far from over. In the late 50s, it was known that DNA contained the hereditary information of the 
cell. Francis Crick reasoned that the sequence of nucleotides in the molecule must function as a code which 
directs the synthesis of proteins. By resolving the puzzle on how DNA leads to the synthesis of proteins 
that are made in the cytoplasm, he established the Central Dogma of molecular biology: The information 
contained in the DNA is transcribed to RNA, which serves as an information carrier to the cytoplasm, where 
RNA is translated into proteins. In 1968, Nirenberg, Khorana and Holley received the Nobel Prize in 
Physiology or Medicine for deciphering the genetic code and describing how it operates in protein 
synthesis. During the second half of last century, many contributions to the area of genetic information and 
its relation to cell function and structure were developed, but it was not until 2003 when the human genome 
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was completed, during what is known as the world largest biological research project, the Human Genome 
Project (HGP). Lead by universities and research centers in the United States, the United Kingdom, Japan, 
France, Germany and China, they sequenced and mapped all the genes, together known as genome, of 
members of the Homo sapiens species. 
All the information revealed during more than 100 years can be translated today into new paths to 
investigate normal human biology, the aberrant processes and elaborate networks of gene, behaviour and 
environment that lead to human disease2,3. However, despite the revelation on how the genetic information 
is stored in the cell and translated into proteins, there is still a gap in the way this overwhelmingly large 
amount of data can be used to understand protein structure, function, interactions and cell localization, as a 
vast number of proteins are still uncharacterized. On the other hand, protein function can be determined by 
the cooperation between different disciplines. Traditionally, biology had predominance over other areas of 
science when concerning the cellular environment. Due to a large number of advancements in life sciences 
in recent years, interest in the nature of the molecules that constitute the essential components of life and 
their interactions has opened an emerging area for the understanding of the molecular basis of life. 
Biological processes can be explained by multiple related chemical reactions. Therefore, the convergence 
of biology and chemistry can result in potent developments towards the study of interactions between 
biomolecules and methodology to synthesize compounds that can mimic their functions. The current 
advances in synthetic and analytical chemistry allow the obtention and characterization of large sized 
molecules possessing specifically designed properties. These supramolecular entities can facilitate the 
comprehension of biological systems. 
The areas of biology and chemistry are thus merging into one discipline, chemical biology, in which 
chemistry provides answers to questions otherwise not possible on the basis of pure biology. The challenge 
of exporting the well-known chemical reactions and mechanisms to biomolecules enables the development 
of new methodologies for bioorganic synthesis. Moreover, chemistry affords well-defined structural 
compounds for the development of novel biological analogs and the study of biological functions on a 
molecular scale. In addition, covalent modifications of materials such as peptides broaden the understanding 
of protein function and can even provide the biologist with new possibilities4. Unnatural modifications of 
proteins are not achievable by the ribosomal machinery in an efficient way. Thus, there is a need for 
compounds containing non-peptidic structural elements that are capable of mimicking or antagonizing the 
biological action of a natural parent peptide. For example, the non-peptidic-part can simplify the overall 
protein structure by substituting sectors of the protein not needed specifically for the biological function. 
Therefore, they are clustered into peptidomimetic compounds1, and can be synthesized by any of the many 
chemical conjugations. 
                                                          
1 For an exact description, a peptidomimetic is a compound that is designed to mimic the biological activity of a 
peptide, but with the desired structural modifications for the improvement of its use as a drug. Their structure 
resembles peptides but with the incorporation of artificial modifications that enable the obtention of the required 
properties. 
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In the current thesis, we aim to mimic biological macromolecules involved in key functions within the cell 
for both inhibiting and modulating their activity. In view of the expertise of the OBCR group in organic 
chemistry, peptide synthesis and bioconjugation strategies, we here present the combination of these tools 
for the successful synthesis of models of the bZIP and bHLH transcription factor families. These models 
are based on a peptidic part and a scaffold which allows the peptide to adopt the correct position for its 
function, and therefore are classified as peptidomimetic compounds.  
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INTRODUCTION 
 
PHOSPHATE RECOGNITION – PAST, PRESENT & FUTURE 
 
The complete role that phosphate anions play in the environment and biology is still very much a mystery 
despite countless efforts towards studying the selective binding of phosphate and phosphorylated molecules 
for more than 100 years. One of the first attempts for the recognition of phosphorus in biological materials 
was carried out by Taylor and Miller in 1914 5. Their strategy consisted of a method based on a colored 
molybdenum (IV) phosphate complex. Further improvements towards less time consuming and non-toxic 
practices focused on enzymes as biological elements that had affinity for the phosphate anion containing 
molecules. Unfortunately, enzymes suffer from poor stability and demanding production costs. As an 
alternative approach and in order to overcome these drawbacks, chemists proposed synthetic receptors for 
the extraction, transport and detection of phosphorylated molecules and phosphate anions. A large variety 
of artificial receptors with successful affinity for phosphates have been documented. Despite these merits, 
the sensitive and selective binding of phosphorylated molecules remains a challenging area of research in 
supramolecular chemistry.  
Phosphate anions are present in molecules with diverse biological functions. Together with sugars, they 
constitute the backbone of DNA in which genetic information is stored. Phosphorylation of proteins occur 
during the posttranslational modification of the protein surface and is involved in switching the enzymatic 
activity for the generation of signaling transduction pathways. Phosphate anions are also present at the 
cellular membrane as phospholipids. The randomization of their distribution along the inner and the outer 
part of the membrane is related to the activation of hemostasis and thrombosis. In addition, cell death and 
clearance by phagocytosis, a process where apoptotic cells are removed from the bloodstream by 
macrophages that specifically recognize phosphatidylserine on the cell surface is also a process phosphate 
anions are involved in.  
Through the course of this thesis, we aim to unravel some of the difficulties that chemists and biologists 
are currently facing regarding phosphate recognition. In chapter 1, we approach small phosphates, 
particularly phosphatidylserine, for the early detection of apoptosis. The following chapters will focus on 
DNA as target for the development of synthetic transcription factor models and artificial nucleases based 
on peptide conjugates. Research is a continuous process and every question answered only raises two more. 
It is this part which makes it challenging, exciting and worth doing. We hope our results will facilitate 
future efforts in this area and enable the development of receptors for phosphate containing molecules for 
broadening scientific knowledge and more specifically for biological applications in vivo. 
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CHAPTER 1 
  
DETECTION OF PHOSPHATIDYLSERINE 
 
The presence of phosphates in many molecules that constitute biological systems make them ideal 
candidates as targets to study and modulate biological functions. Therefore, receptors which could have 
potential for phosphate recognition have been thoroughly studied. Consequently, a broad range of 
recognition units have been developed for their interaction with small phosphate-containing molecules such 
as phospholipids as well as for macromolecules like DNA. During the course of this thesis an overview of 
previous synthetic receptors is presented, together with our contribution to this ever-growing area of 
research. In this chapter, we introduce our first approach for phosphate recognition by the design of 
synthetic receptors for phosphatidylserine for the early detection of apoptosis. 
 
1.1 Phosphatidylserine 
1.1.1 Structure and significance of phosphatidylserine 
Phosphatidylserine (PS) is a glycerophospholipid present in the cellular membrane of all eukaryotic 
organisms. The structure of phosphatidylserine consists of a glycerol backbone esterified on the sn-1 and 
sn-2 carbons of the glycerol moiety, a phosphate group on sn-3 and two fatty acyl chains of variable length 
and saturation (figure 1.1). In comparison with other phospholipids present in the cell membrane, PS 
possesses a serine attached to the phosphate group and is the major anionic phospholipid in the plasma 
membrane. Due to the net negative charge of the hydrophilic head group, the combination of several PS 
molecules provides a net negatively charged layer which is exposed to the cytosol of the cells. 
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Figure 1.1: Structure of phosphatidylserine with the stereospecific numbering (sn) of the glyceric part. 
The main roles of PS involve signaling in both an intra and an intercellular environment. The appearance 
of PS on the cell surface is one of the signals of the early stages of cell apoptosis6 and blood clotting. On 
the other hand, the presence of PS at the intracellular surface of the membrane is essential for the 
localization and activation of proteins such as ubiquitin-protein ligase, protein kinases and phospholipases 
amongst others.  
1.1.2 Localization of PS in the cellular membrane 
The non-random distribution of lipids in the bilayer of the membrane is a common feature in eukaryotic 
cells and is a consequence of the role of particular enzymes. Due to the biophysical properties of lipids, 
they can spontaneously “flip” their polar headgroups through the hydrophobic interior of the membrane. In 
addition to this, the occurrence of active lipid translocation is carried out by transporters (enzymes) across 
the bilayer. These energy-independent and dependent processes are responsible for some of the biological 
functions in the cell, such as signal transduction, membrane fusion, blood coagulation, and cell apoptosis. 
Thus, membrane phospholipids have been targeted for the development of synthetic translocases as 
pharmaceuticals or as chemical tools for biological membrane research7 and for the detection of early-stage 
apoptosis. 
The enzymes responsible for the transport of phospholipids through the bilayer are called translocases. They 
can be divided in three groups: scramblases, which transport phospholipids in a bidirectional manner 
through the membrane. Flippases which are energy-dependent transporters and move phospholipids toward 
the inner surface of the membrane. Finally, floppases which are similar to flippases but move the 
phospholipids away from the inner surface of the membrane. The best known member of the flippase family 
is the aminophospholipid flippase which transports PS and to a lesser extent phosphatidylethanolamine 
(PE) from the outer to the inner monolayer8 (figure 1.2).  
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Figure 1.21. Changes in cell membrane configuration with apoptosis. Redistribution of phospholipids assists in 
formation of membrane blebs and ultimately apoptotic bodies. Also of note is release of 1H histone protein as DNA is 
spliced by caspase3. Free 1Histones are translocated to cell surface by as of yet undescribed mechanisms9.  
In addition, due to the biological influence that PS has on apoptosis and blood clotting, there is a major 
ongoing effort among researchers to target PS for the detection of apoptosis as cell death control. Apoptosis 
is accepted as one of the key readouts for the early prediction of the efficiency of cancer therapies like 
chemotherapy, radiation or anti-angiogenic drugs. Therefore, strategies to detect apoptosis are of great 
interest for disease diagnosis and assessment of treatment responses. Thus, non-invasive imaging 
technologies can be developed based on the detection of PS10–12. 
In this chapter we present our first attempts towards the synthesis of artificial receptors for 
phosphatidylserine as probes for the detection of apoptosis. 
1.2 Apoptosis  
The term apoptosis is a Greek word that describes natural cell death. Over the years, due to the 
developments in cellular biology, it has been adjusted to programmed cell death. Apoptosis occurs in a cell 
when its functions are no longer needed. In addition, it helps to regulate the number of cells in the organism. 
In contrast to necrosis, where cell death takes place as the result of cellular injury, apoptosis is regulated by 
the organism and its dysregulation can lead to dramatic consequences such as the development and 
progression of cancer. The ability of cancer cells to avoid apoptosis and proliferate is one of the trademarks 
of cancer and therefore, also a main target of cancer treatment.  
                                                          
1 Adapted from F. G. Blankenberg and J. F. Norfray, AJR. Am. J. Roentgenol., 2011, 197, 308–17. 
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Usually, PS resides in the inner part of the cell membrane. During apoptosis, the control of the asymmetry 
of the cellular membrane gets disrupted due to the transport of PS from the inner to the outer surface. Once 
the phosphoserine group is exposed to the extracellular environment, it is recognized by Annexin V, a 
protein responsible for the signaling of apoptosis and the consequent activation of phagocytosis. 
1.2.1 Annexin V 
Annexin V is a 36 KDa single stranded protein that binds PS in a Ca2+ dependent manner13,14 and with a 
notably high affinity constant with a Kd < 10-10 M 15. From the X-Ray structure of the protein, the binding 
mode of Annexin V to the glycerophosphoserine group has been determined, where two Ca2+ ions are 
coordinated to the PS headgroup16. Annexin V presents specific features for the recognition of PS based on 
the charge separation and geometrical orientation. Thus, the presence of the other phospholipids does not 
influence the action of Annexin V in the PS-binding functions (figure 1.3). 
 
Figure 1.3: Crystal structure of Annexin V (PDB-ID: 1A8A) with its active sites (yellow) and phospholipid head 
group (blue).  
Due to the high affinity shown by annexin towards PS, imaging of apoptosis can be obtained via strategies 
based on the dye-labeled annexin V as a tool for the assessment of chemo and radiotherapies. Although the 
annexin V modification for PS detection seems promising, there are drawbacks related to the bioavailability 
and biostability of the protein. Apart from its large size and high cost, one hour is required for the 
completion of the annexin binding to PS, which hinders the kinetic assays17. In addition, the dependence of 
annexin V on Ca2+ to interact with the headgroup of PS, can lead to false positive results. This can be due 
to the possibility that scramblases transport PS towards the cellular surface when the concentration of Ca2+ 
increases over the standard level. Moreover, annexin V can also associate with the by-products of lipid 
peroxidation at the membrane surface18. To summarize, an alternative methodology for the detection of PS 
in vivo is required which should be based on a cheap, low-molecular weight, robust mimic, able to bind 
rapidly to PS without penetrating the membrane and independent of the presence of Ca2+. 
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Over the last decade, several research groups have focused on miniature mimics of annexin V as low 
molecular weight molecules for the detection of apoptosis. Thanks to the study of the X-ray structure of 
annexin V, the features of the interaction between the headgroup and the protein could be determined. It 
was observed that the phosphoserine group associates with one of the four binding domains of the protein 
via two Ca2+ 16. This binding mode lead to simplified models based on the appropriate coordination of two 
or more metal dications in an optimized scaffold. The miniature receptor should provide the optimal 
geometry, spatial orientation and charge to interact with the head group of anionic phospholipids 
preferentially over zwitterionic phospholipids. 
1.3 Synthetic receptors for phosphatidylserine 
One of the first models of a synthetic receptor for the recognition of phosphates in aqueous media was 
reported by Hamachi in 200219, in which they designed a binding motif for phosphorylated peptide surfaces 
(figure 1.4). The model was based on the active site of enzymes in which substrates contain a phosphate 
moiety. Therefore, the artificial receptor possesses a metal complex formed by the coordination of Zn2+ in 
a dipicolylamine pocket for the mimicry of the enzymatic interactions. The design includes an anthracene 
as a fluorescent moiety for the quantification of the interaction with the phosphate anion. Results showed 
that the receptor was highly selective towards phosphate anions and presented a remarkable binding affinity, 
with an association constant of 107 M-1. Thus, following the successful results by the group of Hamachi and 
the increasing interest on the detection of phosphatidylserine, the group of Smith studied thereafter the 
interaction of the previously reported receptor with the phosphoserine group of PS. This was done to assess 
the presence of external PS in vesicles and cells by fluorescence microscopy and flow cytometry20. 
 
Figure 1.4: Schematic Representation of the interaction of dipicolylamine zinc(II) complex with a phosphorylated 
peptide.  
Although the receptor could be considered an example of PS recognition in cells using synthetic receptors, 
the anthracene fluorophore suffered from rapid photobleaching, not ideal for time-dependent experiments. 
In addition, the wavelength at which most common flow cytometers work is outside the UV range, and the 
wavelength required for the excitation of the anthracene moiety is 380 nm. Therefore, the use of 
fluorophores that absorb at longer wavelengths was necessary.  
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Consequently, a second generation strategy was adopted by the same group21. The main elements of the 
receptors were the PS binding unit, a linker and a fluorophore. In order to study the parameters that may 
influence the interaction of the binding units with PS, linkers with different hydrophilicities were 
incorporated between the fluorophore and the Zn2+ complexes (figure 1.5). The results showed that the 
tris(ethyleneoxy) linker enhanced the emission of the sensor when binding to PS-enriched membranes. In 
this case, the Zn2+-DPA affinity units are appended to a phenyl ring, which is linked to the 7-nitrobenz-2-
oxa-1,3-diaza-4-yl (NBD) fluorophore. This fluorophore is excited at 470 nm and emits at a broad range 
around 530 nm. Consequently, its use is limited for the study of mechanistic experiments. Thus, different 
fluorophores were tested in the design, including fluorescein22. 
 
Figure 1.5: Modular design of PS sensor1. 
In order to develop a PS sensor with the same specificity towards PS as displayed by PSS-380 and PSS-
480 but with the possibility to detect PS externalization and cell apoptosis, a new series of artificial sensors 
were designed with enhanced fluorescence properties. The new models were based on the conjugation of 
the PS affinity group to CdSe/CdS quantum dot system (PSSgreen QD)22 (figure 1.6). The main advantages 
of the incorporation of quantum dots into PS detection in cells is the resistance towards photobleaching, 
enhanced binding due to the multivalency effect and the feasibility of fluorescence microscopy due to the 
high quantum yield of QDs. On the other hand, extensive washing steps must be done after staining the 
cells and the high brightness of the QDs could lead to false positive results. 
                                                          
1 Reproduced with permission from “Hanshaw, R. G.; Lakshmi, C.; Lambert, T. N.; Johnson, J. R.; Smith, B. D. 
Fluorescent detection of apoptotic cells by using zinc coordination complexes with a selective affinity for membrane 
surfaces enriched with phosphatidylserine. Chembiochem 2005, 6, 2214–2220”. 
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Figure 1.6: CdSe/CdS quantumdot system (PSS-green QD) coated with the PS affinity group1. 
Another design was obtained by exploiting the fact that selective binding to an anionic membrane surface 
can be achieved by two Zn2+-DPA units with an optimal distance23. Thus, a flexible architecture may be 
beneficial for an optimized PS sensor with two widely spaced binding units (figure 1.7). The obtention of 
the dipicolylamine units within the peptide structure was achieved by the modification of two ornithine side 
chains. In contrast to the conclusions gained from previous structural studies22,24, the results proved that 
two closely positioned dipicolylamine binding units are not required to achieve PS detection. The affinity 
constant of the receptor with PS present in artificial vesicles was 5·104 M-1. 
 
Figure 1.7: Dye-labelled Zn2+–DPA peptide. 
The group of Wang developed in 2011 a new type of novel, inexpensive and label-free PS sensor. It was 
based on a new water-soluble, positively charged and fluorescent poly(p-phenylene vinylene) derivative 
(PPV-1)25 (figure 1.8). The characteristics of the design were the water solubility imposed by the 
oligo(ethylene glycol) side chains and the self-brightness obtained from the PPV-1 whose absorption range 
allows the use of fluorescence techniques for the quantification of PS detection. 
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Figure 1.8. Structure of PPV-11. 
One of the more recent receptors developed by the group of Bradley D. Smith in 201026 contains a near-IR 
fluorescent probe for the optical imaging of mammary and prostate tumors in living animals (figure 1.9). 
The near-IR carbocyanine fluorophore absorbs and emits at 794 nm and 810 nm respectively and therefore 
is applicable for imaging through skin and tissue. Moreover, further studies with this sensor indicated the 
possibility of preclinical optical detection of tumor cell death due to therapy27. 
 
Figure 1.9. Chemical structure of PSS-794. 
Apart from annexin V, lactadherin is also involved in the recognition of PS in the outer monolayer of the 
cellular membrane without the need for Zn2+ as cofactor (figure 1.10). Thus, mimics of the protein have 
been developed for the cofactor-free noninvasive detection of PS in cancer cells allowing the 
straightforward assessment of the efficacy of anticancer drugs10. The design developed by the Gao group 
                                                          
1 Reproduced with permission from “Zhu, C.; Yang, Q.; Liu, L.; Wang, S. A potent fluorescent probe for the detection 
of cell apoptosis. Chem. Commun. (Camb). 2011, 47, 5524–5526”. 
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focused on the simplification of lactadherin protein. Due to the circular arrangement of the key residues 
that bind PS in the binding pocket of the protein, Gao suggested a mimic where a cyclic peptide served as 
a scaffold for the appendage of the recognition residues. In addition, this design did not require the 
employment of Zn(II) as a cofactor and bind PS with an affinity constant of 1.25·107 M-1 (figure 1.11). For 
the design of cLac-2, they linked Arg148 to the rest of the molecule by using two spacers: a dipeptide (-
Gly-Gly-, Linker I) bridging Gln85 and Arg148, and a tripeptide (-Gly-Gly-Gly-, Linker II) linking Arg148 
and Trp26. Molecular modeling of cLac-2 shows that the two linkers should be sufficiently long and flexible 
to allow the native-like spatial arrangement of these residues for PS recognition. They also observed that 
hydrophobicity was needed to partition into the membranes, and therefore they substituted phenylalanine 
for biphenylalanine. 
 
Figure 1.10. Crystal structure of Lact-C2 (PDB: 3BN6) naming the residues that are critical for PS recognition. 
Hydrophobic residues Phe81 and Trp26 insert into the membrane and residues Asp80, His83, Gln85 and Arg148 that 
maintain specific polar interactions with the PS headgroup. 
Chapter 1: Detection of phosphatidylserine 
 
12 
 
 
Figure 1.11. Structure of PS-targeting cyclic peptide cLac-2 that incorporates biphenylalanine as a membrane anchor. 
Very recently, the Smith group developed a novel PS sensor based on the formation of liposomes as receptor 
carriers28 (figure 1.12). The new design combines several advantages of previous PS sensors like 
multivalency and selectivity. Furthermore, the pharmacokinetic properties of liposomes allow its 
application on the imaging and theranostic treatment of mammalian cancer cell death, as the liposomes can 
function as drug delivery carriers29,30. In conclusion, the new PS sensor combines cell death targeting and 
cytotoxic delivery within cancerous tissue. 
 
Figure 1.12. Schematic picture of a Zn2BDPA coated liposome with PEG and Zn2BDPA groups on the inner leaflet 
omitted for clarity1.  
                                                          
1 Reproduced with permission from “Turkyilmaz, S.; Rice, D. R.; Palumbo, R.; Smith, B. D. Selective recognition of 
anionic cell membranes using targeted liposomes coated with zinc(ii)-bis(dipicolylamine) affinity units. Org. Biomol. 
Chem. 2014, 12, 5645–5655”. 
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In our group, we became interested in the development of a new type of receptors for PS in our initial steps 
towards phosphate recognition. In view of the large expertise of the OBCR group on the decoration of 
steroids for multiple applications, we have based our research on steroid conjugates as PS receptors. 
Moreover, the precedents of the groups of Anthony P. Davis and Bradley D. Smith on the modification of 
bile acids for their use as scramblases for phospholipid transport across the cell membrane uncovered the 
necessary characteristics for the design of steroid-based receptors to achieve binding of phosphate anions. 
In addition, we envisaged that cofactors were not mandatory for phosphate binding. The idea of the project, 
design and synthesis of the receptors is explained in the following section. 
1.4 Synthetic receptors based on steroid conjugates 
 1.4.1. Phosphatidylserine as a target for the mimicking of scramblases 
Receptors described in the previous section cover a full range of PS targeting models. As mentioned before, 
the importance of phosphate anions and phosphate-containing molecules in biological functions has led to 
the development of synthetic receptors capable of mimicking or modulating the role of natural phosphate 
recognition elements in an organism. Many processes are regulated by the presence of phosphorylated 
molecules in the cellular membrane. The asymmetric distribution of phospholipids in the bilayer membrane 
is a characteristic and sometimes even a requisite for normal cell functions31. The natural appearance of 
phosphatidylserine in the inner part of the membrane is crucial for exocytosis, intracellular fusion processes 
and signal transduction pathways32,33. On the other hand, phospholipid randomization and subsequent 
externalization of PS to the outer membrane surface is an indication of cell death and clearance by 
phagocytosis during apoptosis (section 1.1 and 1.2), as well as an activation signal for hemostasis and 
thrombosis34. It has been shown that PS is also targeted by the Alzheimer’s amyloid-β-peptide35. Therefore, 
several groups have focused on enzymes that have carried out the translocation of PS across the membrane. 
These can serve as models to modulate the transport of phospholipids at the outer and inner surfaces with 
potential applications to cancer therapies and genetic disorders36. Research on synthetic scramblases for the 
recognition and transport of phospholipids has mainly been developed by the group of Anthony P. Davis 
in collaboration with the group of Bradley D. Smith by exploiting their broad expertise on steroid-based 
receptors.  
In 1990, the group of Prof. Davis began exploring the area of anion recognition. Their starting point was 
established by the potential of Valinomycin (figure 1.13 A), a natural transmembrane cation carrier, to 
extract potassium ions from water and transport them across the membrane interior. Unfortunately, no 
anionic counterpart could be found in nature. Thus, Davis proposed a new design of receptors which could 
act as potential anion carriers and named them “anti-Valinomycins”. It seemed a logical conclusion that 
cationic receptors should bind better to anions than electroneutral ones. Unfortunately, lipophilic cations 
were toxic and they required a counter-ion to compensate for their solubility issues, which in turn could 
generate complications during testing of anion binding capability. The first examples of electroneutral 
receptors were based on the neutral H-bond donors in the group of Reinhoudt37,38 (figure 1.13 B). Although 
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it set up a starting point, the design lacked rigidity and pre-organization. Moreover, intramolecular H-bond 
interactions formed decreased the interaction with the anion (figure 1.13 C).  
 
Figure 1.13. A) Valinomycin structure and binding mode to its substrate K+. B) Anion receptors from the group of 
Reinhoudt. C) Representation of the intramolecular interactions in electroneutral receptors that can damage the 
binding site. 
1.4.2. Bile acids as templates 
Davis then proposed the employment of steroids as rigid frameworks and pre-organized functional group-
containing scaffolds for their conversion to H-bond donor arrays. Initial results showed the need for amines 
instead of alcohols as functional groups for the construction of the binding pocket wherein the phosphates 
were accommodated. Thus, the synthesis of protected aminosteroids was successfully investigated and 
reported39–41. Furthermore, it was discovered that for a given H-bond donor geometry, steroid-based 
receptors with more acidic H-bond donors would bind with higher affinity and selectivity. Therefore, 
electron-withdrawing groups were used to increase the NH acidity, like ureas and thioureas (figure 1.14). 
At this point, the group of Davis started a collaboration with the group of Smith in order to test the ability 
of these cholapods as anion transporters interacting with the head-group of phospholipids, such as 
phosphoserine from PS, through membrane interiors, acting as synthetic flippases36,42 (figure 1.15). In 
addition, they have shown that amides and ureas showed preference for phosphates binding over sulphates. 
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Figure 1.14. Model of neutral anion receptors based on steroid constructs. Z groups adjust NH acidity. On the right, 
the different functionalities with one or more H-bond donor groups are shown. 
 
Figure 1.15. Neutral bis(phenylurea)-based receptor developed by Davis. 
 1.4.3. Bile acids as templates for early detection of apoptosis 
Following the success of other groups in the design and synthesis of steroid-based receptors for the 
recognition of PS, the OBCR group was also encouraged to investigate new types of receptors for the early 
detection of apoptosis. We here report our first attempt in this direction. The phosphate anion possesses a 
tetrahedral geometry and in contrast to halogen anions, its extended volume suggested the requirement of 
a bigger receptor’s cavity. We have proposed three different potential receptors of which the cavity can be 
controlled by cyclization. The acyclic form should show more affinity and selectivity towards phosphate 
anions due to a higher flexibility for adapting the geometry as is required for the binding of a tetrahedral 
H2PO4- anion. On the other hand, as the recognition area becomes smaller, the affinity for bulky anions in 
comparison to halogen anions decreases43.  
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In addition, recent studies on the potential of the 1,4-disubstituted 1,2,3-triazole ring to recognize, bind, and 
sense oxoanions44 together with the high regioselectivity and efficiency of CuAAC (Copper(I)-Catalyzed 
Azide Alkyne Cycloaddition) inspired us to incorporate triazoles in the dipodal recognition units amended 
together by the steroid scaffold. The capacity of triazoles to act as H-bond donors and to participate in 
dipole-dipole interactions has been already described45 for anion recognition with a broad variety of 
receptors46 and settled for the C–H hydrogen bond donor as a new noncovalent binding motif. It also 
allowed the modification of peptide structures as amide bond mimics47, establishing triazoles as new, 
versatile and successful anion-binding motifs that can be added to the design of receptors, widening the 
existing list of hydrogen bond donors and Lewis acids already known. Consequently, the group of Pandey 
has explored 1,2,3-triazolium systems in a bile acid template as an anion-sensing moiety for phosphate 
anions with the extra benefit of a protonated triazole, enhancing the hydrogen bond donor capacity (figure 
1.16). Additionally, he observed that the bridging methylene protons participated in hydrogen bonding with 
the anions along with the C-5 triazolium protons. Unfortunately, as previously mentioned, the employment 
of cationic receptors can cause complications.  
  
Figure 1.16. Binding mode of Pandey’s receptor by H-bond donor interactions with the phosphate anion. 
Contrary to the design of Pandey, where he described the appendage of the recognition units by ester bonds, 
and as illustrated by Davis, all the more promising structures encountered at least one NH group attached 
to the steroid. We have recently published an optimized strategy directed towards the synthesis of an 
orthogonally-protected diamine deoxycholic acid, in which one of the intermediates was the 3α,12α-
diamino-deoxycholic acid48 (figure 1.7; compound 1.1).  
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Figure 1.17. Intermediate compound in the synthesis of orthogonally protected diamine deoxycholic acid derivatives. 
Podands to be incorporated onto the scaffold had to ensure the acidity of the NH group and the presence of 
an alkyne for CuAAC. Although thioureas have been known as the motif that best increase NH acidity, we 
proposed amides as the functional group for the linkage of the scaffold with the anion binding motifs as we 
could overcome the possible decrease in affinity of the amines with the presence of the triazoles. Thus, a 
carboxylic acid was required, together with the presence of an alkyne. Due to the excellent results obtained 
in the group of Strömberg for the conjugation of peptides to oligonucleotides by the CuAAC reaction with 
their taylor-made linker: (N-Propynoylamino)-p-toluic acid (PATA) (1.2) affording an activated triple 
bond, we proposed its incorporation onto the scaffold as podand to afford H-bond donor units (figure 
1.18)49. Furthermore, it has been shown that the methylene protons participate in hydrogen bonding. 
 
Figure 1.18. Structure of the PATA linker 1.2. 
The presence of two alkynes allowed multiple derivatizations towards the final synthetic receptors. The 
azides were straightforward to obtain by synthetic methods or commercial sources. This ensured the 
possibility of cyclisation with a bis-azide moiety and the appendage of different units for the synthesis of 
the acyclic receptors. As an approach towards our goal, we decided to use benzyl azide and hexadecylazide 
for the acyclic forms, while 1.11-diazido-3,6,9, trioxaundecane was chosen as linker for the cyclization of 
the podands at both C3 and C12. We here show our first designs for the binding of phosphatidylserine. In 
addition to having the acyclic form, we have incorporated for the first time an aliphatic chain to create extra 
hydrophobic interactions with the lipophilic part of PS. As discussed before, the cyclic form should show 
more affinity for halogen anions. Moreover, publications about artificial receptors for anion recognition 
based on cholapod scaffolds showed designs with a maximum of 6H-bond donors, providing the strongest 
binding constants as compared to receptors with less H bond donor capacity. The presence of 4 amide 
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groups, 2 triazoles and 2 methylene groups should ensure the cooperation of at least 6H-bond donor units 
in the final recognition cage within the receptors.  
 
Figure 1.19. Structures of final receptors 1.4, 1.5 and 1.6. 
In order to test the influence of the scaffold on the PS binding, we synthesized an acetylated receptor as a 
blank. The amine functionalities of compound 1.1 were capped using acetic anhydride and DIPEA to afford 
1.7. 
 
Figure 1.20. Structure of receptor 1.7 used as a blank. 
1.5 Synthesis 
The diamine scaffold was synthesized according to our published method48. The carboxylic acid of PATA 
is less active for coupling due to the electron-withdrawing effect of the benzyl ring. Therefore the 
employment of a more reactive coupling reagent such as HATU was required for the amide coupling to the 
amines. In order to drive the reaction to completion, an excess of PATA was needed. This was probably 
due to the hindrance present at the C12 position, both because of the structure of the steroid nucleus and 
the presence of the linker at C3. The C3 conjugation proceeded faster, as the amine at C3 is more exposed 
to the reaction solution. After purification, the compound was subjected to click reaction with azides, using 
catalytic amounts of CuSO4·5H2O and sodium ascorbate under microwave conditions (figure 1.21). 
Extraction with a saturated solution of EDTA facilitated the removal of Cu particles. Final purification by 
RP-HPLC afforded the 3 desired receptors. 
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Figure 1.21. Synthesis route for the obtention of final receptors 1.4, 1.5 and 1.6. i) HATU, DIPEA, DMF, 16h, rt. ii) 
CuSO4·5H2O, NaAsc, 2,6-Lutidine, DMF/H2O, 1h, 60°C, MW.  
1.6 Isothermal Titration Calorimetry (ITC) as a method for the determination of the binding 
affinity 
As a method to study the interaction of receptors 1.4, 1.5, 1.6 and 1.7 with phosphatidylserine, we chose 
Isothermal Titration Calorimetry (ITC). The basic principle of ITC can be explained as follows: the 
determination 
Ka, Kd and n) is achievable by direct measurement of the heat generated or absorbed when the receptor and 
PS interact. For this purpose, the instrumental setup consist of a reference cell and a sample cell, in which 
a suitable solvent and a solution of the receptor are placed respectively. A syringe containing a solution of 
the ligand is inserted into the sample cell and a precise volume of this solution is delivered in the cell at 
defined time intervals.  The interaction is monitored by measuring the heat required (endothermic event) or 
to be dissipated (exothermic event) to keep the T of the titration cell equal to that of the reference cell after 
each injection. The heat released decreases after every addition of the ligand due to the diminution of the 
binding sites available, and it ceases when saturation is reached. The contribution linked to the ligand 
dilution is determined by injecting the ligand in the solvent used to prepare the receptor solution and 
subtracted from the heat exchange measured in the presence of the receptor.  
In collaboration with Prof. Gilles Bruylants from ULB, we performed ITC measurements of the receptors 
1.4, 1.5, 1.6 and 1.7 with phosphatidylserine. Optimization of the conditions (solvents and concentrations) 
were performed during the course of my PhD. The subsequent work was carried out by Lidia Dumitrescu 
and Vincent Ornelis. The choice of the solvent was based on the solubility of both receptor and ligand, as 
they must be both soluble in the same solvent. In addition, the dilution heat of the solvent with the ligand 
has to be small compared to the interaction heat The concentrations of the receptor and ligand solutions 
were optimized and found to be 240 and 2400 µM respectively for the receptor (in the cell) and ligand 
solutions (in the syringe) in CHCl3. Results showed that receptors 1.7, 1.4 and 1.5 do not interact with 
phosphatidylserine. It was expected that receptor 1.7 would not interact with PS as its structure only consists 
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on the steroid nucleus, and it was used as a blank to assess the influence of the scaffold on the PS binding. 
On the other hand, receptor 1.6 showed affinity in the range of 104 M-1 (figure 1.22), illustrating that 
aliphatic chains might have an influence on the recognition of PS by ensuring the position of PS head group 
into the hydrogen bond cavity and by enhancing the interaction via hydrophobic contacts with the aliphatic 
chains.  
 
Figure 1.22. Thermogram (left) and integrated data (right) linked to the injection of 10 l of a 2400 M PS solution 
in 1 ml of a 240 M solution of 1.6. The profile of the binding isotherm (right) is fitted to the experimental data in 
order to obtain the thermodynamic parameters. 
1.7 Conclusions 
In this chapter we present our first steps in the design of bile acid-based receptors for the detection of 
apoptosis. In addition, we investigated the influence of the size of the binding cavity and the possibility of 
amide bonds as hydrogen bond donors towards PS. Prior steroid-based receptor36 in figure 1.14, was tested 
for the binding of an analogue PS with shorter acyl chains to diminish the aggregation of lipid tails. UV 
titration technique was used to determine the association constant. The experiments were carried out in 99:1 
CHCl3:CH3OH to simulate the lipophilic interior of the bilayer membrane. The association constant was 
(3.4 ± 0.9) x 105 M-1. To the best of our knowledge, the best binding constant reported until now is achieved 
with the cyclic peptide cLac-2 in figure 1.11, and a value of 1.25 x 107 M-1.  
In addition, it is known that lipophilic cations like steroid-based receptor in figure 1.14 are toxic and results 
in solubility problems. Therefore, we present here our first attempts towards the development of neutral 
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steroid receptors for PS based on hydrogen bond interactions. Moreover, the obtained affinity constant 
obtained for receptor 1.6 is comparable with the ones obtained with previous reported receptors.  
On the other hand, the observed affinity could be due only to hydrophobic interactions between the aliphatic 
chains from both the receptor and the ligand. In order to discard this option, ITC measurements using as a 
ligand an aliphatic chain should be performed. Furthermore, the stoichiometry did not correspond to a 1:1 
ratio of receptor:ligand. The value n = 0.3 could be due to low purity of the sample measured or by the 
aggregation of receptors via their lipid tails. In order to investigate if aggregation occurs and if it is 
necessary for the interaction of PS, further studies are needed in which the concentration of receptor in the 
sample cell would be reduced to hamper the aggregation effect. Another alternative to assess the 
interactions within receptors is the employ of Dynamic Light Scattering (DLS) technique, which will allow 
access to the determination of the size distribution profile of small particles that can be formed by the 
aggregation of the receptor. 
As a conclusion, we have synthesized three receptors for the detection of PS varying the size of the binding 
cavity. Receptor 1.6 showed an affinity constant in the order of 104 M-1. However, further studies are needed 
to analyze if the interaction is caused by other factors non-related to the hydrogen-bonding between the 
receptor and the phosphoserine headgroup of PS. 
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CHAPTER 2 
 
RECOGNITION OF LARGE MOLECULES CONTAINING PHOSPHATES: 
DEVELOPMENT OF TRANSCRIPTION FACTOR MODELS 
 
Transcription of DNA is one of the most critical processes in biology as it regulates the expression of genes 
that are needed within the cell to develop essential functions. By targeting DNA in a specific gene, these 
functions can be modified or inhibited. However, targeting specific DNA sequences requires considerable 
sophistication in terms of design and synthesis. Mimicking these transcription factors by synthesizing 
artificial ones gives us valuable insight into the parameters that affect DNA recognition. In this chapter we 
present our initial attempts on the synthesis of transcription factor models towards the sequence selective 
recognition of DNA. 
 
2.1 DNA: Discovery, Structure and Function 
The elucidation of the Deoxyribonucleic acid (DNA) structure by James Watson and Francis Crick in 1953 
was an epoch making discovery in the history of science. Much of our current knowledge with regards to 
how genetic information is used and stored in a cell is based on research projects that were developed as a 
consequence of this discovery. Ever since the ground breaking discovery by Watson and Crick scientists 
all over the world have worked and are still working tirelessly, pouring in their resources to uncover the 
many mysteries that surround DNA.  
To explain in the simplest possible terms the structure of DNA it can be said that each DNA molecule 
consists of two antiparallel coiled strands around each other to form a double helix, a structure like a spiral 
ladder. Each rung of the ladder consists of a pair of chemical groups called bases. There are four types of 
bases – Adenine (A), Guanine (G), Thymine (T) and Cystosine (C) which combine in specific pairs and 
stabilize each other via hydrogen bonding (A-T, G-C) so that the sequence on one strand of the double helix 
is complementary to that on the other. It is this specific sequence of bases which constitutes genetic 
information. 
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Figure 2.1: Structure of dsDNA: base pairs & phosphate backbone1 50. 
In more complicated but structurally and chemically correct terms, DNA is an oligomeric molecule formed 
by the nucleotide units A, G, C, T. These nucleotide units are comprised of a phosphate and a sugar 
molecule. As a chemist, one can explain the connectivity and define the bonds thus: The β-D-2’-
desoxiribose is joined by a β-glycosidic C1’-N bond to a nitrogen base and by a phosphodiester bond to the 
phosphate group at both 3'-hydroxyl and 5'-hydroxyl groups. The phosphates of DNA are quite acidic (the 
pKa is nearly 0!) and therefore nucleic acids are polyanions at physiological pH = 7.365. 
The bases are organized in the form of a helix due to the geometry of the sugar and the hydrophobicity of 
the bases. Their natural tendency is to minimize the contact surface with water. Moreover, as phosphates 
are negatively charged, they are stabilized in contact with water.  The most common conformation of DNA 
under physiological conditions is the B form in which both polynucleotide chains are wound in a right-
handed conformation around a common axis. The final diameter is approximately 20 Å and the turn of the 
helix is 36° for each base pair. Thus, a complete 360° turn consists of 10 base pairs with the pitch of the 
helix measured as 34 Å with 3.4 Å as the length of each nucleotide. The planes of the base pairs are almost 
perpendicular to the axis of the double helix. B-DNA contains 2 grooves of different widths, the major 
groove and the minor groove, due to the asymmetrical attachment of the base pairs to the sugar rings of the 
backbone. The latter one is deep and narrow while the former is wide. 
So what is the purpose of DNA? The truth is nobody knows for sure the full range of functions that DNA 
can perform. Nature chose DNA for a reason – its stability, easy enzyme manipulation, its perfect code 
                                                          
1 Figure 2.1 (right): Chapter 1: DNA Structure: Alphabet Soup for the Cellular Soul. © 2011 P. Shing Ho, Megan Carter. 
Originally published in “Biochemistry, Genetics and Molecular Biology” » "DNA Replication-Current Advances" under 
CC BY-NC-SA 3.0 license. Available from: http://dx.doi.org/10.5772/18536. 
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which can store massive amounts of information. But the truth is, despite over 60 years of research after its 
discovery, we have only scratched the surface. This is hardly surprising since it took millions of years for 
life to evolve. However, what we do know for sure is that in humans, proteins are synthesized based on the 
expression of information stored in DNA during the transcription and translation processes making it vital 
that we understand the intricate processes that surround this giant puzzle. 
2.2. Transcription: From DNA to RNA  
As mentioned before, it has been concluded after years of research that indeed the four different nucleotide 
subunits are responsible for the encoding of genetic information which are then stored in sequences that 
make up DNA. Further developments in cell biology and biochemistry have led to the revelation that this 
genetic information is in turn responsible for cell functions. 
Cells comprise of several things – ranging from sugars to lipids to DNA. Proteins are still, however, one of 
the main components in the cells and determine its structure and function. The synthesis of proteins is 
dictated by the DNA sequence and its encoding process through replication, transcription and translation. 
This process ensures transferring the genetic information from the “language” of the nucleotides to the 
“language” of the amino acids. 
The synthesis of proteins is a complex process in which DNA is the keystone. Once a protein is needed in 
the cell, the nucleotide sequence corresponding to it is transcribed into RNA by an enzyme, RNA 
polymerase II. Each DNA segment containing the required information for the synthesis of a protein is 
called gene. Each gene is thus translated into a protein as and when required. These are the fundamental 
concepts involved in the expression of genetic information and therefore constitute the central dogma of 
molecular biology. 
As part of this thesis, we will focus mainly on the process of transcription. The first step in gene expression 
is to copy the sequence of a specific gene into RNA. This process is called transcription due to the almost 
similar nature of the main elements involved, nucleotides. RNA, as DNA, is a polymer constituted by four 
different nucleotides linked by phosphodiester bonds. Although DNA and RNA have similarities, the 
differences between their structures result in important consequences in terms of the functions they perform. 
RNA, unlike DNA, is single-stranded and therefore can adopt a broad range of 3 dimensional structures. 
This property of folding into different conformations confers upon the RNA the ability to act not only as 
an information storage, but also as a catalyst. In addition, RNA has can also have structural and regulatory 
functions in the cell. 
During transcription, RNA is synthesized from a segment of double-stranded DNA. The process is initiated 
by exposing one of the DNA strands by unwinding the double-stranded DNA of the desired sequence. This 
allows the RNA polymerase II to recognize and bind to the promoter sequence of the gene to be transcribed. 
The enzyme can only bind to its sequence through the presence of certain proteins, transcription factors to 
be precise, that bind selectively to the promoter site and form the transcription initiation complex. One of 
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the two strands serves as a template for the complementary base-pairing synthesis of an antiparallel RNA 
strand. In layman terms these transcription factors “read” the genetic code which is built into dsDNA. 
 
Figure 2.2. Representation of the DNA transcription process1. 
As RNA polymerase II synthesizes RNA in the 5’ to 3’ direction, the complementary DNA strand used as 
the template is the one oriented in the 3’ to 5’ direction. Ribonucleotides are added covalently to the growing 
RNA chain by phosphodiester bonds while the enzyme moves through the DNA template strand unwinding 
the helix and exposing the DNA sequence to complementary base-pairing with the incoming 
ribonucleotides. Elongation of the RNA chain is terminated when the RNA polymerase encounters a 
specific DNA sequence, where the enzyme loses its affinity for the DNA. The newly synthesized RNA 
chain is then released and ready for translation or post-transcriptional functions. 
2.3 DNA transcription as a key process for gene therapy 
Due to several complex mechanisms involved and a lack of clear understanding and knowledge about the 
specificity of the interactions between DNA and proteins the study of the regulation of gene expression has 
always been of particular interest. Moreover, this lack of knowledge has significantly hampered the 
development of gene therapy strategies in the past and hence study of the interactions between proteins and 
DNA has gained a lot of traction in recent years especially where other therapeutic strategies fail. In some 
diseases, particular genes are overexpressed causing interferences with biological functions in the cell. 
Therefore, the prevention of specific genes from being transcribed could ultimately result in a therapeutic 
platform with biomedical applications51. During the past decade, biologists and medicinal chemists have 
been working together in order to target specific genes for this purpose. In nature, some proteins interact 
with DNA in a sequence-specific way by means of their recognition domains, which consists of a short 
sequence of amino acids. Simplification of a protein could ultimately lead to a peptide-based drug in cancer 
treatment. Moreover, due to the improvements in peptide manufacturing, peptide drugs can be obtained 
through synthetic methods and techniques which allow the increase of peptide stabilization. In this context, 
                                                          
1 Reproduced from http://limbiclab.com/. 
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Transcription Factors (TFs) have been studied in great detail for the modification of gene expression and 
the study of DNA binding affinity in the cellular environment.  
2.4 Interactions between DNA and proteins: The key factor regulating transcription 
Transcription factors regulate transcription in eukaryotic cells by determining not only the genes to be 
transcribed but also the rate of transcription. They bind and recognize regulatory DNA sequences related 
to the gene (figure 2.3). The regulation is performed via very specific interactions between the TF with the 
regulatory gene of the target gene by activating or repressing its transcription. 
 
Figure 2.3. Control regions that regulate transcription of a typical eukaryotic protein-coding gene. Although shown 
as distinct entities in the figure for clarity, in vivo the different regulatory proteins bound to the control elements and 
distant enhancers interact with each other and with the general transcription factors of the transcription initiation 
complex to modulate the rate of transcriptional initiation1. 
2.5 Types of interaction between proteins and DNA 
The lack of a general recognition code for the interaction between amino acid sequences within a protein 
and its specific DNA-binding site has promoted the study of the structure of TFs and its interaction with 
the DNA. Although a general formulation of these interactions has not been achieved, some general rules 
can be followed, providing a starting point for the molecular basis of specific DNA recognition. 
Due to the fact that the secondary structures in case of proteins are extremely well defined, very specific 
interactions take place between the amino acids of proteins and the complementary base pairs of DNA. In 
case of TFs, all these interactions occur in the major groove of the DNA, which is wide enough to 
accommodate the α-helix recognition unit.  A detailed explanation of the four major forces between proteins 
and nucleic acids can be summarized as follows: 
1. Electrostatic forces: Salt bridges. These are long range, electrostatic interactions between 
groups of opposite charges. In this case, these are quite important in view of the presence of 
the negatively charged DNA due to the phosphodiester backbone and the positively charged 
                                                          
1 Reproduced with permission from: http://www.expertsmind.com/topic/regulation-of-transcription-by-
rna/mechanism-of-regulation-95614.aspx 
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basic side chains of the amino acids of the protein, such as Lys, Arg and His. These interactions 
contribute to the free energy of association and do not influence the specificity. 
2. Dipolar forces: Hydrogen bonds. These can be defined as short range interactions that 
contribute substantially to the specificity of the interactions that occur between proteins and 
DNA, however, they do not provide stability to the complex. They occur between the polar side 
chains in the proteins and the sugars and bases in the DNA. Higher degrees of specificity can 
be achieved by bidentate hydrogen bonds between a single side chain and a base or base pair.  
3. Entropic forces: The hydrophobic effect. These are short range, non-directional forces and 
contribute to the free energy of association. These non-polar contacts occur between the apolar 
amino acid side chains and the DNA base pairs. 
4. Water-mediated hydrogen bonds. Water molecules behave as space fillers in the protein-DNA 
complexes and influence the positions of hydrogen bond donors and acceptors at the base edges. 
2.6 Families of transcription factors 
The protein structure of TFs can be divided into two broad domains: the DNA binding domain which is the 
part of the protein responsible for the selective interaction with the DNA control sequence for transcription. 
The other domain is the DNA activation domain, the part responsible for the interaction with other TFs or 
with the RNA polymerase II.  
There are several DNA binding domains found in TFs in eukaryotic cells: Helix-turn-helix, zinc finger and 
the basic domain. 
2.6.1 The Helix-Turn-Helix motif: 
It consists of two α-helices brought together by a β-turn formed by a short peptide sequence. The two helices 
are held together at a fixed angle through interactions between them. The C-terminus of the protein is 
inserted in the major groove of the DNA. Sequence-specific recognition is achieved via the interactions 
between the side-chains of the amino acids with the DNA which vary between proteins (figure 2.4). 
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Figure 2.4: The DNA-binding helix-turn-helix motif2. The motif is shown in (A). The recognition helix (red) is located 
at the C-terminal part of the protein. As shown in (B), this helix binds the major groove of DNA, where it is in contact 
with the edges of the base pairs. The N-terminal α-helix (blue) functions basicaly as a structural component that allows 
the optimal position of the recognition helix. 
The binding mode of the helix-turn-helix proteins is very similar to other sequence-specific DNA binding 
proteins. HTH proteins recognize double stranded DNA and arrange themselves symmetrically with respect 
to the DNA sequences having two similar half-sites. This binding feature allows each monomer of the 
protein to interact with one of the half-sites independently and therefore increase the binding affinity, by 
increasing DNA contact interface and the helicity conformation of the peptides. 
2.6.2 Zinc-finger motifs 
The previous helix-turn-helix motif is formed only by amino acids. Zinc-finger motifs present several zinc 
atoms within their structures. There are two main zinc-finger motifs in this family of TFs: the C4 finger and 
the C2H2 finger. The latter one presents one α-helix and two β-strands, held together in a compact structure 
by a loop (figure 2.5). It contains 12 amino acids including two cysteines and two histidines, needed for the 
coordination of a zinc ion within a tetrahedral geometry. The α-helix region of the protein is responsible 
for the interactions with the major groove of the DNA. The C4 zinc finger motif has the same structural 
arrangement as the C2H2 but unlike the C2H2, the C4 has 4 cysteines which coordinate the zinc instead of 
two cysteines and two histidines. 
                                                          
2 Adapted from DNA-Binding Motifs in Gene Regulatory Proteins Cover of Molecular Biology of the Cell Molecular Biology of the Cell. 4th 
edition. Alberts B, Johnson A, Lewis J, et al. New York: Garland Science; 2002. 
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Figure 2.5: One type of zinc finger protein. This protein belongs to the Cys-Cys-His-His family of zinc finger proteins, 
named after the amino acids that contact the zinc. The three-dimensional structure of this type of zinc finger is 
constructed from an antiparallel β sheet followed by an α-helix. The four amino acids that bind the zinc hold one end 
of the α-helix firmly to one end of the β sheet.  
In this motif, the strength and specificity of the DNA-protein interactions has been modulated considerably 
by nature in terms of the number of basic structural units. This can be concluded from the fact that this 
motif is found as a cluster of zinc fingers and its α-helices can interact with the major groove. 
2.6.3 Transcription Factor Domains 
2.6.3a Basic domains: Proteins containing basic domains at the N-terminus are rich in basic 
amino acids (Arg, Lys & His) and possess dimerization domains such as the basic Leucine zipper (bZip) or 
the basic Helix-Loop-Helix (bHLH) which explains how the names of these TFs have been derived. These 
proteins bind dsDNA as dimers of two basic domains. Dimerization between monomers occurs due to the 
interactions between the side chains of hydrophobic amino acids at the dimerization domain, and allows 
the basic domain to dimerize and grip the major groove of the DNA. 
2.6.3b Dimerization domains: 
I. Leucine zippers 
The dimerization domain of bZIP consists of an α-helix with leucines on the same side of the helix every 
seven amino acids (i.e. The 1st, 8th, 15th… amino acids will be on the same side). This helps creating a 
hydrophobic surface and allows the dimerization of the monomers by the interactions within the Leucine 
zipper motif. Consequently, the leucine zipper enables the basic region monomers to face opposite 
directions and wrap around the major groove at palindromic DNA sequences (figure 2.6). 
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Figure 2.6: A leucine zipper dimer bound to DNA. 
II. Helix-loop-helix motif 
The main feature of this motif, which makes it different from other leucine zipper motifs, is that the 
monomers contain a non-helical loop at the interface between the dimerization and the binding domains. 
The C-terminus of these helices consists mainly of hydrophobic amino acids whose side chains face one 
side of the helix allowing hydrophobic interactions between the C-termini of the helices thus forming the 
dimerization region (figure 2.7). 
 
Figure 2.7: A helix-loop-helix dimer bound to DNA. 
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In case of both dimerization motifs, viz. the leucine zippers and the HLHs, the dimerization can occur 
between monomers with different amino acid sequences, forming heterodimers instead of homodimers. 
2.7 Description of the bZIP Leucine zipper GCN4 
The yeast transcriptional activator GCN4 presents one of the simplest protein structures as compared to 
other TFs present in eukaryotes and it controls the activation of several genes in response to amino acid 
starvation. GCN4 binds DNA in a sequence-specific manner and its function is the transcription from 
promoters containing the sequence 5' TGACTC 3'52. Its crystal structure was determined by Ellenberger in 
1992 by X-ray crystallography with a 2.9 Å resolution53, available at the Protein Data Bank (PDB-ID: 
1YSA) (figure 2.8). In general, this TF is geometrically in the shape of a pair of α-helices that form a parallel 
coiled coil that diverges as one moves from the C-terminus to the N-terminus ensuring the proper dimer 
formation and allowing the wrapping of the DNA major groove by its binding domain. The main contacts 
of this region of the protein with the DNA are established via interactions between the bases and phosphate 
groups present in DNA and the basic residues present in the protein. 
 
Figure 2.8: Molecular visualization of the GCN4 bZIP Leucine zipper TF bound to the CRE recognition sequence. 
The leucine zipper stabilizes the coiled-coil dimer due to the hydrophobic and non-polar interactions within 
the monomer forming an extensive van der Waals contact surface. Intra and inter-helical salt bridges are 
present in a low quantity, however, they also contribute to the formation of the dimer.  
The basic region of each monomer adopts the optimal conformation to bind to its respective half site of the 
sequence due to the rigid coiled coil, that imposes a bend of the α-helix towards the axis of the DNA, and 
therefore grip the major groove and interact with the base pairs located there. 
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The DNA binding affinity and specificity of this family of TFs is determined by its bZIP DNA binding 
domain that comprises of 55 to 65 residues, 25 of which are located at the N-terminus and pass through the 
major groove of each half site of DNA. The main residues of the protein involved in the DNA recognition 
comprise of the amino acids numbered 226-248 (DPAALKRARNTEAARRSRARKLQ) of the basic region 
of the GCN4 protein. Numerous contacts of this region with the major groove are based on the positively 
charged polar residues, which establish hydrogen bonds with the unesterified oxygen atoms of the 
phosphate backbone and the base pairs. The N-terminal end of the basic region continues as a helix beyond 
the point of DNA contact, giving the protein an appearance of a pair of α-helical tweezers. 
2.8 Artificial dimerization of the bZIP Leucine Zipper basic regions 
Due to the simplicity of the structure of bZIP leucine zipper TF described above, miniaturization of this 
protein into non-natural versions using chemistry-based synthetic routes has been the target of several 
research groups. The miniature versions should maintain the geometry and the properties of the original 
protein. The first breakthrough was obtained by Kim’s group54. They reported a simple yet efficient 
disulfide bond as a moiety for the substitution of the leucine zipper domain of the GCN4 TF without 
substantial effect on the DNA affinity and selectivity compared to the natural binding domain. 
Other dimerizing units were developed following the basis of Kim’s construct (figure 2.9). One of them is 
the coordination complex described by Schepartz’s group55 in which the two basic regions were connected 
through a bis(terpyridyl)iron(II) complex. The assembling of the recognition units was performed through 
the cis and trans conformation of the complex thereby obtaining different geometries which could in turn 
be used for studying the effect of the orientation of the recognition units on DNA binding. 
In addition, dimerization of the monomers by non-covalent constructs was achieved by the Morii group56. 
The model was based on the inclusion complex formation of an adamantane and a cyclodextrin, each of 
which was conjugated to a single strand of the GCN4 basic region. It was observed that each strand did not 
bind by itself but the formation of the non-covalent complex resulted in a dimer of the two strands which 
could then bind DNA. The synthesis of this design extended the knowledge about the importance of the 
dimer formation. Following these models, the group of Mascareñas studied the modulation of the DNA-
binding affinity using a photoswitchable azobenzene linker as dimerization unit between the GCN4 basic 
regions57. 
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Figure 2.9: Previous scaffolds as dimerizers of GCN4 basic region peptides. A) Disulfide bond, Kim et al54. B) 
Cyclodextrin-adamantane complex by Morii56. C) Iron complex developed by Schepartz and co-workers55. D) 
Diazobenzene unit by Mascareñas57. 
Recently, in our own OBCR group, we have reported a dipodal peptidosteroid mimic of the GCN4 TF58. 
The synthesis was based on the linear coupling of amino acids comprising the basic region to a steroid 
nucleus via SPPS. Although the purity of the final compound was low, it showed DNA recognition 
properties. A comparison of our previous model to this one is discussed in the following section. 
2.8.1 Prelude to the work of the current project: Bile acid as a dimerizer 
Over the last decade, steroidal structures have gained significant attention in fields such as supramolecular 
and bioorganic chemistry, pharmacology and nanotechnology. 
Cholesterol is metabolized in the liver and produces bile acids as end products. Thereafter, the steroid 
nucleus undergoes several hydroxylations one of which includes the loss of an isopropyl group from the 
side chain, to produce primary bile acids. Further chemical alterations produce secondary bile acids, such 
as deoxycholic acid. 
Bile acids feature several structural differences but those present in higher vertebrates share the same 
structural skeleton. They consist of two units, a rigid steroid nucleus and a short aliphatic side chain. The 
steroid nucleus is a tetracyclic hydrocarbon perhydrocyclopentanophenanthrene unit, composed of three 6-
membered rings (A, B and C) and a 5-membered ring (D). They contain two angular methyl groups at 
positions C18 and C19. The A and B rings are in a cis configuration which allows the nucleus to adopt a 
curved shape. It must be noted that the trans configuration is also possible, but not of interest for the current 
thesis. Due to the arrangement of the hydroxyl groups in the core structure, bile acids possess an amphiphilic 
character with a convex hydrophobic upper and a concave hydrophilic lower side (figure 2.10).  
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Figure 2.10: Structure of chosen scaffold for current work.  
The different chemical properties of the hydroxyl groups on the steroid nucleus also result in bile acids 
having individual physical and chemical properties that are different from the other members of the bile 
acid family possessing the same sterane core. This makes them interesting building blocks for the design 
of novel antibiotics59,60, anion and cation receptors61–63, artificial ion channels64, scaffold for combinatorial 
chemistry65 and drug vehicles66 to name a few among several others. 
The specific choice of the steroid scaffold as a dimerizing unit for TF models was inspired by several 
reasons such as its known ability to enhance the proteolytic stability of the attached peptides67–69, its 
amphiphilicity70, its conformational properties ensuring correct positioning of the two appended chains71 
and its potential to increase cellular uptake and bioavailability68. 
 
In our specific case, we needed to ensure that the scaffold can perform a function similar to that of the 
leucine zipper, induces helicity to the basic region next to ensuring the correct distance between the 
peptides. We chose deoxycholic acid as a starting template for the attachment of the DNA-binding peptides 
as we envisaged it could perform this function perfectly72. Deoxycholic acid contains two hydroxyl groups 
at the C3 and C12 positions in an α-stereochemistry and can provide a rigid framework for the directional 
orientation of the peptides. The distance between  C3 and C12 is 7-8 Å73, which ensures sufficient distance 
for the anchoring of peptides which should then perform an insertion into the DNA units of the major 
groove. From a synthetic point of view, deoxycholic acid allows the synthesis of peptides via a solid-phase 
strategy due to the carboxylic acid functional group at C24. This can be connected to a solid support leaving 
the C3 and C12 positions for peptide synthesis. Synthesis on solid phase allows for an easy purification by 
simply washing the resin after a coupling reaction.  
The difficult step in the whole process was the design of a derivative of deoxycholic acid in order to obtain 
an orthogonally protected Alloc, Boc-diamino scaffold for further decoration via amide bonds48,74 (figure 
2.11). Esterification of deoxycholic acid at the natural hydroxyl functions was not suited for automated 
solid-phase procedures, due to the slow rate of the reaction. Moreover, esterification reaction conditions 
are neither suited nor optimized for automatic synthesizers thus far. In addition, the intrinsic lability of the 
ester moiety could possibly prevent further elaboration of extended or complex peptide assemblies since 
repetitive treatment with peptide coupling reagents could result in premature cleavage and/or side reactions. 
Therefore, emphasis was put on the replacement of the hydroxyl by amino functionalities for the synthesis 
of peptidosteroid conjugates75–77. 
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The first steps towards the synthesis of diamine scaffolds were performed by the group of Davis in the 90s. 
They performed the conversion of cholic acid to 3α-NHAlloc, 12αNHBoc-cholate in 11 steps with an 
overall yield of 27 %. The synthesis started with the protection of the carboxylic acid. Prior inversion of 
the hydroxyl group at C3 allowed the selective oxidation of the hydroxyl group at C12 to a ketone, which 
was followed by the re-inversion of the alcohol at C3. Oxyme formation and further two step reduction 
(first with H2/PtO2 and then with Zn/AcOH) led to the boc protected amine. Mesylation of the OH at C3 
followed by nucleophilic substitution with NaN3 allowed the conversion to amine by final reduction of the 
azide with H2/PtO2. Protection of the amine with allyl chloroformate allowed the obtention of the desired 
3-NHAlloc, 12-NHBoc steroid scaffold. 
In our group, a shorter and higher yielding synthetic route towards an orthogonally protected diamine 
scaffold was developed during the PhD work of Dieter Verzele48,78, together with the first attempts in the 
OBCR group on the miniaturization of TFs. This started in 2007 with the simplification of a member of the 
helix-loop-helix zipper (b-HLH-ZIP) family, the cMyc-Max oncoprotein79. For this purpose, he used 
deoxycholic acid as a template. The synthesis was initiated by the oxidation of alcohols at C3 and C12 to 
the formation of the corresponding diketone. Oxime formation and further reduction with sodium76 in n-
PrOH afforded the diamine deoxycholate scaffold. Further selective alloc protection of the amine at C3 
required tedious purification steps prior to the protection of the amine at C12 with boc. Final hydrolysis of 
the propyl ester at C24 generated the desired scaffold (figure 2.11) 
 
Figure 2.11: Double modification of the C3 and C12 to obtain a diamino derivative of cholic acid. Modification.  
The conjugation of the basic region peptides to a steroid nucleus was achieved, but the final compound 
showed no DNA binding properties. Molecular visualization of the protein confirmed that the direct 
attachment of the α-helices led to an abrupt truncation of the construct. As a result of this, no insertion of 
both peptides simultaneously into the major groove could take place due to the rigidity of the conjugate 
which in turn hampered α-helix formation. Based on this work we concluded the need for spacers between 
the steroid moiety and the basic region peptides for subsequent designs (chapter 5). 
Since the cMyc-Max was a considerably more complicated TF to mimic the project was continued by 
choosing the bZip Leucine Zipper as a model TF rather than the cMyc-Max. For this purpose, during the 
PhD of Lieselot Carrette80, a mimic of the bZIP Leucine Zipper GCN4 TF was designed, synthesized and 
tested for DNA recognition. The synthesis route was based on solid phase linear coupling of the amino 
acids forming the basic region GCN4 onto a deoxycholic acid scaffold derivative attached to a solid support. 
Spacers were also incorporated between the scaffold and the first residue of each peptide chain to alleviate 
the rigidity imposed by the steroid nucleus for the first coupling and to give the final construct a certain 
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degree of flexibility, as was previously demonstrated necessary on the bHLH models79. In view of the 
expected difficulties for the linear synthesis of two such long peptide chains at the cholic acid scaffold, 
coupling reactions were carried out under microwave irradiation. The N-terminus was capped with 4-
acetamido-benzoic acid as UV active moiety for HPLC monitoring. After cleavage from the resin by UV 
irradiation and deprotection of the side chains, the final construct was purified by RP-HPLC. Due to the 
highly complex linear nature of the synthesis, the final product could not be obtained in high purity. The 
product obtained after purification was subjected to an EMSA anyway to check its DNA binding affinity. 
A band corresponding with the DNA-peptide complex formation was obtained despite the low purity of the 
construct encouraging us to pursue this project. Due to the impurities of the final product, however, 
smearing bands were observed (figure 2.12). 
 
Figure 2.12: Final construct, HPLC trace (Jupiter C4 300Å in 0-100% ACN in 15 min) and EMSA for the first 
generation dipodal peptidosteroid model. 
In conclusion, although the linear synthesis approach was successful, the low yield, extended synthesis 
route and poor purity of obtained compound led us to develop a convergent strategy for the incorporation 
of the peptide basic regions onto the bile acid-based scaffold. 
2.8.2 Artificial dimerization via a steroid scaffold 
As previously observed79, spacers between the steroid nucleus and the peptides are mandatory for DNA 
binding recognition. These linkers should be bi-functionalized: One end to ensure the coupling to the amine 
functionalities of the scaffold and the other end to conjugate the peptides. Due to the versatility of click 
chemistry in peptide bioconjugation, we decided to explore the use of the Copper-Alkyne-Azide-
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Cycloaddition (CuAAC) as the strategy for the appendage of the DNA-binding peptides to the scaffold. For 
this reason, one end of the spacers contains a carboxylic acid and the other end contains an alkyne or azide 
functionality. The geometric, steric and electronic properties of the 1,2,3-triazole resemble a trans-amide 
bond while also affording resistance to enzymatic degradation47,81–83, hydrolysis and oxidation, making it 
an attractive heterocyclic moiety to replace unstable linkers under physiological conditions in biologically 
active compounds. In addition, successful replacement of two amino acids in α-helical peptides by a triazole 
unit has been shown to not significantly influence the secondary peptide structure47. To date, the triazole 
has only been used once to assemble an apolar tripeptide onto bile acid scaffolds84 , despite the increasing 
interest of these constructs in diverse applications such as HIV inhibitors85,86 and immunogens for vaccine 
development87.  To our knowledge, long polar peptides have not been assembled on bile acid scaffolds in 
this manner due to the highly challenging nature of the conjugation when unprotected amino acid side 
chains are present. Although different synthetic conditions were applied, the planned synthetic route could 
not be performed.  
 
 
 
Figure 2.13: Scheme of the convergent synthesis route on solid phase towards the final dipodal peptidosteroid 
conjugate. The Aha term is derived from Azidohomoalanine. i) 20% TFA/DCM, 2h, rt. ii) Pentynoic acid, PyBOP, 
DIPEA, DMF, 4h rt. iii) Cu(I), DMF (different conditions). iv) Alloc deprotection. Pd(PPh3)4, Bu3SnH, morpholine, 
DCM 2h rt. v) Pentynoic acid, PyBOP, DIPEA, DMF, 4h rt. vi) Cu(I), DMF (different conditions). vii) UV irradiation. 
viii) TFA/TIS/H2O (95:2.5:2.5) 3h, rt and precipitation in cold ether. 
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The first step of the synthesis is the coupling of the scaffold to a solid support by using the carboxylic acid 
at C24, performing the coupling twice with HATU (1-[Bis(dimethylamino) methylene]-1H-1,2,3-
triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate). The solid support is pre-equipped with the Holmes 
photosensitive nitroveratryl-based linker88 and an aminomethyl benzoic acid moiety using PyBOP 
(benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate) as coupling reagent. These 
moieties ensure a combination of sufficient reactivity and adequate UV-sensitivity for HPLC monitoring. 
UV irradiation as an orthogonal and mild cleavage protocol allows the semi-online monitoring of the 
reaction (figure 2.14). 
 
 
 
Figure 2.14: Scheme of the functionalization of the solid support with the photolabile linker, the active UV moiety 
and the scaffold. i) PyBOP, DIPEA, DMF, 3h, rt. ii) 20% piperidine/DMF 2 x 30 min. iii) PyBOP, DIPEA, DMF, 3h, 
rt. iv) 20% piperidine/DMF 2, 5, 15 min. v) HATU, DIPEA, DMF, 2 x 4h rt. 
 
After the attachment of the scaffold to the solid support, a PyBOP mediated coupling of the linker to the 
C12 position is performed. Although the final construct is a homodimeric one (peptide sequences at C12 
and C3 are equal), the synthesis can not be carried out in parallel due to the difference in reactivity of the 
amines at C3 and C12. The C12 position is more sterically hindered, and thus reactions proceed faster at 
C3 and increase the sterical hinderance of position C12 for further reactions. Boc deprotection (20% TFA 
(trifluoroacetic acid) in DCM (dichloromethane)) affords the first anchoring point for the linker, 
functionalized with either an alkyne or azide. Pentynoic acid and 5-azidopentanoic acid were chosen as 
spacers. 
Chapter 2: Recognition of large molecules containing phosphates 
 
40 
 
 
The basic region peptides were synthesized on 2-chlorotrityl chloride polystyrene resin. The first residue at 
the C-terminus bearing an alkyne or azide functionality at the side chain (Fmoc-propargylglycine-OH 
(Fmoc-Pra-OH) or Fmoc-azidohomoalanine-OH (Fmoc-Aha-OH)) is manually attached using PyBOP. 
Fmoc-Gly-OH is subsequently coupled manually to avoid epimerization at the first residue coupling. The 
following residues were coupled using an automated peptide synthesizer using Fmoc/tBu SPPS with HBTU 
(N,N,N′,N′-Tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate) as coupling reagent 
and 20-40% piperidine in NMP (N-methyl-2-pyrrolidone) for Fmoc deprotection. The N-terminus is capped 
with 4-acetamido-benzoic acid for the synthesis progress monitoring by UV in HPLC. Cleavage from the 
solid support is performed with AcOH/TFE/DCM (acetic acid/trifluoroethanol/DCM) (1:1:8) in order to 
keep the peptide protected during subsequent modifications at C3 (figure 2.15). After cleavage, the resin is 
washed with cleavage cocktail and the peptide is precipitated in cold ether (-20°C) by centrifugation at 0-
4°C. The peptides were analyzed by RP-HPLC, LC-MS and/or MALDI. The peptide is not further purified 
and used as such for subsequent reactions. 
 
 
Figure 2.15: Synthesis route towards an azide-functionalized GCN4 basic region peptide. i) Fmoc-Aha-OH, DIPEA, 
Dry DCM, rt, 3h. ii) MeOH/DIPEA, DCM, 3 x 2 min. iii) 40% piperidine in DMF 2 x 30 min. iv) Fmoc-Gly-OH, 
PyBOP, DIPEA, Dry DMF, rt, 2h. v) automated synthesizer. HBTU, DIPEA, 2 x 40 min; 20% piperidine in DMF, 2, 
5, 25 min. vi) AcOH/TFE/DCM (1:1:8), 4h, rt. 
 
For the conjugation of the peptide to the solid support bearing the complementary functionalities for the 
CuAAC, a broad range of conditions were attempted (figure 2.16). Different solid supports, catalyst, 
reductants, solvent systems, bases and additives were tried. The reaction was performed at room 
temperature and at different temperatures ranging from 40°C to 80°C under MW irradiation. Unfortunately, 
Chapter 2: Recognition of large molecules containing phosphates 
41 
 
under none of these conditions, the desired peptidosteroid conjugate was obtained. The unsuccessful results 
can be explained by the interaction of the peptide chain with the resin and the sterical hindrance imposed 
by the solid support to allow the peptide to reach the C12 position.  
 
 
Figure 2.16: Diverse conditions used for CuAAC. 
 
2.8.3 Rethinking the strategy: going back to the roots 
 
After several trials to achieve the conjugation on solid support, we realized that synthesis on a solid phase 
was not feasible. However, as the only advantage of solid phase was to facilitate the final purification of 
the conjugate, we believed there was more to gain by switching to solution phase. As the presence of the 
resin impedes the attachment of the peptide to the scaffold, a solution phase strategy seemed a more suitable 
method for the conjugation of long peptides to an amphiphilic building block. Additionally, it presents 
several other advantages:  
 
 The expensive orthogonally protected diamino scaffold is not required, as appendage of the 
peptides at both positions can be achieved in parallel and by ester bond formation. 
Additionally, deoxycholic acid is cheap and commercially available.  
 There is no need for excess of reagents, especially the peptide, to ensure completion of the 
reaction. 
 Synthesis could be scaled up with more ease as compared to solid phase.  
 Reaction monitoring by HPLC is possible. Moreover, direct analysis of the reaction 
mixture can be accomplished by MALDI and RP-HPLC. 
 
CuAAC
TentaGel 
PEGA 
TentaGel HS
CuSO4
CuSO4·5H2O 
CuBr  
Cu(OAc)2 CuI
Sodium 
Ascorbate, 
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Encouraged by these benefits, we designed a new synthetic route entirely based on reactions in solution. 
Deoxycholic acid is commercially available and can be used directly as a scaffold for peptide dimerization 
of the GCN4 basic region. Indeed, the alcohols can be esterified with the linkers to provide a dialkyne or 
diazide scaffold, after protecting the carboxylic acid functionalities. Following this route, we designed and 
synthesized four different scaffolds based on deoxycholic acid as a starting material (figure 2.17). They 
differ amongst each other with respect to the spacers between the peptide and the steroid skeleton, which 
have different lengths, rigidities and functionalities. This provided a means of evaluating the factors that 
affect recognition of DNA in these synthetic transcription factor models. For this purpose, deoxycholic acid 
was modified at the alcohol positions by attachment of linkers. The linkers chosen for the study were: 
pentynoic acid, azido glycine, 4-azidomethyl-benzoic acid and (N-propynoylamino)-p-toluic acid (PATA). 
The PATA linker has been specifically developed for bioconjugation purposes as an active alkyne for 
preparation of peptide-oligonucleotide conjugates via CuAAC. Funtionalization of the steroid nucleus was 
performed by Steglich esterification, affording final scaffolds (2.17, 2.18 & 2.19). In case of the PATA as 
linker (2.21), the diamino derivative of deoxycholic acid proved necessary for the coupling of the linker, as 
esterification gave rise to byproducts due to high reactivity of the alkyne. 
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Figure 2.17: Synthetic routes towards deoxycholic acid-based scaffolds. i) DBU, BnBr, DMF 50°C, 24h. ii) Pentynoic 
acid, DCC, DMAP, DCM 16h, rt. iii) Boc-Gly-OH, DCC, DMAP, DCM 16h, rt. iv) 20%  TFA/DCM, 2h, rt. v) K2CO3, 
CuSO4·5H2O, Imidazole-1-sulfonyl azide·HCl, MeOH:THF (1:1) 3h, rt. vi) 4-Boc-aminomethyl benzoic acid, EDC, 
DMAP, DCM/THF (1:1) 16h, rt. vii) 20% TFA/DCM, 2h, rt. viii) K2CO3, CuSO4·5H2O, Imidazole-1-sulfonyl 
azide·HCl, MeOH:THF (1:1) 3h, rt. ix) HATU, DIPEA, DMF, 16h, rt. 
 
To obtain peptides of higher purity they were synthesized using a Rink-Amide Chemmatrix resin, which is 
a pure PEG resin, instead of a Polystyrene based resin (figure 2.18). The first residue at the C-terminus 
bearing an alkyne or an azide functionality at the side chains (Fmoc-Pra-OH or Fmoc-Aha-OH) was 
manually attached using HBTU. Fmoc-Gly-OH was subsequently coupled manually to avoid 
epimerization. The following residues were coupled in an automated synthesizer using Fmoc/tBu SPPS 
with HBTU as coupling reagent and 20-40% piperidine in NMP for Fmoc deprotection. The N-terminus 
was capped with 4-acetamido benzoic acid to allow visualization of the peptide when monitoring the click 
reaction by UV in HPLC. Cleavage from the solid support was performed with TFA/TIS/H2O 
(trifluoroacetic acid/triisopropylsilane/water) (95:2.5:2.5), 4h. After cleavage, the resin was washed with 
the cleavage cocktail and peptide was precipitated in cold ether (-20°C) by centrifugation at 0-4°C. The 
peptides were analyzed by RP-HPLC/LC-MS and/or MALDI. The peptide was not purified further and was 
used as such for the click reaction. 
 
 
 
Figure 2.18: Synthesis route towards alkyne and azide-functionalized GCN4 basic region peptide and crude HPLC 
chromatograms (Jupiter C4 300Å, 0-100% ACN in 15 min). i) Fmoc-Pra-OH or Fmoc-Aha-OH, PyBOP, DIPEA, Dry 
DMF, rt, 1h. ii) 40% piperidine/DMF 2 x 30 min. iii) Automated synthesizer. HBTU, DIPEA, DMF 1h. 20% 
piperidine/DMF 2, 5, 15 min. iv) TFA/TIS/H2O (95:2.5:2.5) 3h, rt. v) Precipitation in cold ether. 
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2.8.4 Conjugation 
The GCN4 basic region peptides 2.27 and 2.28, functionalized with an alkyne or with an azide respectively, 
were then attached to the central steroid core, affording four different transcription factor mimics. After a 
laborious optimization of the reaction conditions, the cycloaddition of the peptides to the scaffold via 
CuAAC was performed in a mixture of DMSO (dimethylsulfoxide)/H2O (≈ 3:1), in order to decrease the 
aggregation of the peptide due to the high polarity of DMSO. Given the hydrophilic nature of the 
deprotected peptide and the hydrophobic nature of the scaffold, the DMSO/H2O combination was found to 
be optimum for the CuAAC reaction. Moreover, it is known that polar solvents prevent aggregation of 
copper species. As a catalyst, Cu(CH3CN)4PF6 gave the best results. A high excess of catalyst was needed 
probably due to the complexation of copper with the side chains of the peptide, containing nitrogen 
functionalities especially the amine of lysine and the guanidinium group of arginine. Unexpectedly, an 
excess of scaffold was required for the completion of the reaction, the dipodal construct still being favored 
over the monopodal one under these conditions, The use of reductants or additives was not necessary, 
commonly used to prevent oxidation of the catalyst during the reaction. The reaction was complete after 3 
hours at room temperature under argon (figure 2.19). Final purification of the reaction mixture was achieved 
via RP-HPLC. 
 
Figure 2.19: crude RP-HPLC for the reaction mixture after 3h of compounds 2.29 (top) and 2.32 (botton). Remaining 
scaffold 2.17 and 2.19 is visible at 18.7 and 19.6 min respectively. Final conjugates 2.29 and 2.32 are present at 13.364 
and 13.915 min respectively. (Jupiter C4 300Å; 0-100% ACN in 15 min). 
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Apart from the above mentioned advantages of triazoles, the reaction conditions are compatible with the 
presence of all unprotected amino acids in the sequence. It has been reported that sodium ascorbate can lead 
to covalent modification when residues like lysine and arginine are present, to protein aggregation due to 
the formation of a dehydroascorbate byproduct and other reactive oxygen species generated by copper when 
sodium ascorbate is used as a reductant89,90. No side effects were observed in this case as no reductant is 
used in the conjugation. Through this work we have optimized the conditions for this conjugation which 
could be used in the future to synthesize constructs involving the assembly of peptides on a bile acid 
scaffold. 
Purification of final constructs after completion of the reaction was possible via RP-HPLC (figure 2.20), 
affording compounds 2.29, 2.30, 2.31 and 2.32 in high purity for DNA binding studies. 
 
Figure 2.20: Structure of final constructs 2.29, 2.30, 2.31 and 2.32 and their RP-HPLC chromatograms after 
purification (Jupiter C4 300Å, 0-100% ACN in 15 min). 
2.9 Concentration determination via ERETIC-NMR  
Quantification of both DNA and peptide components is an essential step in the EMSA process. 
Concentration of DNA strands were provided by the commercial source. On the other hand, concentrations 
of final peptidosteroid conjugates 2.29, 2.30, 2.31 and 2.32 needed to be determined accurately, as minor 
errors on concentration determination can compromise the study of DNA binding capability. Current 
electrophoretic evaluation was originally attempted via weighed amounts of isolated compounds. Because 
of the unpredictable salt formation with trifluoroacetic acid during cleavage and deprotection steps, and 
obvious error of the balance when less than 1 mg was weighed, alternative strategies were considered. 
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Despite the broad use of UV-spectroscopy for concentration determination, it was discarded as method to 
calculate the concentration due to the lack of a moiety with a well-known ε-value in the presence of the 
benzyl ring in the scaffold. To improve reliability of present data, 1H-NMR spectroscopy was exploited as 
analytical method for the quantification of the concentration. The ERETIC (Electronic REference To access 
In vivo Concentrations) method was used for determining absolute concentrations in a high-resolution 500 
MHz NMR spectrometer. Introduced by Akoka et al. in 199591, ERETIC relies on an electronically-
generated reference signal. Once calibrated against an external standard solution, determination of absolute 
sample concentration was straightforward via direct proportionality. Description of technical details is 
beyond the scope of present work. Well-resolved aromatic signals from the benzyl ring at the C24 of the 
scaffold, capping moieties and 5-H triazole were used to quantify final compounds. 1H-NMR was 
performed in D2O and the aromatic region was amplified for better integration due to the low concentration 
of the sample. The benzyl rings at the N-termini of the peptides generates a doublet of doublets at 7.7 ppm 
and 7.5 ppm, each integrating by 4 protons. The two 5-H protons from the triazoles appear in the same shift 
as the doublet at 7.7 ppm of the benzyl ring (figure 2.21). The correlation between the integral values and 
the reference sample gave the concentration of the sample: 34 µM. 
 
Figure 2.21. 1H-NMR (D2O, 500 MHz) of the aromatic region of compound 2.29 an integration of the signals 
corresponding to the 4-acetamido-benzoamide moieties at the N-termini of the peptides. 
2.10. DNA Binding studies using Electrophoretic Mobility Shift Assay 
 2.10.1 EMSA Protocol 
The protocol is described in section 10.4. 
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DNA binding affinities of mimics 2.29, 2.30, 2.31 and 2.32 were evaluated using an Electrophoretic 
Mobility Shift Assay (EMSA). Qualitative study of the interaction of mimics was based on titration of a 
DNA sequence containing the ATF/CREB recognition site (5’ – CGG ATG ACG TCA TTT TTT TTC – 
3’) and Random (5’ – GCG CGA GAA GGA AAG AAA GCC GG – 3’) at a concentration of 0.167 µM 
in all the wells with increasing concentrations of compounds 2.30, 2.31 and 2.32, lanes 1-10 contained 
respectively 0, 0.167, 0.501, 0.668, 0.751, 0.835, 1.002, 1.169, 1.336, 1.67 µM. The range of concentration 
of the mimic 2.29 in the wells were optimized for better visualization of the binding, and lanes 1-10 
comprised respectively 0, 0.04, 0.12, 0.17, 0.20, 0.22, 0.26, 0.30, 0.35, 0.44 µM. As shown in figure 2.21, 
constructs possessing an aliphatic spacer 2.29 and 2.30 showed DNA affinity, while models with aromatic 
linkers 2.31 and 2.32 did not show a shifted band corresponded to the formation of peptide-DNA complex. 
The fact that a band of the dsDNA did not appear in the gel at the lanes in which higher concentration of 
peptides were added, was due to the unspecific interaction of the peptide with the DNA. Because of the 
electrostatic interactions that occur between the peptides and the dsDNA, the ratio m/z is increased due to 
an increase in the mass and a reduction in the total charge thereby resulting in their aggregation in the wells.  
 
Figure 2.22: EMSA titration of the four constructs to the CRE binding site stained with SybrGold. 
In order to check specificity, compounds 2.29 and 2.30 were tested with the random dsDNA sequence. 
Concentration of DNA in the wells was 0.167 µM and the concentration of the peptide 2.29 in lanes 1-10 
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were 0, 0.04, 0.12, 0.17, 0.20, 0.22, 0.26, 0.30, 0.35, 0.44 µM respectively, and for peptides 2.30, 2.31 and 
2.32 were  0, 0.167, 0.501, 0.668, 0.751, 0.835, 1.002, 1.169, 1.336, 1.67 µM respectively (figure 2.22).  
 
 
Figure 2.23: EMSA titration of binding constructs to the random sequence stained with SybrGold. 
 2.10.2 32P-Radiolabelled EMSA protocol 
The protocol is described in section 10.5. 
For the quantification of the affinity, 32P-radiolabelled duplex DNA sequences containing the ATF/CREB 
recognition site and the random sequence were used, with increasing concentrations of compounds 2.29, 
and 2.30. From the electrophoresis experiments, we can confirm that compound 2.29 shows higher DNA 
affinity than 2.30. Calculation of the Kd values is ongoing. Based on this we can conclude that aromatic 
rigid linkers do not allow the GCN4 basic region to adopt the correct orientation to bind the major groove 
and a flexible linker can favor the correct positioning of the peptides. Moreover, as compound 2.29 binds 
at lower concentration than compound 2.30, a longer, more flexible linker seems to be favorable for 
enhanced binding. 
Peptides: 10 µL stock solutions (10x) were prepared in MiliQ water (0, 0.5, 0.625, 0.75, 0.875, 1, 1.125 
and 1.25 µM). 
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Figure 2.24. EMSA titration of the dipodal peptidosteroid conjugates 2.29 and 2.30 to the 5’-labeled 32P-CRE 
sequence (5’ – CGG ATG ACG TCA TTT TTT TTC – 3’) at 5 nM: First lane in all the gels: pyrimidine strand. Lanes 
2-9 contain peptide concentrations of 0, 0.05, 0.0625, 0.075, 0.0875, 0.1, 0.1125 and 0.125 µM for 2.29 and 2.30. 
 
2.11 CONCLUSION 
In summary, we have synthesized major groove DNA binders based on peptidosteroid conjugates. The 
study of the influence of the spacer between the scaffold and the DNA recognition unit allowed us to further 
understand the characteristics that have an effect on DNA interaction. Our synthetic protocol was initially 
based on bioconjugations on solid phase. Due to the negative results following this synthetic route, we here 
describe the disadvantages for the attachment of peptides to a solid-supported molecule. Therefore we 
considered other alternatives and we here propose an optimized CuAAC protocol for the conjugation of 
deprotected peptides to a steroid nucleus in solution phase, allowing the application of click chemistry for 
the conjugation of long peptides to non-peptidic counterparts 
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CHAPTER 3 
 
ARTIFICIAL DIMERIZATION VIA CYCLODEXTRIN SCAFFOLDS 
 
Encouraged by the outcome of our peptidosteroid conjugates with regard to the synthesis and the influence 
of the linker on the DNA recognition ability, we envisaged the exploration of other structural features such 
as the distance between the C-termini of both basic regions in artificial TF models. Cyclodextrins, like 
cholic acid, also possess a rigid structure and therefore their dimensions are fixed and well-known. The 
conversion of the primary alcohols at the rim to azides allows the appendage of basic region peptides by 
CuAAC. By conjugation of the GCN4 basic region peptides to α, β and γ-cyclodextrin derivatives, the 
influence of the dimerization distance upon DNA recognition was investigated. 
 
3.1 Structure of cyclodextrins 
Cyclodextrins are natural products obtained from starch during an enzymatic degradation carried out by 
cyclomaltodextrin glucanotransferase and α-amylase among others. Cyclodextrins are cyclic glucose 
oligosaccharides. They consist of α-D-glucopyranose units linked via an α-1,4 bond, forming a lipophilic 
central cavity due to the skeletal carbons and the oxygens of the glucose units. They have, in addition, a 
hydrophilic outer surface. Cyclodextrins have the shape of a truncated cone due to the chair like 
conformation of the glucopyranose units. Therefore, the hydroxyl groups are oriented towards the exterior 
of the cone, with the secondary hydroxyl groups of the sugar residues at the wider edge of the cone and the 
primary hydroxyl groups at the narrower edge.  
Most common cyclodextrins contain 6 to 8 units of glucose monomers in a ring. They are named as α 
(alpha)-cyclodextrin, β (beta)-cyclodextrin and γ (gamma)-cyclodextrin respectively (figure 3.1). 
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Figure 3.1: α (alpha)-cyclodextrin, β (beta)-cyclodextrin and γ (gamma)-cyclodextrin respectively in their simplest 
2D form. 
3.2 Applications of Cyclodextrins 
The basis of cyclodextrin production was established at the end of the 19th century92 and beginning of the 
20th century93. The first patent on complex formation with cyclodextrins was registered in 195394. Due to 
the high production costs, only a small scale production of cyclodextrins was possible, hampering the 
industrial exploitation of cyclodextrins in the pharmaceutical industry. It was not until the 70s95,96, when 
advancements in synthetic technologies allowed the production of pure α, β, γ-cyclodextrins with affordable 
production costs. Due to the unique structure of cyclodextrins, they can form inclusion complexes with 
appropriately sized hydrophobic molecules. Consequently, these carbohydrates are mainly used to increase 
the aqueous solubility, stability, and bioavailability of drugs. But they can also be used, for example, to 
convert liquid drugs into microcrystalline powders, prevent drug-drug or drug-additive interactions, reduce 
gastrointestinal or ocular irritation, and reduce or eliminate unpleasant taste and smell of drugs by forming 
a complex with CDs. Recent advances in the chemistry of cyclodextrins have allowed the development of 
cyclodextrin conjugates with enhanced potential as drug carriers97–101. Nevertheless, peptide chemistry has 
also benefited from the properties of CDs as peptide-cyclodextrin conjugates have been previously 
developed for a broad range of applications, such as drug release systems102,103, enantioselective ester 
hydrolysis catalysts104, and for the creation of new types of chemosensors105 and enzyme mimics106. 
Although the system has been intensively studied, we here show for the first time the possibility of selective 
dsDNA binding by peptide-cyclodextrin conjugates.  
3.3 Cyclodextrin-peptide conjugates as DNA binders 
In chapter 2, we explained the importance of DNA binding models to unravel the code followed by proteins 
which enable them to bind DNA sequence-selectively and their uses in gene therapy. We also presented the 
influence of the spacer between the dimerization unit and the basic region peptides on the DNA binding 
capacity of the final peptidosteroid conjugates. Encouraged by these results, in this chapter, we have 
attempted to discover other factors that influence DNA recognition in artificial TF models. Also, we further 
elucidate the requirements that a DNA binding model should possess to bind DNA in the correct, sequence 
specific manner. In this chapter, we have scanned and evaluated the importance of the distance between the 
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two dimerized peptides. For this purpose, we substituted the dimerization domain of the GCN4 protein by 
a scaffold in which the geometry could be accurately regulated. Due to the varying sizes of different natural 
cyclodextrins, we were able to control the distance between basic region peptides by the use of α, β and γ-
cyclodextrins. Cyclodextrins were of special interest to us as we had quickly gauged the possibility of 
mimicking the dimerization domain of bZIP leucine zipper TF using cyclodextrins since the diameter of 
the primary rim almost equals the width required to append the peptides which bind to the major groove of 
the DNA. From a synthetic point of view, their chemical reactivity allows the selective functionalization of 
hydroxyl functionalities in two opposite positions at the primary rim for the dimerization. 
Attachment of the basic region peptide of the GCN4 protein onto opposite positions of the primary rim of 
the cyclodextrins allows the control of the dimerization distance. In addition, the rigid structure of 
cyclodextrins and the orientation of the functionalities of the primary rim ensures the correct position of the 
basic region peptides and facilitated the anchoring on the major groove. Moreover, it has been observed 
that cyclodextrins improved the bioavailability of the attached peptides107. 
Based on the diameter of the primary rim of the α, β and γ–cyclodextrins which are 5.7, 7.8 and 9.5 Å 
respectively108 (figure 3.2), three different peptide-cyclodextrin conjugates were synthesized, keeping in 
mind that the width of the major groove is 11.2 Å.  
 
Figure 3.2: Characteristics of the cyclodextrin structure. 
3.3.1 Synthesis of the cyclodextrin derivatives 
Before the use of our well established click chemistry, the CDs need to be functionalized by means of 
chemical modifications. One of the most useful functionalizations is the introduction of an azide group in 
the “cyclostructure” by substitution reactions of the hydroxyl groups. Hence, the obtained azido-CDs are 
good candidates for our click chemistry and for attaching the GCN4 basic region peptides. In view of the 
expertise of the group of Tomas Kraus at the Academy of Sciences of the Czech Republic, Prague, on the 
selective modification of cyclodextrins, we established a collaboration to gain access to the required 
modified CDs as starting materials. Starting from 6I,6IV-dideoxy-6I,6IV-dibromo-cyclodextrins109, direct 
nucleophilic substitution with NaN3 afforded 6I,6IV-Dideoxy-6I,6IV-diazido-α-cyclodextrin, 6I,6IV-Dideoxy-
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6I,6IV-diazido-β-cyclodextrin and 6I,6V-Dideoxy-6I,6V-diazido-γ-cyclodextrin in 90%, 83% and 70% yield 
respectively (figure 3.3). These compounds were kindly provided to us for further derivatisation. 
 
 
 
Figure 3.3: Chemical structure of diazido-cyclodextrin derivatives 3.6, 3.7 and 3.8 and 3D representation of 6I,6IV-
diazido-α-cyclodextrin, 6I,6IV-diazido-β-cyclodextrin and 6I,6V - diazido-γ-cyclodextrin. 
3.3.2 Synthesis of basic region peptides 
The GCN4 DNA recognition peptides D226-Q248 were synthesized on solid phase. Modifications of the 
peptide sequence were performed at the C-terminus. An alkyne was incorporated for the CuAAC 
conjugation to cyclodextrin. In addition, as we have previously shown in chapter 2, correct length and 
flexibility of linkers are a must regarding DNA recognition in artificial TF models. Through molecular 
modelling we inferred that direct conjugation of the basic region peptides to the cyclodextrins would not 
afford the desired conjugates. Direct conjugation would instead result in the peptide not adopting the proper 
conformation for DNA binding in the major groove due to a lack of flexibility. Thus, incorporation of a 
spacer between cyclodextrin-based dimerizer and peptide was once again mandatory for optimal sequence-
selective DNA binding. The length and flexibility that pentynoic acid afforded to the previous 
peptidosteroid conjugate 2.29 was mimicked in the peptide-CD conjugates by the incorporation of γ-
aminobutyric acid as a second residue at the C-terminus of the peptide. In order to check the purity of the 
peptide after cleavage and deprotection and to follow the reaction with the cyclodextrin by RP-HPLC, the 
N-terminus was capped with 4-acetamido-benzoic acid as UV absorption moiety (figure 3.4). 
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Figure 3.4: Modification of the GCN4 peptide for suitable attachment to CDs. 
Rink-amide ChemMatrix resin was chosen as solid-support for peptide synthesis. Couplings were 
performed using HBTU and DIPEA. Final deprotection and cleavage was achieved with 95% TFA, 2.5% 
H2O and 2.5% TIS. Precipitation in cold Et2O and analysis on MALDI and RP-HPLC showed that the 
desired peptide was obtained with sufficient purity for further conjugations. 
 
Figure 3.5: Synthesis scheme and HPLC trace of the crude modified GCN4 peptide 3.5 for conjugation to the CDs 
(Jupiter C4 300Å, 0-100% ACN in 15 min). i) Fmoc-Pra-OH, HBTU, DIPEA, Dry DMF, rt, 1h. ii) 40% 
piperidine/DMF 2 x 30 min. iii) Fmoc-GABA-OH, HBTU, DIPEA, Dry DMF, rt, 1h. iv) 20% piperidine/DMF 2, 5, 
15 min. v) Automated synthesizer. HBTU, DIPEA, DMF 1h. 20% piperidine/DMF 2, 5, 15 min. vi) TFA/TIS/H2O 
(95:2.5:2.5) 3h, rt. vii) Precipitation in cold ether. 
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3.3.3 Click with Cyclodextrins  
Before the development of click-chemistry, different strategies for the formation of a covalent link between 
various ligands and cyclodextrins have been reported. Glycosilation, formation of thiourea or amide 
bridges, amidation and nucleophilic substitutions were investigated for the formation of cyclodextrin-based 
conjugates110,111. More recently, cyclodextrin conjugation via CuAAC has been investigated in depth since 
its discovery by the Meldal and Sharpless research groups82,112 in 2001. Translation of optimized protocols 
and conditions from organic chemistry to supramolecular chemistry allowed the synthesis of a large variety 
of cyclodextrin-based conjugates, and therefore CuAAC has been documented as a high yielding and 
kinetically fast reaction for the preparation of carbohydrate conjugates. CuAAC with cyclodextrins was 
first introduced for biological applications in 2007 for the synthesis of different glycoconjugates as 
synthetic activators in cell adhesion, stimulation of monocytes and for the elaboration of a controlled drug 
delivery system in the oral cavity113,114. Other groups have applied CuAAC for the decoration of 
cyclodextrin with polymers115 and for the synthesis of nontoxic drug delivery carrier systems based on 
stable helical polypeptide-grafted cyclodextrin bioconjugates116. 
We report here for the first time the application of cyclodextrin conjugates for sequence-specific DNA 
recognition and the optimized conditions for CuAAC of cyclodextrin derivatives with relatively long, 
deprotected peptides (figure 3.6). Inspired by the properties of 1,2,3-triazoles in resembling a trans-amide 
bond and affording resistance to enzymatic degradation47,81–83, hydrolysis and oxidation, it made an 
attractive heterocyclic moiety to replace unstable linkers under physiological conditions in biologically 
active compounds. In addition, successful replacement of two amino acids in α-helical peptides by a triazole 
unit has been shown to not significantly influence the secondary peptide structure47. Moreover, through this 
work we have shown that our conditions can be easily translated to the synthesis of other peptide conjugates 
as the reaction protocol and conditions are similar to the ones reported in chapter 2 for the functionalization 
of steroid-based scaffolds with peptides. DMSO/H2O (≈ 3:1) was used as solvent in the CuAAC of the 
cyclodextrin-based scaffold and the peptide. DMSO was required to dissolve the scaffold, while the peptide 
was quite soluble in water. Moreover, the DMSO/water mixture provided a polar medium to avoid the 
aggregation of the peptide and copper species. As a catalyst, Cu(CH3CN)4PF6 gave the best results as was 
observed for the peptidosteroid conjugate synthesis. Unfortunately, once again a high excess of catalyst 
was needed due to the complexation of copper with the side chains of the peptide, containing nitrogen 
functionalities especially the amine of lysine and the guanidinium group of arginine. As it was previously 
observed, an excess of cyclodextrin derivative was required for the completion of the reaction, and the 
dimer formation was favored over the monomeric one. The use of reductants or additives was not necessary. 
The reaction was stopped after 3 hours at room temperature under argon. Final purification of the reaction 
mixture was achieved via RP-HPLC (figure 3.7). As mentioned in chapter 2, the absence of sodium 
ascorbate as reductant in the reaction mixture avoided side reactions already observed in peptides 
containing lysines and arginines 89,90. 
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Figure 3.6: Click reaction with CD. 
 
Figure 3.7: HPLC traces of crude (A) and final compound 3.6, 3.7 and 3.8 (B) (Jupiter C4 300Å, 0-100% ACN in 15 
min). 
After the synthesis and purification the cyclodextrin derivatives 3.6, 3.7 and 3.8 functionalized with GCN4 
basic region peptides and the dimers were subjected to DNA binding studies.  
3.4 Concentration determination via ERETIC-NMR  
As reported in chapter 2, 1H-ERETIC technique was chosen as method to accurately determine the 
concentration of the samples 3.6, 3.7 and 3.8 for the EMSA study. Aromatic signals from the 4-acetamido-
benzamide moieties at the N-termini and the 5-H of the triazoles were used as signals to estimate the 
concentration of the sample from the reference sample. 1H-NMR was performed in D2O and the aromatic 
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region was amplified for better integration due to the low concentration of the sample. The benzyl rings at 
the N-termini of the peptides generate a doublet of doublets, each integrating for 4 protons (figure 3.8). The 
correlation between the integral values and the reference sample gave the concentration of the sample: 77 
µM. The two protons from the triazole were not well resolved and therefore they were not taken into account 
for the calculations. The same procedure was repeated for both 3.6 and 3.8 compounds, as they present the 
same NMR spectra at the aromatic region. 
 
Figure 3.8. 1H-NMR (D2O, 500 MHz) of the aromatic region of compound 3.7 an integration of the signals 
corresponding to the 4-acetamido-benzoamide moieties at the N-termini of the peptides. 
3.5 DNA binding studies using EMSA 
The DNA binding affinities of mimics 3.6, 3.7 and 3.8 were evaluated using an Electrophoretic Mobility 
Shift Assay (EMSA). Tests were first performed in UGent using non-radiolabelled duplex DNA (figure 
3.9) followed by tests in Karolinska Institute in Sweden using 32P-radiolabelled duplex DNA (figure 3.10 
top). 
The protocol is described in section 10.4. 
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Figure 3.9: EMSA titration of the dipodal peptidocyclodextrin conjugates 3.6, 3.7 and 3.8 from top to botton to the 
CRE sequence (5’ – CGG ATG ACG TCA TTT TTT TTC – 3’). Lanes 1-10: dsDNA (0.167 µM); lanes 1-10: 0, 
0.167, 0.501, 0.668, 0.751, 0.835, 1.002, 1.169, 1.336, 1.67 µM of peptide, and to the Random sequence (5’ – GCG 
CGA GAA GGA AAG AAA GCC GG – 3’); lanes 1’-5’: 0. 0.167, 0.501, 0.668, 1.67 µM of peptide.  
The study was based on the titration of a 32P-radiolabelled duplex DNA sequence containing the 
ATF/CREB recognition site (5’ – CGG ATG ACG TCA TTT TTT TTC – 3’) and Random (5’ – GCG CGA 
GAA GGA AAG AAA GCC GG – 3’) with increasing concentrations of compounds 3.6, 3.7 and 3.8. From 
the electrophoresis experiments, we could calculate KD values of 50 ± 20, 30 ± 20 and 100 ± 60 nM 
respectively, with compound 3.7 showing highest DNA affinity. Unlike in the case of the peptidosteroid 
conjugates, in which we saw that the linker had the potential to completely obstruct sequence-selective 
DNA recognition, the modification of distance between the C-termini did not hinder DNA binding to that 
great an extent, as a band corresponding to the DNA-peptide complex was visible in all the gels of 
cyclodextrin-peptide conjugates. We consider that it only influences the way in which the peptides 
recognize the DNA and the orientation of the side chains of the amino acids towards the nitrogen bases. 
Despite this, the perturbation was not so great as to completely mitigate DNA binding. Previous models 
developed by Morii and Mascareñas possess the same length of the basic region peptides (D226-Q248) and 
therefore are comparable with our systems. The group of Morii developed a system in which the 
dimerization unit was a complex of cyclodextrin and adamantane. Both counterparts were anchored to a 
GCN4 basic region peptide and bind only when dimerized. EMSA studies were performed with < 1 nM 
radiolabelled CRE, obtaining a Kd < 150 nM56. More recent models designed by the group of Mascareñas 
employed a diazobenzene moiety for dimerization, with a Kd < 5 nM using < 1 nM radiolabelled CRE. 
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They also reported the affinity of a disulfide-bridged GCN4 basic region, with a Kd of < 150 nM 
approximately for a DNA concentration of 50 nM117. The latest model consisted on a dual mimic in which 
dimerization arrangement and DNA selectivity was controlled by selected external parameters118. The basic 
region peptides were functionalized with a cysteine and a terpyridine moiety attached to the residues at the 
N- and C- termini of the peptide chain to achieve selective dimerization at both sites. Depending on the 
conditions, the disulfide-based or the metal-terpyridine complex-based dimers were preferred, and different 
DNA sequences could be targeted. By dimerizing the peptide in the presence of Ni2+, the construct was 
bound to the CRE sequence with a Kd of 299±26 nM, using a DNA concentration of 100 nM, ~100 pM 
labeled with 32P. For these 3 last models, it should be noted that the nonionic detergent (NP-40) and BSA 
were used during EMSA, known to decrease aggregation of peptides and proteins and therefore favor the 
interaction with the DNA119,120. A rough comparison thus indicates that our new constructs, apart from 
being synthesized in a straightforward and convergent manner, display comparable binding properties to 
those described in literature. The obtained values are further within the same order of magnitude as those 
calculated for the binding of bacterially expressed GCN4 and synthetic versions thereof. For instance, a 
dimer comprising of a 56mer GCN4 basic region (residues 226-281) also binds CRE in the nanomolar range 
(Kd ~ 12 nM)121–123. No data for the dissociation constant of the natural protein have been reported so far.  
In order to better explain the results obtained from the binding pattern on the gels and the determination of 
the Kd values, we performed a molecular visualization of the dimerization interface of the bZIP GCN4 TF 
obtained by discarding the leucine zipper domain from the crystal structure of the natural protein (figure 
3.10, D). The distance between the C-termini of the basic regions is shown in figure 3.10 at different 
perspectives of the protein-DNA interface, and is found to be 15.052 Å. The Kd values showed that 
derivative 3.7 was the one with the best binding capability to the CRE sequence. Therefore, we consider 
that beta CD is the dimerizer which allows optimal anchoring of the peptides on the major groove of the 
DNA. In the protein the C-termini are placed at a distance of approximately 15 Å. In case of our constructs, 
although the diameter of the primary rim of the cyclodextrins is known (figure 3.10, left), due to the 
flexibility of the linker, the exact distance between the C-termini of the peptides on 3.5, 3.6 and 3.7 could 
not be predicted accurately. However, we observed that increasing or decreasing the distance between the 
attachment points of the peptides by the use of different CD scaffolds results in a deviation of the optimum 
geometry of the system. This is reflected in terms of decreased binding affinity and lower Kds. It should 
also be noted that these results are specific for the basic region GCN4 peptide sequence and the given 
spacers. In case these parameters are varied, different conclusions are expected. 
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Figure 3.10: EMSA titration of the dipodal peptidocyclodextrin conjugates 3.6, 3.7 and 3.8 from left to right (top) to 
the 5’-labeled 32P-CRE sequence (5’ – CGG ATG ACG TCA TTT TTT TTC – 3’) at 5nM: First lane in all the gels: 
pyrimidine strand. Lanes 2-9 contain peptide concentrations of 0, 0.5, 0.625, 0.75, 0.875, 1, 1.125 and 1.25 µM for 
3.6 and 3.7, and lanes 2-8 with 0, 0.6, 1.25, 2.5, 5, 10, 20 µM for 3.8. Bottom: 3D structure of α, β and γ-cyclodextrin 
and primary rim diameter distance (A, B and C respectively) and crystal structure of the GCN4 basic region peptides 
appended to the major groove of the DNA from different perspectives. Distance between C-termini indicated in 
angstroms (PDB: 1YSA) (D).  
 
3.6 Conclusion 
To conclude, we have presented the design and synthesis of three peptide-cyclodextrin conjugates for 
sequence-selective DNA recognition. This was achieved by the use of α, β and γ-cyclodextrin derivatives 
as scaffolds for the appendage of the peptides by CuAAC. 6I,6IV-diazido-α-cyclodextrin, 6I,6IV-diazido-β-
cyclodextrin and 6I,6V-diazido-γ-cyclodextrin were successfully synthesized and fully characterized by the 
group of Tomas Kraus at the Academy of Sciences in the Czech Republic. Though examples exist of 
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CuAAC reactions with CD derivatives116,124–126, to the best of our knowledge long, deprotected peptides 
have so far not been conjugated to cyclodextrins via CuAAC. We here present optimized conditions for the 
anchoring of peptides to cyclodextrin units via click chemistry.  
Our results indicate the usefulness of an optimized dimerization configuration between both peptides in 
artificial TF models. Indeed, it was shown that the distance between the anchoring points has a notable 
influence on DNA binding. Successful models can be obtained by trying to approach the exact features of 
the protein at the interface between the dimerization and the basic region domains of the bZIP TF to achieve 
DNA binding comparable to that of the natural TF. 
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CHAPTER 4 
 
CELL PENETRATION STUDIES 
 
The next step after the achievement of sequence-selective dsDNA recognition was to establish “proof of 
concept” that this system could also be adapted for cells. With this in mind we tested the cell uptake of the 
peptidosteroid conjugate 2.29 and peptidocyclodextrin conjugate 3.7, as future applications in vivo will 
necessitate the constructs to reach the nucleus and to bind DNA. This study was developed during the 
master thesis of Dorien Van Lysebetten, under the guidance of Abhishek Iyer. Benoit Louage and Prof. 
Bruno De Geest are thanked for their valuable contributions to this work. 
 
4.1 Introduction 
The idea that bile acids can increase cellular uptake of peptides is proposed in many papers66,67,69. However 
long peptides conjugated to bile acids have not yet been tested for cell uptake because of the challenging 
conjugation between cationic, hydrophilic CPPs and a hydrophobic steroid moiety. Through this work the 
synthetic challenges have been reduced to great extent. The development of sequence-specific DNA binders 
based on peptidosteroid conjugates is directed towards new strategies in cancer therapy. Consequently, an 
important requirement would be that the compound should penetrate through the membrane of the cell and 
reach the nucleus. This in itself requires overcoming several challenges. Firstly, the peptide-steroid 
conjugate must be cell penetrating. Moreover, it must not be trapped in the endosomes and must be able to 
perform endosomal escape. Finally, it must be able to enter the nucleus. Several sequence specific DNA 
binders exist55–58,127. However, none, to the best of our knowledge, have been tested or have known to show 
enhanced cell penetration. 
Cell penetrating peptides (CPP) define a broad class of peptides generally 5-30 residues in length which are 
taken up by different cell types at low concentrations while not inducing cytotoxicity128,129 . The basic DNA 
binding region of the GCN4 protein, a 23-mer peptide with 6 arginine residues mainly responsible for the 
positive charges, is classified as a cationic CPP. Although it does not bind DNA in its monomeric form, its 
dimerized version is known to show high affinity towards dsDNA. In this study the dimerization has been 
performed via a steroid scaffold allowing DNA recognition as shown in chapter 2. In this section we have 
explored the cell penetration ability of the dimers 4.4 and 4.5 and the monopodal version 4.3.  
Research into the cell permeability of the peptides was carried out with the help of flow cytometry and 
confocal microscopy whereby the latter gives qualitative information about the localization into the cell130. 
These methods are based on measuring emitted light of a fluorophore which demanded the (re)synthesis of 
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all peptides described in chapter 2 and 3 with the incorporation of a fluorescent group. This was done in a 
fairly straightforward manner by coupling the N-hydroxy-succinimide (NHS) ester of fluorescein (figure 
4.1) to the N-terminus of the peptides following solid phase synthesis. Fluorescein-labelled basic region 
GCN4 (4.1) and basic region GCN4 dimer (4.2) obtained as a side product in a parallel project focusing on 
Cysteine derivatives of GCN4 for peptide stapling, were used as controls as they do not bind DNA. 
Fluorescein-labelled monopodal peptidosteroid conjugate (4.3), although non-DNA binding was designed 
specifically to study of the influence of a steroid in the cell uptake of the GCN4 peptide. Fluorescein-
labelled dipodal peptidosteroid (4.4) and peptide β-cyclodextrin (4.5) conjugates were also tested as they 
were found to possess the best DNA binding properties as shown in chapters 2 and 3. 
 
Figure 4.1: NHS Fluorescein 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4: Cell penetration studies 
65 
 
 
 
 
 
 
 
 
Figure 4.2: Structures of constructs synthesized for this study. 
Questions about protease stability and toxicity were answered by testing the stability in serum and 
performing an MTT assay respectively. The specific choice of the steroid scaffold is based on its ability to 
enhance proteolytic stability of attached peptides131,132, by its amphiphilicity70, by its conformational 
properties ensuring correct positioning of the two appended chains71and by its potential to increase cellular 
uptake and bioavailability68. Additional tests were also performed to investigate the kinetics of uptake 
which is measured with the help of flow cytometry. Comparing the uptake at different temperatures will 
increase the understanding of the uptake mechanism of the peptides133. 
4.2 Serum protein complexation  
Bovine serum albumine (BSA) is a globular protein consisting of 583 amino acids counting for a molecular 
weight around 66.5 kDa. It is the most abundant protein in fetal bovine serum (FBS) and therefore an 
important factor in uptake experiments. This protein has a relatively high hydrophobic character and can 
easily interact with other hydrophobic molecules. The GCN4 peptide could therefore stick to this abundant 
BSA which could as result in a decrease of the free peptide concentration drastically. In addition to the 
above, the bigger BSA peptide complex can be recognized by the cells as a particle which is internalized 
by a different mechanism. The specific type of cells determines how easily particles are internalized. For 
example, the RAW264.7 cells used in current thesis can easily take up particles. Therefore, it was important 
to check for complexation of peptides with serum proteins in order to measure cellular uptake by free 
peptide only129.  
Complexation was measured by Dynamic Light Scattering, abbreviated as DLS. DLS is a method to 
measure the size distribution of small particles in solution based on their ability to scatter light with a 
wavelength larger than the particles. The light scattered by these particles will fluctuate with time due to 
the Brownian motion of these particles in solution. The time scale of these fluctuations can be correlated to 
the particle size. In principle, not the particle size but the hydrodynamic radius is measured. DLS 
measurement is also possible for proteins whose size is within the range of DLS. Note that the intensity of 
a particle peak cannot be directly correlated to the number of particles corresponding to that size.  
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DLS was measured in a solution of 1 µM peptide concentration in filtered DMEM-CM (Dulbecco's 
Modification of Eagles Medium-Culture Medium). Compound 4.3 was measured in an overall 
concentration of 2 µM due to an error in concentration determination. The DMEM contains 10 % (v/v) of 
FBS. Figure 4.3 shows the size distribution of a mixture of the peptides and cell culture medium separated 
by a small shift. No complexation for the GCN4 peptide 4.1 occurred because the size distribution in 
function of volume fraction was similar to that of filtered DMEM-CM. The compounds with a deoxycholic 
acid scaffold (4.3 and 4.4) formed complexes with serum proteins to some extent probably due to their 
higher hydrophobicity. However, by comparing the volume fraction of these peptides to the one of pure 
DMEM, it was clear that almost no complexation occurred due to the limited shift of the size distribution 
(figure 4.3). 
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Figure 4.3: Distribution of particle size in solution in function of volume fraction. 
In order to further estimate the influence of particles taken up by the cell, fluorescent microscopy was used. 
A drop of compound 4.3 solution on a cover glass is evaluated by fluorescent microscopy. The presence of 
a large amount of BSA peptide complex should show a dotted pattern in fluorescence microscopy. In this 
case, a homogeneous solution is present which means that complexation occurs to a very small extent 
(figure 4.4). Therefore, it is unlikely that complexation will positively influence the cellular uptake. 
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Figure 4.4: Fluorescence microscopy image showing the absence of BSA-protein complexes1. 
4.3 Toxicity: MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) assay  
The MTT assay is a colorimetric assay that measures the number of viable cells after incubating the cells 
with a potential cytotoxic compound134. All peptides which were subjected to cell penetration tests were 
checked for their toxicity toward cells using different concentrations.  
The MTT assay is based on the enzymatic reduction of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide to formazan in living cells (figure 4.5). Several dehydrogenase enzymes are 
responsible for the conversion of the MTT dye in active mitochondria134. Formazan crystals, which are 
insoluble in water, are generated in proportion to the amount of active mitochondria. In principle, the MTT 
assay does not measure cell viability as such but metabolic activity within cells represented by the activity 
of mitochondria. The cell viability is often proportional to the metabolic activity.  
 
Figure 4.5: Conversion of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium ion to formazan. 
RAW264.7 cells cultivated in DMEM (104/well, 200 µL) were plated in a 96-well plates and incubated 
overnight at 37 °C and 5 % CO2. The peptides and control compounds were added in an overall 
concentration of 0.25 µM and 1 µM and incubated for 24h under the same conditions. The MTT solution 
was then added to the aspirated wells and incubated for 3 h. After removal of the cell medium, purple 
                                                          
1 Reproduced with permission from the master thesis of Dorien Van Lysebetten: “Design and Synthesis of Stapled 
Peptides for Enhanced DNA Binding and Cell Penetration”265 
Pep. Solution of 
4.4 in DMEM 
Glass plate 
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formazan crystals were dissolved in DMSO. Then, UV-measurement at 570 nm was performed with a plate 
reader to check cell viability quantitatively. An observation with the naked eye already gave a good idea 
about the toxicity of the compounds due to the disappearance of color in the well. Comparison of the 
absorbance of the formazan solution of the sample to the absorbance of a positive (incubation with ultrapure 
water) and a negative control (incubation with DMSO) gave quantitative results of cell viability as in the 
equation 1: 
𝐶𝑒𝑙𝑙 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (%) =  
𝐴 −  𝐴𝑝𝑜𝑠
𝐴𝑛𝑒𝑔 − 𝐴𝑝𝑜𝑠
∗ 100 
Equation 1: A, Apos and Aneg refers to absorbance, absorbance due to water and absorbance due to DMSO 
respectively. 
   
Figure 4.6: MTT assay for all the peptides measured at 0.25 µM and 1 µM. 
Cell viability was evaluated according to the ISO10993-5 norms which state that compounds are cytotoxic 
if the assay points to a cell viability lower than 70 %. Figure 4.5 shows the percentage of viable cells for all 
peptides. At 0.25 µM, the cell viability of 4.3 was close to 70 %. On the other hand, at 1 µM, the deoxycholic 
scaffold containing compounds (4.3 and 4.4) and the dimerized GCN4 (4.2) were cytotoxic. This was not 
unexpected because bile acids have detergent like properties that can damage the membrane resulting in 
cell death.  A cell viability higher than 100 % which was observed for 4.5 is possible due to higher metabolic 
activity in the cells. Because the formation of formazan is dependent of the activity of mitochondria, 
stressing of cells, with foreign compounds, can increase the activity of the cell. 
4.4 Cell penetration and localization  
4.4.1 Confocal microscopy  
4.4.1.1 Description of the technique  
Confocal microscopy is an ideal method to investigate the localization of fluorescent peptides in the cell. 
The laser of the microscope excites the fluorescently labelled CPP which then emits light. A special detector 
which suppresses out-of-focus light, creates an image of this emitted light. Staining of specific cell 
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compartments by fluorophores emitting at different wavelengths than fluorescein, allows subsequent 
detection and localization of these compartments. By merging different emission patterns at different 
wavelengths, localization of the fluorescently labelled peptide is possible. In current thesis, cells are stained 
using Hoechst and Cholera toxin subunit B (CTB) Alexa Fluor 647 conjugate to visualize the cell nucleus 
and cell membrane respectively. The Hoechst dye has specific affinity for the minor groove of DNA135 and 
therefore colours the nucleus blue136. CTB, on the other hand, has affinity for the cell membrane which 
colours red due to the conjugated Alexa Fluor 647 dye137. The peptides used were labelled with 
fluorescein138 which emits green light. Due to the difference in emission wavelength, the three dyes can be 
detected separately. Processing of the data gave overlay images whereby nucleus, cell membrane and 
fluorescein connected molecules are shown in blue, red and green respectively.   
4.4.1.2 Localization of peptides measured by confocal microscopy  
RAW264.7 cells cultivated in DMEM (105/well, 300 µL) were plated in confocal plates and incubated 
overnight at 37 °C and 5 % CO2. Peptides were added in an overall concentration of 0.25 µM and incubated 
for 2 h at the same conditions or on ice. Cells were washed and fixated with 2 % of Paraformaldehyde for 
30 min at 37°C. Cells were stained by 30 min incubation with a 0.2 % solution of CTB-AF647 and 0.2 % 
of Hoechst in PBS with 1 % BSA. This was done to visualize the cell nucleus (blue) and cell membrane 
(red) respectively. Cells were resuspended in PBS and measured with confocal microscope (Leica SP5 
equipped with a 63x (1.4 NA) oil immersion objective) at 3 different wavelengths (405 nm, 488 nm and 
643 nm). The peptides used were labeled with fluorescein which emits green light. To understand the uptake 
mechanism better, three samples are made in duplicates and incubated at 4 °C to inhibit active transport. 
Due to the difference in emission wavelength, the three dyes can be detected separately. Processing the data 
with the software Image J gave overlay images whereby the nucleus, cell membrane and fluorescein are 
shown in blue, red and green respectively. 
 
The GCN4 sequences coupled to deoxycholic acid (4.3 and 4.4) or coupled to cyclodextrin (4.5) were 
compared to GCN4 peptide control (4.1) and the dimerized GCN4 sequence (4.2) (figure 4.7 and 4.8). All 
these peptides were taken up at 37 °C although dimer 4.2 and 4.5 aggregated on the outer cell surface which 
was indicated by oversaturated green dots outside the red cell membrane (figure 4.7 A and B). This 
aggregation was less present for the deoxycholic acid peptides (4.3 and 4.4). Although all the compounds 
were taken up at 37 °C, there is clearly an enhanced uptake when deoxycholic acid is used as a scaffold as 
seen from the mean fluorescence values (figure 4.10 left). The mimic using a cyclodextrin scaffold shows 
considerably lower uptake than the cholic acid but similar to that of the non-binding GCN4 dimer 4.2. The 
monopodal deoxycholic acid derivative 4.3, also non-DNA binding and more hydrophobic, has properties 
similar to those of its dimeric counterpart 4.4 in terms of uptake. 
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Figure 4.7: Confocal microscopy images of the uptake of (A) 4.1, (B) 4.3 at 37 °C and 0.25 µM. Upper panels show 
accumulated images of DNA (blue), cell membrane (red) and fluorescein (green). Lower panels show fluorescein 
image. (Scale bar = 20 µm). 
 
Figure 4.8: Confocal microscopy images of the uptake of (A) 4.2, (B) 4.5 and (C) 4.4 at 37 °C and 0.25 µM. Upper 
panel shows accumulated images of DNA (blue), cell membrane (red) and fluorescein (green). Lower panel shows 
fluorescein image. (Scale bar = 20 µm). 
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4.4.2 Flow cytometry  
4.4.2.1 Description of the technique  
Flow cytometry is an laser-based analysis technique that consists in measuring light scattering and 
fluorescence emission of particles or cells in suspension139. These particles or cells move one by one in a 
flow chamber and their scattering properties are measured by a laser beam in combination with measuring 
the fluorescence light emitted from a dye inside or connected to the cell. Therefore, information about the 
size and granularity of the cell can be obtained by analyzing the forward and side scattering respectively. 
In addition, quantitative information can be achieved by measuring the fluorescence emission at a specific 
wavelength. In general, a flow cytometer consists of a hydraulic system, a set of lasers and detectors and a 
computer that collects and converts the data from the detector139. The hydraulic system ensures the correct 
arrangement of the cells in order to make them pass one by one through the laser beam. The laser produces 
monochromatic light that can be used to excite a dye inside or attached to the cell. A histogram plots the 
emission intensity in function of the counted cells as for example in figure 4.9.  
 
Figure 4.9: Principle of data representation of flow cytometry. A threshold is established to separate the fluorescence 
emitted by the cells (autofluorescence) from the one emitted by cells containing fluorescently labeled peptides. For 
example, peptide 1 is not taken up by all cells, as the area under the curve is in the autofluorescence zone and the 
percentage of peptide positive cells is lower than 100 % proportional to the colored area under the curve. Peptide 3 
was taken up better due to its higher mean fluorescence value (Mean 3), although the percentage of peptide positive 
cells for both peptide 2 and 3 is 100 %. It is therefore important to both compare the mean fluorescence and the amount 
of peptide positive cells3.  
 
RAW264.7 cells cultivated in DMEM (105/well, 1 ml) were plated in a 24-well plate and incubated 
overnight at 37 °C and 5 % CO2. Peptides were added in an overall concentration of 0.25 µM and 1 µM 
and incubated for 2h at the same conditions or on ice. Cells were washed with PBS and detached with 
                                                          
3 Reproduced with permission from the master thesis of Dorien Van Lysebetten: “Design and Synthesis of Stapled 
Peptides for Enhanced DNA Binding and Cell Penetration”265. 
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Na4EDTA. Cells were re-suspended in PBS and added to the BD Accuri flow cytometer. The amount of 
peptide associated to the cell was measured by flow cytometry. Experiments were carried out in duplicate. 
In order to control the fluorescence of the background, blank cells were measured and the signal received 
corresponded to auto-fluorescence. This allowed the establishment of a threshold to separate cells emitting 
light due to auto-fluorescence from cells containing fluorescently labeled peptides. Thus, the number of 
cells which emit sufficient intensity of fluorescence due to the presence of fluorescently labeled peptides 
could be achieved by measuring the area under the histograms beyond this threshold. This number was 
further referred to as the percent of peptide positive cells. As an example, by measuring two different 
peptides, they can have 100% of peptide positive cells, but one can be better uptaken in the cell due to its 
higher mean fluorescence value. If a peptide is not taken up by all cells, the percentage of peptide positive 
cells is lower than 100 % proportional to the colored area under the curve. It is therefore important to 
compare both the mean fluorescence and the amount of peptide positive cells. 
 
 4.4.2.2 Analysis of the peptides by Flow Cytometry 
 
During flow cytometry measurements no comparison was possible between the results of single 
fluorescently labeled peptides and the peptides containing two fluoresceins. Therefore the single 
fluorescently labeled peptides (4.1 and 4.3) were discussed separately from the ones containing two 
fluoresceins (4.2, 4.5 and 4.4). 
 
A concentration dependent uptake was observed for all peptides. Compound 4.3 which is a single GCN4-
strand grafted on a deoxycholic scaffold had substantially higher uptake (figure 4.10). These findings 
emphasize the importance of conjugating peptides to a bile acid.  
Figure 4.10: Mean fluorescence (left) and peptide positive cells (right) of  
third test of single fluorescently labeled peptides. 
The increased uptake of 4.3 at 0.25 µM and 1 µM compared to the other peptides was not unexpected. 
However, a decrease in mean fluorescence was observed when switching from 0.25 µM to 1 µM. The 
tendency of a bile acid to disrupt the cell membrane due to its detergent like properties can be responsible 
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for a maximum uptake level. However, the reason for the decrease in the mean fluorescence when 
increasing the concentration from 0.25 µM to 1 µM is unknown. 
As mentioned before the uptake of the peptides labeled with two fluoresceins was interpreted separately 
from the other peptides. In figure 4.11, mean fluorescence and peptide positive cells are shown for these 
doubly fluorescent labeled peptides. The uptake of peptides 4.4 and 4.5 which contain deoxycholic acid or 
cyclodextrin scaffold coupled to two peptide strands, was compared to the dimerized GCN4 peptide 4.2 
which was used as control. All these peptides labeled with two fluoresceins were taken up by 100 % of the 
cells at both concentrations. The mean fluorescence value of dipodal cholic 4.4 was considerably higher 
compared to dimer 4.2 as was also observed for peptide 4.3 compared to the control 4.1. Also here, the 
mean fluorescene value did not increase as much as expected upon switching to the higher concentration 
which can indicate a maximum uptake level of the peptides coupled to deoxycholic acid. Coupling of a 
cyclodextrin scaffold did not enhance the uptake (figure 4.10, left). This was not an unexpected result and 
once again established the importance of the bile acid in cellular uptake.  
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Figure 4.11: Mean fluorescence (left) and peptide positive cells (right) as a result of the first test with doubly 
fluorescent labeled peptides. 
4.5 Description and studies of uptake mechanisms 
4.5.1 Endocytosis 
The mechanisms through which Cell Penetrating Peptides (CPPs) are imported into the cell have been of 
interest since more than 25 years ever since the discovery of the trans-activating transcriptional factor 
(TAT) CPP in 1988140.  Due to the enormous complexity of these mechanisms, in reality, we are far away 
from explaining what truly happens to a peptide in cellulo. However, a general explanation has been 
provided in this section. From the previous studies on cell uptake described in literature141,142, we can 
conclude that one of the major pathways through which CPPs interact with the cellular membrane is by 
inducing an endocytic uptake by the enclosure of the CPPs in a vesicle. This vesicle is further pinched off 
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from the plasma membrane and release into the cytosol, generating an intracellular organelle, called 
endosome. The release of the CPPs from the endosome to the cytosol is caused by the acidification of the 
vesicle, allowing the CPPs to interact with the target141.  
Several internalization pathways have been described (figure 4.12) and they have been classified depending 
on the size of the particle taken up by the cell. These mechanisms are named as phagocytosis and 
pinocytosis. The first one is related to the uptake of large particles, for the elimination of pathogens and for  
apoptotic and infected cells141–143. On the other hand, pinocytosis is involved in the internalization of small 
particles such as fluids, solutes and components of the cellular membrane. It comprises a subgroup of four 
different mechanisms: (1) macropinocytosis, (2) clathrin-mediated uptake, (3) caveolae-mediated uptake 
and (4) clathrin-/caveolai independent uptake. The last three mechanisms are named as raft-dependent 
endocytosis, as they are supported by the presence of lipid rafts. These lipid rafts are part of the cell 
membrane with high composition in cholesterol, sphingolipids and receptors142. 
 
Figure 4.12: Different endocytic uptake mechanisms142.  
During macropinocytosis, the plasma membrane bends giving rise to curved ruffles, that when shielded, 
forms large vesicles called macropinosomes. Due to this mechanism, the cell is able to internalize big 
volumes of fluids and dissolved particles, such as viruses, bacterias and cellular fragments142,143. One of the 
modes of uptake of arginine rich peptides is by macropinocytosis as described by Wadie and coworkers. 
The escape from these type of vesicles is achieved by lowering the pH to a point at which the peptides 
degrade, thereby leaking out of the internalized components144. CPPs that are taken up by macropinocytosis 
are not further internalized to lysosomes (vesicles specialized in breaking down biomolecules), preventing 
their degradation145. 
A second type of mechanism is the clathrin-mediated endocytosis (CME), which is the most extensively 
studied and best understood. The CPPs that go through this mechanism of uptake firstly interact with a 
receptor located at the extracellular surface, generating a clathrin coated pit141,146. When it is pinched off, a 
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clathrin-coated vesicle (CCV) is formed together with the removal of the clathrin protein. These uncoated 
vesicles are then fused to form an early endosome. Studies have revealed the importance of CME in the 
regulation of signal transduction (i.e. the activation of a specific receptor located inside the cell or on the 
cell surface by an extracellular molecule147,148), as it is related to the number of receptors at the outer surface 
of the membrane. 
In case of Caveolae-mediated endocytosis, like in the previous two mechanisms, flask-shaped 
invaginations, called caveolaes are formed141,142,149. Caveolaes contain caveolin proteins and lipid rafts like 
cholesterol and sphingolipids. Although this mechanism is still not well understood, it has been shown that 
it participates in cell adhesion and anchoring-dependent cell growth141,142. 
The last class, clathrin-/caveolae- independent endocytosis, does not fit within the description of the 
previous uptake mechanisms150,151. The presence of uncoated invaginations on the surface of the cell 
membrane encouraged the investigation of a possible alternative endocytic mechanism. Although it has 
been classified separately, there is still a lack of information and understanding required to fully understand 
both the molecular basis of membrane deformation and scission and the different pathways and their 
individual functions in their physiological contexts.  
Studies performed in live cells demonstrated that CPPs are taken up by endocytotic pathways such as 
macropinocytosis, CME and caveolin-mediated endocytosis although other mechanisms cannot be 
completely discarded141. The specific uptake mechanism of CPPs is determined by the use of specific 
markers, uptake inhibitors and knock-down cells. However, due to the dependence of the mechanism on 
the type of cell line used, the obtained results are not entirely specific for one mechanism. For example, the 
inhibition of one pathway can enhance the effect of others and therefore can result in one drawing the wrong 
conclusions. In addition, other factors such as incubation time, concentration and physiochemical 
parameters restrict the access to general conclusions about the uptake of CPPs143.  
The most common CPPs for the transport of cargo through the cell membrane are the TAT-peptide, 
polyarginine and penetratin. Their uptake mechanisms have been evaluated and are understood better 
despite the differences based on the variations in cargo152–154. In general, it is documented that the Tat-
peptide is taken up by macropinocytosis, clathrin-mediated, independent of clathrin and even caveolae-
mediated  endocytosis128. On the other hand, the uptake of polyarginine occurs via micropinocytosis and 
the length of the sequence is crucial for internalization141. In both cases, binding to the heparin sulfate 
proteoglycans on the outer face is essential for cell uptake. However, in the case of polyarginine, there are 
indications that other mechanisms are involved during internalization of the peptide, such as the inability 
of polyarginine R16 to penetrate128,141. Finally, penetratin mainly penetrates via clathrin-mediated 
endocytosis or clathrin-independent and lipid raft-dependent endocytosis.   
Due to all the parameters described above which affect cell uptake, namely the type of peptide and cell line 
and concentration of the peptide it is not possible to draw conclusions about the exact mechanisms of CPPs 
internalized in the cell. However, the ongoing research on specific inhibitors and markers for each of the 
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pathways should elucidate and unravel the factors involved in each mechanism, as well as the dependence 
of the cargo on the cell uptake process.  
4.5.2 Transduction  
Despite the importance of the endocytic pathway, there are peptides internalized by mechanisms that do 
not require the formation of endosomes. These mechanisms are grouped under the name transduction and 
occur when the physical-chemical properties of the peptides stimulate interaction with the cell membrane155. 
Transduction is also defined as direct translocation, as it is independent of energy consumption and 
therefore it is not inhibited upon incubation at 4°C. This is contrary to endocytosis which needs a higher 
temperature for the active uptake. Recently, three different pathways for transduction have been described 
by the group of Copolovici: the inverted micelle model, the carpet model and pore formation143.  
The inverted micelle pathway has been proposed for the penetratin family156. This mechanism consists of 
the interactions between the positively charged residues of the peptide with the negatively charged heads 
of the phospholipids. The hydrophobic residues are responsible of the formation of the inverted micelle by 
membrane destabilization. The polar groups of the peptide helix point inside the micelle. The peptide is 
then transported through the non-polar core of the bilayer in an inverted micelle, before reaching the polar 
intracellular environment (figure 4.13 A). Due to the lack of hydrophobic residues in the sequence of tat 
and polyarginine peptides, this pathway cannot explain their uptake mechanism. The carpet model is based 
on the initial interactions between the peptide and the lipid head groups that lead to rotation of the helix, 
permitting the non-polar residues to establish contact with the lipid tails. As a consequence, the membrane 
bilayer is disrupted and the peptide can penetrate in the cell. This process is favored by the presence of 
guanidinium groups, such as in the case of polyarginine and tat peptides (figure 4.13 B). The last 
mechanism, pore formation, is generated by the aggregation of several α-helices containing an amphipathic 
phase. The hydrophobic part of the helices interact with the membrane forming a tunnel, in which the 
hydrophilic parts are oriented into the tunnel. In this model, the peptides stay inserted in a transmembrane 
orientation and in an associative state to form a cylindrical structure or ‘pore’. There are two types of pores 
that can be formed by this pathway, the barrel-stave pore (figure 4.13 C left) or the toroidal pore (figure 
4.13 C right). 
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Figure 4.13: Model of transduction of peptides157.  
Apart from the three transduction mechanisms explained above, the presence of other pathways has also 
been observed. Although these are not well characterized, definitions have been reported in literature. 
Electroporation, a well-established physical method of disrupting cell membranes and consequently 
allowing the permeabilization of CPPs by their interactions with the membrane or by internalization via 
weak spots in the membrane is one such example. Another described method by the group of Bechara128 is 
adaptive translocation in which positively charged and arginine-containing oligomers can form membrane-
soluble ion pair complexes by association with negatively charged, bidentate hydrogen bond acceptor 
groups of endogenous membrane constituents. A decrease of the polarity of the ion-pair complexes when 
inserted in the cell membrane causes the partition of the lipid bilayer and the migration of the peptide 
towards the cytosol. The rate of migration depends on the membrane potential. Finally, the complex 
dissociates in the inner part of the membrane and the peptide enters the cytosol. Although these examples 
have been documented in literature, the ambiguous proof-of-concept for these mechanisms and the 
dependence on the peptide used and the concentration for these mechanisms causes uncertainty about their 
validation. 
In general, it should be noted that independent of the uptake mechanism, the first interaction arises when 
the CPPs interact electrostatically with the negatively charged proteoglycans, phospholipids and less 
commonly proteins. Although the importance of these negatively charged groups on the outer surface is not 
denied, their further influence on the uptake is still unclear. Another important aspect independent of the 
uptake mode is the concentration of CPPs needed to give a biological response. Ideally, this should not 
exceed 10 µM to ensure one has a therapeutically useful concentration for further testing158.  
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4.5.3 Endosomal escape 
The endocytic processes explained in the section 4.5.1 require the formation of endosomes where the CPPs 
can be internalized and then taken up into the cell. However, in certain cases CPPs need to be released from 
the endosomes to reach their final localization (ex. the cytoplasm or the nucleus). Despite the importance 
of endosomal escape for the uptake of CPPs, very little is understood about the parameters that control it128. 
In order to observe endosomal leakage, polyarginine R6 and Tat peptides have been linked to a fluorescein 
isothiocyanate (FITC), allowing the access to privileged information about the release of peptides from 
endosomes159. 
Once the CPPs are internalized in the endosomes, they should be released to be able to exert their function 
inside the cytoplasm or nucleus. The endocytic pathway is based on the formation of early to late endosomes 
with an internal pH of 5 that will fuse with lysosomes containing digestive enzymes afterwards160 (figure 
4.14). This can result in degradation or capture of the peptide before it has had the chance to reach its 
desired target and perform its function. Therefore, endosomal capture is considered as a problem in cellular 
delivery. Thus, several strategies have been developed to avoid the sequestration of CPPs inside endosomes 
and enhance their bioactivity. These are based on mechanisms that allow endosomal escape, such as pore 
formation in the endosomal membrane, conformation changes on the enhancers of endosomal escape and 
pH buffering effect161. The endosomal-releasing agents that facilitate these methods are classified into viral 
and bacterial proteins and synthetic biomimetics for nucleic acid and protein delivery among others. 
However, the usage of these systems is limited due to stability problems. It is established that an optimal 
delivery agent should be efficient and non-toxic.  
 
Figure 4.14. Representation of the internalization of therapeutics into the cell through endocytosis and subsequent 
endosomal escape162. 
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As an example of this strategy, the group of Bernard Lebleu and cowrokers have modified Penetratin via 
an elongation of the N-terminus by varying numbers of arginines for the delivery of PNA to the nucleus in 
the absence of endosomolytic agents163. From the various peptides synthesized, the R6Pen peptide 
(RRRRRRRQIKIWFQNRRMKWKKGGC) is the most active towards nuclear uptake. Other peptides 
undergo endosomal escape by changing their conformation depending in the pH, the subsequent endosomal 
membrane disruption and the final leakage of the contents. These peptides are called fusogenic and they 
are part of the N-terminal sequence of the influenza virus hemagglutinin subunit HA-2164.  
  4.5.4 Uptake mechanism tested by flow cytometry  
Due to the limited knowledge and understanding about some uptake mechanisms, research into 
distinguishing the different mechanisms is highly complicated. In addition, the overall interplay and 
interconnection between the mechanisms and the absence of highly specific inhibitors or markers which on 
itself will not influence the experiment, impede the determination of a final conclusion. On the other hand, 
the well-known distinction between the two main mechanisms, endocytosis and transduction, can be 
investigated by simultaneous incubation at 4 °C (or lower) and 37 °C. Therefore, half of the 24-well plates, 
which were plated the day before, were incubated on ice to make sure the temperature of cell culture 
medium, cells and well plate was below 4 °C. The other half was incubated at normal conditions. Then the 
peptides were added and the plates were incubated at 4 °C and 37 °C for 2 h, on ice or in the oven 
respectively.  The cells were then washed, detached from the plates and measured by flow cytometry. In 
order to process the results and to create histograms, plot overlays and quantitation, we used FlowJo, a 
software commonly used to analyze flow cytometry data and that can be employed independently of the 
instrument used. GraphPad Prism, a commercial scientific 2D graphing and statistics software was also 
used for statistical analysis. 
The following parameters were used while performing cell cultivation: DMEM (105/well, 1 ml) plated in 
24-well plates and incubated overnight at 37 °C and 5 % CO2. The peptides were added such that the overall 
concentration was 0.25 µM and 1 µM. They were then incubated for 2h in the same conditions mentioned 
above or on ice. The cells were washed with PBS and Na4EDTA was used for the detachment of the cells. 
They were then re-suspended in PBS and added to the BD Accuri flow cytometer. All experiments were 
repeated twice to check for consistency. To measure the amount of peptide associated to the cells flow 
cytometry was used. Blank cells were measured and the signal received through those cells corresponded 
to auto-fluorescence. A suitable threshold was chosen to distinguish the auto-fluorescent cells from those 
fluorescently labelled. Care was taken to ensure that the area under the histograms beyond the threshold 
chosen contained sufficient cells and provided enough intensity of fluorescence to label the peptides present 
in those cells. This number is referred to as the percent peptide positive cells. Two factors have to be 
considered in case of cell uptake: peptide positive cells and the mean fluorescence. It is quite possible that 
two peptides may have 100% peptide positive cells but one of them could be better if it had a higher mean 
fluorescence value. If the peptide positive cells is lower than 100% the percentage of peptide positive cells 
is proportional to the area under the curve. 
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Once again a concentration dependent uptake was observed for both monomeric peptides 4.1 and 4.3 and 
compound 4.3 had substantially higher uptake than monomeric GCN4 peptide 4.1 irrespective of the 
temperature or concentration (figure 4.13). The enhancement on cell uptake at 37°C for 4.3 was 
significantly higher than for 4.1, revealing the influence of a bile acid in active uptake. 
Figure 4.15: Mean fluorescence (left) and peptide positive cells (right) as a result of incubation at 4 °C and 37 °C at 
a concentration of 0.25 μM or 1 μM. 
For the dimeric constructs, the first test was performed at 0.25 μM only. Once again, peptides labeled with 
one fluorescein (4.1, 4.3) could not be compared with peptides labeled with two fluoresceins (4.2, 4.4, 4.5). 
The quantitation of the uptake was visualized using the mean fluorescence and the percent of peptide 
positive cells at the two temperatures is as depicted in figure 4.15 for the singly fluorescent labeled peptides. 
The dipodal GCN4 mimic 4.4 was internalized in all cells at both 4 °C and 37 °C which is depicted in figure 
4.16. Peptide 4.2 was also taken up both passively and actively whereby at 37 °C both the pathways were 
possible which resulted in an increased mean fluorescence at 37 °C compared to the mean fluorescence at 
4 °C. At 4 °C, the dimerized GCN4 peptide 4.2 was only present in 20 % of the cells where at 37 °C all 
cells were ‘dimer 4.2-positive’. This peptide was probably translocated via endocytic pathways which also 
resulted in a lower mean fluorescence value at 4 °C. An important aspect is the lower cell membrane 
flexibility at low temperature which can result in decreased passive uptake at 4 °C compared to passive 
uptake at 37 °C128. In this study, this was not taken into account due to the difficulty in measuring the 
influence of cell membrane flexibility.  
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Figure 4.16: Mean fluorescence (left) and peptide positive cells as a result of incubation at 4 °C and 37 °C of doubly 
fluorescent labeled peptides at a concentration of 0.25 μM. 
 
The dependence of the number of arginines on the transduction mechanism was described by Lättig-
Tünneman et al. In addition, they also studied the concentration-dependent threshold which exists for this 
mechanism165. A low micromolar range threshold usually points to an endocytotic pathway, however, this 
may not always be the case and may not always be known either158. For our specific case, we decided to 
check for a trend based on the theory proposed by Lättig-Tünneman by repeating the tests using 
concentrations of 0.25 µM and 1 µM. Due to the limited material at hand further increasing the 
concentration was not feasible. However, according to Tünneman, it is quite possible that the threshold 
concentration was exceeded when the test was performed at 1 µM as the threshold range is between 1 and 
10 µM166. 
The monopodal GCN4 mimic 4.3 and the dipodal GCN4 mimic 4.4 proved to benefit from an increased 
uptake compared to the GCN4 peptide 4.1 and the GCN4 dimer 4.2 respectively (figures 4.15 and 4.16). 
Even at 4 °C and a 1 μM concentration, almost a 100% of cells contained peptide 4.3. The same was true 
at 4 °C and 0.25 μM, although this time the uptake was not 100 % but still significant. Therefore, monopodal 
mimic 4.3 may be taken up both passively and actively which was indicated by the increased mean 
fluorescence value at 37 °C compared to 4 °C, similar to the observations for peptide 4.4 in the first test 
(figure 4.16). To confirm the uptake at 4 °C, confocal microscopy is needed. 
4.5.5 Uptake mechanism tested by confocal microscopy  
The control peptide was not internalized at 4 °C as can be seen from figure 4.17 A. This points to the uptake 
via an active transport mechanism. Remarkably for compound 4.4 at 4 °C only insertion in the cell 
membrane was observed which is displayed in figure 4.17 A. The yellow dots on the cell membrane are a 
combination of red signal from the cell membrane and green signal from fluorescein (figure 4.17 A, upper 
panel). Due to accumulation in or onto cell membrane, it was possible to measure 100 % peptide positive 
cells and a high mean fluorescence in flow cytometry observed in figure 4.16. However, at 37°C, whereby 
both passive and active uptake is possible, the uptake is considerably higher (figure 4.16). This proved that 
the deoxycholic acid coupled peptides were also internalized via active transport. Passive transport was not 
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possible because the peptides stayed in the cell membrane or on the outer cell surface. Unfortunately, no 
peptides were localized inside the nucleus. This absence could be a result of rapid degradation of the 
peptides, endosomal entrapment or the absence of a NLS. 
 
Figure 4.17: Confocal microscopy images of the uptake of 4.4 at 4 °C (A) and at 37 °C (B) and 4.2 at 4 °C (C) and 
at 37 °C (D). Upper panel shows accumulated images of DNA (blue), cell membrane (red) and fluorescein (green). 
Lower panel shows fluorescein image in case of A and B. (Scale bar = 20 μm). 
The confocal microscopy confirmed that the GCN4 dimer 4.2 has almost no uptake at 4 °C (figure 4.17 C) 
but is taken up by the cells at 37°C (figure 4.17 D) indicating an endocytotic pathway.  
4.6 Conclusion & Perspectives 
The synthesized scaffold-based mimics of the GCN4 leucine zipper TF that showed sequence specific DNA 
binding towards the CRE sequence were tested for DNA binding in vivo. For the compounds that have 
affinity for the DNA, only those peptides bearing a steroid scaffold were able to penetrate the cell 
membrane. The CD conjugate showed accumulation in and around the cell membrane rather than uptake in 
the endosomes. The moiety responsible for the high mean fluorescence even at 4°C is the steroid nucleus. 
However, studies on the uptake mechanism of 4.4 revealed that the internalization occurred via active 
transport despite the high amount of peptide positive cells. 
Although all the compounds were taken up at 37 °C (figure 4.16 and 4.17), there is clearly an enhanced 
uptake when deoxycholic acid is used as a scaffold as seen from the mean fluorescence values (figure 4.15 
left). The mimic using a cyclodextrin scaffold 4.5 shows considerably less uptake than 4.4 but similar to 
that of the non-binding GCN4 dimer 4.2. The monopodal deoxycholic acid derivative 4.3, also non-DNA 
binding and more hydrophobic has properties similar to those of its dimeric counterpart 4.4 in terms of 
uptake (figures 4.7 and 4.8). The most interesting results were obtained when comparing the localization 
of the DNA binding cholic acid dimer 4.4 at 4°C and 37°C (figure 4.17). At 4°C, where active transport is 
inhibited, only insertion in the cell membrane was observed. Accumulation in and around the cell membrane 
resulted in a high mean fluorescence and high percentage of peptide positive cells (figure 4.16 left). 
However, at 37°C, where both passive and active uptake are possible, the uptake is considerably higher. 
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This indicates that the deoxycholic acid coupled peptides 4.3 and 4.4 are internalized via active transport. 
Despite the enhanced uptake shown by 4.4 there is no uptake in the nucleus. We already know that  
increased uptake of peptides bearing arginine residues is observed due to the bidentate character of the 
guanidinium groups. The cell surface contains negatively charged groups like phosphates and carboxylate 
groups. From the behaviour of compound 4.4 (figure 4.17A) one can conclude that deoxycholic acid prefers 
membrane association. Since this interaction is also prevalent at 4°C, unlike the other peptides, 4.4 shows 
uptake at 4°C. Compound 4.4 is accumulated in and around the cell membrane which is most likely due to 
passive transport. 
Despite these results no peptides were localized inside the nucleus. We believe that coupling a short NLS 
to the peptides or the scaffold can perhaps increase nuclear localization granting access to in cellulo DNA 
binding. The most suitable attachment point for this would be the modification of the carboxylic acid at 
C24 in the steroid scaffold.  Only  a  few  of  these  bioactive  CPPs  are  known  today143. It is therefore  
important  to  fully  exploit  the possibilities  of  these bioactive  CPPs  by  further research into  stability,  
cell penetration and  localization of these peptides.
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CHAPTER 5 
 
FROM ARTIFICIAL HOMODIMERIC TF MIMICS TO A 
HETERODIMERIC TF MIMIC 
 
Synthesis of GCN4 bZIP transcription factor models has been successfully achieved with the steroids and 
cyclodextrins as keystones for substitution of the dimerization domain of the TF. Using the gained expertise 
on simplifying proteins by chemical tools, we decided to attempt the miniaturization of the cMyc/Max bHLH 
transcription factor, whose role in the development of tumors make it an interesting target towards gene 
therapy. By broadening the scope of our synthetic toolbox we can target different DNA sequences and 
mimic the various complex, natural TFs. 
 
5.1 Introduction 
 5.1.1 Description of c-Myc/Max bHLH Leucine Zipper transcription factor 
Over the last few decades, development in areas such as biotechnology and chemical biology have led 
towards new directions in anti-cancer therapy research. Among the promising approaches that have gained 
attention recently, the inhibition of oncogenes and/or the reactivation of tumor suppressor genes are of 
particular interest. This is mainly due to the fact that they are responsible for encoding transcription factors 
that control gene expression and signaling pathways in cancer. They are also related to the maintenance and 
progress of tumor growth167. During cancer development, these transcription factors suffer from an aberrant 
activation which has consequences on the tumor formation and metastasis. On the other hand, as they are 
inactive under normal physiological conditions, they can be regarded as desirable targets in gene therapeutic 
strategies.  
One of the major families of transcription factors related to human cancer and consequently targeted for 
cancer therapy is the Myc/Max/Mad network168. These oncoproteins are heterodimers composed of proteins 
from the Myc, Max and Mad families. Myc-Max binds DNA in a sequence-specific manner and its function 
is the transcription from promoters containing the sequence CACGTG. The disregulation of the c-Myc gene 
causes its overexpression which is related to the progression of diseases such as Burkitt’s lymphoma, cancer 
in infancy in the form of neuroblastomas and lung, breast and colon carcinomas. The oncogenic biological 
activity of the c-Myc protein is regulated by its ability to establish protein-protein interactions with its 
partner Max to form a heterodimeric transcription factor. In contrast, Max forms stable homodimers that 
bind the same DNA sequence but do not activate transcription, thus antagonizing the activity of the cMyc-
Max heterodimer by competing for the same target sequence. The heterodimer formation is controlled by 
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the interactions at the leucine zipper domain. While the Max homodimer is formed when a Gln91-Asn92-
Gln91-Asn92 tetrad occurs near the C-terminal end of the zipper region, the heterodimer creation is 
regulated by the Arg423-Arg424-Gln91-Asn92 tetrad establishment (figure 5.1).  
 
Figure 5.1: Structures of the (A) Myc-Max Heterodimer (B) Max-Max Homodimer and interactions between the C-
terminal helix region in case of (C) Myc-Max and (D) Max-Max. 
 5.1.2 Towards synthetic mimics 
Due to the relevant role of this oncoprotein in cancer development, Kent et al169 made a first approach in 
the form of the total synthesis of the cMyc-Max protein. Unlike the natural protein Kent synthesized a 
covalently-linked dimer mimic by convergent chemical ligation of unprotected peptide segments. This 
approach was chosen as the obtention of a heterodimer composed by Myc and Max counterparts was 
hampered by the favoured Max/Max homodimeric formation at the supraphysiologic protein concentration. 
Therefore, Kent proposed the total chemical synthesis of the protein in this manner as an alternative to the 
construction of native Myc/Max proteins (figure 5.2). In addition, this approach permitted the introduction 
of structural modifications such as introduction of unnatural amino acids and point mutants and allowed 
the replacement of E. coli expression systems that are frequently related with protein instability and toxicity. 
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Figure 5.2: Structure of Myc/Max bHLH protein mimic synthesized by Kent. The green ribbon represents the residues 
that constitute the Max peptide, while the orange ones refers to the Myc peptide. Oxime ligation and thioester 
formation allow connecting the two different fragments. 
The biological functions of the cMyc-Max bHLH ZIP transcription factor as an oncoprotein have not been 
deeply investigated. One of the reasons could be the lack of good synthetic routes or ligation strategies 
which could provide sufficient material to investigate the functions of the protein in detail. Unfortunately, 
the simplification of this construct has not been deeply investigated either. On the other hand, despite 
sharing the same mode for DNA recognition, artificial models of bZIP transcription factors have been 
developed by several groups56–58,127,170 as presented in chapter 2. The eukaryotic bZIP and bHLH-ZIP motifs 
have one of the simplest protein structures capable of sequence-specific DNA recognition on the major 
groove. The structural motif of bHLH is very similar to the bZIP. They are both characterized by a 
dimerization domain, the basic Helix-Loop-Helix-Zipper, which is a prerequisite for DNA binding. They 
both also havea DNA recognition domain – the basic region Max (Ala701-Asp716) and Myc (Asn500-
Asn515), which contain the α-helical peptides responsible of the specific DNA binding. The main 
difference is, however, the interface between the two domains. In case of the bHLH proteins, the α-helices 
are interrupted by a loop, while in bZIP they are continuous (figure 5.3).  
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Figure 5.3: Crystal structures of the (A) cMyc-Max protein and (B) GCN4 protein bound to DNA. 
Despite the lack of chemical models for the cMyc/Max TF, a successful mimic of the MyoD-MyoD bHLH-
type TF was reported by the Morii group171. This encouraged us to modify our successful peptidosteroid 
conjugation strategy to synthesize a heterodimeric counterpart. In our group we have previously attempted 
to synthesize artificial mimics of this oncoprotein, however, with unsuccessful DNA binding172. As a 
conclusion in the article, it was proposed that a spacer between the steroid-like dimerizer moiety and the 
basic region of the peptides would facilitate the appendage of the peptides in the correct position to bind to 
the major groove. Therefore, we report here the synthesis of an optimized model of bHLH ZIP transcription 
factor that binds specifically to its nonpalindromic target DNA sequence. 
5.2 First design developed in the OBCR group 
Our first model was developed during the PhD thesis of Dieter Verzele78 and was based on the decoration 
of an orthogonally protected diamine deoxycholic acid-based scaffold, C3α-NHAlloc, C12α-NHBoc-
diamino-5β-cholan-24-oic acid48,74 with the cMyc and Max basic region peptides at the C3 and C12 
positions respectively synthesized by linear Fmoc/tBu SPPS79. As a result of orthogonal N protection, a 
unique feature of the applied scaffold is the straightforward solid-phase generation of homo- as well as 
heterodimeric peptidosteroid tweezers. As reported in chapter 2, steroidal building blocks have been 
broadly studied in drug design due to their amphiphilic nature, bioavailability and trend to enhance peptide 
biostability. More importantly the properties they possess are vital and related to the design of transcription 
factor models, i.e. they have a rigid core structure, the correct dimensions for the appendage of peptides 
which allow major groove binding and they also increase helicity of appended peptides. For synthetic ease, 
the natural spacer and carboxylic acid functionality at C24 allowed the anchoring of the scaffold on 
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TentaGel solid support and the development of a strategy on solid phase. UV irradiation of the Holmes’ 
photolabile linker (nitroveratryl-based photosensitive linker 2 (4-{4-[1-(9-
fluorenylmethoxycarbonylamino)ethyl]-2-methoxy-5-nitrophenoxy}-butanoic acid)88 was chosen as a 
cleavage strategy due to its compatibility with other functional groups and orthogonality to the conditions 
used during peptide synthesis and to Alloc and Boc deprotections. The desired compound could thus be 
released as a primary carboxamide at C24 (Figure 5.4).  
 
Figure 5.4: Synthesis scheme for the appendage of the linker and the scaffold to the solid support. i) PyBOP, DIPEA, 
DMF, 3h, rt. ii) 20% piperidine/DMF 2 x 30 min. iii) HATU, DIPEA, DMF, 2 x 4h.  
 
Decoration of the C12 position with the first peptide should precede the C3 derivatization due to steric 
constraints imposed by the steroid structure and additional hindrance upon the presence of peptide at C3. 
Relying on the orthogonality of Alloc and Boc protecting groups, acidic deprotection afforded a free amine 
at the C12 position on which the protected amino acid residues corresponding to the cMyc or Max peptides 
were coupled. HATU/DIPEA couplings were performed for efficient peptide synthesis. Capping of the N-
terminus was necessary for further decoration at the C3. Alloc deprotection of the amine at the C3 gave the 
second anchoring point for the coupling of cMyc or Max amino acid residues using HATU once again as 
an efficient coupling reagent for the sterically hindered amines. The final capping of the peptide strand at 
the N-terminus afforded the protected peptidosteroid tweezer. After cleavage from the resin and 
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deprotection of the side chains, the desired cMyc/Max bHLH TF model was obtained (figure 5.5) and 
subjected to DNA binding studies by the Electrophoretic Mobility Shift Assay (EMSA) (figure 5.6). 
 
Figure 5.5: Synthesis scheme of model developed by Dieter Verzele. iv) 20%TFA/DCM 2h, rt. v) automated 
synthesizer. HBTU, DIPEA, 3h; 20% piperidine in DMF, 2, 5, 25 min. vi) Alloc deprotection. Pd(PPh3)4, Bu3SnH, 
morpholine, DCM 2h rt. vii) automated synthesizer. HBTU, DIPEA, 3h; 20% piperidine in DMF, 2, 5, 25 min. viii) 
UV irradiation. ix) TFA/TIS/H2O (95:2.5:2.5) 3h, rt, precipitation in cold ether. 
Careful analysis of the results obtained from the EMSA indicated that the interactions were non-specific in 
nature as the peptide-DNA conjugate precipitated in the wells (Lanes 4 and 5). This was due aggregation, 
mainly based on electrostatic “sticking” of the mimics to the phosphate backbone, which is qualitatively 
very distinct from tight, sequence-specific insertion of α-helices in the DNA-major groove as observed with 
genuine TFs (Fig. 5.6).  
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Figure 5.6: EMSA titration of the heterodimer and monomer (lanes 2 and 2’) to the E-Box binding site (lanes 1-5) 
and to a random sequence (lanes 1’-5’) to dsDNA (68.75 nM). Lane 1-5 contain respectively 0, 50, 4, 20, 40 µM, 
stained with SybrGold. Target dsDNA 5’-CTACTAGCACGTGCTAGTAG-3’. Random dsDNA 5’-
GAAAATCACCCAACTGCA-3’. 
 
Figure 5.7: Pictorial illustration of different DNA binding modes to dimeric TF models. 
Molecular visualization of the first generation design allowed the assessment of the structural restrictions 
for DNA binding at the major groove. Insight into the view of the cMyc-Max synthetic protein bound to its 
target E-box DNA sequence, determined at a high 1.9 Å resolution, provided an excellent model for present 
research168. This data can be found at the Protein Data Bank website under the name “PBD-ID: 1NKP”. 
Visualization and evaluation of the DNA binder in the presence of the E-Box target sequence by 
modification of the PDB file features with Discovery Studio allowed the identification of the main problems 
for DNA recognition. The X-ray structure is shown in figure 5.8. The heterodimeric protein is depicted as 
helical ribbons with different color codes for each monomer.  
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As shown in figure 5.8, due to the direct appendage of the cMyc and Max basic region peptides onto the 
steroid scaffold, correct dimerization of these peptide helices was hampered. Because of the incorrect 
insertion of these peptide helices in the DNA major groove, essential contacts between the side chains and 
DNA are absent, causing the disruption of the DNA recognition. Due to the steric encumbrance of the 
peptide at the surface of the major groove, it was demonstrated that the model could not properly grip the 
DNA due to the rigidity imposed by the scaffold and the large space between the C-termini of both basic 
region peptides (Figure 5.6). Therefore, we proposed the need for an adapted design, once again indicating 
potential benefits of a spacer moiety between steroid scaffold and basic region peptides. This was to be 
done via the addition of 1 helical turn (approximately 4 amino acids) at the C-termini to the 17-residue 
cMyc/Max peptides. In following section, we will describe the design of an optimised Myc/Max bHLH TF 
model taking into account the synthetic conclusions from chapter 2.   
 
Figure 5.8: Molecular visualization of Myc/Max bHLH TF model (A) and its insertion into the DNA major groove 
from different perspectives (B, C and D).  
5.3 Design of an artificial c-Myc/Max bHLH Leucine Zipper TF with the potential for sequence-
selective DNA recognition. 
Based on the conclusions of our previous results, we decided to elongate the basic region peptides at the C-
terminus and incorporate a linker on the final peptide-steroid conjugate in order to increase flexibility and 
correct conformation in an attempt to achieve binding in the major groove of the DNA.  
As a result of our successful methodology in chapter 2, a convergent approach was again applied for the 
appendage of the peptides onto the scaffold. In order to dimerize the peptides cMyc and Max onto the 
scaffold, an orthogonally-functionalized deoxycholic acid derivative was synthesized. This would then 
allow the incorporation of the basic region peptides of cMyc and Max oncoproteins in a sequential fashion. 
As we have previously reported, an aliphatic linker is needed for DNA binding of our transcription factor 
mimics. Therefore, we chose 4-maleimido-butyric acid and pentynoic acid as potential linkers to allow 
DNA recognition at the major groove and selective conjugation of both peptide strands onto the 
heterodipodal scaffold. The first conjugation at the C12 position was performed via a thiol-ene conjugation 
through a Michael nucleophilic addition to a cysteine-contained peptide resulting in a succinimidyl 
thioether moiety. The second conjugation was achieved via CuAAC at the C3 alkyne-functionalized 
scaffold. The conjugation was compatible with the presence of the peptide chain at C12. Both succinimidyl 
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thioether and triazole moieties are generally accepted as stable linkages under physiological conditions. 
Because of the results obtained when using CuAAC as a conjugation strategy for the GCN4 deprotected 
peptides to the 3,12-diyl bis(pent-4-ynoate) linkers of scaffold 2.29, we considered CuAAC as the 
anchoring strategy for the challenging C3 position, sterically hindered by the presence of the monomeric 
peptide at C12.  
The steroid nucleus afforded a unique advantage for the modification in case of the heterodimeric tweezers. 
The concave structure of the inner face of deoxycholic acid ensured different chemical reactivity for the 
alcohols at the C3 and C12 positions173. Esterification of the alcohol group at C3 is therefore favored over 
C12. Prior to this derivatization, a nucleophilic substitution with benzyl bromide for the protection of 
carboxylic acid at C24 was mandatory to avoid side reactions while performing the esterification of 
hydroxyl groups. Selective attachment of pentynoic acid to the C3 was achieved by Steglich 
esterification174–176 in DCM by means of EDC (1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide 
hydrochloride) and catalytic amounts of DMAP (4-dimethylaminopyridine) as an efficient catalyst that 
increases the reactivity of the carboxylic acid towards the alcohol group. Complete esterification at C12 
with Boc-GABA-OH (4-(Boc-amino)butyric acid) was accomplished with EDC and stoichiometric 
amounts of DMAP in DCM. Acidic deprotection of the amine and subsequent maleimide formation 
provided the desired hetero-functionalized scaffold (figure 5.9). 
 
Figure 5.9: Synthesis scheme for the derivatization of deoxycholic acid (5.1) into the orthogonally functionalized 
deoxycholate derivative (5.4). i) DBU, Benzyl bromide, Dry DMF, 50°C, 24h. ii) Pentynoic acid, EDC·HCl, DMAP, 
dry DCM, rt, overnight. iii) Boc-Gaba-OH, EDC, DMAP, dry DCM rt, overnight. iv) 20% TFA/DCM, 2h, rt. v) 
Maleic anhydride, dry toluene. 80°C, 24h.  
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The elongated cMyc and Max basic region peptides were synthesized on a Rink amide ChemMatrix resin. 
Both peptides sequences were modified at the C-terminus. A cysteine was added to the C-terminus of the 
cMyc and the azido-homoalanine was added to the C-terminus of the Max. These residues were coupled 
manually. Further automated SPPS of the cMyc (NVKRRTHNVLERQRRNELKRGC) and Max 
(ADKRAHHNALERKRRDHIKDGAha) peptides was performed with HBTU as a coupling reagent and 
DIPEA as a base. N-terminal capping was done with 4-acetamido-benzoic acid and the final cleavage and 
deprotection using TFA/TIS/H2O = 95/2.5/2.5 afforded the recognition units for the conjugation onto the 
scaffold.  
 
Figure 5.10: Synthesis scheme for (A) cysteine and (B) azido-functionalized GCN4 peptides (5.10 and 5.13 
respectively) and crude RP-HPLC chromatograms (Jupiter C4 300Å, 0-100% ACN in 15 min). a) Fmoc-Cys(Trt)-OH 
or Fmoc-Aha-OH, PyBOP, DIPEA, Dry DMF, rt, 1h. b) 40% piperidine/DMF 2 x 30 min. c) Automated synthesizer. 
HBTU, DIPEA, DMF 1h. 20% piperidine/DMF 2, 5, 15 min. d) TFA/TIS/H2O (95:2.5:2.5) 3h, rt. e) Precipitation in 
cold ether. 
 
The heterodipodal peptidosteroid conjugate was synthesized by the conjugation of the cMyc-derived 
peptide to the maleimide-containing scaffold. The reaction was performed in ACN/H2O (1:4) to ensure 
maximum solubility of both the peptide and the scaffold. NH4HCO3 buffer was used to fix the pH at 6.5. A 
slight excess of peptide was added. The reaction proceeded rapidly under mild conditions and with high 
specificity at room temperature and in an open atmosphere. Formation of the monomeric intermediate and 
consumption of the peptide was monitored by HPLC and MALDI. Maximum consumption of the scaffold 
was achieved after 2 hours. Presence of excess scaffold and absence of the peptide indicated that the 
impurities in the peptide in the form of salts or deletion sequences affected the ratio of peptide/scaffold. 
Because of the compatibility of the thiol-maleimide and CuAAC conjugations, we decided to continue with 
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the final step. Due to the compatibility of the excess reagents with the subsequent CuAAC, the crude 
reaction mixture was subjected to the conjugation at C3 without purification of the monomeric construct. 
Residue 5.5 was dissolved in DMSO and the elongated Max peptide dissolved in ACN/H2O (1:4) was added 
in excess. Cu(CH3CN)4PF6 dissolved in dry DMSO was then added to the reaction mixture. Consumption 
of the monomeric starting material was followed by HPLC. The reaction was found to be complete after 
3h. Due to the excess of scaffold 5.4, the monomeric peptidosteroid conjugate at C3 5.6.b was also present. 
Compound 5.6 was purified by RP-HPLC (figure 5.11). 
 
Figure 5.11: Synthesis scheme of final heterodipodal Myc/Max steroid conjugate 5.6 and RP-HPLC chromatograms 
of peptide 5.10 (A), cysteine conjugation reaction mixture towards 5.5 (B) and second conjugation via CuAAC to 
obtain final compound 5.6 (C), further purified by RP-HPLC (D) (Jupiter C4 300Å, 0-100% ACN in 15 min). i) 
H2O/ACN 1:1 NH4HCO3 pH 6.5 rt, 2h. ii) Cu(CH3CN)4PF6 DMSO/H2O rt, 3h. iii) CuAAC to excess of scaffold 5.4 
as side reaction. 
5.4 Concentration determination via ERETIC-NMR  
As reported in chapter 2 and 3, 1H-ERETIC technique was again chosen as method to accurately determine 
the concentration of 5.6 for the EMSA study. Aromatic signals from the 4-acetamido-benzamide moieties 
at the N-termini, the 2 protons of each histidine of the peptides, the 5 protons of the benzyl ring at the C24 
of the scaffold and the 5-H of the triazole were present at the aromatic region. The coupling pattern of the 
histidines is 4 singlets at 8.5 ppm from the 2-H and at 7.1 ppm from the 5-H of the imidazole moieties at 
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the side chains. The 5 protons of the benzyl ring at C24 show a multiplet at 7.25 ppm. The 4-acetamido 
benzoamide shows a more complex coupling than previous compounds, probably due to the fact that the 
last amino acids at the N-termini are different. Doublet of doublets are present at 7.65 ppm and at 7.42 ppm, 
each corresponding to four protons. On the other hand, the proton of the triazole is not visible, probably 
due to the low concentration of the sample and the low intensity of the signal (figure 3.8). The protons of 
histidine were used as signals to estimate the concentration of the sample from the reference sample. 1H-
NMR was performed in D2O and the aromatic region was amplified for better integration due to the low 
concentration of the sample. The correlation between the integral values and the reference sample gave the 
concentration of the sample: 88 µM.  
 
Figure 5.12. 1H-NMR (D2O, 500 MHz) of the aromatic region of compound 5.6 an integration of the signals 
corresponding to the 4-acetamido-benzoamide moieties at the N-termini of the peptides. 
5.5 DNA binding studies using EMSA 
The procedure for the EMSA study is described in section 10.4. 
Figure 5.12 shows the formation of an upper band corresponding to the DNA-peptide complex formation. 
Due to the incomplete annealing of DNA, a ssDNA band on the bottom of the gel is present. Since there is 
no binding to the single strands, we hereby see the potential of the peptidosteroid tweezers to resemble the 
affinity of the natural bHLH TF families to their dsDNA sequence. In the last lane of the gel all material 
has disappeared probably due to unselective electrostatic interactions which are common at higher 
concentrations due to increase in both positive and negative charges and mass. 
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Figure 5.13: EMSA titration of the dipodal peptidosteroid to the E-box binding site stained with SybrGold.  
Concentrations for lanes 1-10 in µM: (0, 0.167, 0.334, 0.501, 0.584, 0.668, 0.751, 0.835, 1.169, 1.67). 
For a better interpretation of the peptide-DNA complex, a molecular visualization process was performed 
for compound 5.6 with the dsDNA using Discovery Studio. In figure 5.13 it is observed that the dimer can 
perfectly interact with the major groove of the DNA. 
 
Figure 5.14: Molecular visualization of Myc/Max bHLH TF model 5.6 (A) and its insertion onto the DNA major 
groove from different perspectives (B, C and D). 
In order to obtain a more quantitative picture, an electrophoretic Mobility Shift Assay (EMSA) with 32P-
radiollabeled DNA of the purified compound 5.6 was performed to test the DNA binding affinity of the 
synthetic mimic to the natural binding site of the protein (E-Box: 5’ – CTA CTA GCA CGT GCT AGT 
AG – 3’) in a suitable concentration range of the construct.  
5.6 Conclusion 
To conclude, we have presented here the first successful synthetic mimic of the cMyc-Max heterodimer. 
The potential of a reduced-size bHLH-ZIP cMyc/Max TF to recognize its dsDNA binding sequence was 
also tested and the results show that an optimized and miniaturized version of the protein contains all the 
necessary features to form a complex with dsDNA in a sequence-specific manner (Figure 5.12). In addition, 
we show the possibility of selective functionalization of steroid-based scaffolds to synthesize heterodimeric 
peptide-based conjugates, broadening the application of current methodology to other families of TF, such 
as bZIP Fos/Jun TF. In addition to the above, our design overcomes the difficulties of the decoration of 
Chapter 5: From artificial homodimeric TF mimics to a heterodimeric TF mimic 
 
98 
 
building blocks by the well-known SPPS, since it is based solely on conjugation strategies in solution phase. 
This can be considered the first model of an oncoprotein accessible by synthetic methods. 
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CHAPTER 6 
 
DEVELOPMENT OF A NEW, CONVERGENT ONE-POT CROSS-RESIN 
LIGATION (OPCRL) APPROACH 
 
Solid-phase synthesis to access peptidosteroid conjugates has been extensively researched by the OBCR 
group. The continuous exploration of this area has given the group new methodologies which overcome the 
difficulties of the linear coupling of amino acids to bile acid scaffolds. PhD theses prior to this one have 
been devoted to finding better synthetic routes for the same. The diverse application and broad scope of 
this unique conjugation has always encouraged the group to search for new conjugation methodologies. In 
this chapter we look at one such technique. 
 
6.1 Introduction 
 6.1.1 Protein/peptide synthesis in solution phase 
The synthesis of proteins has been a long-standing challenge. Isolation of proteins from complex biological 
mixtures is tedious and low yielding. Recent advancements in biotechnology utilizing site-directed 
mutagenesis and recombinant expressions have allowed synthesis of larger quantities of proteins, although 
with low yield due to aggregation issues. Despite the merits of these strategies, protein composition is 
limited by the ribosome-mediated biosynthesis. Protein structure, function and properties are further 
restricted by the genetic code. On the other hand, synthetic chemistry represents a source of versatility for 
protein modifications by segment ligations, incorporation of unnatural amino acids and building blocks and 
conjugation with other macromolecules. Development of new synthetic methods and improving the 
efficiency of peptide and protein assembly are thus one of the major challenges in bioorganic chemistry. 
Ligation protocols for protein synthesis have been studied for more than 100 years, with the first precedent 
in 1906 developed by Emil Fisher177. Classical methods for ligation of fully-protected peptide segments 
consist of the condensation of the N- and C- termini in organic solvents due to solubility issues of the 
fragments. Due to poor purification, execution and analysis, ligation methodologies based on the 
conjugation of deprotected peptides by natural amide bonds were needed. Native chemical ligation (NCL) 
involving the chemoselective reaction of an N-terminal cysteine residue and a C-terminal thioester moiety 
allowed the exploration of natural amide bond formation between deprotected peptides. 
Although NCL has been subjected to several improvements and achievements, synthesis of complex protein 
structures requires the condensation of more than 2 peptide fragments. Therefore, different orthogonal 
conjugation strategies involving several functional groups compatible with each other need to aim at 
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formation of natural amide bonds or the chemoselective formation of a non-peptidic bond. Within the latter 
one, bioconjugation strategies with wide utility involve of the formation of thioesters and thioethers. More 
recently the Copper Alkyne-Azide Cycloaddition (CuAAC) has gained particular attention due to the close 
resemblance of triazoles with amide bonds. On the other hand, amide bond formation can be achieved by 
other synthetic strategies that are compatible with NCL, allowing the synthesis of the backbone of native 
proteins. Next to the thioacid-azide amidation ligation and the reverse NCL, traceless Staudinger and 
KAHA (α-Ketoacid–Hydroxylamine) ligation are gaining particular attention. 
The production of larger proteins requires the application of multiple ligation steps. The efficiency depends 
on the number of segments to be assembled and the yield of each ligation. Condensation steps mostly 
require repeated purification and lyophilisation procedures. Handling of peptide fragments results in low 
yields, hampering the generation of higher quantities of protein. In principle, a solid-support would prevent 
material losses and enhance the yield of the peptide segments assembly as in this case the purification and 
ligation steps can be avoided.  
 6.1.2 Protein/peptide synthesis on solid phase 
Total chemical synthesis of proteins has been achieved with solid-phase peptide synthesis. It started 
however with peptide synthesis and not protein synthesis. The first description of solid-phase synthesis of 
a peptide was reported in 1963 by Merrifield178. He successfully attached an amino acid to the solid support 
via its carboxylic group, followed by the coupling of the next amino acid, bearing an activated carboxyl 
group and a protected amino terminus. After more than 30 years of improvements on the original 
methodology, the total chemical synthesis of a protein, the HIV-1 protease was achieved179. Despite the 
recent developments in solid phase chemistry by the introduction of new polymeric supports, linkers and 
protecting groups, the complexity of the protein structure and length hinder the access to protein synthesis 
by the sequential assembly of amino acids. On the other hand, complex proteins have been synthesized by 
the convergent assembly of protected or deprotected peptide segments by sequential chemoselective 
reactions on the polymer-supported polypeptide chain – the so called solid-phase chemical ligation 
(SPCL)180. 
Convergent approaches on solid phase towards peptide conjugations have not been limited to the synthesis 
of proteins. They are commonly employed for the preparation of bioconjugates of peptides and building 
blocks such as carbohydrates, cyclodextrins, bile acids and oligonucleotides. Bile acids have received 
special attention over the last decades due to a unique combination of rigidity and chirality coupled with a 
broad range of functionalization patterns with tunable reactivity, high availability and biocompatibility. 
Previous constructs developed in the OBCR group such as artificial estrogen receptors for endocrine 
disruptor chemicals181, serine proteases71 and haemagglutinin noose epitopes (HNE)182 mimics and DNA 
binders58,172 based on bile acid-peptide conjugates encouraged us to explore new synthetic strategies to 
overcome difficulties in the synthesis of peptidosteroid conjugate with long peptide chains mainly due to 
aggregation of protected peptides with the steroid. The limitations observed and encountered while using 
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peptide ligation in general intrigued us to investigate the development of a new convergent strategy for the 
synthesis of peptide conjugates.  
6.2 New protocol for peptide chemical ligation 
 6.2.1 The need for a new strategy in peptide conjugation 
Convergent ligation of peptides on solid-phase has been studied from a broad perspective and several 
difficulties have been encountered. Assembly of protected peptides to non-peptidic structures or to other 
protected peptides is synthetically challenging due to the poor solubility of such hydrophobic compounds. 
Losses while handling these segments and poor ionization makes the analysis of protected peptides 
complicated. Therefore, we felt a need to return to the basics of peptide handling and protection. From a 
practical perspective, we considered focussing on a solid-phase resin as a keystone for peptide synthesis. 
The sole precedent is of DeGrado and co-workers183 who dealt with the synthesis of linear oligopeptides. 
The group of DeGrado employed oxime resin derived esters of a peptide, which was cleaved by 
transacylation with a nucleophilic activator to form an active ester in solution. The transfer of the peptide 
to the second resin occurred via a nucleophilic attack of a primary amine on solid phase, resulting in an 
amide bond formation. Due to the particular characteristics of this methodology, they named it as a Resin-
to-Resin Transfer Reaction (RRTR). RRTRs are characterized as triphasic systems involving two 
independent solid-phases and a shared solution phase. It usually also involves a transfer between them and 
a reaction involving both resins as the name implies. Following this idea, the group of Hall reported the 
synthesis of arylglycine derivatives184 and unsymmetrically functionalized biphenyl compounds185 by 
RRTR. Consequently, we here present the possibility of applying the original RRTR methodology on the 
synthesis of peptide-based conjugates, an emerging area in supramolecular chemistry and multivalency186–
188 and of rejuvenating the concept of RRTR from its currently unknown status. 
 6.2.2 Description of our new protocol 
First attempts towards the development of this protocol were carried out during the PhD thesis of Dieter 
Verzele. He designed the synthesis of a heterodimeric, peptidosteroid, tweezer-type construct by RRTR, 
providing a proof-of-concept to our new strategy. His initial results encouraged us to continue exploring 
the optimal conditions which could provide the final conjugate. We hereby describe the so-called resin-to-
resin transfer reactions (RRTRs) to facilitate convergent peptide assembly by the one-pot conjugation of a 
resin-bound steroid and a polymer-supported protected peptide. The reaction is based on the in-situ 
liberation of the peptide from the donor resin and the appendage via amide bond formation to the acceptor 
resin bearing the steroid. This results in a peptidosteroid conjugate attached to a solid-phase (figure 6.1). 
Our new strategy requires the presence of two types of linkers, the side-chain protecting groups of the 
peptide and functionalities with the required reactivity for the ligation. 
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Figure 6.1. Triphasic Resin-to-Resin Transfer Reaction (RRTR) for the assembly of multivalent peptide conjugates, 
combining Ellman’s Safety-Catch (SC) linker and Holmes’ Photocleavable Linker (PL) with a chaperone that 
mediates solution-phase transfer by acting as both nucleophilic cleavage agent and activated carboxyl leaving group 
for in situ amidation. 
Orthogonality is thus one of the main challenges of the present idea. RRTR requires the selective cleavage 
from one resin without affecting the other. Therefore both linkers should be orthogonal and the cleavage 
steps should not require acid treatment due to the undesired premature deprotection of the side-chains. 
Therefore, we have chosen a photolabile linker for the appendage of the steroid scaffold. Described by 
Holmes in 199588, the o-Nitrobenzyl photolabile linker allows the release of the final peptidosteroid 
conjugate by simple UV irradiation of the resin. On the other resin, the peptide is attached to the solid 
support via a safety catch linker. Pioneered by Kenner in 1999189, he synthesized an arenesulfonamide linker 
and defined the safety-catch principle as “a stable bond that is eventually labilised at the appropriate 
moment by a specific chemical modification”. The two-stage cleavage protocol is an essential feature of the 
safety-catch methodology. Release of the assembled peptide from the solid-support requires a distinct 
activation step prior to liberation. Intrinsic stability of the specifically-designed, inactivated linker moiety 
prevents premature loss of the compound. Further improvements of the proof-of-concept were developed 
by Ellman and co-workers190,191. They synthesized 3-carboxypropanesulfonamide as a safety-catch linker 
in which the activation involves the selective N-alkylation of the N-acylsulfonamide group. The cleavage 
is performed by the attack of a mild nucleophile (figure 6.2). 
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Figure 6.2: C-terminal modification of peptides by Ellman’s safety-catch methodology. 
6.2.3 The solid phase as keystone 
The discovery of Solid-Phase Peptide Synthesis (SPPS) in 1963 by Merrifield178 resulted in a turning point 
in peptide synthesis research. It facilitated faster and more efficient peptide purification, shortened reaction 
times and increased the final yield. Due to the mentioned advantages, SPPS was chosen as the preferred 
strategy for further improvements in peptide and protein production over the now obsolete solution phase 
peptide synthesis. Since the synthetic difficulty depends largely on sequence composition and properties, it 
encouraged the rapid development of a broad range of solid supports, side-chain protecting groups and 
coupling reagents. Regarding the bioconjugation of protected peptides on solid-phase, the success of the 
reaction relies on the structural, physical and chemical properties of the beads. In addition, the polymeric 
support should be mechanically stable, inert to a broad range of conditions and swell sufficiently in polar 
and non-polar solvents. Reaction progress depends on the grade of diffusion of the side-chain protected 
peptide in the resin matrix. RRTR requires two solid supports for the assembly of both the steroid and the 
peptide. During the reaction, the peptide should have easy access to the polymer-supported steroid scaffold. 
Therefore, the penetration of the peptide into the beads is an important factor controlling the progress of 
the reaction. Consequently, we proposed TentaGel resin as solid-support for both counterparts. TentaGel 
resin (Rapp Polymere Ltd.) consists of polyethylene glycol (PEG) units cografted onto a low-cross-linked 
polystyrene, which confers a hydrophilic character and good swelling properties in water as well as other 
polar organic solvents such as DMF and DCM. Studies on bead permeability have revealed that the 
molecular motion in the matrix of the beads is similar to that in solution. In particular, it has been shown 
that trypsin, a 23.5-kDa enzyme, can penetrate into the core of the 90-μm TentaGel beads192. Keeping these 
properties in mind, commercially available TentaGel-based solid supports were assessed and the TentaGel-
NH2 resin was chosen for the attachment of the scaffold. Preloaded H-Gly-Sulfamylbutyryl NovaSyn TG 
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resin was chosen for the appendage of the peptide. As discussed above, the sulfamylbutyryl safety-catch 
linker is used to ensure the cleavage of the peptide by nucleophilic substitution. 
6.2.4 Synthetic procedure 
The first step in the synthesis of the acceptor counterpart on TentaGel-NH2 resin was the coupling of 
Holmes’ photolabile linker using PyBOP/DIPEA as a coupling mixture. The lack of adequate monitoring 
via HPLC due to UV-inactivity of the scaffold was efficiently solved via the incorporation of the 
chromophoric moiety. Thus, the second residue to be appended was 4-aminomethyl benzoic acid, to follow-
up the reaction progress by HPLC. Attachment of these moieties does not interfere with the subsequent 
RRTR methodology at the C12 (and C3) appendage. The orthogonally protected diamino deoxycholic acid 
derivative was coupled to the resin at the C24 position by a double-coupling with PyBOP. For 
straightforward decoration, the peptide generation at the C12-position should precede C3-derivatization in 
view of steric constraints. Already impeded by the steroid framework, additional hindrance upon prior C3-
derivatization generally renders the C12-position inaccessible. Therefore it is mandatory that the reaction 
at C12 be done first. Boc deprotection afforded the free amine at C12 (figure 6.3). 
 
Figure 6.3: Synthesis route for acceptor counterpart. i) PyBOP, DIPEA, DMF, 3h, rt. ii) 20% piperidine/DMF 2 x 30 
min. iii) PyBOP, DIPEA, DMF, 3h, rt. iv) 20% piperidine/DMF 2, 5, 15 min. v) HATU, DIPEA, DMF, 2 x 4h rt. vi) 
20% TFA/DCM 2h, rt. 
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The peptide was synthesized on a preloaded H-Gly-Sulfamylbutyryl NovaSyn TG resin using standard 
Fmoc/tBu protocols in an automated peptide synthesizer using HBTU as a coupling reagent and DIPEA as 
a base. The peptide sequence comprised of the C-terminal residues of GCN4 basic region (A244-Q248). 
As both the unprotected or N-Fmoc protected amino group would interfere during nucleophilic cleavage of 
the peptide, an N-terminal capping is required to block the nucleophilicity of the amino-terminus. Capping 
was mediated through the treatment of the resin with 1-AcIm in CHCl3, as a loss of compound has been 
reported when using acetic anhydride acetylation193. Prior to the RRTR, preactivation of the safety-catch 
linker was necessary to ensure proper liberation of the peptide during the reaction. N-cyanomethylation of 
the N-acylsulfonamide linker with iodoacetonitrile allowed cleavage of the amide bond by nucleophilic 
attack to the carbonyl group of the highly reactive N-cyanomethyl N-acylsulfonamide (figure 6.4).  
 
Figure 6.4. Synthesis route for donor peptide 6.9 comprising of the first 5 residues at the C-terminus of GCN4 basic 
region peptide. 
Once the peptide was activated, the donor and acceptor resin were mixed in a peptide reactor. Incorporation 
of NMP as a solvent allowed the swelling of the beads. The reaction started with the cleavage of the peptide 
from the donor resin and the activation of the carbonyl group by reaction with a NaSPh/HOBt/DIPEA 
cocktail. The presence of a thiophenolate ensured the rapid cleavage of the peptide with a thioester 
functionality at the C-terminus. In-situ equilibration of the thioester group yielded the corresponding OBt-
ester as a potential intermediate for facilitated coupling via the current convergent methodology (figure 
6.5).  
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Figure 6.5. Tentative mechanism of cleavage and peptide activation. 
A nucleophilic attack of the amine on the acceptor resin to the active OBt-ester resulted in the desired amide 
bond formation. A mere 5 equivalents of the donor-resin resulted in a significant conversion of starting 
material upon a 24h treatment. 50 equivalents of NaSPh, HOBt and DIPEA were added. Despite the basic 
properties of a sodium thiophenolate containing mixture, addition of DIPEA was essential for deprotonation 
of the accepting amine and thus ensuring its nucleophilicity. Washing and filtration steps allowed the 
removal of excess reagents and UV irradiation of a portion of the resin in ACN cleaved the C12-
peptidosteroid conjugate from the acceptor resin (figure 6.6).  
 
Figure 6.6. First RRTR to C12 bile acid position. (A) Synthetic conditions. (B) crude RPHPLC of starting acceptor 
after photocleavage. (C) crude RPHPLC after photocleavage showing complete conversion to (side-chain protected) 
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monomeric C12-peptidosteroid conjugate 6.11. (cleavage as C24-carboxyamides, equivalents relative to acceptor 
resin) (RP-HPLC conditions: Jupiter C4 300 Å; gradient 0 to 100% ACN  in 15 min). 
To prevent hydrolysis of the activated ester moieties which could be detrimental for the product, carefully 
dried components were applied. Instead of the generally applied hydrate form, hydroxybenzotriazole 
(HOBt) was used as such.  
Subsequent decoration at the C3 position towards obtention of the peptidosteroid tweezers by applying our 
RRTR methodology required the Alloc deprotection of the amine. The palladium-mediated 
hydrostannolysis with tributyltin hydride was used in the present work. Deprotection involved a palladium-
catalyzed transfer of the allyl-unit to a nucleophile (i.e. a scavenger) in the presence of a proton source. The 
same reaction conditions for the RRTR at C12 were applied at C3. Unfortunately, no trace of the desired 
compound was observed after UV-irradiation. Therefore, further studies were performed for the 
optimization of the final conjugation via RRTR towards obtaining the peptidosteroid tweezers. 
We concluded that there was a slow diffusion of the bulky, apolar side-chain, protected peptide 
intermediates in the cross-linked polystyrene matrix of the Tentagel-acceptor resin. Moreover, due to the 
sterical hindrance imposed by the scaffold, we proposed the incorporation of a linker at C3 to obtain a less 
hindered amine for nucleophilic attack onto the donor resin (figure 6.7).  
 
Figure 6.7. Derivatization of 6.11 with a GABA linker. i) Alloc deprotection. Pd(PPh3)4, Bu3SnH, morpholine, DCM 
2h rt. ii) Fmoc-GABA-OH, HATU, DIPEA, DMF, 4h rt. iii) 20% piperidine in DMF, 2, 5, 15 min. 
A variety of chaperone agents were tested in order to find the optimum conditions for the conjugation at 
the more challenging C3 position: HOBt, HOAt, HOSu and Oxyma Pure (ethyl 2-cyano-2-(hydroxyimino) 
acetate)194. Again, in line with the DeGrado precedent, either HOBt or HOSu performed equally well. HOSu 
was a good choice considering commercial scarcity of explosive benzotriazole-based reagents. A similar 
excess of donor 6.9 was reasonable considering the resin accumulation during the reaction, which can 
inhibit the cleavage of the peptide from the resin and the posterior conjugation to the acceptor resin. A 
larger excess of DIPEA was also needed, due to the sterically hindered position of the amine at the C3 and 
the resin accumulation. Monitoring of the intermediate compounds was carried out by RP-HPLC. In 
addition, the protected peptidosteroid conjugates were analyzed on a Jupiter C4 300Å column for polarity 
reasons due to the hydrophobic nature of the compounds. After the deprotection of the side chains, the 
desired final compound could be analyzed in good integrity, with both RP-HPLC and MALDI (figure 6.8).  
Chapter 6: Development of a new, convergent one-pot cross-resin ligation approach 
 
108 
 
 
Figure 6.8. Second RRTR to C3-position upon Alloc deprotection and GABA introduction to yield the desired dimeric 
peptidosteroid upon final deprotection and cleavage. (A) Crude RP-HPLC of (side-chain protected) C3-GABA derived 
acceptor intermediate 6.12. (B) Crude RPHPLC showing complete C3-RRTR conversion towards side-chain protected 
C12-C3 dimeric peptidosteroid 6.13. (C) Crude RPHPLC and (D) MALDI of desired dimeric peptidosteroid upon 
final cleavage and side-chain deprotection 6.14. (equivalents relative to acceptor resin) (RPHPLC with Jupiter C4 300 
Å; 0-100% ACN in 15 min and MALDI recorded in the positive and reflection mode). 
6.3 Conclusion 
In summary, we hereby present an upgrade of the classical condensation strategy, without the practical 
encumbrances often associated with synthesizing, isolating/purifying and handling of the separate peptide 
fragments to be conjugated. We have achieved the synthesis of a supramolecular, multivalent 
(bio)conjugate with precise geometrical and appendage composition through a fully and genuine solid-
supported methodology. Moreover, protected peptide fragment manipulations are troublesome due to 
solubility issues. Our convergent methodology combines the orthogonality of  Ellman’s safety-catch linker 
with the use of Holmes’ photolinker to obtain multipolymeric schemes with notable advantages over the 
last Convergent Solid Phase Peptide Synthesis. Consequently, it is a shortcut towards synthesis of larger 
and more complex polypeptides and architectures. Furthermore, it compensates for time-consuming 
purification.  
To highlight the main features of our procedure: there are no intermediates in solution which is typical for 
other ligations and excesses are easily removed. Therefore, handling of intermediate peptidosteroid 
conjugates is not necessary, ensuring higher yields and shortening the synthetic route. The proof-of-concept 
we present here is delivered using a scaffold featuring a combination of characteristics that include sterically 
hindered and concave positions. In close proximity, this could possibly cause problems such as incomplete 
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couplings with other ligation methodologies. Furthermore, we have achieved the strategic integration of 
Fmoc, Boc and Alloc chemistries, combined with the nucleophile susceptible Safety-Catch and photolabile 
cleavage.  
As mentioned above, advanced orthogonality, a simple and fine-tuned procedure and an entirely solid-phase 
procedure characterizes our methodology.  Moreover, our design can be adapted for other purposes such as 
to include an extra position between the scaffold attachment point and the photocleavable linker. This 
provides an extra dimension for multivalency which can be combined with further RRTR procedures as 
described herein. In conclusion, we describe the first use of resin-to-resin for multivalent decoration to 
access conjugates. Our strategy can be useful for solid-phase conjugations amenable to library formats. It 
is also applicable in areas as diverse as protein models, receptor enzyme design, chemical biology and 
classical medicinal chemistry, and compatible with microwave and flow chemistry.
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CHAPTER 7 
  
CASE STUDY: DESIGNING AN ARTIFICIAL SEQUENCE-SELECTIVE 
dsDNA NUCLEASE – SCOPE AND CHALLENGES 
 
The current PhD thesis has been developed within a Marie Curie ITN Network, PhosChemRec (short for 
Phosphate Chemistry Recognition), in which different European universities and companies have 
collaborated with each other for the study of phosphate recognition and cleavage. Due to the expertise in 
phosphate cleavage within the group of Nick Williams at Sheffield University, his PhD students Zeyed 
Abdulkarim and Emmanuel Tirel were involved in a collaborative effort directed towards the obtention of 
sequence selective dsDNA cleavers. In this chapter we describe phosphate cleavage and the design of the 
catalytic system, based on our peptidesteroid conjugate as a DNA recognition unit.  
 
7.1 DNA as storage for the genetic information   
The human genome consists of an estimated 20000 to 25000 human protein-coding genes. Each relevant 
gene should ideally be transcribed into mRNA and then translated into a protein. Due to the important role 
of DNA as the carrier of the genetic information in the cell function, degradation or damage of the DNA 
sequences by mutations and loss of the mRNA can have dramatic consequences. Thus, the integrity of the 
genetic code depends on the bonds in which the nucleosides are linked together in both DNA and RNA. 
Nature has selected phosphodiester bonds as stable linkages for shielding of the oligonucleotides’ 
composition and structure. The half-life of the hydrolysis of the DNA phosphodiester bonds at 25°C and 
pH 7.2 is approximately 31 million years, and has a k = 7 x 10-16 s-1 195. On the other hand, RNA is more 
prone to hydrolysis due to the presence of a 2’-hydroxyl group at the ribose ring. The estimated half-life 
for RNA is four years under the same conditions as those mentioned above for the hydrolysis of DNA196.  
This robustness of DNA is essential for the survival of all living beings from the tiniest simple cellular 
organisms to the one of the most complex being on earth in terms of genetic encoding – humans. If DNA 
was to degrade at a rate more rapidly than it was replenished in the human body, we would all have much 
shorter life spans. On the other hand, such hydrolytic inertness can also be a problem. Elimination of foreign 
DNA, excision and reparation of mutations and damages in the DNA sequence need to be addressed to 
ensure proper transcription and translation of the genetic information. To accomplish this task, enzymes 
called hydrolases are responsible for the hydrolysis of DNA at a physiologically relevant timescale. Despite 
the extreme inertness of the phosphodiester bonds, cleavage of these same bonds by natural enzymes is 
very efficient, providing impressive rate acceleration. As examples, serine or threonine phosphatases 
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accelerate the cleavage of phosphate monoesters by about 1021 -fold, while staphylococcal nuclease raises 
the rate of P–O cleavage in DNA by about 1017 -fold197.   
7.2 Cleavage of DNA: applications 
The enormous scope of having access to artificial, site-specific DNA cleavage coupled with the recent 
progress in genomics, biotechnology and manipulation of DNA for the execution of several processes has 
encouraged researchers to look towards synthetic tools capable of cleaving nucleic acids. Molecular 
biologists have attempted to cut DNA at a site that is not recognized by natural restriction enzymes. This 
can only be achieved if synthetic constructs which recognize these DNA sequences and cleave them are 
available to us since cleavage at a non-recognized site is not possible using natural restriction enzymes. 
Recognition and incision of sequences within double stranded DNA (dsDNA) are widely used in gene 
manipulation198 making this a highly pursued area of research. Thus, the design of synthetic enzymes 
tailored for the hydrolytic cleavage of DNA at the place of interest has found great utility199.  
In addition, synthetic hydrolases could serve as conformational probes for the determination of the three 
dimensional structure of nucleic acids, typically resolved by NMR and X-ray crystallography. Moreover, 
synthetic mimics could be helpful for the elucidation of the precise function of metal ions at the active site 
of natural hydrolases and also for the development of more efficient systems. DNA cleavers can also be 
found in antitumor antibiotics200,201 and chemotherapeutic drugs202–204. In view of our advances on dsDNA 
recognition, we proposed the decoration of our DNA binders with cleaving agents for the sequence-
selective cleavage of dsDNA. 
7.3 Mechanism 
Before we consider venturing into the challenging task of the artificial cleavage of phosphodiester bonds in 
DNA, a deep understanding of the mechanism of hydrolysis is required. Physical organic chemistry studies 
have provided a large amount of data concerning substitution reactions in phosphodiester groups205–208. In 
this chapter we explain the main points of the mechanism. The hydrolysis of phosphoester bonds involves 
substitution reactions and a pentacoordinate intermediate or transition state, called phosphorane and 
subsequent scission of the P-O3’ bond (scheme 1.1). 
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Figure 7.1: Proposed reaction mechanism for the hydrolysis of DNA. The enzymatically promoted 3’-O-P scission is 
shown. Lewis acids can be involved in activating water or the hydroxide as nucleophile or activating the phosphate 
group towards a nucleophilic attack (left).  
Depending on the grade of substitution of the phosphoester, the reaction may follow three limiting 
mechanisms (figure 7.2)197:  
1) The leaving group departure precedes the attack of the nucleophile and a metaphosphate intermediate is 
formed (DN+AN).  
2) The attack of the nucleophile occurs before the departure of the leaving group and the formation of a 
phosphorane intermediate occurs. A two-step mechanism (AN+DN) is operative.  
3) The bond formation between the nucleophile and the phosphorus atom along with the bond fission 
between the leaving group and the phosphorus occur simultaneously in a concerted mechanism (ANDN) 
and no intermediates are formed.  
Phosphate esters in general follow the last mechanism, and the structure of the transition state depends on 
the esterification grade of the phosphate, moving from higher dissociative to more associative character as 
going from mono- to di- and to tri-esters209. 
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Figure 7.2. More O’Ferral-Jencks diagram for the mechanism of phosphate esters hydrolysis4. 
The common feature of these three mechanisms is the maintenance of a -1 charge on the phosphoryl group 
in the transition state210. Thus, in phosphomonoesters the leaving group possesses a full negative charge. In 
phosphodiesters, the phosphoryl group holds the -1 charge during the process. In the case of neutral 
phosphotriesters, the negative charge is given by the nucleophile in a tighter transition state. In addition, 
the reaction mechanism is affected by the pH. At lower pHs, protonation of the non-esterified oxygen atoms 
decreases the charge of the phosphoryl group, and in order to maintain -1 charge, the hydrolysis shifts 
towards a more associative mechanism.   
Metal ions facilitate the hydrolysis of phosphoesters when acting as Lewis acids. The function of the 
metallic centers is the activation of the phosphate group for the nucleophilic attack, activation of water or 
hydroxide ions as nucleophiles or the increasing of the ability of the departing alcohol as the leaving group. 
These Lewis acids can activate the phosphate group towards a nucleophilic attack, activate water or a 
hydroxide as nucleophile or increase the leaving group ability of the departing alcohol211. The elucidation 
of the mechanism of hydrolysis of phosphate esters shows the properties that metals at the active site of 
enzymes possess. The metal binds the oxygen atoms and polarizes both the phosphate group and 
nucleophile. Therefore, both hardness and Lewis acid properties are desirable. To ensure turn-over of the 
catalyst, rapid exchange of the ligands coordinated to the metal should be feasible. 
7.4 First attempts towards synthetic nucleases 
In nature, hydrolysis of a phosphate bond can be carried out by different enzymes such as phosphatases212, 
nucleases (including restriction enzymes)213, and topoisomerases214, all via similar mechanisms. A 
substantial amount of research has already been conducted to develop artificial nucleases for the hydrolysis 
of phosphate esters and the hydrolysis of DNA. However, due to the extremely complex nature of the 
                                                          
4 Adapted from F. Mancin, P. Scrimin, P. Tecilla, Chem. Commun. (Camb). 2012, 48, 5545–59. 
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mechanisms and the kinetics involved there are still several questions unanswered. Some of the mimics 
which can be regarded as synthetic nucleases are described below: 
7.4.1 The precedents: free ions and mononuclear complexes 
In the early 90s, it was discovered that trivalent lanthanide ions accelerate the hydrolysis of DNA215,216. Ions 
do differ among themselves with regards to their affinity for DNA, but in general they show similar 
reactivity. Studies on Ce(IV) showed that this ion was 20 to 1000 times more efficient than any trivalent 
lanthanide217,218. Its higher efficacy was attributed to its very high electron withdrawing ability. Due to the 
toxicity of aqueous lanthanide ions in biological environments, it was concluded that free metal ions are 
not suitable for the design of artificial nucleases and that the formation of metal complexes is compulsory. 
On the other hand, formation of complexes with lanthanide metals decreases the activity in comparison 
with the free metal ion. One exception, however, is the Ce(IV)/EDTA complex which maintains the 
hydrolase activity. Other mononuclear complexes have also been reported, such as Co(III)219 and Cu(II)220. 
7.4.2 Bimetallic complexes 
Further improvements in design of artificial nucleases relied on the cooperation between two or more 
metallic centers to improve the catalytic efficiency. X-ray studies on natural metallonucleases with various 
metallic centers show that metal ions are in close proximity to each other. Consequently, an accurate 
location of the ions is needed when constructing the synthetic catalyst to benefit from the multiple 
interactions with the substrate and the activation modes that they provide to the hydrolysis. The first 
bimetallic centers for phosphate hydrolysis appeared in 1996, when simultaneous studies with mononuclear 
complexes revealed the potential of trivalent lanthanides to catalyze the reaction. Complexes containing 
two Eu(III), Pr(III) and Er(III) were reported, but low affinity for the substrate or low activity of the catalyst 
was obtained. In contrast to this result, double strand scission of plasmid DNA and linear dsDNA was 
achieved with Ce2(HXTA)221, with preference for the hydrolysis at the P-O3’ site.  
 
Figure 7.3. Structures of HXTA, HPTB and DPTB ligands. 
Besides lanthanides, Fe(III) is also present in phosphatases. Strategies towards bimetallic artificial 
nucleases based on Fe(III) have led to two main complexes, Fe2(HPTB)222,223 and Fe2(DTPB)224 (HPTB 
denotes N, N, N', N'-tetrakis(2-benzimidazolylmethyl)-2-hydroxy-1,  3-diaminopropane, and DTPB is the 
abbreviation of 1,1,4,7,7-pentakis(1H-benzimidazol-2-ylmethyl)-1,4,7-triazaheptane) (figure 7.3). The 
latter one has been thus far the best plasmid DNA cleavage agent under hydrolytic conditions. The case of 
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Cu(II) and Zn(II) is of particular interest225, as bimetallic centers of these ions did not improve the efficiency 
compared to their monomeric counterparts. It was concluded that strict structural requirements in dinuclear 
complexes were essential and significant work had to be put in before success with Cu(II) and Zn(II) were 
achieved. It has been proposed that introduction of flexibility in the final constructs may overcome the 
impediments observed. In order to improve cooperativity between cleaving units in artificial models, it was 
proposed that these should be appended on the helical structure of a peptide by side-chain modifications 
and on the surface of nanoparticles, to promote the self-assembling. Peptides and nanoparticles afford 
cleaving moieties with sufficient flexibility to enforce a proper orientation which can allow phosphate 
cleavage. 
7.4.3 DNA affinity units 
Results on DNA cleavage by oxidative agents suggested that an increase in DNA affinity could lead to 
higher reactivity. The first examples reporting the employment of DNA affinity units onto synthetic catalyst 
were based on intercalators such as ruthenium and rhodium complexes, naphthalene units, phenanthridine 
and anthraquinone-based conjugates. More sophisticated models include the polyamides or Dervan peptides 
226–228, PNA229, peptides230 and zinc-finger motifs231.  
7.4.4 Sequence selective elements 
The major applications of DNA hydrolytic catalysts are the development of artificial restriction enzymes 
and chemotherapeutic agents. Since the natural enzymes are highly sequence-specific, the synthetic DNA 
cleaving units must also have this property as part of their structure. This could be achieved by the 
conjugation of cleaving moieties to DNA recognition units with specificity towards a particular sequence. 
Due to the convergence of two highly challenging aspects, phosphate hydrolysis and DNA recognition, few 
models have been built so far which can recognize dsDNA and cleave it at a specific site. 
Since mimicking major groove transcription factors is synthetically challenging most of the models which 
can recognize a specific DNA sequence and cleave it use other DNA recognizers like the Dervan peptides 
(polyamides) or PNA or conjugated systems. Without going into too much detail a few examples are cited 
here. One of them achieved by Komiyama and co-workers232, in which Ce(IV) complexated into a DNA-
iminodiacetate cleaved a ssDNA at the P-O5’ site. Krämer followed another approach by the appendage of 
Zr(IV) complexes to PNA chains for the ssDNA cleavage at the P-O3’ bond233. Further improvements by 
Komiyama allowed dsDNA cleavage by Ce(IV)/EDTA complexes onto an oligonucleotide recognition 
unit234 or complementary PNA chain235. Very recent models could achieve dsDNA cleavage randomly by 
a polyamide-Zn(II) complex conjugate236 (figure 7.4 A) and specifically by a PNA-polyamide construct237 
through dsDNA invasion in addition to binding in the minor groove (figure 7.4 B and C). 
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Figure 7.4: A) Structure of a polyamide-Zn(II)-based conjugate236. B) Scheme of the recognition of dsDNA by 
combining the PNA invasion and Py-Im polyamide binding (recognizing 6 bp DNA). C) Structure of the PNA/hairpin 
polyamide conjugate237. DNA sequences recognized by each portion are presented. PEG=polyethyleneglycol. 
7.5 Our design: Towards a sequence-selective DNA nuclease inspired by the bZip TF 
As reported in chapter 2, we have been inspired by the leucine zipper motifs (bZIP) for the construction of 
DNA binders. Due to the simplicity of the structure, in which the basic DNA recognition region binds to 
the major groove as a dimer, inserting two α-helices held in the correct position by a dimerization domain, 
the bZIP TF can be modified into a design which could allow incorporation of cleaving moieties for the 
sequence-selective cleavage of dsDNA in the major groove. Simplification of the synthetic route via a 
CuAAC between the basic region peptides and the steroid scaffold took us to the next step which was design 
of sequence selective DNA nuclease. 
Encouraged by the low KD values obtained, we envisioned the usage of our artificial DNA binder as an 
efficient construct which could be used to study the mechanism of phosphate transfer within a protein-like 
construct. Since this system can mimic the interaction of natural nucleases to DNA more precisely than 
synthetic metal complexes we believe it can provide excellent insight into dsDNA cleavage with artificial 
nucleases in the major groove. However, several challenges have to be overcome in order to achieve our 
goal. The high affinity to CRE must not be destroyed when the synthetic nucleases are incorporated. Also, 
proximity and scission at both strands of the DNA, sequence selectivity, cooperativity, flexibility, reactivity 
and turnover of the catalyst are some of the factors which need to be considered before starting any synthetic 
work.  In view of the particular manner in which bZIP proteins bind DNA with each basic region binding 
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to only one DNA strand, we proposed the appendage of cleaving moieties in the side-chains of each peptide 
to achieve dsDNA cleavage. Despite the success in employing CuAAC for the conjugation, we foresaw 
possible competition between Cu(II) and Zn(II) ions for their complexation with the ligands. Therefore, we 
proposed maleimide-thiol conjugation for the appendage of basic region peptides to the scaffold (figure 
7.5) 
 
Figure 7.5. Design of DNA nuclease model based on bZIP TF. 
 7.5.1 Structural requirements. 
As investigated in previous models, the models which enable cooperativity between bimetallic centers 
showed higher reactivity than those which employed mononuclear centers. The use of peptides as templates 
for the appendage of catalytic unit allows the incorporation of various metallic centers by modification of 
the required peptide side-chains. Moreover, the strict structural requirements to form a bimetallic catalyst 
are overcome by the flexible secondary structure of a peptide. Thus, cooperativity between metal complexes 
can be achieved due to the self-assembly of the peptides in a favorable conformation towards a phosphate 
group in a single DNA strand. As mentioned before the substitution of residues in the basic region peptides 
is challenging as it should not compromise DNA affinity. However, if non-DNA binding residues are 
modified the cleavers will not be oriented in the correct direction. Therefore, we reasoned that only those 
residues with no direct contact with DNA but having an indirect interaction (via a phosphate or water to 
base) can be modified. As GCN4 is an α-helix, the side chains of the amino acids located every 3.6 residues 
are oriented in the same direction. Since it is not possible to modify the 3.6th residue in peptide sequence 
modelling was performed on the i, i+3rd and i, i+4th residue to facilitate cooperation between the cleaving 
agents (figure 7.6). 
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Figure 7.6. Bimetallic complexes on a peptide scaffold and their approach towards phosphodiester bonds in DNA. 
As previously mentioned, DNA recognition should not be hampered. Therefore, a molecular visualization 
was performed on the system to select the residues that could be modified for DNA cleavage. As the amino 
acids responsible for the DNA interaction were mainly in the middle of the sequence, we proposed the 
alteration of the peptide at the C or N-terminus. By molecular visualization, we concluded that suitable 
amino acids are Ala244-Leu247 and Ala228-Lys231 (figure 7.7). 
 
Figure 7.7. Molecular visualization of synthetic DNA nuclease and complex interaction with phosphates. 
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 7.5.2 Synthesis of the scaffold 
As mentioned in chapter 2, the steroid nucleus can serve as dimerizer for bZIP GCN4 transcription factor 
peptides. The optimization of the length and flexibility of the linker proved to be essential for enhancing 
sequence-specific DNA recognition. On the other hand, previous scaffolds were functionalized with 
alkynes or azides for the incorporation of the basic region peptides via CuAAC. Due to the possible 
interaction of copper in the cleaving ligands, DNA cleavage could be hampered as Zn ions will not be able 
to be complexed to form the cleaving units. Therefore, a different bioconjugation strategy was selected for 
the appendage of the peptides. Because of the availability of cysteine, and the possibility to functionalize 
the scaffold with maleimides, maleimide-thiol conjugation was chosen as method for the incorporation of 
GCN4 basic region peptides modified with the cleaving moieties.  
The first step in the synthesis was the protection of the carboxylic acid at C24, followed by esterification 
of both hydroxyl groups at C3 and C12 with Boc protected GABA. Further deprotection of the amines and 
conversion to maleimides with maleic anhydride provided the desired scaffold for dsDNA cleavage (figure 
7.8). 
 
Figure 7.8: Synthesis scheme for the derivatization of deoxycholic acid (7.1) into the maleimide functionalized 
deoxycholate derivative (7.4). i) DBU, Benzyl bromide, Dry DMF, 50°C, 24h. ii) Boc-GABA-OH, DCC, DMAP, dry 
DCM, rt, overnight. iii) 20% TFA/DCM, 2h, rt. iv) Maleic anhydride, dry toluene. 80°C, 24h. 
7.5.3 Cleaving units 
Catalytic units were designed and synthesized by Zeyed Abdulkarim, a PhD student in the group of Prof. 
Nick Williams at Sheffield University. As a partner of the PhosChemRec Network, we had the opportunity 
to combine our expertise in DNA recognition with their knowledge of phosphate cleavage. In collaboration 
with Sheffield, we designed a construct (figure 7.5) and proposed a synthetic route for the incorporation of 
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artificial nucleases into our construct which showed sequence specific DNA recognition (figure 7.8). We 
envisaged this construct could be the first major groove dsDNA cleaver to be synthesized in a difficult 
albeit doable synthetic route. Previous studies by Nick Williams and co-workers238–240 in Zn(II) complexes 
for phosphate ester cleavage served as a basis for the design of the cleaving moieties. The best results were 
obtained with complexes in which the ligands are based on pyridine moieties. In order to enhance the 
binding and the catalytic activity, two amino substituents have been incorporated to the pyridyl heterocycle 
as hydrogen bond donors for the stabilization of the transition state and to provide additional interactions 
in the active site238. Their successful results in bimetallic centers for phosphate esters hydrolysis prompted 
us to further investigate their incorporation on the basic region peptides. 2-aminobipyridyl ligands were 
modified for the assembly to amino acid side-chains via CuAAC (7.6). Formation of Zn(II) bimetallic 
centers is formed by the cooperation between monomers installed on residues A244 and L247 or A228 and 
K231. 
During this project, we discussed which metal complexes should be included and the synthetic strategy for 
their incorporation on the peptide (figure 7.9). We envisage that excellent results obtained at the group of 
Prof. Nick Williams in the synthesis and study of rate-accelerating and catalytic turn-over Zn(II) complexes 
will allow further modification for its conjugation onto DNA recognition peptides. CuAAC conjugation 
towards compound 7.7 was achieved. Further improvements in the optimization of the purification step is 
necessary. 
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Figure 7.9. A) Synthesis route of cleaving moiety 7.7 with a free carboxylic acid (in blue) for further incorporation 
into the peptide by SPPS. Conjugation of Fmoc-Propargylglycine-OH (7.5) to cleaving ligand (7.6) by CuAAC (i) to 
afford cleaving moiety 7.3. B) Synthesis route of GCN4 basic region peptides with cleaving moieties 7.7 to afford 
7.12 and 7.13 peptides. ii) 1st coupling: Fmoc-Cys(Trt)-OH 0.5M; PyBOP 0.5M; DIPEA 2M in Dry DMF, 2h, rt. 
Capping: AcO, DIPEA 2M, dry DMF; 2x30min. iii) Automatic synthesizer: cycles AA corresponding to GCN4 0.5M; 
HBTU 0.5M; DIPEA 2M in NMP, 1h, rt. Fmoc deprotection: 20% piperidine/NMP; 2, 5, 15 min. iii*) Manual 
coupling of cleaving moiety 7.7. Cleaving moiety 0.5M; HATU 0.5M; DIPEA 2M in Dry DMF, 4h, rt. Fmoc 
deprotection: 20% piperidine/NMP; 2, 5, 15 min. iv) Cleavage and deprotection: TFA:TIS:H2O (95:2.5:2.5) 3h, rt 
followed by precipitation in cold ether. 
7.6 Conclusion 
In this chapter we present our initial idea for the synthesis of artificial dsDNA nucleases on the major 
groove, based on transcription factor mimics. We have synthesized the required scaffold for the 
appendage of the peptides by maleimide-thiol coupling and we have identified the positions at which the 
cleaving moieties can be incorporated on the peptide for the optimal approach to the phosphates of the 
dsDNA. On the other hand, optimization of the catalytic activity of the ligands and the synthesis of the 
final catalytic moieties for the incorporation on the peptides need to be performed. 
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CHAPTER 8 
 
COLLABORATIVE PROJECTS WITHIN UGENT 
 
8.1 Design and synthesis of an artificial estrogen receptor as endocrine disruptor chemical 
binders. 
The first months of my PhD were dedicated towards the continuation of the work of Sara Figaroli, a former 
PhD student who defended her PhD in 2010181,241,242. The main aim of her research was the development of 
synthetic receptors for the binding of endocrine disruptor chemicals (EDCs). In this section, the synthesis 
of a new type of synthetic receptor for endocrine disruptor chemicals designed by Sara Figaroli is presented. 
EDCs are environmental pollutants and possess estrogenic activity. A large interest around these 
compounds has been generated as they interfere with hormone production and regulation and the 
reproductive systems of humans and wildlife. EDCs cover a broad range of compounds – from synthetic 
and natural hormones to pesticides and additives used in industry for the production of plastics. In addition, 
they are active at concentrations even below 1 ng/L. Thus, trace determination of EDCs in environmental 
samples is vital because of their activity at extremely low concentrations. Unfortunately, the trace 
determination of their presence in environmental samples is also tedious at such low concentrations given 
the limited tools at our disposal. Moreover, the analysis of EDCs in water is not straightforward due to the 
complexity of the environmental matrix. Examples of EDCs and their impact when binding the Estrogen 
Receptor at the Hormone-Binding Domain (ER-HBD) have been determined for diethylstilbestrol (DES), 
bisphenol-A (BPA), and 17β-estradiol (E2) (figure 8.1) among others243. 
 
Figure 8.1. EDCs studied via X-ray diffraction of their corresponding ER-complexes. From left to right: Estradiol 
(E2), diethylstilbestrol (DES) and bisphenol-A (BPA). 
To solve the challenging problems described above, the development of a high-throughput system was 
proposed which involved the pre-concentration of EDCs for further analysis. It was based on a solid-phase 
extraction (SPE) cartridge in which the artificial receptor was appended on a polymeric surface.  
The design of the artificial receptor was based on the structural data of the ligand-binding cavity of the 
Estrogen Receptor (ERLBC) with its natural ligand (E2) available at the Protein Data Bank (PDB). The 
binding pocket is constituted by amino acids that interact by hydrophobic and hydrophilic interactions with 
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the ligand. Thus, studying these interactions was crucial for the rational design of the synthetic receptor. 
The detailed analysis of the data of PDB 1ERE (figure 8.2)244 enabled the characterization of the single 
interactions between each amino acid with 17β-estradiol (E2). It was shown that the phenolic hydroxyl 
group of the A-ring interacted via hydrogen bonds with the carboxylate of Glu353, the guanidinium group 
of Arg 394, and a water molecule. The alcohol functionality at C17 established a hydrogen bond with 
Hys524. The remain parts of the E2 were involved in hydrophobic contacts via its A, B and D rings with 
the side chains of Ala350, Leu387, Met388, Leu391, Phe404, His524 and Leu525. 
 
Figure 8.2. Detailed view of ER-LBD complexed with E2 (1ERE). Only amino acid side chains with contact residues 
are depicted. 
In order to obtain a three dimensional cavity and better mimic the natural receptor, a steroid scaffold was 
used as the skeletal structure for the receptor. For a better mimic of the cavity, a cage-like receptor was 
designed by linking scaffolds together245,246. Further decoration of the scaffold with the necessary amino 
acids should provide the hydrophilic contacts to E2. With the aim of obtaining the optimal interactions 
between the amino acids, the hydrophobic moieties and the E2, we proposed a steroidal cage-like structure. 
This structure could afford the required hydrophobicity, while hydrophilic contacts were maintained by the 
replacement of the imidazole unit of histidine by a triazole ring and the arginine and glutamic acid were 
positioned at the C24 on the steroid nuclei, resembling the face-to-face interaction in the natural binding 
cavity. Due to the essential presence of the triazole, the cage-like structure could be obtained by CuAAC 
of both steroidal parts (figure 8.3).   
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Figure 8.3. Structure of the cage-like receptor 8.3 and its retrosynthesis. 
The synthetic receptor in figure 8.3 was modelled by Dr. P. Hendrickx using the software Accelrys 
Discovery Studio 1.7 (figure 8.4a). From those results, we could conclude that the cavity should allow 
accommodation of a molecule of E2. An overlap of the cage-like receptor in blue with the main residues of 
the natural ER-HBD in green complexed to E2 is depicted in figure 8.4b. The main structural differences 
between both receptors is: 1) the distance between the side chains of glutamine and arginine and 2) the 
position of both amino acids relative to the E2 molecule, as they are not facing the phenolic hydroxyl group 
in the artificial receptor.  
Figure 8.4. Molecular modelling of receptor with E2 (a) and comparison with the natural receptor (b)1.  
                                                          
1 Adapter from: PhD Thesis of Sara Figaroli. “Development of a Synthetic Receptor for Trace Determination of 
Endocrine Disruptor Chemicals”. Promoter: Prof. Dr. Annemieke Madder. Ghent University. 2012 
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For the evaluation of the binding capability of the synthetic receptor to E2, diffusion NMR was performed. 
Unfortunately, it was shown that the receptor did not have affinity for E2. As an improvement to this design 
for future studies, we suggested that a spacer between the amino acids arginine and glutamine and the 
scaffold may help to accommodate a molecule of 17β-estradiol. 
 8.1.1. Synthesis 
The synthesis of both alkyne and azide-containing components 8.1 and 8.2 were performed on a 2-
chlorotrityl chloride resin. The first step was the coupling of the amino acids arginine or glutamine followed 
by the anchoring of the scaffold. Further Alloc deprotection provided a free amine for the appendage of the 
linkers with an alkyne or an azide (figure 8.5). 
 
Figure 8.5. Synthetic scheme for the obtention of the alkyne and azide parts 8.11 and 8.12 respectively. i) Fmoc-aa-
OH, DIPEA, DCM (dry), RT 3h. ii) 20% piperidine/DMF, RT 2 x 20 min. iii) scaffold, PyBOP, DIPEA, NMR, RT 
24h. iv) PhSiH3, Pd(PPh3)4, DCM, RT 3 x 1h. v) 4-pentynoic acid, PyBOP, DIPEA, NMR RT 3h. vi) Fmoc-Gly-OH, 
PyBOP, DIPEA, NMP RT 3h. vii) 20% piperidine/NMP 2 x 20 min. viii) TfN3, NaHCO3, CuSO4·5H2O, MeOH, RT 
24h. 
Cleavage of both counterparts and conjugation via CuAAC afforded the cage-like receptor. Final 
deprotection of the Boc, tBu and Pbf groups and lyophilization with NaHCO3/Na2CO3 allowed formation 
of the correctly charged product 8.13. This charged state could enable the formation of a salt bridge between 
the side chains of arginine and glutamine that warranted the closure of the structure in a cage conformation 
that could act as the EDC’s receptor (figure 8.6). 
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Figure 8.6. Cleavage, conjugation and deprotection towards the obtention of compound 8.13. A) LC-MS 
chromatogram of pure compound 8.13 before lyophilization (Luna C18 (250x4.6 mm, 5 µm at 35°C; 0-100% ACN 
in 15 min). B) Corresponding ESI-MS spectrum at 11.250 min. M = 1345.7. Found = 1344.8 [M-H-] 671.5 [M/2 – H-
] and 447.2 [M/3 – H-]. 
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8.1.2. Conclusion 
The synthesis of a cage-like receptor for the accommodation of an estradiol molecule has been optimized. 
Unfortunately, NMR studies showed that there was no affinity between both counterparts. For further 
optimization of the design, we propose the incorporation of a spacer between arginine and glutamine and 
the scaffold, in order to enlarge the cavity for the proper interaction with 17β-estradiol. 
 
8.2 Development of water-soluble NHC-Cu Catalysts: Applications in click chemistry, 
bioconjugation and mechanistic analysis.    
This section has been published in Organic and Biomolecular Chemistry in 2014 (Online manuscript, DOI: 
10.1039/C4OB01350F) and as authors Heriberto Díaz Velázquez, Yara Ruiz García, Matthias Vandichel, 
Annemieke Madder and Francis Verpoort 247.  
This project was developed in collaboration with Prof. Francis Verpoort and his PhD student Heriberto 
Diaz to develop water-soluble NHC-Cu Catalysts: Applications in Click Chemistry, Bioconjugation and 
Mechanistic Analysis. The next paragraph serves as an introduction to this section, adapted from the article 
we published248. Although several catalysts have been developed for the Copper catalyzed Alkyne-Azide 
Cycloaddition reactions (CuAAC, better known as the Click reaction), in most cases they require the 
presence of co-catalysts such as auxiliary ligands, bases – mainly amines and reducing or oxidizing agents 
depending on the Cu source used, in order to enhance their catalytic activity, although in recent years single 
Cu salts have also been succesful249,250. Generally high Cu loading must be applied to ensure good 
performance of the catalyst251. Several Cu(I) complexes holding N-heterocyclic carbene (NHC) ligands are 
reported as catalysts for the Huisgen Cycloaddition reaction, however the catalysis is carried out at elevated 
temperatures and in the presence of organic solvents, under two-phase systems (when both reactants are 
not soluble) and only the 1,4-disubstituted triazoles are generated252,253. Moreover, their activity in solution-
phase is significantly lower than the other catalytic systems5. Here we report an unique Cu(I) based catalyst 
that enables the synthesis of triazoles with different substitution patterns, e.g. 1-, 4-, 1,4- or 1,4,5-substituted 
triazoles and at the same time, able to generate triazoles from acetylene in water, able to produce tosyl 
acetamides in aqueous media (figure 8.7).    
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Figure 8.7. A Synthesis of catalysts 5-8; B. Standard Click reaction monitored by 1H-NMR using catalysts 5 and 7; 
C Triazoles synthesized in this work. 
In the last decade, bioconjugation has become a common tool for chemists and biochemists as a result of 
the increase in peptide and protein research and development. This covalent functionalization of these 
biomacromolecules under physiological conditions gives rise to new areas of research such as drug 
discovery, high-throughput screening and in vivo testing. Therefore, many ligation methodologies have 
been studied and optimized254,255. The development of Click chemistry has caused an emerged interest in 
the functionalization of peptides with alkynes and azides, resulting in a broad variety of building blocks 
such as unnatural amino acids being currently commercially available. In practice, the application of 
CuAAC in peptide chemistry requires extra efforts for the optimization of the reaction conditions255. Traces 
of O2 can be reduced by CuI and sodium ascorbate into H2O2, a reactive oxygen species that can induce 
degradation of amino acids and cleavage of the polypeptide chain127,256–258. Thus, a catalytic system able to 
perform click reactions in biomacromolecules under reductant-free aqueous conditions will lead to a major 
step forward in bioconjugation chemistry. Furthermore, bioconjugation impose specific requests, such as 
exquisite chemoselectivity, biocompatibility, and the ability to work at low temperature still enabling fast 
transformations.  
To date the CuAAC reaction in the absence of an accelerating ligand is simply too slow259. In this context, 
we have studied the performance of our water-soluble NHC-Cu (I) catalysts for CuAAC reactions with 
unprotected peptides in aqueous conditions. We have chosen the DNA binding domain of the transcription 
factor protein GCN4, belonging to the bZIP Leucine Zipper family as a substrate for the reaction53. Indeed, 
modification of the GCN4 binding domain in the design of transcription factor models has been of particular 
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interest for gene therapy260. Surprisingly, there are no studies so far on the application of click chemistry 
on the modified GCN4 binding domain for conjugation purposes. Here, we report the successful 
functionalization of the peptide comprising the basic region DNA binding domain with an organic azide 
via click chemistry using the sulfonated NHC-Cu (I) catalysts.  
To further expand and illustrate the scope and potential of the developed catalysts, bioconjugation 
experiments with alkyne and/or azide tagged peptides were carried out.  Hereto, two peptides, one 10 mer 
and one 23 mer, comprising part of the N-terminal basic region of the Transcription Factor protein GCN4, 
were synthesized on 2-chlorotrityl chloride polystyrene resin. Propargyl glycine was incorporated as the 
first, C-terminal amino acid residue (figure 8.8) to provide for the alkyne functionality for further click 
reaction with benzylazide. Click reaction was carried out at ambient temperature in a deoxygenated mixture 
of water and hexafluoroisopropanol to disrupt H-bonding interactions within the peptide using 1.5 
equivalents of catalyst (6 for modification of 10mer GCN4 and 7 for 23mer GCN4 due to its higher stability) 
under anaerobic conditions overnight. The resulting modified peptides were purified by High Performance 
Liquid Chromatography (HPLC) and further characterized by Electrospray Ionization Liquid 
Chromatography connected to a Mass Spectrometer (LC-MS-ESI) and MALDI-TOF. Generation of the 
Cu-acetylide intermediate in such an environment is highly challenging, therefore a slight excess of catalyst 
6 is needed. In current context, it is further worth noticing that both sequences are rich in arginine residues, 
of which the guanidinium side chain can easily coordinate with copper and inhibit the reaction.   
 
Figure 8.8. The transcription factor protein GCN4, belonging to the bZIP Leucine Zipper family and the derived 
model peptide comprising the DNA binding domain. 
Functionalization of a peptide with an alkyne allows cycloaddition-based modification with a non-peptide 
azide moiety. These experiments underscore the potential for application of our water-soluble (NHC)2Cu 
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(I) catalysts 6 and 7 in the functionalization of deprotected peptides applying the CuAAC strategy. We 
haver further shown the use of sulfonate functionalized bis-NHC-Cu(I) water-soluble complexes in 
bioconjugation experiments, attaining for the first time the functionalization of an unprotected 25-
aminoacid chain peptide using low catalyst loading, which otherwise would need a much higher amount of 
Cu(I) to achieve high efficiency due to the chelating properties of certain aminoacid residues.  
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CHAPTER 9 
 
CONCLUSIONS & PERSPECTIVES 
 
Through this work, we have achieved the successful synthesis of major groove DNA binders based on bZIP 
and bHLH transcription factors for the sequence-selective recognition of DNA. Different models have been 
designed and synthesized and have given us insight in the structural features that influence the DNA binding 
capabilities of artificial binders. Moreover, we have also studied the cellular uptake of these constructs. 
In parallel, we have also achieved the development of peptidosteroid conjugates by means of a new peptide 
chemical ligation strategy. Finally, we have also taken the first steps towards the development of synthetic 
receptors of phosphatidylserine and its application on the early detection of apoptosis and as flippase 
mimics. 
 
9.1 Detection of phosphatidylserine 
Receptors with different cavities to accommodate phosphate anions were synthesized and tested for the 
detection of PS. The acyclic receptor with aliphatic chains (1.6) proved to be the best binder, probably due 
to the aliphatic chains that contribute via hydrophobic interactions with the lipid tails of PS.   
Prior to analysis in cells, the receptor should be tested for cell penetration. Detection of PS on the outer part 
of the membrane requires a compound that will not be able to transport the phospholipid across the cellular 
membrane. Although this could be possible, this negative result can be transferred to the development of 
synthetic flippases, the enzymes that transport PS from the outer face of the membrane to the inner face.   
In order to assess the externalization of PS in the cell, we envisage that a fluorophore will be needed for 
further analysis by flow cytometry. The special features of the steroid scaffold allow the assembling of this 
moiety through the C24 terminus (figure 9.1).  
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Figure 9.1. Structure of a fluorescently labelled receptor. 
9.2 Transcription factor models and cell uptake 
From the four peptidosteroid models of the GCN4 bZIP transcription factor presented in chapter 2, the one 
with a longer and more flexible linker proved to be the best synthetic DNA binder. This could be attributed 
to the fact that the longer linker allowed the construct to grip the major groove of the DNA like a pair of 
tweezers which was not possible in the case of the less flexible linkers. Its binding affinity was comparable 
with the earlier described models of GCN4 TFs, however, the synthetic route towards obtaining the current 
construct was considerably simplified. We also illustrated an unprecedented, optimized CuAAC strategy to 
conjugate relatively long, deprotected peptides to bile acid scaffolds in a convergent manner. In addition, 
our best DNA binding construct showed a clearly enhanced cell uptake when tested against RAW264.7 
mouse macrophages illustrating the particular properties of the cholic acid scaffold as a versatile dimerizing 
unit with low cytotoxicity at concentrations which allowed sequence specific DNA binding (figure 9.2).  
 
Figure 9.2: Characterization of (A) final synthetic construct using (B) HPLC (C) DNA binding (D) Confocal 
microscopy at 4°C and (E) 37°C. 
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In order to obtain further insight in the influence of the structural features for DNA recognition in synthetic 
binders we explored the potential of peptide-cyclodextrin conjugates for sequence-selective DNA 
recognition. This was achieved by the use of α, β and γ-cyclodextrin derivatives as scaffolds for the 
appendage of the peptides by CuAAC. Though examples exist of CuAAC reactions with CD derivatives, 
to the best of our knowledge long, deprotected peptides have so far not been conjugated to cyclodextrins 
via CuAAC. We here presented optimized conditions for the anchoring of such long peptides to 
cyclodextrin units via click chemistry. Our results indicated the usefulness of an optimized dimerization 
configuration between both peptides in artificial TF models. Indeed it was shown that the distance between 
the anchoring points influenced DNA binding (figure 9.3).  
 
Figure 9.3: EMSA for α, β and γ-cyclodextrin-peptide conjugates. 
To conclude, the potential of a reduced-size bHLH-ZIP cMyc/Max TF to recognize its dsDNA binding 
sequence was tested. The results showed that an optimized and miniaturized version of the protein contained 
the necessary features to form a complex with dsDNA in a sequence-specific manner (figure 9.4).  
In addition, we showed the possibility of selective functionalization of steroid-based scaffolds to synthesize 
heterodimeric peptide-based conjugates, broadening the application of the current methodology to other 
families of TFs, such as bZIP Fos/Jun TF. In addition to the above, our design overcame the difficulties of 
the decoration of building blocks by the well-known SPPS, since it is based solely on conjugation strategies 
in solution phase. This can be considered the first model of this oncoprotein accessible by synthetic 
methods. 
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Figure 9.4: Crystal structure of the cMyc-Max protein bound to DNA, designed synthetic mimic and DNA binding 
pattern. 
9.3 Resin to Resin Transfer Reaction (RRTR) 
In chapter 6 we described the last steps and optimisation of a new peptide chemical ligation strategy based 
on the resin-to-resin conjugation of the peptide and a steroid scaffold (figure 9.5). Our strategy can be useful 
for solid-phase conjugations amenable to library formats and applicable in areas as diverse as protein 
models, receptor enzyme design, chemical biology and classical medicinal chemistry. It can also be 
compatible with synthesis under microwave conditions. 
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Figure 9.5: Overview of the RRTR. 
9.4 Perspectives 
In the current thesis,  the DNA binding mimics of the basic region of the GCN4 Leucine zipper TF were  
the  key  compounds  that  were  tested  for  possible  future  applications  for  DNA binding  in cells.  
Despite the high binding affinity of the mimics towards dsDNA as shown via EMSA, there is still work to 
be done if this system has to succeed in vivo. Since there was no uptake in the nucleus for any of the 
constructs, we believe the first next step should be adding a short NLS to the construct which may enhance 
uptake in the nucleus as is observed for the Tat peptide261. For this purpose the –COOH functionality of the 
scaffold is the synthetically most accessible point. 
In chapter 7, we described our perspectives for the employment of synthetic DNA binders as artificial 
nucleases by the incorporation of cleaving moieties on the side chains of the peptide. We strongly believe 
that joint efforts between experts on peptide design for DNA recognition and phosphate hydrolysis will 
result in constructs with the potential to cleave sequence-selectively dsDNA on the major groove via 
hydrolysis of the phosphate group in the DNA backbone. Due to the on-going research on development of 
Zn(II) complexes for phosphate cleavage and mechanistic studies, different features towards more efficient 
catalysts have been revealed. Therefore, future attempts should provide a suitable catalyst for the 
challenging cleavage of a phosphodiester bond within dsDNA. 
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10.1 Products 
10.1.1 Solvents 
All organic solvents were purchased from commercial suppliers and used without further purification or 
drying. DMF extra dry (with molecular sieves, water < 50 ppm) and other dry solvents with sieves namely 
tetrahydrofuran (THF), pyridine and methanol (MeOH) were acquired from ACROS Organics. Anhydrous 
N-Methyl-2-pyrrolidone (NMP) was acquired from Fluka. N,N-Dimethylformamide (DMF) an NMP 
(peptide synthesis grade) were purchased from Biosolve. Ethyl Acetate, Acetonitrile, Methanol, Diethyl 
Ether, Et3N and DIPEA supplied as extra dry, redistilled, were purchased from Sigma Aldrich. HPLC grade 
quality Hexane and Chloroform were purchased from Fisher Scientific. Deuterated solvents CDCl3 (99.8% 
atom D), CD2Cl2 (99.9% atom D) and CD3OD (99.8% atom D) were obtained from Sigma-Aldrich. Water 
with the Milli-Q grade standard was obtained in-house either from a Millipore ROs 5 purification system 
or a Sartorius Arium 611 DI.  
TentaGel NH2 (0.28 mmol/g, 90 µm) was obtained from Merck Novabiochem and IRIS Biotech GmbH. 
preloaded H-Gly-Sulfamylbutyryl NovaSyn TG resin (0.24 mmol/g, 90 µm) were obtained from Merck 
Novabiochem.  
10.1.2 Reagents for peptide synthesis 
Rink-Amide ChemMatrix (100-200 μm, manufacturer’s loading: 0.52-0.54 mmol/g) was obtained from 
Biotage. 2-Chlorotrityl Chloride resin (100-200 manufacturer’s loading 1.6 mmol/g) was purchased from 
Iris Biotech GmbH. 
Fmoc-Propargylglycine-OH, Fmoc-Azidohomoalanine-OH, PyBOP and HBTU coupling reagents were 
obtained from either Merck Novabiochem or IRIS Biotech GmbH, while HATU (purum ≥ 98.0 %) was 
acquired from Fluka. TFA was purchased from Iris Biotech GmbH. NHS-Fluorescein was purchased from 
Thermo Scientific. Triisopropylsilane (TIS) and tris(2-carboxyethyl)phosphine hydrochloride (TCEP) were 
purchased from Sigma Aldrich and Phenylsilane was purchased from ACROS Organics.The Nα-Fmoc 
protected amino acids were purchased at Merck Novabiochem, IRIS Biotech GmbH and Fluka, or supplied 
by MultiSynTech GmbH. All chiral α-amino acids used in this paper possessed the L configuration. 
Throughout this work, residues with standard acid-sensitive side-chain PGs were used: Cys(Trt) [C], 
Asp(OtBu) [D], Glu(OtBu) [E], His(Trt) [H], Lys(Boc) [K], Asn(Trt) [N], Gln(Trt) [Q], Arg(Pbf) [R], 
Ser(tBu) [S], Thr(tBu) [T]. 
All reagents were acquired from commercial sources and used without prior purification. 
10.1.4 Reagents for EMSA 
Tris-borate-EDTA buffer 10x pH 8.3 (TBE buffer), ammonium persulfate (APS), 
tetramethylethylenediamine (TEMED), were obtained from Merck. SYBR Gold Nucleic acid gel stain was 
purchased from Life Technologies. 
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10.1.5 Oligonucleotides 
CRE   5’ – CGG ATG ACG TCA TTT TTT TTC – 3’ 
CRE complement  5’ – GAA AAA AAA TGA CGT CAT CCG – 3’ 
Random   5’ – GCG CGA GAA GGA AAG AAA GCC GG – 3’ 
Random Complement  5’ – CCG GCT TTC TTT CCT TCT CGC GC – 3’ 
E-Box    5’ – CTA CTA GCA CGT GCT AGT AG – 3’ 
E-Box Complement 5’ – CTA CTA GCA CGT GCT AGT AG – 3’ 
All oligonucleotides used were commercially purchased from Eurogentec (HPLC purified using RP-
cartridge-Gold, 200 nm scale) and were used as such. 
10.1.6 Other reagents, chemicals and materials 
1.11-diazido-3,6,9, trioxaundecane was purchased from Toronto Research Chemicals. Anilinium p-
toluenesulfinate, which was synthesized according to Nagakura et al.1 HOBt (98 %) and HOAt (98 %) and 
benzylamine ≥ 99.5 % pure were purchased from ACROS Organics. NaSPh was technical grade (90 %), 
purchased from Sigma-Aldrich. HOBt, HOAt and NaSPh were dried under high vacuum prior to use. 
Tetrakis-(triphenylphosphin)-palladium(0), 99 % pure was purchased from Sigma. Tributyltin hydride from 
Fluka was purum ≥ 96.0 %. Morpholine from Sigma-Aldrich was ≥ 99 %.  
Merck silica refers to: Kieselgel Merck Typ 9385 230-400 mesh, 60 Angström, and specifications of 
Biosolve silica are: 60 Å, 0.063-0.200 mm.  
Occasional sonication to aid dissolution/suspension/homogeneity was performed in a Branson 2510 water 
bath. Falcon tubes were composed of high-clarity polypropylene, with a capacity of either 15 mL, (17 x 
120 mm; BD Falcon), or 50 mL (VWR). 
10.2 Automated Peptide Synthesis 
Automated peptide syntheses were performed on a fully-automated SYRO Multiple Peptide Synthesizer 
robot, equipped with a vortexing unit for the 24-reactor block (MultiSynTech GmbH). Reactions were open 
to the atmosphere and were executed at ambient temperature with protection from light. 
Standard Fmoc/tBu chemistry was used for SPPS with HBTU as a coupling reagent and 20-40% piperidine 
in NMP for Fmoc deprotection. The resin is preswollen in NMP for 10 min and then filtered off.  The 
following protocols were used for Fmoc deprotection and coupling: 
                                                          
1  Honda, M.; Morita, H.; Nagakura, I. J. Org. Chem. 1997, 62, 8932-8936. Deprotection of allyl groups with 
sulfinic acids and palladium catalyst. 
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Fmoc deprotection: Fmoc deprotection is performed by adding a solution of 20-40% piperidine in NMP to 
the resin and shaking for 2 min, 5 min & 15 min durations.  After each addition and shaking cycle, the resin 
is filtered off and washed with NMP (6 x 45 s). 
Coupling: Single couplings using 10 equivalents of a 0.5 M solution of the Nα protected amino acid in 
NMP/DMF, 10 equivalents of a 0.5 M solution of HBTU in DMF and 10 equivalents of a 2.0 M solution 
of DIPEA in NMP which are added to the resin in that order. The reaction mixture is shaken for 1 hour. 
The resin is filtered off and washed with NMP (9 x 2 min). 
Capping: 4-Acetamidobenzoic acid used for capping was coupled using the protocol in coupling above.  In 
case of fluorescein a manual coupling was performed as described in coupling above. 
10.3 Analysis & Equipment 
10.3.1 HPLC analysis and purification 
Reversed-Phase HPLC analysis and purification was performed on an Agilent 1100 Series instrument with 
diode array detector (at 214, 254, 280, 310, 360 nm), equipped with a Phenomenex Luna C18 100 Å column 
(250 x 4.6 mm, 5 μm, at 35 °C) or a Phenomenex Jupiter C4 300 Å column (250 x 4.6 mm, 5 μm, at 35 
°C). Linear gradient elutions were performed by flushing 2 min with A followed by 0 to 100% buffer B in 
15 minutes and finally by a 5 min flushing with B using a binary solvent system composed of buffer A: 
0.1% TFA in H2O and B: MeCN with a flow of 1.0 mL/min at 35°C. 
Semi-prep purification was performed using a Phenomenex Luna C18 100 Å column (250 x 10 mm, 5 μm, 
at 35 °C) with a flow rate of 4.5 mL/min and prep purification was performed using a Phenomenex Luna 
C18 100 Å column (250 x 21 mm, 5 μm, at 35 °C) with a flow rate of 17.5 mL/min. Gradients were varied 
depending on the separation. 
10.3.2 LC-MS analysis 
LC-TIC-MS data (reversed phase) were recorded on an Agilent 1100 Series instrument with diode array 
detector (at 214, 254, 280, 310, 360 nm), equipped with a Phenomenex Kinetex C18 100 Å (150 x 4.6 mm, 
5 µm, at 35 °C), hyphenated to an Agilent ESI-single quadrupole MS detector type VL. Mass detection 
operated in the positive mode. Linear gradient elutions were performed by flushing 0.5 min with A followed 
by  0 to 100% buffer B in 6 minutes and finally by a 2 min flushing with B using a binary solvent system 
composed of buffer A: 0.1% HCOOH in H2O and B: MeCN with a flow of 1.0 mL/min at 35°C. Pre and 
post flushing is included in the LC-MS and RP-HPLC results. 
10.3.3 ESI-MS analysis 
ESI-MS spectra were recorded on a quadrupole ion trap LC mass spectrometer (Thermo Finnigan MAT 
LCQ), equipped with electrospray ionization. MeOH/H2O (4/1 ± 0.1 % formic acid) was used as carrier 
solution. All reported data were collected in the positive mode, at 250 °C. 
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10.3.4 MALDI-TOF 
MALDI-TOF-MS data were acquired on an Applied Biosystems Voyager-DE STR Biospectrometry 
Workstation, equipped with a high performance nitrogen laser (337 nm). All spectra were recorded in the 
positive and reflector mode, with delayed extraction. A solution of 4-5 mg α-cyano-4-hydroxycinnamic 
acid in 500μl MeCN, 490μl mQ, 10μl 1M ammoniumcitrate, 1μl TFA was used as matrix for MALDI-
TOF-MS.  
10.3.5 NMR Spectra 
NMR spectra were recorded at room temperature on a Bruker Avance-300 spectrometer at 300 MHz for 1H 
NMR and on a Bruker Avance-500 spectrometer at 500 MHz for 1H NMR and 125 MHz for 13C spectra. 
Chemical shifts (δ units) are expressed in parts per million (ppm) relative to tetramethylsilane (TMS) and 
the internal solvent peak was used for calibration. Wherever peak multiplicities have been reported, the 
following abbreviations have been used: s, singlet; d, doublet; t, triplet; m, multiplet; br, broad. Coupling 
constants (J values) are expressed in Hertz (Hz). The Attached Proton Test (APT) technique was used to 
assign 13C peaks (C, CH, CH2, CH3). All 1H spectra of deoxycholic acid derived products contain a region 
of high signal overlap between 1.00 and 2.00 ppm. Therefore, the detailed analysis of this envelop is almost 
impossible and often not mentioned or reported as a series of multiplets. Fortunately, in the analysis of the 
synthesized scaffolds all necessary information was shifted downfield from this region. 
Concentration of final products were determined by 1H-NMR ERETIC (Electronic REference To access In 
vivo Concentrations)91 with a high-resolution 500 MHz NMR-spectrometer. 
10.4 Electrophoretic Mobility Assay (EMSA) 
10.4.1 Sample preparation 
The following stock solutions were prepared (fresh each time, except for DNA and peptide): 
DNA: A concentration of 1.67 µM prepared from the required DNA and its complement. DNA solutions 
were made (commercially purchased) by diluting with 20 µL 0.5 M Tris, pH = 8, 40 µL 2.5 M NaCl, 40 
µL 0.025 M EDTA and then adding milliQ water such that the total volume is 1 mL.  The DNA was 
annealed by heating in a Thermomixer from room temperature to 95°C and maintaining the temperature at 
95°C in total time of 24 min.  The machine was then turned off and the sample was allowed to cool down 
slowly. 
In order to ensure physiological conditions, proper solubility and optimal charges in both peptide and DNA, 
a loading buffer was prepared, consisting in 20 µL Tris 1 M, pH = 7.6, 20 µL KCl 0.2 M, 20 µL MgCl2 0.1 
M and 40 µL EDTA 0.025 M. The main purpose of using loading buffers is to ensure good solubility and 
ionization as is required for gel electrophoresis. A high amount of salt concentration can however 
significantly decrease DNA binding due to an increase in ionic strength and subsequent decrease in the 
peptide-DNA interactions. EDTA is used to bind to stray metal ions such as Mg2+, Ca2+ but does not 
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significantly affect peptide-DNA interactions. Sucrose ensures that the loading solution is heavier than the 
buffer used to run the gels so that the solution does not flow over the well.  
Sucrose: 30% sucrose in mQ (300 mg/mL). 
Peptides: 10 µL stock solutions (10x) were prepared in MiliQ water.  
Loading mixture: The loading mixture comprised of: 10 µL mQ, 4 µL sucrose, 2 µL loading buffer, 2 µL 
DNA, 2 µL peptide. The loading mixture was prepared only 1-2 hr prior to running of gels and kept on ice 
as soon as ready. 
10.4.2 Preparation of Gels (for 2 Gels) 
In a clean falcon tube the following were added (in given order): 15.595 mL mQ, 0.4 mL TBE, 4.005 mL 
of 40% acrylamide solution, 200 µL APS (10% w/w in mQ). The solution was mixed by sonication to 
remove any air bubbles and cooled to 0°C (1 h under ice).  20 µL of TEMED was then added to the mixture 
and was again mixed properly before pouring it gently along parallel glass plates. The glass plates were 
tapped gently to ensure removal of all air bubbles and the markers were squeezed between the plates to 
ensure uniform width of each well.  Sufficient time was given for polymerization (~1 h). 
10.4.3 Gel Electrophoresis 
A pre-run of the gels was performed prior to loading them. Care was taken to see that the gels were properly 
immersed in 0.2x TBE buffer (non-denaturing gel, without urea) and the loading wells were free from any 
air bubbles. Instrument settings: 150 V, 100 mA, 19 W for 30 mins at 4°C. The wells were washed after 
the pre-run. 5 µL of the loading mixture was then loaded onto the wells. Instrument settings: 150 V, 100 
mA, 19 W for 45 mins at 4°C. 
10.4.4 Staining of gels 
After the run, the gels were removed from the glass and were stained using 100 mL of 0.2x TBE buffer + 
10 µL Sybr Gold (commercially purchased stock solution 10,000X in DMSO).  The gels were then washed 
twice with mQ and gently placed under a UV lamp (dark room) to observe the gel pattern. 
10.5 Electrophoretic Mobility Shift Assay (EMSA) for quantification of the 
dissociation constant 
The EMSA for the quantification of the dissociation constant were carried out by Vladimir Pabon at 
Karolinska Institute in Sweden. 
10.5.1 Preparation of 32P-labeled dsDNA target 
The required oligonucleotide was 5’-labeled using [γ-32P] ATP and T4 polynucleotide kinase (Fermentas) 
according to the manufacturer’s protocol and then purified using QIAquick Nucleotide Removal Kit 
(Qiagen). The 5’-end labeled pyrimidine oligonucleotide was annealed with the unlabeled complementary 
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strand. An amount of 5nM dsDNA was prepared diluting 20 µL 0.5 M Tris, pH = 8, 40 µL 2.5 M NaCl, 40 
µL 0.025 M EDTA and then adding milliQ water such that the total volume is 1 mL.  The DNA was 
annealed in a heat block by heating from 95°C during 5 minutes and then slow cooling to room temperature. 
Loading buffer: 20 µL Tris 1 M, pH = 7.6, 20 µL KCl 0.2 M, 20 µL MgCl2 0.1 M, 40 µL EDTA 0.025 M. 
Sucrose: 30% sucrose in mQ (300 mg/mL) 
Peptides: 10 µL stock solutions (10x) were prepared in MiliQ water. 
Loading mixture:  The loading mixture comprised of: 10 µL mQ, 4 µL sucrose, 2 µL loading buffer, 2 µL 
DNA, 2 µL peptide.  The loading mixture was prepared only 1 hour prior to running of gels and kept on ice 
as soon as ready. 
10.5.2 Preparation of Gels (for 1 Gel) 
In a clean glass beaker the following were added (in given order): 21.57 mL mQ, 0.6 mL TBE, 7.5 mL of 
40% acrylamide solution (29:1), 0.3 mL APS (10% w/w in mQ) and 30 µL of TEMED was then added to 
the mixture and mixed properly before pouring it gently along parallel glass plates.  The glass plates were 
tapped gently to ensure removal of all air bubbles and the markers were squeezed between the plates to 
ensure uniform width of each well. Sufficient time was given for polymerization (40 minutes). 
10.5.3 Electrophoresis 
A pre-run of the gels was performed prior to loading them.  Care was taken to see that the gels were properly 
immersed in 0.2x TBE buffer (non-denaturing gel, without urea) and the loading wells were free from any 
air bubbles. The wells were washed after the pre-run.  Instrument settings: 150 V, 100 mA, 19 W for 30 
minutes with circulation water-cooling. 5 µL of the loading mixture was then loaded onto the wells.  
Instrument settings: 150 V, 100 mA, 19 W for 45 minutes with circulation water-cooling.  
The gels were frozen and analyzed by phosphor imaging using Molecular Imager FX and the data were 
processed using Quantity One software (BioRad). 
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Chapter 11.1 
11.1.1 Synthesis and characterization of compounds 
Synthesis of Hexadecylazide262  
 
 
Hexadecylamine 11.1.1 (100 mg, 0.41 mmol) was dissolved in MeOH (3 mL) and treated with K2CO3 
(114.48 mg, 0.828 mmol) followed by CuSO4·5H2O (1 mg, 0.0041 mmol). To this mixture, imidazole-1-
sulfonyl azide·HCl (105.04 mg, 0.501 mmol) dissolved in MeOH (2 mL) was added and the reaction was 
stirred at room temperature under argon for 2h. The reaction was quenched by the addition of H2O (3 mL). 
This was acidified with AcOH and extracted with hexane (2x4 mL). The combined organic layers were 
dried under MgSO4 and evaporated to give a colorless glue 11.1.2 (105 mg, 95%). 
1H-NMR (300 MHz, CDCl3); δ 3.25 (m, 2 H), 1.6 (m, 2 H), 1.25 (br m, 26 H), 0.85 (t, 2 H). 13C NMR (125 
MHz, CDCl3): δ = 50.4854 (CH2), 30.9200 (CH2), 29.3015 (CH2), 28.6783 (CH2), 28.6519 (CH2), 28.6177 
(CH2), 28.5380 (CH2), 28.4780 (CH2), 28.3559 (CH2), 28.2332 (CH2), 28.1522 (CH2), 27.8352 (CH2), 
25.7130 (CH2), 21.6831 (CH2), 21.0841 (CH2), 13.1012 (CH3).  
 
Figure 11.1.1. 1H NMR spectrum of compound 11.1.2. 
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Figure 11.1.2. 13C NMR spectrum of compound 11.1.2. 
 
** The Diamino scaffold 11.1.8 was synthesized according to reference 48,74 
** The PATA linker was synthesized according to reference 49 
 
Compound 11.1.11: Coupling of PATA linker 11.1.10. Compound 11.1.9 (100 mg, 0.231 mmol) was 
dissolved in 3 mL dry DMF. Then, a solution of HATU (352 mg, 0.926 mmol) and DIPEA (0.161 mL, 
0.926 mmol) in dry DMF was added and stirred for 10 min. Next, a solution of PATA (188 mg, 0.926 
mmol) in dry DMF (4 mL) was added. The reaction mixture was stirred for 16 h at room temperature. The 
solvent was evaporated in vacuo. The residue was purified by column chromatography (silica gel 
EtOAc/Hexane 0.6:1; Rf: 0.17) to give 11.1.11 as a white powder (151 mg, 82% yield). 1H-NMR (500 
MHz, CD3OD); δ  7.8 (d, J = 6.86 Hz, 2 H), 7.65 (d, J = 6.66 Hz, 2 H), 7.35 (m, 4H), 7.2 (t, 2 H), 4.40 (m, 
4 H), 4,00 (t, J = 6.5 Hz, 2 H), 3.65 (s, 1 H), 3.60 (s, 1 H) 2.35–2.10 (m, 2 H), 1,2 (s, 3 H), 0.90 (s, 3 H), 
0.85 (d, J = 6.40 Hz, 3 H), 0.80 (s, 3 H). 13C NMR (125 MHz, CD3OD): δ = 175.93 (COOR-C24), 169.69 
(CONH-C3), 169.16 (CONH-C12), 154.65 (2CONH linker), 142.85 (C), 142.76 (C), 135.49 (C), 135.01 
(C), 131.03 (CH), 130.78 (CH), 129.83 (CH), 128.82 (CH), 128.69 (CH), 128.60 (CH), 128.54 (CH), 122.14 
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(CH), 78.09 (C), 76.37 (C), 67.04 (CH2- Pr ester), 55.80 (CH-alkyne), 54.75 (CH-alkyne), 51.91 (CH), 
50.62 (CH), 45.91 (C), 44.08 (CH), 43.85 (CH2), 43.76 (CH2), 37.32 (CH), 37.00 (CH2), 36.02 (CH), 35.41 
(C), 33.10 (CH2), 32.10 (CH2), 32.03 (CH2), 28.50 (CH2), 28.30 (CH2), 28.16 (CH2), 27.80 (CH2), 26.80 
(CH2), 24.83 (CH2), 23.89 (19-CH3), 23.01 (CH2), 18.69 (CH), 17.89 (CH), 17.26 (21-CH3), 14.25 (CH), 
13.14 (18-CH3), 10.74 (CH3). (ESI-MS m/z (% rel. int.) calcd. 802.4 (100), found 803.4 (100) [M+ H+]. 
HR-MS (ES) m/z calcd. for C49H62N4O6 802.4669, found 803.4734 (M + H+; Δ = 1 ppm). 
 
Compound 11.1.11 
 
Figure 11.1.3. 1H NMR spectrum of compound 11.1.11. 
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Figure 11.1.4. 13C NMR spectrum of compound 11.1.11. 
 
Diamino scaffold 11.1.8 capped with Ac2O 
Scaffold 11.1.8 (20 mg, 0.046 mmol) was dissolved in dry DCM (2 mL), then acetic anhydride (0.017 mL, 
0.185 mmol) and DIPEA (0.064 mL, 0.37 mmol) were added. The reaction mixture was stirred at room 
temperature for 3h. Solvent was evaporated and compound 11.1.8 was analyzed without prior purification. 
(21.4 mg, 90 % yield). 1H-NMR (500 MHz, CD3OD); δ  4.25 (m, 4 H), 4.00 (t, J = 6.5 Hz, 2 H), 3.65 (br. 
m, 1 H), 2.31–2.40 (m, 2 H), 2.18–2.26 (m, 2 H), 2.1 (s, 3H), 1.90 (s, 3H), 1.2 (s, 3 H), 0.90 (s, 3 H), 0.85 
(d, J = 6.40 Hz, 3 H), 0.80 (s, 3 H). (ESI-MS m/z (% rel. int.) calcd. 516.4 (100), found 517.4 (100) [M + 
H+]. HR-MS (ES) m/z calcd. for C31H52N2O4 516.3927, found 517.4008 (M + H+; Δ = 2.6 ppm). 
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Figure 11.1.5. 1H NMR spectrum of compound 11.1.12. 
 
Click cyclic receptor 
 
Scaffold 11.1.11 (20 mg, 0.0249 mmol) was dissolved in 1 mL of dry DMF. 1.11-diazido-3,6,9, 
trioxaundecane (6.08 mg, 0.0249 mmol) was added followed by the addition of CuSO4·5H2O (3.1 mg, 
0.012 mmol) in 0.1 mL dry DMF and 2,6-Lutidine (5.8 μL, 0.049 mmol). A solution of Na ascorbate (9.82 
mg, 0.049 mmol) in 0.2 mL H2O was subsequently added and the reaction mixture was stirred for 1h at 
60°C under MW irradiation. 
The solvent was evaporated and the reaction was extracted with DCM and a saturated solution of EDTA 
(3x40 mL). The organic phases were dried under MgSO4 and filtered. The solvent was evaporated and the 
crude compound was purified by RP-HPLC. (ESI-MS m/z (% rel. int.) calcd. 1046.5 (100), found 1047.5 
(100) [M+ H+]. HR-MS (ES) m/z calcd. for C57H78N10O9 1046.5953, found 1047.6032 (M + H+; Δ = 0.6 
ppm).. 
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Figure 11.1.6: RP-HPLC Chromatogram of HPLC crude compound 11.1.13 (C18 100 Å column (250 x 10 mm, 5 
μm, at 35 °C) using a gradient from 75 to 100 % CH3CN in 15 minutes). 
 
Figure 11.1.7: RP-HPLC Chromatogram of HPLC purified compound 11.1.13 (C4, 300Å column using a gradient 
from 0 to 100 % CH3CN in 15 minutes). 
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Figure 11.1.8: MALDI-TOF Spectrum of HPLC purified compound 11.1.13. Calculated m/z (100%) = 1046.60; m/z 
(62.9%) = 1047.60. Found: 1069.13 = M + Na+. 
The synthesis of receptor 11.1.13 was more challenging due to the possibility of the diazido linker to react 
with the alkynes and form acyclic structure. In order to verify the obtention of 11.1.13 in the crude reaction 
mixture, we compared the analysis data with the results previously acquired from the synthesis of receptor 
11.1.13 on TentaGel solid phase, on which cyclization could be better controlled and monitored. The first 
step was the incorporation of the photolabile linker for UV cleavage and a UV absorption moiety (tag) on 
the solid phase. The next step was the attachment of an orthogonally protected amine scaffold 11.1.13d.  
 
Figure 11.1.9: Synthesis scheme for the attachment of the steroid scaffold to the solid phase. i) PyBOP, DIPEA, DMF, 
3h, rt. ii) 20% piperidine/DMF 2 x 30 min. iii) PyBOP, DIPEA, DMF, 3h, rt. iv) 20% piperidine/DMF 2, 5, 15 min. 
v) HATU, DIPEA, DMF, 2 x 4h rt. 
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Due to the orthogonal protection of the amines, selective coupling of PATA linker to C12 was achieved by 
the deprotection of the Boc. Further appendage of PATA linker afforded one alkyne for the conjugation 
with one azide of the diazo moiety via CuAAC. The Alloc deprotection of the second amine and the 
attachment of the PATA linker provided the acyclic receptor 11.1.13h after UV cleavage. In order to obtain 
the cyclic form, compound 11.1.13g was subjected to CuAAC to get compound 11.1.13i, followed by UV 
irradiation to get the cyclic receptor 11.1.13j cleaved from the resin. The comparison between the RP-
HPLC profile of 11.1.13h and 11.1.13j with 11.1.13 allowed its structural characterization. 
 
 
Figure 11.1.10: Synthesis scheme for cyclic and acyclic version of receptor 11.1.13 on solid phase. i) 20%TFA in 
DCM 2h rt. ii) PATA, HATU, DIPEA, DMF, 4h rt. iii) CuSO4·5H2O, NaAsc, DIPEA, MW 70°C 1h. iv) Alloc 
deprotection. Pd(PPh3)4, Bu3SnH, morpholine, DCM 2h rt. v) PATA, HATU, DIPEA, DMF, 4h rt. vi) CuSO4·5H2O, 
NaAsc, DIPEA, MW 70°C 1h. vii) UV irradiation, 3h. 
Chapter 11: Chapter-wise experimental section 
159 
 
 
Click acyclic receptor  
 
Scaffold 11.1.11 (20 mg, 0.0249 mmol) was dissolved in 1 mL of dry DMF. Benzyl azide (6.52 mg, 0.049 
mmol) was then added followed by the addition of CuSO4•5H2O (3.1 mg, 0.012 mmol) in 0.1 mL dry DMF 
and 2, 6-Lutidine (5.8 μL, 0.049 mmol). A solution of Na ascorbate (9.82 mg, 0.049 mmol) in 0.2 mL H2O 
was subsequently added and the reaction mixture was stirred for 1h at 60°C under MW irradiation. 
The solvent was evaporated and the reaction was extracted with DCM and a saturated solution of EDTA 
(3x40 mL). The organic phases were dried under MgSO4 and filtered. The solvent was evaporated and the 
crude compound was purified by RP-HPLC. ESI-MS m/z (% rel. int.) calcd. 1068.5 (100), found 1069.5 
(100) [M+ H+]. HR-MS (ES) m/z calcd. for C63H76N10O6 + H+ 1068.5949, found 1069.6027 (M + H+; Δ = 
0.5 ppm). 
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Figure 11.1.11: RP-HPLC Chromatogram of HPLC crude compound 11.1.15 (C18 100 Å column (250 x 10 mm, 5 
μm, at 35 °C) using a gradient from 75 to 100 % CH3CN in 15 minutes). 
 
Figure 11.1.12: RP-HPLC Chromatogram of HPLC purified compound 11.1.14 (C4, 300Å column using a gradient 
from 0 to 100 % CH3CN in 15 minutes). 
 
Figure 11.1.13: MALDI-TOF Spectrum of crude compound 11.1.14. Calculated m/z (100%) = 1068.59; m/z (69.2%) 
= 1069.60. Found: 1091.59 = M + Na+. 
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Click aliphatic receptor 
 
Scaffold 11.1.11 (20 mg, 0.0249 mmol) was dissolved in 1 mL of dry DMF. Hexadecylazide 11.1.2 (13.3 
mg, 0.049 mmol) was then added followed by the addition of CuSO4·5H2O (3.1 mg, 0.012 mmol) in 0.1 
mL dry DMF and 2,6-Lutidine (5.8 μL, 0.049 mmol). A solution of Na ascorbate (9.82 mg, 0.049 mmol) 
in 0.2 mL H2O was subsequently added and the reaction mixture was stirred for 1h at 60°C under MW 
irradiation. 
The solvent was evaporated and the reaction was extracted with DCM and a saturated solution of EDTA 
(3x40 mL). The organic phases were dried under MgSO4 and filtered. The solvent was evaporated and the 
residue was purified by column chromatography (silica gel DCM/MeOH 9:1) (62 % yield). ESI-MS m/z 
(% rel. int.) calcd. 1337.0 (100), found 1338.0 (100) [M+ H+]. HR-MS (ES) m/z calcd. for C63H76N10O6 
1337.00183, found 1396.0153 (M + OAc-; Δ = 0.3 ppm).. 
 
 
Figure 11.1.14: RP-HPLC Chromatogram of HPLC crude compound 11.1.15 (C4, 300Å column using a gradient 
from 50 to 100 % CH3CN in 15 minutes). 
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Figure 11.1.15: RP-HPLC Chromatogram of HPLC purified compound 11.1.15 (C4, 300Å column using 
a gradient from 50 to 100 % CH3CN in 15 minutes) 
 
Figure 11.1.16: MALDI-TOF Spectrum of compound 11.1.15. Calculated m/z (100%) = 1337.00; m/z (83.9%) = 
1338.01. Found: 1359.59 = M + Na+. 
 
11.1.2 ITC measurements 
Preparation of the solution of the ligand [phosphatidylserine (molecular weight: 790 g/mol)] 
Concentration: 2400 µM: Dissolution of 3.792 mg in 2 mL of CHCl3. 
General protocol 
Titrations were performed by introducing 1 mL of the solution of the receptor at the desired concentration 
in the measurement cell and 250 µL solution of phosphatidylserine (ligand) at the required concentration 
was loaded in the syringe. Titrations consisted in one injection of 5 l followed by 24 injections of 10 l at 
300 s time intervals in the cell with stirring at 300 rpm. 
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Blank 
In order to consider the influence of the solvent on the heat exchange during the titrations with the receptors, 
a blank experiment was performed. The procedure consisted on the injection of solvent from the syringe to 
the sample cell, in which only the solvent was present. 
 
Figure 11.1.17: ITC curve of the titration with the solvent as blank. 
 
Receptor 11.1.12 
A 240 µM solution of the receptor 11.1.12 was prepared by weighing 1.24 mg in 10 mL of CHCl3. The 
titration was performed in the same conditions as described previously. 
Conclusion: After correction for the dilution heat, no significant heat exchange corresponding to the 
formation of a specific interaction complex could be observed. 
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Figure 11.1.18: Receptor 11.1.12 at 240 µM with phosphatidylserine at 2400 µM.  
 
Receptor 11.1.13  
In order to get the 235 µM solution, we dissolved 2.1 mg of the product in 8.53 mL of CHCl3. We ran the 
experiment with the concentrated solutions as previously described but no binding was observed. 
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Figure 11.1.19: Receptor 11.1.13 at 235 µM with phosphatidylserine at 2400 µM. A small interaction is observed, 
however with a 0.08 stoichiometry, which probably do not correspond to a specific interaction with the receptor but 
to a non-specific interaction or to the presence of an impurity. 
Receptor 11.1.14 
In order to get the 240 µM solution, we dissolved 3.42 mg of the product in 13.32 mL of CHCl3. We ran 
the same experiment previously described but no binding was observed. 
 
Figure 11.1.20: Receptor 11.1.14 at 240 µM with phosphatidylserine at 2400 µM. 
 
Receptor 11.1.15  
We ran the experiment with a 240 µM concentration of reception and 2400 µM concentration of ligand. 
We dissolved 3.46 mg of the product in 10.77 mL of CHCl3.  
Conclusion: Receptor 11.1.15 showed affinity for phosphatidylserine with Ka in the 105 range 
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Figure 11.1.21:  Receptor 11.1.15 at 240 µM with phosphatidylserine at 2400 µM. A binding isotherm was detected 
with a Ka of 1.4 105 M-1, a H° of 10.8 kJ/mol and a stoichiometry of 0.34. 
Summary of the studies of the interaction of the receptors with PS by ITC: 
ITC measurements (ligand: phosphatidylserine) in CHCl3 
Receptor 
Molecular weight 
(g/mol) 
Conc. 
Receptor (µM) 
Conc. 
Ligand (µM) 
Binding/ 
Ka (M-1) 
11.1.12 516.756 240 2400 No 
11.1.13 1047.291 235 2400 No 
11.1.14 1069.341 240 2400 No 
11.1.15 1337.946 240 2400 
Yes/  
1.4 105 
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Chapter 11.2 
11.2.1 Synthesis of Scaffolds 
Benzyl 3α, 12α-dihydroxy-5β-cholan-24-oate (11.2.2). To a solution of deoxycholic acid (11.2.1) (3 g, 
7.642 mmol) in DMF (7 mL), DBU (1.38 mL, 9.25 mmol) and benzyl bromide (1.1 mL, 9.25 mmol) were 
added and the mixture was stirred at 50 °C for 24 h. DMF was removed under vacuum, 10 % HCl (80 mL) 
was added to the residue and the product was extracted with CH2Cl2 (100 mL). The organic layer was 
washed with water (100 mL) and aq. NaHCO3 (100 mL) and dried over anhyd. Na2SO4. The crude product 
obtained after removal of the solvent was purified using column chromatography on silica gel using 5 % 
EtOAc/CHCl3 (Rf: 0.38) to yield 78 % of compound 11.2.2 as a white solid (2.81 g). 1H-NMR (300 MHz, 
CDCl3); δ 7.36 − 7.38 (m, 5 H), 5.15 (d, 1H,  J  = 14.13 Hz), 5.11 (d, 1H,  J = 14.13 Hz), 3.92 (s, 1 H), 3.60 
(br, m, 1 H), 2.45 – 2.36 (m, 1 H), 2.30 – 2.20 (m, 1 H), 0.90 (d, J = 6.28 Hz, 3 H), 0.80 (s, 3 H), 0.63 (s, 3 
H). ES-MS m/z (% rel. int.) calcd. 482.3 (100), found 541.3 (100) [M + OAc-]. 
 
Benzyl 3α, 12α-dipentynoate-5β-cholan-24-oate (11.2.3). Compound 11.2.2 (50 mg, 0.1037 mmol) was 
dissolved in 1.5 mL dry DCM. Then a solution of pentynoic acid (30.52 mg, 0.311 mmol), DCC (64.21 
mg, 0.311 mmol) and DMAP (50.7 mg, 0.415 mmol) in dry DCM (2.5 mL) was added. The reaction mixture 
was stirred for 16h at room temperature. The precipitate formed was filtered off and the solvent was 
evaporated under vacuo. The residue was purified by column chromatography (silica gel EtOAc/Hexane 
0.6:1; Rf: 0.60) to give compound 11.2.3 as a yellow oil (64.6 mg, 97% yield). 1H-NMR (300 MHz, CDCl3); 
δ 7.38 − 7.36 (m, 5 H), 5.15 (s,  H), 5.15 (d, 1H,  J  = 13.56 Hz), 5.11 (d, 1H,  J = 13.75 Hz), 4.6 (br, m, 1 
H), 2.55-2.45 (m, 4 H), 2,43-2.40 (m, 4 H), 2.35 – 2.33 (m, 1 H), 2.30 – 2.20 (m, 1 H), 2.21 (t, J = 12 Hz, 
2 H), 0.85 (s, 3 H), 0.75 (d, J = 6.40 Hz, 3 H), 0.65 (s, 3 H). 13C NMR (125 MHz, CDCl3): δ = 173.90 
(COOR-C24), 171.2 (COOR-C3), 170.87 (COOR-C12), 136.03 (C - benzyl group), 128.53 (2CH-benzyl 
ring), 128.25 (2CH- benzyl ring), 128.20 (CH-benzyl ring), 82.69 (C alkyne), 82.67 (C alkyne), 76.36 (CH 
ester), 74.57 (CH ester), 69.37 (CH2), 68.95 (CH2), 66.13 (CH2 benzyl ester), 49.34 (CH), 47.61 (CH), 
45.10 (C), 35.63 (CH), 34.80 (CH), 34.70 (CH), 34.69 (CH2), 34.50 (CH), 34.45 (CH), 34.31 (CH), 34.05 
(C), 33.91 (CH2), 33.64 (CH2), 32.16 (CH2), 31.24 (CH2), 30.80 (CH2), 27.34 (CH2), 27.10 (CH2), 26.83 
(CH2), 26.59 (CH2), 23.44 (CH2), 22.98 (19-CH3), 17.50 (21 – CH3), 14.42 (CH2), 12.32 (18-CH3). ES-MS 
m/z (% rel. int.) calcd. 642.4 (100), found 660.4 (100) [M+ NH4+]. HR-MS (ES) m/z calcd. for C41H54O6 
642.3920, found 660.4268 (M + NH4+; Δ = 1.2 ppm).. 
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Benzyl 3α, 12α-Gly-5β-cholan-24-oate (11.2.4). Compound 11.2.3 (50 mg, 0.1037 mmol) was dissolved 
in 1.5 mL dry DCM. Then a solution of Boc protected glycine (54.52 mg, 0.311 mmol), DCC (64.21 mg, 
0.311 mmol) and DMAP (50.7 mg, 0.415 mmol) in dry DCM (2.5 mL) were added. The reaction mixture 
was stirred for 16 h at room temperature. The precipitate formed was filtered off and the solvent is 
evaporated under vacuo. The residue was purified by column chromatography (silica gel EtOAc/Hexane 
0.6:1; Rf: 0.45) to give 11.2.4 as a yellow oil (76.8 mg, 93% yield). 1H-NMR (300 MHz, CDCl3); δ 7.36 − 
7.38 (m, 5 H), 5.2 (s, 1 H), 5.15 (m, 2 H), 4.6 (br, m, 1 H), 3.88 (d, 2 H), 3.85 (d, 2 H), 2.35 – 2.33 (m, 1 
H), 2.30 – 2.20 (m, 1 H), 2.21 (t, J = 12 Hz, 2 H), 1.40 (s, 18 H), 0.85 (s, 3 H), 0.75 (d, J = 6.40 Hz, 3 H), 
0.65 (s, 3 H). ES-MS m/z (% rel. int.) calcd. 796.5 (100), found 819.3 (100) [M+ Na+]. 
 
Compound 11.2.5 (Boc deprotection). Compound 11.2.4 (76.5 mg, 0.096 mmol) was treated with 10 mL 
of a solution of TFA (30%) in DCM for 2 h at room temperature. The solvent was evaporated and the white 
powder obtained was analyzed without further purification (Rf: 0.1, 56.7 mg, 99% yield). 1H-NMR (300 
MHz, CDCl3); δ 7.36 − 7.38 (m, 5 H), 5.2 (s, 1 H), 5.15 (m, 2 H), 4.6 (br, m, 1 H), 3.87 (m, 4 H), 2.35 – 
2.33 (m, 1 H), 2.30 – 2.20 (m, 1 H), 2.21 (t, J = 12 Hz, 2 H), 1.40 (s, 18 H), 0.85 (s, 3 H), 0.75 (d, J = 6.40 
Hz, 3 H), 0.65 (s, 3 H). ES-MS m/z (% rel. int.) calcd. 596.4 (100), found 597.3 (100) [M+ H+]. 
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Compound 11.2.6 Diazotransfer reaction. Boc deprotected compound 11.2.5 (57 mg, 0.096 mmol) was 
dissolved in 2 mL MeOH/THF (1:1) and treated with K2CO3 (53 mg, 0.386 mmol) followed by 
CuSO4·5H2O (0.725 mg, 0.0029 mmol). To this mixture, imidazole-1-sulfonyl azide·HCl (61 mg, 0.290 
mmol) dissolved in 1 mL MeOH/THF (1:1) was added to the reaction mixture and stirred at room 
temperature for 3 h under argon. The reaction was quenched with 4.5 mL of water and 0.5 mL of AcOH 
was added. Then, the reaction mixture was extracted 2 times with hexane (5 mL). The organic phase was 
dried under MgSO4. The solvent was evaporated and the residue purified by column chromatography (silica 
gel DCM/MeOH 9.5:0.5; Rf: 0.20) to get a yellowish oil (59.7 mg, 96% yield). 1H-NMR (300 MHz, 
CDCl3); δ 7.36 − 7.38 (m, 5 H), 5.2 (s, 1 H), 5.15 (d, 1H,  J  = 13.75 Hz), 5.10 (d, 1H,  J = 13.94 Hz), 4.6 
(br, m, 1 H), 3.98-3.90 (d, 2 H), 3.90-3.80 (d, 2 H), 2.35 – 2.33 (m, 1 H), 2.30 – 2.20 (m, 1 H), 2.21 (t, J = 
12 Hz, 2 H), 1.40 (s, 18 H), 0.85 (s, 3 H), 0.75 (d, J = 6.40 Hz, 3 H), 0.65 (s, 3 H). 13C NMR (125 MHz, 
CDCl3): δ = 173.85 (COOR-C24), 167.76  (COOR-C3), 167.47 (COOR-C12), 135.99 (C - benzyl group), 
128.52 (2CH-benzyl ring), 128.25 (2CH- benzyl ring), 128.19 (CH-benzyl ring), 77.97 (CH-C3), 75.97 
(CH-C12), 66.14 (CH2 benzyl ester), 50.91 (CH2 ester glycine C3), 50.51 (CH2 ester glycine C12), 47.64 
(CH), 45.22 (CH), 45.06 (C), 41.67 (CH), 35.53 (CH), 33.95 (C), 31.93 (CH2), 31.17 (CH2), 30.70 (CH2), 
29.66 (CH2), 27.24 (CH2), 26.90 (CH2), 26.70 (CH2), 25.90 (CH2), 25.77 (CH), 25.63 (CH), 25.40 (CH2), 
23.34 (CH2), 22.85 (19-CH3), 17.61 (21 – CH3), 12.32 (18-CH3). ES-MS m/z (% rel. int.) calcd. 648.4 
(100), found 666.4 (100) [M+NH4+]. HR-MS (ES) m/z calcd. for C35H48N6O6 648.3635, found 666.3968 
(M + NH4+; Δ = 0.9 ppm). 
 
Compound 11.2.7 (esterification with boc-aminomethylbenzoic acid). 4-Boc-aminomethyl benzoic acid 
(417.4 mg, 1.6596 mmol) was dissolved in 4 mL dry DCM/dry THF (1:1) at room temperature. EDC (0.294 
mL, 1.6596 mmol) was added in portions and stirred for 30 min. DMAP (405.5 mg, 3.319 mmol) was added 
to the reaction mixture. Compound 11.2.2 (200 mg, 0.4149 mmol) dissolved in 6 mL dry DCM was then 
added and the reaction was stirred overnight. The solvent was evaporated and the residue purified by 
column chromatography (silica gel EtOAc/Hexane 3:1; Rf: 0.57) obtaining 11.2.7 with 82 % yield (322.7 
mg). 1H-NMR (300 MHz, CDCl3); δ  8.1 (d, J = 7.75 Hz, 2 H), 7.9 (d, J = 8.63 Hz, 2 H), 7.45 (d, J = 8,2 
Hz, 2 H), 7.38 (d, J = 8 Hz, 2 H),  7.36 − 7.38 (m, 5 H), 5.3 (s, 1 H), 5.15 (m, 2 H), 4.7 (br, m, 1 H), 4.3 (br 
m, 4 H), 2.35 – 2.33 (m, 1 H), 2.30 – 2.20 (m, 1 H), 2.21 (t, J = 12 Hz, 2 H), 2,00 (s, 18 H), 0.85 (s, 3 H), 
0.75 (d, J = 6.40 Hz, 3 H), 0.65 (s, 3 H). ES-MS m/z (% rel. int.) calcd. 948.5 (100), found 1007.5 (100) 
[M + OAc-]. 
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Compound 11.2.8 (Boc deprotection). Compound 11.2.7 (55 mg, 0.058 mmol) was treated with 10 mL 
of a solution of TFA (30%) in DCM for 2 h at room temperature. The solvent was evaporated and the white 
powder obtained was analyzed without further purification (Rf: 0.12, 43 mg, 99% yield. 1H-NMR (300 
MHz, CDCl3); δ  8.1 (d, J = 7.75 Hz, 2 H), 7.9 (d, J = 8.63 Hz, 2 H), 7.45 (d, J = 8,2 Hz, 2 H), 7.38 (d, J = 
8 Hz, 2 H), 7.36 − 7.38 (m, 5 H), 5.3 (s, 1 H), 5.15 (m, 2 H), 4.7 (br, m, 1 H), 4.3 (m, 2 H), 4.1-3.9 (m, 2 
H), 2.35 – 2.33 (m, 1 H), 2.30 – 2.20 (m, 1 H), 2.21 (t, J = 12 Hz, 2 H), 0.85 (s, 3 H), 0.75 (d, J = 6.40 Hz, 
3 H), 0.65 (s, 3 H). ES-MS m/z (% rel. int.) calcd. 748.5 (100), found 749.5 (100) [M + H+]. 
 
Compound 11.2.9. Diazotransfer reaction. Compound 11.2.8 (50 mg, 0.067 mmol) was dissolved in 2 
mL MeOH/THF (1:1) and treated with K2CO3 (36.9 mg, 0.267 mmol) followed by CuSO4·5H2O (0.5 mg, 
0.002 mmol). To this mixture, imidazole-1-sulfonyl azide·HCl (54 mg, 0.2 mmol) dissolved in 1 mL 
MeOH/THF (1:1) was added to the reaction mixture and stirred at room temperature for 3h under argon. 
The reaction was quenched with 4.5 mL of water and 0.5 mL of AcOH was added. Then, the reaction was 
extracted 2 times with hexane (5 mL). The organic phase was dried under MgSO4. The solvent was 
evaporated and the residue purified by column chromatography (silica gel EtOAc/Hexane 1:1; Rf: 0.65) to 
obtain a yellow oil (51.5 mg, 96% yield). 1H-NMR (300 MHz, CDCl3); δ  8.1 (d, J = 7.75 Hz, 2 H), 7.9 (d, 
J = 8.63 Hz, 2 H), 7.45 (d, J = 8,2 Hz, 2 H), 7.38 (d, J = 8 Hz, 2 H), 7.36 − 7.38 (m, 5 H), 5.3 (s, 1 H), 5.18 
(d, 1H,  J  = 13.75 Hz), 5.15 (d, 1H,  J = 13.75 Hz), 4.7 (br, m, 1 H), 4.40 (s, 2 H), 4.38 (s, 2 H), 2.35 – 2.33 
(m, 1 H), 2.30 – 2.20 (m, 1 H), 2.21 (t, J = 12 Hz, 2 H), 0.85 (s, 3 H), 0.75 (d, J = 6.40 Hz, 3 H), 0.65 (s, 3 
H). 13C NMR (125 MHz, CD3OD): δ = 173.88 (COOR-C24), 165.47  (COOR-C3), 165.40 (COOR-C12), 
140.45 (C), 140.30 (C), 140.13 (C), 136.04 (C-benzyl ester), 130.76 (C), 130.01 (2CH), 129.97 (2CH), 
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128.52 (2CH), 128.22 (2CH), 128.17 (CH), 127.95 (2CH), 127.79 (2CH), 76.67 (CH ester linker C3), 74.83 
(CH ester linker C12), 66.09 (CH2 benzyl ester), 54.26 (CH2 ester linker C3), 54.23 (CH2 ester linker C12), 
50.14 (CH), 48.00 (CH), 45.51 (C), 41.77 (CH), 35.80 (CH), 35.74 (CH), 34.72 (CH), 34.05 (C), 32.29 
(CH2), 31.24 (CH2), 30.75 (CH2), 30.10 (CH2), 27.37 (CH2), 26.82 (CH2), 26.47 (CH2), 25.99 (CH2), 25.89 
(CH2), 23.50 (CH2), 23.05 (19-CH3), 17.46 (21-CH3), 12.55 (18-CH3). (ES-MS m/z (% rel. int.) calcd. 800.4 
(100), found 818.4 (100) [M+ NH4+]. HR-MS (ES) m/z calcd. for C47H56N6O6 800.42613, found 818.4592 
(M + NH4+; Δ = 0.9 ppm). 
. 
 
The Diamino scaffold 11.2.14 was synthesized according to reference 1 and 2 48,74 
PATA linker was synthesized according to reference 3 49  
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Compound 15. Coupling of PATA linker. Refer to section 11.1.3 for synthesis and characterization of 
11.2.15 
 
 
11.2.2 NMR Spectra for steroid template molecules:  
Compound 11.2.2: 
 
Figure 11.2.1. 1H NMR spectrum of compound 11.2.2. 
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Compound 11.2.3: 
 
 
Figure 11.2.2. 1H NMR spectrum of compound 11.2.3. 
 
 
Figure 11.2.3. 13C NMR spectrum of compound 11.2.3. 
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Compound 11.2.4: 
 
Figure 11.2.4. 1H NMR spectrum of compound 11.2.4. 
 
Compound 11.2.5 
 
 
Figure 11.2.5. 1H NMR spectrum of compound 11.2.5. 
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Compound 11.2.6 
 
 
 
Figure 11.2.6. 1H NMR spectrum of compound 11.2.6. 
 
 
Figure 11.2.7. 13C NMR spectrum of compound 11.2.6. 
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Compound 11.2.7 
 
Figure 11.2.8. 1H NMR spectrum of compound 11.2.7. 
 
Compound 11.2.8 
 
 
Figure 11.2.9. 1H NMR spectrum of compound 11.2.8. 
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Compound 11.2.9 
 
 
Figure 11.2.10. 1H NMR spectrum of compound 11.2.9. 
 
 
Figure 11.2.11. 13C NMR spectrum of compound 11.2.9. 
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Compound 11.2.15 
 
 
Figure 11.2.12. 1H NMR spectrum of compound 11.2.15. 
 
 
 
 
 
 
 
 
 
 
Figure 11.2.13. 13C NMR spectrum of compound 11.2.15. 
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11.2.3. Design and Synthesis of linear peptides: 
The following six linear peptides were synthesized in context of this study. Since the NHS Fluorescein used 
is bought in the 5-6 isomer form, all fluorescein containing peptides have a double peak. 
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Manual coupling protocols: 
Immobilization of Fmoc-Pra-OH on Rink amide ChemMatrix resin 
 
To a suspension of resin 11.2.16 (50 mg, 0.54 mmol/g, 0.027 mmol) in DMF (dry, 10 mL/g resin), were 
added Fmoc-Pra-OH (27.2 mg, 0.081 mmol, 4 eq.), PyBOP (42.1 mg, 0.081 mmol, 4 eq.) and DIPEA (0.028 
mL, 0.162 mmol, 8 eq.). The mixture was shaken at room temperature for 1 h. After the reaction, the resin 
was washed with DMF, ACN and MeOH. The loading was 100%. The resin was then capped with acetic 
anhydride (0.016 mL, 0.162 mmol, 8 eq.) and DIPEA (0.028 mL, 0.162 mmol, 8 eq.) in dry DMF (2 mL) 
twice for 30 min. 
Immobilization of Fmoc-Aha-OH on Rink amide ChemMatrix resin 
 
To a suspension of resin 11.2.16 (50 mg, 0.54 mmol/g, 0.027 mmol) in DMF (dry, 10 mL/g resin), were 
added Fmoc-Aha-OH (29.7 mg, 0.081 mmol, 4 eq.), PyBOP (42.1 mg, 0.081 mmol, 4 eq.) and DIPEA 
(0.028 mL, 0.162 mmol, 8 eq.). The mixture was shaken at room temperature for 1 h. After the reaction, 
the resin was washed with DMF, ACN and MeOH and dried in vacuum for 1h. The loading was calculated 
to be 0.412 mmol/g, indicating a coupling yield of 92%. The resin was then capped with acetic anhydride 
(0.016 mL, 0.162 mmol) and DIPEA (0.028 mL, 0.162 mmol) in dry DMF (2 mL) 2 times for 30 min. 
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Fmoc deprotection and coupling of Fmoc-Gly-OH and Fmoc-GABA-OH 
 
 
 
 
Fmoc deprotection of compounds 11.2.17 & 11.2.20. After an initial DMF washing step, resin 11.2.17 
(0.022 mmol) was treated twice successively for 30 min with a piperidine solution in DMF (40 % v/v, 2 
mL) at ambient temperature, applying intermediate filtration under reduced pressure and washing with 3 x 
DMF, 3 x ACN, 3 x DCM and 3 x DMF. 
Coupling of Fmoc-Gly-OH to 11.2.17. Fmoc-Gly-OH (19.5 mg, 0.065 mmol, 0.5 M), PyBOP (34.15 mg, 
0.065 mmol, 0.5 M) and DIPEA (0.012 mL, 0.065 mmol, 2 M) were added to a suspension of resin in dry 
DMF (2 mL). The mixture was shaken at room temperature for 2 h. After the reaction, the resin was washed 
again with DMF/MeOH/DCM/Et2O/DMF.   
Coupling of Fmoc-Gly-OH to 11.2.20. Fmoc-Gly-OH (22.3 mg, 0.075 mmol, 0.5 M), PyBOP (39 mg, 0.075 
mmol, 0.5 M) and DIPEA (0.013 mL, 0.075 mmol, 2 M) were added to a suspension of resin in dry DMF 
(2 mL). The mixture was shaken at room temperature for 2 h. After the reaction, the resin was washed again 
with DMF/MeOH/DCM/Et2O/DMF.   
Coupling of Fmoc-GABA-OH. To Fmoc deprotected resin (0.025 mmol), Fmoc-Gaba-OH (35.1 mg, 0.108 
mmol, 0.5 M), PyBOP (56.2 mg, 0.108 mmol, 0.5 M) and DIPEA (0.019 mL, 0.108 mmol, 2 M) were 
added to a suspension of resin in dry DMF (2 mL). The mixture was shaken at room temperature for 2 h. 
After the reaction, the resin was washed again with DMF/MeOH/DCM/Et2O/DMF.   
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Coupling of Fluorescein: 3 eq. of NHS-fluorescein predissolved in 0.5 mL DMF. 6 eq. of DIPEA and 3 eq. 
of HOBt predissolved in 0.5 mL DMF and are added successively to the resin. After shaking for 15 h, the 
reaction mixture was filtered off and the resin washed with 3x DMF, 3x MeOH, 3x DMF and 3x Et2O. 
Automated synthesis of linear peptides: 
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Automated solid phase peptide synthesis was carried out according to protocols described in sections 10.2. 
The peptides were simultaneously cleaved from the resin and deprotected with a cocktail of TFA/TIS/water 
= 95: 2.5: 2.5 for 4h (4 mL/50 mg). After cleavage the resin was washed with neat TFA and was precipitated 
in cold ether (-20°C) by centrifugation at 0-4°C. The peptides were analyzed by RP-HPLC/LC-MS and/or 
MALDI. 
11.2.4. Analysis of linear peptides 
 
Figure 11.2.14: RP-HPLC Chromatogram of crude compound 11.2.19 (C4, 300Å column using a gradient from 0 to 
100 % CH3CN in 15 minutes). 
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Figure 11.2.15: MALDI-TOF Spectrum of crude compound 11.2.19. Calculated m/z (100%) = 2947.63; m/z (73.9%) 
= 2948.63. Found: 2948.5489 = M + H+.  
 
Figure 11.2.16: RP-HPLC Chromatogram of crude compound 11.2.22 (C4, 300Å column using a gradient from 0 to 
100 % CH3CN in 15 minutes). 
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Figure 11.2.17: MALDI-TOF Spectrum of crude compound 11.2.22. Calculated m/z (100%) = 2978.64; m/z (65.1%) 
= 2979.65. Found: 2979.6821 = M + H+. 
 
Figure 11.2.18: RP-HPLC of compound 11.2.24 (0-100% ACN in 6 min on Kinetex C18 100 Å, 150 x 2.1 mm, 2.6 
µm, at 35 °C) (Double peak due to the isomers of fluorescein). 
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Figure 11.2.19: ESI-MS from LC-MS at t = 3.324 min for crude compound 11.2.24. E.M calcd. for C135H215N51O39 = 
3174.64 and deconvoluted mass found 3175.91. 
 
 
 
Figure 11.2.20: RP-HPLC of compound 11.2.25 (0-100% ACN in 6 min on Kinetex C18 100 Å, 150 x 2.1 mm, 2.6 
µm, at 35 °C) (Double peak due to the isomers of fluorescein). 
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Figure 11.2.21: ESI-MS from LC-MS at t = 3.324 min for crude compound 11.2.25. E.M calcd. for C140H221N49O40 = 
3228.68 and deconvoluted mass found 3229.75. 
 
 
 
Figure 11.2.22: RP-HPLC of compound 11.2.26 (0-100% ACN in 6 min on Kinetex C18 100 Å, 150 x 2.1 mm, 2.6 
µm, at 35 °C) (Double peak due to the isomers of fluorescein). 
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Figure 11.2.23: ESI-MS from LC-MS at t = 4.277 min for crude compound 11.2.26. E.M calcd. for C129H206N46O37 = 
2991.57 and deconvoluted mass found 2992.54. 
 
 
 
Figure 11.2.24: RP-HPLC trace of HPLC purified compound 11.2.26 (0-100% ACN in 6 min on Kinetex C18 100 Å, 
150 x 2.1 mm, 2.6 µm, at 35 °C) (Double peak due to the isomers of fluorescein). 
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Figure 11.2.25: ESI-MS from LC-MS at t = 3.332 min. E.M calcd. for C129H206N46O37 = 2991.57 and deconvoluted 
mass found 2992.80. 
 
 
 
Figure 11.2.26: RP-HPLC trace of HPLC crude compound 11.2.27 (0-100% ACN in 6 min on Kinetex C18 100 Å, 
150 x 2.1 mm, 2.6 µm, at 35 °C) (Double peak due to the isomers of fluorescein). 
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Figure 11.2.27: ESI-MS from LC-MS at t = 4.314 min for crude compound 11.2.27. E.M calcd. for C129H206N46O37S2 
= 3055.51 and deconvoluted mass found 3056.61. 
Synthesis of compound 11.2.28 
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Peptide 11.2.27 (5 mg, 1.63 µmol) was dissolved in 0.1 M NH4HCO3 buffer (1 mL) and stirred vigorously 
for 24h. The reaction was then quenched with TFA.  A mixture of peptides containing 2 peptide strands but 
with single or double disulfide bonds was isolated using RP-HPLC. No higher mass products were 
observed. 
 
 
Figure 11.2.28: RP-HPLC Chromatogram of reaction mixture showing product 11.2.8 at t = 10.65 min (C18, 100Å 
column using a gradient from 0 to 100 % CH3CN in 15 minutes). 
 
 
 
Figure 11.2.29: RP-HPLC trace of HPLC purified compound 11.2.28 (0-100% ACN in 6 min on Kinetex C18 100 Å, 
150 x 2.1 mm, 2.6 µm, at 35 °C). 
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Figure 11.2.30: ESI-MS from LC-MS at t = 3.259 min for purified compound 11.2.28. E.M calcd. for 
C258H408N92O74S4 = 6106.99 and C258H410N92O74S4 = 6109.00 and deconvoluted mass found 6109.75. 
11.2.5 CuAAC Conjugation I: peptides & steroids 
Scaffold-Peptide Conjugation Protocol via CuAAC 
COMPOUNDS FOR DNA BINDING 
Pentynoic acid (11.2.29): Scaffold 11.2.3 (3.2 mg, 5 µmol) was dissolved in 0.2 mL dry DMSO in a 5 mL 
round bottom flask.  Peptide 11.2.23 (3.7 mg, 1.2 µmol) was dissolved in 0.1 mL miliQ water and added it 
to the reactor. Cu(CH3CN)4PF6 (4.63 mg, 12 µmol) was dissolved in 75 µL dry DMSO and added it to the 
reaction mixture. The reaction was stirred for 3 h at room temperature under argon. The reaction was 
monitored by RP-HPLC and purified by fraction collection in RP-HPLC. Fractions were lyophilized and 
analyzed by RP-HPLC and MALDI-TOF. 
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Figure 11.2.31: RP-HPLC Chromatogram of crude compound 11.2.29 eluting at 13.3 min (C4, 300Å column using a 
gradient from 0 to 100 % CH3CN in 15 minutes). 
 
 
Figure 11.2.32: RP-HPLC Chromatogram of pure compound 11.2.29 (C4, 300Å column using a gradient from 0 to 
100 % CH3CN in 15 minutes). 
 
Figure 11.2.33: RP-HPLC of compound 11.2.29 (0-100% ACN in 6 min on Kinetex C18 100 Å, 150 x 2.1 mm, 2.6 
µm, at 35 °C). 
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Figure 11.2.34: ESI-MS spectrum from LC-MS at t = 3.765 min of pure compound 11.2.23. EM calcd. for 
C287H478N104O76 = 6597.67 and deconvoluted mass found 6600.2. 
 
Gly (11.2.30): Scaffold 11.2.6 (3.2 mg, 5 µmol) was dissolved in 0.2 mL dry DMSO in a 5 mL round 
bottom flask.  Peptide 11.2.22 (3.7 mg, 1.2 µmol) was dissolved in 0.1 mL miliQ water and added it to the 
reactor. Cu(CH3CN)4PF6 (4.68 mg, 13 µmol) was dissolved in 75 µL dry DMSO and added it to the reaction 
mixture. The reaction was stirred for 3 h at room temperature under argon. The reaction was monitored by 
RP-HPLC and purified by fraction collection in RP-HPLC. Fractions were lyophilized and analyzed by RP-
HPLC and MALDI-TOF. 
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Figure 11.2.35: RP-HPLC Chromatogram of crude compound 11.2.30 eluting at 13.3 min (C4, 300Å column using a 
gradient from 0 to 100 % CH3CN in 15 minutes). 
 
 
 
Figure 11.2.36: RP-HPLC Chromatogram of pure compound 11.2.30 (C4, 300Å column using a gradient from 0 to 
100 % CH3CN in 15 minutes). 
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Figure 11.2.37: RP-HPLC trace of compound 11.2.30 (0-100% ACN in 6 min on Kinetex C18 100 Å, 150 x 2.1 mm, 
2.6 µm, at 35 °C). 
 
 
Figure 11.2.38: ESI-MS spectrum from LC-MS at t = 3.688 min of compound 11.2.30. EM cacld. for C283H470N104O76 
= 6541.61 and deconvoluted mass found 6543.74. 
Azidobenzoic acid (11.2.31): Scaffold 11.2.9 (4 mg, 5 µmol) was dissolved in 0.2 mL dry DMSO in a 5 
mL round bottom flask. Peptide 11.2.22 (3.7 mg, 1.2 µmol) was dissolved in 0.1 mL miliQ water and added 
it to the reactor. Cu(CH3CN)4PF6 (4.68 mg, 13 µmol) was dissolved in 75 µL dry DMSO and added it to 
the reaction mixture. The reaction was stirred for 3 h at room temperature under argon. The reaction was 
monitored by RP-HPLC and purified by fraction collection in RP-HPLC. Fractions were lyophilized and 
analyzed by RP-HPLC and MALDI-TOF. 
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Figure 11.2.39: RP-HPLC Chromatogram of crude compound 11.2.31 eluting at 13.9 min (C4, 300Å column using a 
gradient from 0 to 100 % CH3CN in 15 minutes). 
 
Figure 11.2.40: RP-HPLC Chromatogram of pure compound 11.2.31 (C4, 300Å column using a gradient from 0 to 
100 % CH3CN in 15 minutes). 
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Figure 11.2.41: RP-HPLC trace of compound 11.2.31 (0-100% ACN in 6 min on Kinetex C18 100 Å, 150 x 2.1 mm, 
2.6 µm, at 35 °C). 
 
Figure 11.2.42: ESI-MS from LC-MS at t = 3.777 min of compound 11.2.31. EM calcd. for C295H478N104O76 = 6693.97 
and deconvoluted mass found 6696.10. 
PATA linker (11.2.32): Scaffold 11.2.15 (4 mg, 5 µmol) was dissolved in 0.2 mL dry DMSO in a 5 mL 
round bottom flask.  Peptide 11.2.22 (3.7 mg, 1.2 µmol) was dissolved in 0.1 mL miliQ water and added it 
to the reactor. Cu(CH3CN)4PF6 (4.63 mg, 12 µmol) was dissolved in 75 µL dry DMSO and added it to the 
reaction mixture. The reaction was stirred for 3 h at room temperature under argon. The reaction was 
monitored by RP-HPLC and purified by fraction collection in RP-HPLC. Fractions were lyophilized and 
analyzed by RP-HPLC and LC-MS. 
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Figure 11.2.43: RP-HPLC Chromatogram of crude compound 11.2.32 eluting at 13.368 min (C4, 300Å column using 
a gradient from 0 to 100 % CH3CN in 15 minutes). 
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Figure 11.2.44: RP-HPLC Chromatogram of pure compound 11.2.32 (C4, 300Å column using a gradient 
from 0 to 100 % CH3CN in 15 minutes). 
 
Figure 11.2.45: RP-HPLC of compound 11.2.32 (0-100% ACN in 15 min on Kinetex C18 100 Å, 150 x 2.1 mm, 2.6 
µm, at 35 °C). 
 
Figure 11.2.46: ESI-MS spectrum from LC-MS at t = 3.746 min of compound 11.2.26. EM calcd. for C295H486N108O76 
= 6757.75 and deconvoluted mass found 6760.35. 
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COMPOUNDS FOR CELL PENETRATION 
Synthesis of 11.2.33: Scaffold 11.2.3 (0.27 mg, 0.4 µmol) was dissolved in 0.2 mL dry DMSO in a 5 mL 
round bottom flask. Peptide 11.2.24 (4 mg, 1.2 µmol) was dissolved in 0.1 mL miliQ water and added it to 
the reactor. Cu(CH3CN)4PF6 (2.34 mg, 6.3 µmol) was dissolved in 75 µL dry DMSO and added it to the 
reaction mixture. The reaction was stirred for 3 h at room temperature under argon. The reaction was 
monitored by RP-HPLC and purified by fraction collection in RP-HPLC. Fractions were lyophilized and 
analyzed by RP-HPLC and MALDI-TOF. 
 
 
 
Figure 11.2.47: RP-HPLC Chromatogram of crude compound 11.2.33 (C4, 300Å column using a gradient from 0 to 
100 % CH3CN in 15 minutes). 
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Figure 11.2.48: RP-HPLC trace of compound 11.2.33 (0-100% ACN in 15 min on Kinetex C18 100 Å, 150 x 2.1 
mm, 2.6 µm, at 35 °C). 
 
Figure 11.2.49: ESI-MS from LC-MS at t = 3.954 min for pure compound 11.2.33. E.M calcd. for C311H484N102O84 = 
6991.67 and E.M. + NH4+ = 7009.67 and deconvoluted mass found 6994.22 and 7008.79 respectively. 
Synthesis of 11.2.34: Scaffold 11.2.3 (3.11 mg, 5 µmol) was dissolved in 0.2 mL dry DMSO in a 5 mL 
round bottom flask.  Peptide 11.2.24 (3.85 mg, 1.2 µmol) was dissolved in 0.1 mL miliQ water and added 
it to the reactor. Cu(CH3CN)4PF6 (4.51 mg, 12 µmol) was dissolved in 75 µL dry DMSO and added it to 
the reaction mixture. The reaction was stirred for 3 h at room temperature under argon. The reaction was 
monitored by RP-HPLC and purified by fraction collection in RP-HPLC. Fractions were lyophilized and 
analyzed by RP-HPLC and MALDI-TOF. 
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Figure 11.2.50: RP-HPLC Chromatogram of crude compound 11.2.34 (C4, 300Å column using a gradient from 0 to 
100 % CH3CN in 15 minutes). 
 
Figure 11.2.51: RP-HPLC trace of compound 11.2.34 (0-100% ACN in 15 min on Kinetex C18 100 Å, 150 x 2.1 
mm, 2.6 µm, at 35 °C). 
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Figure 11.2.52: ESI-MS from LC-MS at t = 4.656 min for pure compound 11.2.34. E.M calcd. for C176H269N51O45 = 
3817.03 and deconvoluted mass found 3818.35. 
 
11.2.6 EMSA studies I 
All gels have been run according to the protocols described in sections 10.4 & 10.5 (depending on whether 
non-radiolabelled or radiolabelled DNA was used): 
 
Figure 11.2.53. (left) EMSA titration of the dipodal peptidosteroid 11.2.29 to the Random dsDNA. Lane 1-10 contain 
respectively 0, 0.04, 0.12, 0.17, 0.20, 0.22, 0.26, 0.30, 0.35, 0.44 µM  and compound 11.2.30 (right) lanes 1-10 contains 
respectively 0, 0.167, 0.501, 0.668, 0.751, 0.835, 1.002, 1.169, 1.336, 1.67 µM of the mimic, stained with SybrGold.  
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Figure 11.2.54. EMSA titration of the dipodal peptidosteroid 11.2.29 (left) and 11.2.30 (right) to the Random dsDNA. 
Lane 1-10 contain respectively 0, 0.167, 0.501, 0.668, 0.751, 0.835, 1.002, 1.169, 1.336, 1.67 µM of the mimic, stained 
with SybrGold.  
 
 
Figure 11.2.55. EMSA titration of the dipodal peptidosteroid 11.2.31 (left) and 11.2.32 (right) to the Random dsDNA. 
Lanes 1-10 contain respectively 0, 0.167, 0.501, 0.668, 0.751, 0.835, 1.002, 1.169, 1.336, 1.67 µM of the mimic, 
stained with SybrGold.  
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Figure 11.2.56. EMSA titration of the dimeric GCN4 11.2.28 to the CRE binding site. Lane 1-10 contain respectively 
0, 0.25, 0.5, 0.68, 0.75, 1.0, 1.25, 1.5, 2.0, 2.5 µM of the mimic, stained with SybrGold.  
 
Figure 11.2.57. EMSA titration of the dipodal peptidosteroid conjugates 2.29 and 2.30 to the 5’-labeled 32P-CRE 
sequence (5’ – CGG ATG ACG TCA TTT TTT TTC – 3’) at 5nM: First lane in all the gels: pyrimidine strand. Lanes 
2-9 contain peptide concentrations of 0, 0.05, 0.0625, 0.075, 0.0875, 0.1, 0.1125 and 0.125 µM for 2.29 and 2.30. 
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CHAPTER 11.3 
11.3.1 Peptide synthesis 
Attachment of the first residue was performed manually. Glycine and GABA were coupled as second and 
third residues respectively to increase the space between the scaffold and the peptide. Residues D226-Q248 
were coupled by automated peptide synthesis using HBTU as coupling reagent and 20% piperidine/NMP 
for Fmoc deprotection. As a last residue and to increase UV-absorption and facilitate HPLC analysis, 4-
acetamidobenzoic acid was coupled to the N-terminus. Cleavage and deprotection of the peptide was 
performed with a cocktail mixture containing TFA/TIS/H2O (95/2.5/2.5) for 4 hours at room temperature. 
Peptide was obtained by precipitation with cold ether and lyophilization. In view of the satisfying crude 
integrity of the peptide, no further purification efforts were undertaken at this stage. 
Manual coupling protocols: 
Immobilization of Fmoc-Pra-OH on Rink amide ChemMatrix resin 
 
To a suspension of resin 11.3.1 (100 mg, 0.54 mmol/g) in DMF (dry, 10 mL/g resin), were added Fmoc-
Pra-OH (54.5 mg, 0.162 mmol), PyBOP (84.3 mg, 0.162 mmol) and DIPEA (0.056 mL, 0.324 mmol). The 
mixture was shaken at room temperature for 1 h. After reaction, the resin was washed with DMF, ACN and 
MeOH. The resin was then capped with acetic anhydride (0.031 mL, 0.324 mmol) and DIPEA (0.056 mL, 
0.324 mmol) in dry DMF (2 mL) 2 times for 30 min. 
Fmoc deprotection and coupling of Fmoc-GABA-OH 
 
NHFmoc deprotection of 11.3.2. After an initial DMF washing step, resin 11.3.2 (0.054 mmol) was 
successively treated twice for 30 min with a piperidine solution in DMF (40 % v/v, 2 mL) at ambient 
temperature, applying intermediate filtration under reduced pressure and washing with DMF, while the 
final resin is additionally washed with ACN and DCM. 
Coupling of Fmoc-GABA-OH. After Fmoc deprotection, Fmoc-GABA-OH (70.2 mg, 0.216 mmol, 0.5 M), 
PyBOP (112.4 mg, 0.216 mmol, 0.5 M) and DIPEA (0.038 mL, 0.216 mmol, 2 M) were added to a 
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suspension of resin in dry DMF (3 mL). The mixture was shaken at room temperature for 2 h. After the 
reaction, the resin was washed again with DMF/MeOH/DCM/Et2O/DMF.   
Automated synthesis of linear peptide Aba-DPAALKRARNTEAARRDRARKLQG-Gaba-Pra-
CONH2 
 
 
Automated solid phase peptide synthesis was carried out on a Syro synthesizer from Biotage using standard 
Fmoc/tBu chemistry with HBTU as coupling reagent and 20% piperidine in NMP as deprotection reagent. 
Fmoc protected resin (0.054 mmol) was subjected to automated synthesis where solutions of Fmoc-Nα-
protected amino acids (0.5 M in NMP) were prepared. Each coupling reaction lasted 1h (amino acids 0.250 
mmol; HBTU 0.250 mmol in DMF, 0.5 M; DIPEA 0.250 mmol 2 M) and was followed by Fmoc 
deprotection with 40% piperidine in NMP. After each reaction the resin was washed with NMP (9 x). The 
peptide was then cleaved for the resin and deprotected with a cocktail of TFA/TIS/water = 95:2.5:2.5 for 
4h. After precipitation in cold ether, the peptide was analyzed by RP-HPLC and MALDI. 
 
Figure 11.3.1: RP-HPLC Chromatogram of crude compound 11.3.4 (Jupiter C4, 300Å column using a gradient from 
0 to 100 % CH3CN in 15 minutes). 
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Figure 11.3.2: MALDI-TOF Spectrum of crude compound 11.3.4. Calculated m/z (100%) = 3032.68; m/z (91.8%) = 
3033.68. Found: 3033.7916 = M + H+.  
11.3.2 Synthesis of Cyclodextrin Scaffolds 
Complete synthesis and characterization has been performed by the group of Prof. Tomas Kraus (to be 
published). A part of the synthesis is described here. 
2. I Cyclodextrin template molecules: 
General experimental procedures: Preparative reversed–phase (RP) chromatography was carried out using 
medium pressure columns containing C-18 modified silica (Phenomenex Luna, 15 μm). Thin-layer (TLC) 
and reversed-phase thin-layer chromatography (RPTLC) were performed with precoated Silica Gel 60F 
and RP-18 F plates (E. Merck) respectively, which were visualized by spraying with an aqueous solution 
of phosphomolybdenic acid containing 5% of H2SO4 and heating. All chemicals used were commercially 
available. Compounds 11.3.8, 11.3.9 and 11.3.10 were prepared according to the known procedure109,263,264. 
Satisfactory elemental analysis could not be obtained for hydrophilic compounds 1 – 3 unless variable 
numbers of water molecules were taken into account. Thus, calculations based on weights of these 
compounds (molarity, yield) are related to the hydrated molecules. 
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6I,6IV-Dideoxy-6I,6IV-diazido-α-cyclodextrin 11.3.8 
 
To a solution of 6I,6IV-dideoxy-6I,6IV-dibromo-α-cyclodextrin trihydrate[1] 11.3.5 (0.367 g, 0.318 mmol) in 
DMF (5 ml)  sodium azide (0.130 g, 2 mmol) was added. The mixture was stirred at 50 °C for 20 h under 
argon atmosphere and then the solvent was evaporated under reduced pressure. The solid material was 
dissolved in a warm mixture of methanol-water (8:2, 5 ml) and charged onto RP column. Gradient elution 
with a mixture of methanol-water from 1:9 to 4:6 followed with evaporation of selected fractions and drying 
of the isolated material over phosphorus pentoxide in vacuo gave compound 11.3.8 as white amorphous 
material (0.305 g, 90%, calcd. for dihydrate).  Rf = 0.3 (RP-TLC, methanol-water 1:1). Elemental analysis: 
Calcd. for C36H58N6O28. 2H2O: C, 40.83, H 5.90; N 7.94; Found: C, 40.70, H, 5.77, N 7.63. ESI-MS calcd 
for [M + Na+]: 1045.3; found: 1045.3. 1H NMR (see Table 11.3.1); 13C NMR (see Table 11.3.2). 
6I,6IV-Dideoxy-6I,6IV-diazido-β-cyclodextrin 11.3.9. 
 
To a solution of 6I,6IV-dideoxy-6I,6IV-dibromo-β-cyclodextrin tetrahydrate[2] 11.3.6 (0.392 g, 0.294 mmol) 
in DMF (8.5 mL)  sodium azide (0.115 g, 1.76 mmol) was added and the mixture was stirred at 50 °C for 
24 h under argon atmosphere. Then the solvent was evaporated under reduced pressure to about a half of 
the volume and acetone (50 mL) was added under stirring. The precipitate, which formed upon addition of 
acetone, was collected on a glass frit, washed with acetone and dried in vacuo. Subsequently, it was 
dissolved in a warm mixture of methanol-water (9:1, 5 ml) and charged onto RP column. Gradient elution 
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with a mixture of methanol-water from 1:9 to 4:6 followed with evaporation of selected fractions gave 
compound 11.3.9 (320 mg, 83 %, calcd as heptahydrate) as white amorphous material after drying the 
isolated material over phosphorus pentoxide in vacuo.  Rf = 0.3 (RP-TLC, methanol-water 1:1). Elemental 
analysis: Calcd for C42H68N6O33. 7H2O: C, 38.48; H, 6.30; N, 6.41; Found: C, 38.35, H, 6.48, N 5.60. ESI-
MS calcd for [M+Na+]: 1207.4; found 1207.4. 1H NMR (see Table 11.3.1); 13C NMR (see Table 11.3.2). 
6I,6V-Dideoxy-6I,6V-diazido-γ-cyclodextrin 11.3.10. 
 
To a solution of 6I,6V-dideoxy-6I,6V-dibromo-γ-cyclodextrin pentahydrate[3] 11.3.7 (43 mg, 28.4 μmol) in 
DMF (1 ml)  sodium azide (11 mg, 0.171 mmol) was added. The mixture was stirred at 50 °C for 24 h 
under argon atmosphere and then solvents were evaporated under reduced pressure. The residue was 
dissolved in a mixture of methanol-water (8:2, 3 ml) and charged onto RP column (10 g, Phenomenex Luna 
15 μm). Gradient elution with a mixture of methanol-water from 1:9 to 4:6 followed with evaporation of 
selected fractions and drying of the isolated material over phosphorus pentoxide in vacuo gave compound 
11.3.10 as white amorphous material (32 mg, 77%, calcd for hexahydrate).  Rf = 0.4 (RP-TLC, methanol-
water 4:6). Elemental analysis: Calcd for C48H78N6O38. 6H2O: C, 39.62, H 6.23, N 5.78; Found: C, 39.73, 
H, 5.91, N 5.39. HR-MALDI-MS calcd for [M+Na+]: 1369.4248; found 1369.4266. 1H NMR (see Table 
11.3.1); 13C NMR (see Table 11.3.2). 
2. II NMR spectra of cyclodextrin template molecules 
The NMR spectra of compounds 11.3.8, 11.3.9 and 11.3.10 were measured on Bruker AVANCE-600 
instrument (1H at 600.13 MHz and 13C at 150.9 MHz) with a cryoprobe in CD3OD at 25 °C. Spectra were 
referenced to solvent peak (using δH (CHD2OD) = 3.31 ppm; δC (CD3OD) = 49.0 ppm). Structural 
assignment of proton and carbon signals was achieved combining 1D-1H and 13C-spectra with homonuclear 
2D-H,H-COSY, 2D-H,H-TOCSY, 2D-H,H-ROESY and heteronuclear 2D-H,C-HSQC and 2D-H,C-
HMBC spectra. The 1H and 13C NMR data are summarized in Tables S1 and S2. Complete sequential 
structural assignment of proton and carbon signals has been achieved only for “symmetrical” α-cyclodextrin 
derivative 11.3.8. For β- and γ-cyclodextrin derivatives 11.3.9 and 11.3.10, respectively, only partial 
structural assignment was possible due to the poor separation of signals. The sequential positions of glucose 
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units in Table S1 and S2 are labeled with numbers I to VIII as it is shown in Figure S1. All observed 
coupling constants J(H,H) of ring protons of glucose units (not given in Table 1) showed the values 
characteristic for 4C1 conformation (J(1,2) = 3.5 – 4.0 Hz, J(2,3) ~ J(3,4) ~ J(4,5) = 8.5 – 10.0 Hz).   
Table 11.3.1.   Proton chemical shifts of compounds 11.3.8-10 in CD3OD at 600.13 MHz 
 
Comp. Glucose 
residue 
H-1 
(d) 
H-2 
(dd) 
H-3 
(dd) 
H-4 
(dd) 
H-5 
(ddd) 
H-6a 
(dd) 
H-6b 
(dd) 
11.3.8 I, IV 4.971 3.509 3.916 3.447 3.961 3.728 3.612 
 II, V 4.940 3.494 3.935 3.517 3.821 ~3.882 (2H) 
 III, VI 4.907 3.494 3.911 3.469 3.793 ~3.833 (2H) 
         
11.3.9 I  4.994  
 
 
3.53-3.50 
(7H) 
 
 
 
3.88-3.83 
(7H) 
3.456 3.891 
 (2H) 
3.713 3.590 
 IV 4.994 3.450 3.713 3.580 
 II 4.975 3.428  
 
3.76-3.71 
(5H) 
 
 
3.88 – 3.83 (10H) 
 III 4.968 3.424 
 V 4.962  
3.51 (3H)  VI 4.943 
 VII 4.937 
         
11.3.10 I, V 5.032 3.528 3.826 3.424 3.878 3.695 3.568 
 II, VI 5.013 3.516 3.839 3.510 3.742  
3.80-3.89 (12H)  III, VII 5.004 3.516 3.833 3.493 3.738 
 IV, VIII 4.978 3.522 3.817 3.462 3.705 
 
a Chemical shift values in columns may be interchanged (except for H-6a,H-6b). 
 
Table 11.3.2.   Carbon-13 chemical shifts of compounds 11.3.8-10 in CD3OD at 150.9 MHz 
 
Comp. Glucose 
residue 
C-1 C-2 C-3 C-4 C-5 C-6 
11.3.8 I, IV 103.43 73.84 74.92 84.36 72.50 52.82 
 II, V 103.67 73.82 75.15 83.38 73.75 61.93 
 III, VI 103.71 73.76 75.23 83.40 73.89 61.99 
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11.3.9 I  103.99 74.21 74.82 (2C) 84.26 73.85 52.76 
 IV 103.97  
74.17 (3C) 
84.21 73.81 52.73 
 II 103.92 74.77 83.23 73.70 61.95 (2C) 
 III 103.91 74.68 83.20 73.67 
 V 103.84 74.14 74.65 83.04 (2C) 73.63 61.87 (2C) 
 VI 103.53 (2C) 74.09 74.55 72.42 (2C) 
 VII 74.07 74.52 83.02 61.84 
        
11.3.10 I, V 103.44 74.42 (2C) 74.50 83.95 72.49 52.71 
 II, VI 103.84 74.56 82.64 73.79 61.99 
 III, VII 103.90 74.47 74.62 82.82 73.74 61.92 (2C) 
 IV, VIII 104.02 74.50 74.65 82.87 73.95 
 
a Chemical shift values in columns may be interchanged (except for C-6). 
 
11.3.3 CuAAC Conjugation II: peptides & cyclodextrins 
Peptide-Cyclodextrin conjugation protocol via CuAAC 
Using alfa cyclodextrin 
Synthesis of 11.3.11: 6I,6IV-Dideoxy-6I,6IV-diazido-α-cyclodextrin 11.3.6 (6.75 mg, 6.6 µmol) was 
dissolved in 0.2 mL dry DMSO in a 5 mL round bottom flask. Peptide 11.3.4 (5 mg, 1.6 µmol) was 
dissolved in 0.1 mL milliQ water and added it to the reactor. Cu(CH3CN)4PF6 (6.15 mg, 16 µmol) was 
dissolved in 75 µL dry DMSO and added to the reaction mixture. The reaction was stirred for 3h at room 
temperature under argon. The reaction was monitored by RP-HPLC and purified by fraction collection in 
RP-HPLC to obtain compound 11.3.11. Fractions were lyophilized and analyzed by RP-HPLC and 
MALDI-TOF. 
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Figure 11.3.3: RP-HPLC trace (0-100% in 15 min on Jupiter C4, 300 Å) of the reaction mixture after 3 h. 
The chromatogram shows two main peaks corresponding to the unreacted peptide (11.1 min) and desired 
conjugate (11.5 min). The sharpness of the peak of the conjugate allowed for easy purification by fraction 
collection. 
Using beta cyclodextrin 
Synthesis of 11.3.12: 6I,6IV-Dideoxy-6I,6IV-diazido-β-cyclodextrin (6.25 mg, 5 µmmol) was dissolved in 
0.2 mL dry DMSO in a 5 mL round bottom flask.  Peptide 11.3.4 (4 mg, 1.3 µmol) was dissolved in 0.1 
mL milliQ water and added it to the reactor. Cu(CH3CN)4PF6 (4.91 mg, 13 µmol) was dissolved in 75 µL 
dry DMSO and added to the reaction mixture. The reaction was stirred for 3h at room temperature under 
argon. The reaction was monitored by RP-HPLC and purified by fraction collection in RP-HPLC to obtain 
compound 11.3.12. Fractions were lyophilized and analyzed by RP-HPLC and MALDI-TOF. 
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Figure 11.3.4: RP-HPLC trace (0-100% in 15 min on Jupiter C4, 300 Å) of the reaction mixture after 3 h. The 
chromatogram shows two main peaks corresponding to the unreacted peptide (11.1 min) and desired conjugate (11.4 
min). The conjugation of the peptide to the β-cyclodextrin derivative proceeded better than to α and γ ones, as the 
major peak is the desired compound. The sharpness of the peak of the conjugate allowed for easy purification by 
fraction collection. 
Synthesis of 11.3.13: 6I,6IV-Dideoxy-6I,6IV-diazido-β-cyclodextrin (1 mg, 0.8 µmol) was dissolved in 0.2 
mL dry DMSO in a 5 mL round bottom flask.  Peptide 11.2.25 (8 mg, 2.5 µmol) was dissolved in 0.1 mL 
milliQ water and added it to the reactor. Cu(CH3CN)4PF6 (1.56 mg, 4 µmol) was dissolved in 75 µL dry 
DMSO and added to the reaction mixture. The reaction was stirred for 3 h at room temperature under argon. 
The reaction was monitored by RP-HPLC and purified by fraction collection in RP-HPLC to obtain 
compound 33. Fractions were lyophilized and analyzed by LC-MS. 
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Figure 11.3.5: RP-HPLC trace (0-100% in 15 min on Jupiter C4, 300 Å) of the reaction mixture 11.3.13 after 3 h. 
Using gamma cyclodextrin 
Synthesis of 11.3.13.14: 6I,6V-Dideoxy-6I,6V-diazido-γ-cyclodextrin (8.9 mg, 6.6 µmol) was dissolved in 
0.2 mL dry DMSO in a 5 mL round bottom flask. Peptide 11.3.4 (5 mg, 1.6 µmol) was dissolved in 0.1 mL 
milliQ water and added it to the reactor. Cu(CH3CN)4PF6 (6.15 mg, 16 µmol) was dissolved in 75 µL dry 
DMSO and added to the reaction mixture. The reaction was stirred for 3h at room temperature under argon. 
The reaction was monitored by RP-HPLC and purified by fraction collection in RP-HPLC to obtain 
compound 11.3.14. Fractions were lyophilized and analyzed by RP-HPLC and MALDI-TOF.
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Figure 11.3.6: RP-HPLC (0-100% in 15 min on Jupiter C4, 300 Å) of the reaction mixture after 3 h. 
The chromatogram shows two mean peaks corresponding to the unreacted peptide (11.1 min) and desired 
conjugate (11.5 min). The sharpness of the peak of the conjugate allowed for easy purification by fraction 
collection. 
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11.3.4 Analytical data of purified peptide-cyclodextrin conjugates 
Compound 11.3.11  
 
 
Figure 11.3.7: RP-HPLC Chromatogram of pure compound 11.3.11 (C4, 300Å column using a gradient from 0 to 
100 % CH3CN in 15 minutes). 
 
 
 
Figure 11.3.8: ESI-MS of compound 11.3.11.  Calcd. E.M. = 7085.68, M + Na+ = 7108.68, Obsd. M = 7088.94, M + 
Na+ = 7110.23. 
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Figure 11.3.9: HPLC trace from LC-MS for compound 11.3.11 (0-100% ACN in 6 min on Kinetex C18 100 Å, 150 
x 2.1 mm, 2.6 µm, at 35 °C). 
 
 
 
Figure 11.3.10: ESI-MS from LC-MS at r.t. = 3.159 min for purified compound 11.3.11. E.M = 7085.68 and 
deconvoluted mass found 7088.40. 
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Compound 11.3.12 (Beta conjugate) 
 
 
Figure 11.3.11: RP-HPLC Chromatogram of pure compound 11.3.12 (Jupiter C4, 300Å column using a gradient from 
0 to 100 % CH3CN in 15 minutes). 
 
 
 
Figure 11.3.12: ESI-MS of compound 11.3.12.  Calcd. E.M. = 7247.74, M + Na+ = 7270.74 and deconvoluted masses 
found 7251.04 and 7272.62 + other minor impurities. 
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Figure 11.3.13: HPLC trace from LC-MS for compound 11.3.12 (0-100% ACN in 6 min on Kinetex C18 100 Å, 150 
x 2.1 mm, 2.6 µm, at 35 °C). 
 
Figure 11.3.14: ESI-MS from LC-MS at r.t. = 3.153 min for purified compound 11.3.12. E.M. = 7247.74, M+NH4+ 
= 7265.74 and deconvoluted mass found 7250.88 and 7264.78. 
Compound 11.3.13 (Beta conjugate with fluorescent peptides). 
 
Figure 11.3.15: RP-HPLC trace of compound 11.3.13 (0-100% ACN in 15 min on Kinetex C18 100 Å, 150 x 2.1 
mm, 2.6 µm, at 35 °C). 
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Figure 11.3.16: ESI-MS from LC-MS at t = 3.386 min. for pure compound 11.2.13. E.M calcd. for C322H510N104O113 
= 7641.74 and deconvoluted mass found 7644.63. 
Compound 11.3.14 (Gamma conjugate). 
 
 
Figure 11.3.17: RP-HPLC Chromatogram of pure compound 11.3.14 (Jupiter C4, 300Å column using a gradient 
from 0 to 100 % CH3CN in 15 minutes). 
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Figure 11.3.18: ESI-MS of compound 11.3.14. Calcd. E.M. = 7409.79, M + 114.02 (TFA salt) = 7523.81 and 
deconvoluted masses found 7412.93 and 7526.93 + other minor impurities. 
 
Figure 11.3.19: HPLC trace from LC-MS (0-100% ACN in 6 min on Kinetex C18 100 Å, 150 x 2.1 mm, 2.6 µm, at 
35 °C). 
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Figure 11.3.20: ESI-MS from LC-MS at r.t. = 3.159 min. Cacld. E.M. = 7409.79 and deconvoluted mass found 
7412.55. 
 
11.3.5 EMSA studies II 
All gels have been run according to the protocols described in sections 10.4 & 10.5 (depending on whether 
non-radiolabelled or radiolabelled DNA was used): 
 
 
Figure 11.3.21: EMSA titration of the dipodal peptidocyclodextrin conjugates 11.3.11, 11.3.12 and 11.3.14 from top 
to botton to the CRE sequence (5’ – CGG ATG ACG TCA TTT TTT TTC – 3’). Lane 1-10: dsDNA (0.167 µM); 
lanes 1-10: 0, 0.167, 0.501, 0.668, 0.751, 0.835, 1.002, 1.169, 1.336, 1.67 µM of peptide. 
 
Chapter 11: Chapter-wise experimental section 
225 
 
 
 
Figure 11.3.22: EMSA titration of the dipodal peptidocyclodextrin conjugates to the random sequence: 
Concentrations: 0.167 µM dsDNA; Lanes 1-5: 0. 0.167, 0.501, 0.668, 1.67 µM. Lanes 1-5 for compound 11.3.11 (alfa 
conjugate). Lanes 1’-5’ compound 11.3.12 (beta conjugate). Lanes 1’’-5’’ Compound 11.3.14 (gamma conjugate). 
 
 
 
Figure 11.3.23: EMSA titration of the dipodal peptidocyclodextrin conjugates to the 5’-labeled 32P-CRE sequence: 
Concentrations mentioned above. First lane in all the gels: pyrimidine strand. Gels from left to right: 11.3.11, 11.3.12 
and 11.3.14. 
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CHAPTER 11.4 
All cell lines, Fetal Bovine Serum, PBS (Gibco) and DMEM (Gibco)  were  provided  by  prof.  Dr.  Ir.  B.  
De  Geest. The synthesis of compounds relevant for this chapter have been described in chapters 11.2 and 
11.3. 
11.4.1 Confocal Microscopy: additional image 
 
Figure 11.4.1: Confocal microscopy images of (A) the uptake of the GCN4 peptide 4.1 at 4 °C, (B) 37 °C Upper panel 
shows accumulated images of DNA (blue), cell membrane (red) and fluorescein (green). Lower panel shows 
fluorescein image. (Scale bar = 20 µm). 
From figure 11.4.1, it is clear that the GCN4 peptide (4.1) was internalized at 37 °C but not at 4°C pointing 
to an endocytic pathway. 
11.4.2 Flow cytometry: additional information 
The cell lines grow at a constant temperature of 37 °C in an 5 % CO2 -atmosphere. A DMEM grow medium 
is enriched with fetal bovine serum, penicillin, pyruvate and glutamine after which the culture medium is 
sterilized through a filter. The medium, PBS and other reagents are always preheated at a temperature of 
37 °C  before they are added to the cells. To work under sterile conditions, cells are handled in a laminar 
flow cabinet (Nuaire). 
Plating of cells 
To perform the test on larger scale, 24-  or 96-well plates are used. Therefore a specific amount of cells are 
divided along the wells. In order to divide the cells properly, the cells are counted in a Bürker counting 
chamber which is a glass microscope slide with a grid of perpendicular lines. For the macrophages 
(RAW264.7), the following protocol was used:  
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● Remove medium from the confluent flask using the vacuum system  
● Wash the cells once with 10 ml of preheated PBS (37 °C) 
● Add 5 ml of preheated culture medium 
● Detach cells with the cell scraper 
● Transfer cells to 15 ml tube and centrifuge (300 G for 5 min) 
●  Resuspend cells in culture medium 
●   From  this  tube,  transfer  20 µl  of  cell  suspension  to  an  eppendorf  and  add 180 µl of trypan 
blue and mix well. 
● Transfer the mixture to the Burker  counting chamber to look at the cells with the microscope (Leica 
DMIL, NA 10x). 
An average of the counts in 4 grids is multiplied by 10000 which gave the number of cells per  mL.  An  
amount  of  cells/well  is  chosen  and  a  cell  dilution  is  made  based  on  the number  of  cells per  mL.  
The  cells  are  then plated  in  the  well plates  and  incubated  for 24 hrs at 37 °C and 5 % CO2. 
11.4.3 Serum stability assay 
To a 100 µL solution containing 5 µM of Fluorescein labelled peptide dissolved in mQ, 10 µL Fetal Bovine 
Serum (FBS) was added and incubated at 37°C. 20 µL aliquots were taken after 0 h, 1 h, 2 h, 4 h and 24 h, 
diluted with 100 µL mQ and centrifuged for 30s.  The supernatant was pipetted out and 100 µL was injected 
into the HPLC.  The UV signal was measured at 490 nm. The % peptide remaining was calculated via 
manual integration by determining the area of the peak and comparing it to the area obtained for the same 
peak at t = 0 h. 
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Figure 11.4.2: Graph of the serum stability assay by calculating the % peptide remaining using RP-HPLC via manual 
integration at λ = 490 nm. 
 
The serum tests indicated that compounds 4.5, 4.4 & 4.3 had degraded much faster than compounds 4.1 & 
4.2.  The use of a cholic acid or a cyclodextrin scaffold in this case does not seem to enhance the stability 
of the peptides. Normally one would expect enhanced stability in serum due to the shielding effects 
possessed by these scaffolds, instead compounds 4.5, 4.4 & 4.3 were found to degrade completely in 2 h or 
less.  An explanation for this could be that the compounds 4.5, 4.4 & 4.3 have a certain amount affinity for 
the serum proteins resulting in rapid degradation or they simply precipitate with the serum proteins when 
diluted and centrifuged.  In case of 4.4 and 4.3 an alternate explanation could be the rapid cleavage of the 
ester bonds used for attaching the linkers to the scaffold.  Due to the amphiphilic and complex nature of the 
compounds, it is however difficult to explain the unexpected, rapid degradation of the compounds in FBS 
via a simple serum test in vitro.  
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CHAPTER 11.5 
11.5.1 Scaffold Synthesis 
Benzyl 3α, 12α-dihydroxy-5β-cholan-24-oate (11.5.2). For synthesis, refer to 11.2.1. 
 
Benzyl 3α-pentynoate-5β-cholan-24-oate (11.5.3). Compound 11.5.2 (500 mg, 1.037 mmol) was 
dissolved in 2 mL dry DCM. Then a solution of 4-pentynoic acid (122.1 mg, 1.24 mmol) and DMAP (12.7 
mg, 0.104 mmol) in dry DCM (2.2 mL) was added and stirred for 10 min in an ice bath. Then, EDC·HCl 
(298.3 mg, 1.55 mmol) in 1 mL dry DCM was added portion-wise to the reaction mixture and stirred for 
30 min at 0°C, then the reaction mixture was stirred at room temperature overnight. The residue was purified 
by column chromatography (silica gel EtOAc/Hexane 1:3; Rf: 0.33) to give 11.5.3 as a yellow oil (349.9 
mg, 60% yield). 1H-NMR (300 MHz, CDCl3); δ 7.38 − 7.36 (m, 5 H), 5.15 (m, 2H), 4.75 (br, m, 1 H), 3.9 
(m, 1H), 2.5 (s, 1H), 2.55-2.45 (m, 4 H), 2.1-2.0 (m, 2 H), 1.95-1.90 (t, J = 12 Hz, 2 H), 0.85 (s, 3 H), 0.75 
(d, J = 6.40 Hz, 3 H), 0.65 (s, 3 H). ES-MS m/z (% rel. int.) calcd. 562.4 (100), found 621.3 (100) [M + 
OAc-].  
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Figure 11.5.1. 1H NMR spectrum of compound 11.5.3. 
 
Benzyl 3α-pentynoate-12α-Boc-aminobutyrate-5β-cholan-24-oate (11.5.4). Compound 11.5.3 (300 mg, 
0.534 mmol) was dissolved in 1 mL dry DCM. Boc-GABA-OH (162 mg, 0.8 mmol) in 0.4 mL dry DCM 
and DMAP (130 mg, 1.068 mmol) in 0.4 mL dry DCM. The reaction mixture was allowed to stir at 0°C 
under argon for 10 min after which EDC was added portion wise and the stirring was allowed to continue 
for another 30 minutes in an ice bath. Finally, the reaction mixture was allowed to warm slowly and was 
left to stir overnight at room temperature. The residue was purified by column chromatography (silica gel 
Hexane/EtOAc 3:1; Rf: 0.38) to give 11.5.4 as a yellow oil (159.6 mg, 40% yield). 1H-NMR (300 MHz, 
CDCl3); δ 7.38 − 7.36 (m, 5 H), 5.15 (m, 3H (12β + 2H)), 4.75 (br, m, 1H 3β), 3.15 (br m, 2H),2.60-2.50 
(m, 2H), 2.55-2.45 (m, 4 H), 2.25 (br m, 2H), 2.1-2.0 (m, 2 H), 1.95-1.90 (t, J = 12 Hz, 2 H), 0.85 (s, 3 H), 
0.75 (d, J = 6.40 Hz, 3 H), 0.65 (s, 3 H). ES-MS m/z (% rel. int.) calcd. 747.5 (100), found 806.5 (100) [M+ 
OAc]-.  
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Figure 11.5.2. 1H NMR spectrum of compound 11.5.4. 
 
Boc deprotection (11.5.5). Compound 11.5.4 (374.41 mg, 0.501 mmol) was dissolved in 4 mL DCM and 
0.8 mL TFA was added. The reaction was stirred for 2h at room temperature. Then the solvent was 
evaporated and no further purification was needed (Rf: 0.13). Compound 11.5.5 obtained with 99% yield 
(321 mg). 1H-NMR (300 MHz, CDCl3); δ 7.38 − 7.36 (m, 5 H), 5.15 (m, 3H (12β + 2H)), 4.75 (br, m, 1H 
3β), 3.15 (br m, 2H),2.60-2.50 (m, 2H), 2.55-2.45 (m, 4 H), 2.25 (br m, 2H), 2.1-2.0 (m, 2 H), 1.95-1.90 (t, 
J = 12 Hz, 2 H), 0.85 (s, 3 H), 0.75 (d, J = 6.40 Hz, 3 H), 0.65 (s, 3 H). ES-MS m/z (% rel. int.) calcd. 647.4 
(100), found 648.4 (100) [M+ H+].  
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Figure 11.5.3. 1H NMR spectrum of compound 11.5.5. 
 
Benzyl 3α-pentynoate-12α-4-maleimido-butyrate-5β-cholan-24-oate (11.5.6). Compound 11.5.5 (107.6 
mg, 0.166 mmol) was dissolved in 2mL dry toluene. Maleic anhydride (32.56 mg, 0.332 mmol) is added to 
the reaction in 2 mL dry toluene. The reaction is refluxed at 80°C for 24h. The solvent was evaporated and 
the residue was purified by column chromatography (fine silica gel Hexane/EtOAc 4:1; Rf: 0.2) to give 
11.5.6 as a brownish oil (45.9 mg, 38% yield). 1H-NMR (300 MHz, CDCl3); δ 7.38 − 7.36 (m, 5 H), 6.65 
(s, 2H), 5.17 (d, 1H,  J  = 13.57 Hz), 5.12 (d, 1H,  J = 13.56 Hz), 4.75 (br, m, 1H 3β), 3.55 (t, 2H),2.55-2.50 
(m, 2H), 2.45 (m, 4 H), 2.25 (br m, 2H), 1.95-1.90 (t, J = 12 Hz, 2 H), 0.85 (s, 3 H), 0.75 (d, J = 6.40 Hz, 3 
H), 0.65 (s, 3 H). ). 13C NMR (125 MHz, CDCl3): δ = 174.13 (COOR-C24), 172.10 (2C maleimides), 171.46 
(COOR-C3), 171.16 (COOR-C12), 136.88 (C - benzyl group), 134.51 (2CH maleimides), 128.88 (2CH-
benzyl ring), 128.54 (2CH- benzyl ring), 128.20 (CH-benzyl ring), 76.34 (CH ester), 74.90 (CH ester), 
69.00 (C-Alkyne), 66.33 (CH2-benzyl ester), 49.72 (CH), 47.93 (CH), 45.50 (C), 42.33 (CH), 37.56 (CH2), 
36.11 (CH), 35.16 (CH), 34.78 (CH), 34.47 (CH2), 34.02 (C), 32.50 (CH2), 32.20 (CH2), 31.55 (CH2), 31.20 
(CH2), 26.80 (CH2), 26.65 (CH2), 26,10 (CH2), 25.05 (CH2), 25.00 (CH2), 24.51 (CH2), 23.87 (CH2), 23.21 
(19-CH3), 17.71 (21 – CH3), 14.71 (CH2), 12.54 (18-CH3). ES-MS m/z (% rel. int.) calcd. 727.4 (100), 
found 745.4 (100) [M+ NH4+]. HR-MS (ES) m/z calcd. for C44H57NO8 727.4084, found 745.4448 (M + 
NH4+; Δ = 3.5 ppm). 
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Figure 11.5.4. 1H NMR spectrum of compound 11.5.6. 
 
Figure 11.5.5. 13C NMR spectrum of compound 11.5.6. 
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11.5.2 Peptide synthesis: 
Manual coupling protocols 
Immobilization of Fmoc-Aha-OH on Rink amide ChemMatrix resin 
 
 
To a suspension of resin (200 mg, 0.54 mmol/g) in DMF (dry, 10 mL/g resin), were added Fmoc-Aha-OH 
(118.7 mg, 0.324 mmol), HBTU (122.87 mg, 0.324 mmol) and DIPEA (0.112 mL, 0.648 mmol). The 
mixture was shaken at room temperature for 1 h. The resin was then capped with acetic anhydride (0.061 
mL, 0.648 mmol) and DIPEA (0.112 mL, 0.648 mmol) in dry DMF (3 mL) 2 times for 30 min. 
Immobilization of Fmoc-Cys(Trt)-OH on Rink amide ChemMatrix resin 
 
At a suspension of resin (200 mg, 0.54 mmol/g) in DMF (dry, 10 mL/g resin), were added Fmoc-Cys(Trt)-
OH (189.7 mg, 0.324 mmol), HBTU ( 122.9 mg, 0.324 mmol) and DIEA (0.112 mL, 0.648 mmol). The 
mixture was shaken at room temperature for 1 h. After the reaction, the resin was washed with DMF, ACN 
and MeOH. The resin was then capped with acetic anhydride (0.061 mL, 0.648 mmol) and DIPEA (0.112 
mL, 0.648 mmol) in dry DMF (3 mL) 2 times for 30 min. 
Automated synthesis of linear peptides 
 
 
Chapter 11: Chapter-wise experimental section 
235 
 
 
Automated solid phase peptide synthesis was carried out as described in 10.2. 
The peptide was then cleaved for the resin and deprotected with a cocktail of TFA/TIS/water = 95: 2.5: 2.5 
for 4h. After precipitation in cold ether, the peptide was analyzed by RP-HPLC and MALDI. 
 
Figure 11.5.6: RP-HPLC Chromatogram of crude compound 11.5.10 (C4, 300Å column using a gradient from 0 to 
100 % CH3CN in 15 minutes). 
 
Figure 11.5.7: MALDI-TOF Spectrum of compound 11.5.10 from peak at t = 10.034 min. E.M. calcd. for 
C117H189N49O33 = 2808.46. Found M + H+ = 2810.5187. 
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Figure 11.5.8: RP-HPLC chromatogram of crude compound 11.5.11 (C4, 300Å column using a gradient from 0 to 
100 % CH3CN in 15 minutes). 
 
Figure 11.5.9: MALDI-TOF Spectrum of crude compound 11.5.11 from peak at t = 10.651 min. E.M. calcd for 
C121H208N50O33S = 2921.59. Found: 2923.5332 = M + H+.  
11.5.3 Conjugation of peptides to the steroid scaffold 
Conjugation of peptide cMyc to C12 position of scaffold 
Scaffold 11.5.6 (1.24 mg, 0.002 mmol) and peptide 11.5.11 (8 mg, 0.003 mmol) were dissolved in 1 mL of 
a mixture H2O/ACN (4:1). The pH was adjusted to 6.5 with NH4HCO3 buffer. The reaction was stirred for 
2h and it was monitored by MALDI and HPLC. The solvent was evaporated and the crude compound 
11.5.12 was subjected for CuAAC without prior purification. 
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Figure 11.5.10: RP-HPLC Chromatogram of reaction mixture for synthesis of 11.5.12 after t = 2 h (C4, 300Å column 
using a gradient from 0 to 100 % CH3CN in 15 minutes). 
Conjugation of peptide Max to C3 position of compound 11.5.12 
Compound 11.5.12 (5 mg, 0.0013 mmol) was dissolved in 0.2 mL dry DMSO. Peptide 11.5.10 (6.15 mg, 
0.0022 mmol) in 0.1 mL H2O/ACN 4:1 was added to the scaffold and the reaction was stirred for 10 min 
under argon. Cu(CH3CN)4PF6 (5.1 mg, 0.014 mmol) dissolved in 0.075 mL dry DMSO was added to the 
reaction mixture. The reaction was monitored by HPLC and it was completed after 3h. Compound 11.5.13 
was purified by RP-HPLC. 
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Figure 11.5.11: RP-HPLC Chromatogram of reaction mixture for synthesis of 11.5.13 at t = 3 h (C4, 300Å column 
using a gradient from 0 to 100 % CH3CN in 15 minutes). 
 
Figure 11.5.12: RP-HPLC Chromatogram of RP-HPLC purified compound 11.5.13 (C4, 300Å column using a 
gradient from 0 to 100 % CH3CN in 15 minutes). 
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Figure 11.5.13: ESI-MS of RP-HPLC purified compound 11.5.13.  E.M. calcd. for C282H454N100O74S = 6457.46 and 
deconvoluted mass found 6460.38. 
 
 
 
Figure 11.5.14: RP-HPLC trace from LC-MS for HPLC purified compound 11.5.13 (0-100% ACN in 6 min on 
Kinetex C18 100 Å, 150 x 2.1 mm, 2.6 µm, at 35 °C). 
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Figure 11.5.15: ESI-MS from LC-MS at r.t. = 3.727 min. E.M. calcd. for C282H454N100O74S = 6457.46 and 
deconvoluted mass found 6460.21. 
11.5.4 EMSA studies III 
All gels have been run according to the protocols described in sections 10.4 & 10.5 (depending on whether 
non-radiolabelled or radiolabelled DNA was used): 
 
Figure 11.5.16: EMSA titration of the dipodal peptidosteroid 11.5.13 to the ramdom dsDNA stained with 
SybrGold.  
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Figure 11.5.17. EMSA titration of the dipodal peptidosteroid 11.5.13 to the E-box binding site stained with 
SybrGold.  
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CHAPTER 11.6 
11.6.1 Chapter Specific Material and Methods 
Special instructions 
All manual reactions involving the photocleavable linker were shielded from direct light exposure by foil 
wrapping. These means were complemented by standard laboratory glassware.  Reactions were usually 
performed at room temperature. Occasional cooling was established by using a special double-walled glass 
reactor (~7 mL), combined with a Julabo F70 cryostat controlled by a Julabo VC. Photolyses were carried 
out on a small scale with a 4W Bioblock Scientific compact UV lamp, set at 365 nm. For large scale 
cleavages, a 451 W UV ACE glass incorporated 7225-34 immersion lamp equipped with a Schott WG320 
UV cut-off filter was used. The resin suspension was thereby continuously agitated by N2 bubbling, and 
solvent regularly replenished, to prevent direct resin irradiation by complete solvent evaporation. All 
samples were cleaved at a distance of ~1 cm from the lamp.   
Analytical techniques and instrumentation 
Occasionally measured resin loadings were calculated from UV-data collected with a Varian Cary 3E UV-
VIS spectrophotometer at room temperature, operating in double beam mode, using standard quartz 
cuvettes (l = 1 cm, ~600 µL). 
By using a binary solvent system composed of (A =) H2O + TFA (0.1 %) and (B =) ACN as mobile phases, 
linear gradient elution has been performed. After injection, the column was flushed with x % B for 3 min, 
followed by a linear increase of B (versus A) to 100 % in y min, finishing by flushing with 100 % B for 5 
min, after which the gradient returns to x % B in 0.5 min, concluding the cycle by flushing with x % B for 
3 min. 
 Gradient 1: refers therein to (x,y) = (0, 15), or a 0 to 100 % linear increase of B in 15 min 
 Gradient 2: refers therein to (x,y) = (75, 15), or a 75 to 100 % linear increase of B in 15 min 
 
In addition to these, all other gradients follow the same profile.  
All MALDI spectra were recorded in the positive and reflector mode, with delayed extraction. 2,5-
dihydroxybenzoic acid (DHB) was 98.0 % pure, and α-cyano-4-hydroxycinnamic acid (α-CHCA) was 99 
% pure. All spectra were calibrated against MePEOH (Mn ≈ 2000, PD = 1.06), spotted from a MeOH (2 
mg/mL) solution. Following matrix solutions were utilized (made in eppendorf tubes, stored in freezer, 
carefully defrosted and homogenized upon use): 
Predominantly used (and referred to in presented analytical data): 
 Standard DHB: DHB (10 mg) + ACN (500 µL) + H2O (470 µL) + TFAaq (30 µL, 3 %) 
 Standard α-CHCA: α-CHCA (10 mg) + ACN (500 µL) + H2O (400 µL) + TFAaq (100 µL, 3 %) 
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Occasionally tested (alongside Table 4.10, Figure 4.5 and Figure 5.5): 
 Alternative DHB 1: DHB (10 mg) + ACN (500 µL) + MeOH (470 µL) + TFAaq (30 µL, 3 %)  
 Alternative DHB 2: DHB (1 .54 mg) + CHCl3 (666 µL) + MeOH (333 µL) 
By using a binary solvent system composed of (A =) H2O + formic acid (0.1 %) or H2O + NH4OAc (5 mM) 
and (B =) ACN as mobile phase, linear gradient elution has been performed. After injection: flushing the 
column with x % B for 2 min, followed by a linear increase of B (versus A) to 100 % in 15 min, finishing 
by flushing with 100 % B for 5 min, after which the gradient returns to x % B in 0.5 min, concluding the 
cycle by flushing with x % B for 3 min. 
Similar to aforementioned RPHPLC profiles, yet with a shorter (2 instead of 3 min) initial flushing phase 
and different additives (formic acid or NH4OAc instead of TFA) the following gradients have also been 
used: 
 Gradient 1: refers therein to x = 0, or a 0 to 100 % linear increase of B (versus A) in 15 min 
 Gradient 2: refers therein to x = 75, or a 75 to 100 % linear increase of B (versus A) in 15 min 
Recurring SPPS procedures     
 Colour testing 
TNBS test1 
A minute resin sample (~1-5 mg) was transferred to a miniature glass test tube, to which a DIPEA solution 
in DMF (10 % v/v, 4 drops) and a TNBS solution in DMF (2 % v/v, 4 drops) were added. Intense, orange/red 
coloration of beads indicates presence of free primary amine functions. Unaffected beads support absence 
(i.e. derivatization) of these functions, yet results are only indicative. Comparison with starting material or 
reference compounds has generally been made for reliable interpretation. Since sensitive to steric 
impediment, prolonged (> 30 min) treatment might be required or test might fail for hindered substrates, 
while premature NHFmoc deprotection by the DIPEA component might bias conclusions.    
NF31 test2 
A minute resin sample (~1-5 mg) was transferred to a mini glass test tube, to which an NF31 solution in 
ACN (2 mM, 4 drops) was added. The mixture was heated for 10 minutes at 70 °C. The reagent solution 
was carefully removed and the resin repeatedly washed with small volumes of DMF, MeOH, ACN and 
                                                          
1 Provides for detection of primary amines . 
 Hancock, W. S.; Battersby, J. E. Anal. Biochem. 1976, 71, 260.264. A new micro-test for the detection of 
incomplete coupling  reactions in solid-phase peptide synthesis using 2,4,6-trinitrobenzenesulphonic acid.  
2  Provides for detection of both primary, secondary and aromatic amines. 
(a) Madder, A.; Farcy, N.; Hosten, N. G. C., De Muynck, H.; De Clercq, P. J.; Barry, J.; Davis, A. P. Eur. 
J. Org. Chem. 1999, 2787-2791. A novel sensitive colorimetric assay for visual detection of solid-phase 
bound amines. 
(b) Van der Plas, S. E.; De Clercq, P. J.; Madder, A. Tetrahedron Lett. 2007, 48, 2587-2589. Fast and easy 
detection of aromatic amines on solid support. 
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DCM. Being less affected by steric impediment and claimed more sensitive, red-pink coloured beads 
indicate presence of free amino functions (both primary, secondary and aniline-like), while completely 
colourless beads are aimed for confirming adequate derivatization.  
 UV-Fmoc loading determination 
A carefully weighed amount of thoroughly dried resin material is transferred to a volumetric flask, to which 
DCM (400 µL) and piperidine (400 µL) is added, aiming to ensure adequate homogenization at the bottom 
of the flask, preventing sticking of beads to the neck.1 For 30 minutes, suspension was occasionally swirled. 
MeOH is added (1.6 mL) and DCM completes the exact flask volume, after which the mixture is left to 
settle. A blank solution, lacking the resin, is similarly prepared. Aiming for ~0.1 mM concentration to 
ensure linearity of the Lambert-Beer law, the appropriate flask volume and amount of resin are estimated 
via theoretical, calculated loadings, prior to the experimental procedure. 
An aliquot of resulting solution is transferred to a standard quartz cuvette (l = 1 cm), and UV-absorption of 
the generated piperidine-dibenzofulvene adduct is measured at both 300 and 301 nm. At 300 nm, the 
concentration was calculated from a previously-established calibration curve,2 while the reported ε301 = 
7800 M-1.cm-1 allowed for alternative determination via the Lambert-Beer law: Abs = ε.c.l. Taking flask 
volume and weighed amount of resin into account, experimental loadings could be estimated, usually 
averaging values.  
 Small scale release of photolinker-immobilized compounds 
Either aiming analytical verification or proceeding towards compound isolation, a resin sample (~1-5 mg) 
is transferred to a miniature glass test tube and suspended in the appropriate solvent (~4-8 drops), which 
has usually been ACN or EtOH. The tube was flushed with argon and sealed with a septum. Placed near-
horizontally at a distance of ~1 cm from the small scale UV-lamp (365 nm), resin was irradiated for ~3 
hours, with occasional manual homogenization of the suspension. Using a glass syringe with a narrow bore, 
cemented needle, resulting solution was carefully separated from the resin, ready for further manipulation 
or analysis. 
 Reagent B acidolytic cocktail 3 
Consists of 88 % TFA (8.8 mL), mixed with 5 % H2O (500 µL), 2 % TIS (200 µL) and 5 % phenol (weighed, 
535.5 mg, ~500 µL) prior to addition. Maroon-purple coloration indicates decomposition after prolonged 
storage.  
                                                          
1  Adapted from The Combinatorial Index (Bunin, B. A.; Academic Press 1998). And: ww.combinatorial.com 
2  Nadia Farcy, PhD thesis, 2002: Efforts towards the synthesis of a tripodal library for the discovery of 
serine-protease mimics. 
3  Solé, N. A.; Barany, G. J. Org. Chem. 1992, 57, 5399-5403. Optimization of solid-phase synthesis of 
[Ala8]-dynorphin A. 
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11.6.2 Synthesis of donor peptides on Ellman’s Safety-Catch resin 
SPPS elongation of peptide building blocks on Ellman’s loaded donor resin 
 
 
Starting resin 11.6.1 were transferred to SYRO-tubes of appropriate size.  
Equal volumes of AA/DMF (0.5 M stock solution), DIPEA (dry)/NMP (0.9 M stock solution) and 
HBTU/DMF (0.5 M stock solution) were sequentially added to the SYRO reactor(s), ultimately supplying 
5 equivalents of active species to the resin(s). Single couplings were performed in 1 ½ hour, with 
intermediate vortexing. DMF was used as washing solvent and a piperidine/DMF (40 % v/v) solution was 
applied for Fmoc-deprotection for 2, 5 and 15 min. 
Capping of the N-terminus with 1-acetylimidazole 
 
 
Resin 11.6.2 was manually washed with ACN, DCM and CHCl3, prior to overnight capping of the N-
terminus with 1-AcIm (10 eq) in CHCl3 at room temperature to obtain compound 11.6.3. 
TNBS test: colourless   
Activation by cyanomethylation of peptide-bearing Ellman’s 4-sulfamylbutyryl safety-catch donor 
resin 
 
Beads 11.6.3 (0.184 mmol/g, 0.096 mmol) where washed with NMP prior to cyanomethylation. In the 
original SYRO tube (10 mL), swollen resin was resuspended in NMP (1.5 mL). Dry DIPEA (85 µL, 0.48 
mmol, 5 eq.) and ICH2CN (140 µL, 1.92 mmol, 20 eq.) were added and the pale yellow-orange mixture 
flushed with argon. Reaction proceeded for 24 hours at room temperature. 
Significantly darkened, brown mixture was filtered under reduced pressure, resin 11.6.4 was washed with 
DMF, ACN, DCM and Et2O and thoroughly dried under high vacuum.  
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Peptide cleavage & analysis 
 
In order to check if the synthesis of the peptide was complete, a small portion of resin 11.6.4 was cleaved 
(20 mg, 0.0037 mmol, 0,185 mmol/g), using HOBt (5 mg, 0.037 mmol, 10 eq) and DIPEA (6.5 µL, 0.037 
mmol, 10 eq) were added to the resin suspended on dry DMF (160 µL). The reactor was flushed with argon 
and stirred for 24 hours at room temperature. 
The supernadant solution containing the peptide 11.6.5 was filtered under reduced pressure and the solvent 
was evaporated. 
Side-chain protected, C-terminally hydrolyzed AcHN-ARKLQG-OH (11.6.5)  C67H93N11O14S  
RPHPLC:  Jupiter C4 300 Å;          
 gradient 1: tret = 18.7 min 
 
Figure 11.6.1: RP-HPLC analysis using Jupiter C4 300 Å; gradient: 0 to 100 % increase of B (versus A) in 15 min: 
tret = 18.7 min. 
Maldi-TOF-MS (DHB): Exact identity of C-terminal functionality remains uncertain due to presumable 
Maldi-induced hydrolysis of labile species. Complementing data of above chaperone cleavage experiments: 
calcd. EM 1307.7; MW 1308.6; found m/z 1308.5 [M + H]+, 1330.5 [M + Na]+, 1346.5 [M + K]+, 1208.5 
[M - Boc + H]+, 1056.5 [M - Pbf + H]+ 
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Figure 11.6.2: MALDI-TOF Spectrum of crude compound 11.6.5. Calculated m/z (100%) = 1307.7; m/z (74.1 %) = 
1308.67. Found: 1308.5 = M + H+, 1330.5 [M + Na]+, 1346.5 [M + K]+, 1208.5 [M - Boc + H]+, 1056.5 [M - Pbf + 
H]+  MALDI-TOF Spectrum of crude compound 5. Calculated m/z (100%) = 1307.7; m/z (74.1 %) = 1308.67. Found: 
1308.8 = M + H+, 1330.9 [M + Na]+. 
11.6.3 RRTR to C12 to obtain intermediate peptidosteroid conjugate 
Optimized RRTR prototype validation for decoration of the Tentagel-bound, steroid scaffold  
Synthesis of photolinker-bearing TentaGel resin  
 
In a large glass reactor, TentaGel resin 11.6.6 (0.14 mmol based on manufacturer’s loading of TentaGel 
precursor, synthesized as detailed above) was immersed in dry DMF (3 mL) and NHFmoc-protected 
Holme’s Photolabile linker (218.6 mg, 0.42 mmol, 3 eq.), dry DIPEA (146 µL, 0.84 mmol, 6 eq.) and 
PyBOP (218.5, 0.42 mmol, 3 eq.) were consecutively added. Solid reagents were readily dissolved, 
generating an intense orange mixture. Additional dry DMF (2 mL) completed the reaction mixture, which 
was flushed with argon and shielded from light. Coupling reaction proceeded for 3 hours at room 
temperature, excess reagents and solvent were removed by filtration under reduced pressure and resin was 
washed with DMF, ACN and DCM. 
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Synthesis of C24 p-aminomethylbenzyl amide tagged acceptor construct on Tentagel resin  
Coupling of p-(NHFmoc)aminomethylbenzoic acid to photocleavable construct and NHFmoc peprotection 
 
In a large glass reactor, pale orange-yellow, photolinker-bearing TentaGel resin 11.6.7 (0.14 mmol) was 
immersed in dry DMF (3 mL) and NHFmoc-protected p-aminomethylbenzoic acid (156.8 mg, 0.42 mmol, 
3 eq), dry DIPEA (140 µL, 0.84 mmol, 6 eq) and PyBOP (218.7, 0.42 mmol, 3 eq) were consecutively 
added. Solid reagents were readily dissolved, generating an intense orange mixture. Additional dry DMF 
(2 mL) completed the reaction mixture, which was flushed with argon and shielded from light. Coupling 
reaction proceeded for 3 hours at room temperature, excess reagents and solvent were removed by filtration 
under reduced pressure and resin was washed with DMF, ACN and DCM.  
Coupling was repeated (2 ½ hour) after washing the resin with additional dry DMF. 
TNBS test: colourless (pale yellow resin) for prolonged time (> 1 hour) 
Removal of the NHFmoc-protectant proceeded by the usual, triple treatment with piperidine/ DMF (20 % 
v/v, 5 mL) as described earlier. 
TNBS test: intense orange-red in 5 minutes 
Coupling of steroid scaffold and C12-NHBoc deprotection  11.6.9 
 
Adopting the procedure described above, steroid scaffold was attached to the resulting construct 11.6.8 by 
double coupling at room temperature, once overnight and once for 3 hours.  
TNBS test: colourless 
Subjecting resulting resin 11.6.9 to TFA/DCM (20 % v/v, 5 mL) for 2 hours, C12-NHBoc group was 
removed, generating the desired TentaGel-bound acceptor construct. Final, orange-brownish resin was 
washed with DCM, ACN and DCM and thoroughly dried under high vacuum. 
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H2N-C12, AllocHN-C3-steroid-C24-‘ABA’-CONH2 C36H54N4O4  
 
Figure 11.6.3: RP-HPLC analysis using Jupiter C4 300 Å; gradient: 0 to 100 % increase of B (versus A) in 15 min: 
tret = 14.5 min. 
 
Figure 11.6.4: ESI-MS of RPHPLC-isolated (Luna C18 100 Å; gradient 1) main peak: calcd. EM 606.4, MW 606.8; 
found m/z (% rel. int.) 607.4 (100) [M + H]+, 629.4 (2) [M + Na]+. 
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HOBt-mediated transfer of side-chain protected AcHN-ARKLQG-Ellman (4) to H2N-C12-, 
AllocHN-C3-steroid-C24-‘ABA’-Tentagel. 
 
 
 
Bearing the photocleavable, UV-active steroid scaffold acceptor, TentaGel resin 11.6.9 (20.0 mg, 
theoretical loading calcd. from TentaGel: 0.23 mmol/g, 0.0046 mmol) was weighed in a SYRO tube (2 
mL). Providing the shuttled peptide with preloaded, C-terminal glycine residue, activated safety-catch 
donor resin 11.6.4 (124.3 mg, 0.184 mmol/g, 0.023 mmol, 5 eq) and fresh, dry NMP (700 µL) were added. 
After gently swirling the resin mixture, NaSPh (30.4 mg, dried, 0.23 mmol, 50 eq), HOBt (31.1 mg, 0.23 
mmol, 50 eq) and dry DIPEA (38 µL, 0.23 mmol, 50 eq) were added, the reactor flushed with argon and 
the reaction vortexed overnight (24 hours) at room temperature. Excess reagents and solvent were removed 
by filtration under reduced pressure and the filtrate was isolated in a round-bound flask under argon 
atmosphere. A sample was diluted with ACN (1/12) and analyzed.  
Discarding the washing batches, beads were further rinsed with NMP, ACN and DCM. The resin mixture 
(containing ~86 wt% inert safety-catch beads) was sampled in a glass tube and desired peptidosteroid 
conjugate (10) photolytically released in ACN. Filtrates were diluted in ACN (1/12th) and together with 
cleaved samples analyzed by RPHPLC and Maldi-TOF-MS. 
Side-chain protected AcHNARKLQG-C12, AllocHN-C3-steroid-C24-‘ABA’-CONH2 C103H145N15O17S  
 
 
 
 
Figure 11.6.5: RPHPLC analysis using Jupiter C4 300 Å; gradient 0 to 100% increase of B (versus A) in 15 min: tret 
= 19 min. 
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Figure 11.6.6: MALDI of crude compound: calcd. EM 1896.07, MW 1897.41; Found m/z (% rel. int.) 1919 [M + 
Na]+ , 1527 [M-Pbf-Boc-18 + H]+. 
11.6.4 RRTR to C3 and final deprotection 
Alloc deprotection  
 
Prior to alloc deprotection, resin 11.6.10 (40 mg, 0.23 mmol/g, 0.092 mmol) was swollen with DCM. After 
the swelling of the resin, dry DCM was added to the reactor, followed by the addition of Pd(PPh3)4 (106.3 
mg, 1 eq.), Bu3SnH (247 µL, 10 eq.) and morpholine (716 µL, 90 eq.). Yellow/orange mixtures were flushed 
with argon, shielded from light and agitated for 2 hours. 
Excess reagents and solvent were removed under reduced pressure and the resin was washed with DCM, 
ACN and DCM. 
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Side-chain protected AcHNARKLQG-C12, H2N-C3-steroid-C24-‘ABA’-CONH2 C99H141N15O15S 
Figure 11.6.7: RPHPLC analysis using Jupiter C4 300 Å; gradient 0 to 100% increase of B (versus A) in 15 min: tret 
= 18 min. 
Figure 11.6.8: MALDI of crude compound: calcd. EM 1811.05, MW 1812.34; Found m/z (% rel. int.) 1812 [M + 
H]+, 1834 [M + Na]+, 1850 [M + K]+. 
Coupling of Fmoc-Gaba-OH at C3 
 
In a glass reactor, scaffold-bearing resin 11.6.11 (30 mg, loading 0.27673 mmol/g) was swollen in dry 
DMF. After the swell process was repeated three times for 2 minutes, it is suspended in dry DMF (1 mL) 
and dry DIPEA (5 µL, 0,0276 mmol, 4 eq), Fmoc-Gaba-OH (8,98 mg, 0,0276 mmol, 4 eq.) and HATU 
(10,49 mg, 0,0276 mmol, 4 eq.) are successively added and shaked for homogeneity. The mixture is flushed 
with argon, shielded from light and gently shaken for four hours at room temperature. 
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Excess of reagents were removed by filtration. The resin was washed with DMF, ACN, MeOH and DCM. 
The coupling is repeated twice to get the reaction into completion. 
Side-chain protected AcHNARKLQG-C12, Fmoc-HN-GABA-HN-C3-steroid-C24-‘ABA’-CONH2 
C118H158N16O18S. 
 
Figure 11.6.9: RP-HPLC analysis using Jupiter C4 300 Å; gradient 0 to 100% increase of B (versus A) in 15 min: tret 
= 19.5 min. 
 
 
 
 
 
 
 
 
 
 
Figure 11.6.10: MALDI of crude compound: calcd. EM 2119.17, MW 2120.68; Found m/z (% rel. int.) 2143.42 [M 
+ Na]+. 
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Fmoc deprotection 
 
 
The amine from the Gaba linker was deprotected with a mixture of 20% piperidine in DMF (v/v). 1 mL 
was added for 30 mg of resin. The procedure is repeated 3 times for 2, 5 and 15 minutes. After each 
repetition, the solution is filtered and the resin is washed throroughly with DMF. The final washing step is 
achieved with DMF, ACN and DCM. 
Side-chain protected AcHNARKLQG-C12, H2N-GABA-HN-C3-steroid-C24-‘ABA’-CONH2 
C103H148N16O16S. 
 
 
 
 
 
Figure 11.6.11: RPHPLC analysis using Jupiter C4 300 Å; gradient 0 to 100% increase of B (versus A) in 15 min: tret 
= 17 min. 
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Figure 11.6.12: MALDI of crude compound: calcd. EM 1897.10, MW 1898.44; Found m/z (% rel. int.) 1920.89 [M 
+ Na]+. 
RRTR to C3 
 
TentaGel acceptor resin 11.6.13 (5 mg, 0.00115 mmol, 0.23 mmol/g) was transferred to a filter reactor (2 
mL). Activated donor-bearing safety-catch resin 11.6.4 (32.9 mg, 0.00575 mmol, 5 eq.) and dry DMF was 
added, followed by NaSPh (7.6 mg, 0.0575 mmol, 50 eq.), dry DIPEA (20 µL, 0,115 mmol, 100 eq) and 
HOSu (6.62 mg, 0.0575 mmol, 50 eq.). The resulting mixture was flushed with argon and vortexed 
overnight (24 hours) at room temperature, shielded from light.  Resin was purified by filtration under 
reduced pressure and washed with DMF, ACN and DCM. 
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Table 11.6.1: Experiments without Gaba linker at C3 
Chaperone Equivalents  DIPEA  Donor resin 
HOBt 50 50 5 
HOAt 50 50 5 
HOSu 50 50 5 
Oxyma pure 50 50 5 
 
Table 11.6.2: Experiments with Gaba at C3 
Chaperone Equivalents  DIPEA  Donor resin 
HOBt 50 100 5 
HOAt 50 100 5 
HOSu 50 100 5 
Oxyma pure 50 100 5 
 
Side-chain protected AcHNARKLQG-C12, AcHNARKLQG-HN-GABA-HN-C3-steroid-C24-‘ABA’-
CONH2    C170H239N27O29S2. 
 
Figure 11.6.13: RPHPLC analysis using Jupiter C4 300 Å; gradient 0 to 100% increase of B (versus A) in 15 min: tret 
= 19.5 min. 
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Figure 11.6.14: MALDI of crude compound: calcd. EM 3186.75, MW 3189.01; Found m/z (% rel. int.) 3212.34 [M 
+ Na]+. 
Final cleavage and deprotection 
 
Resin 11.6.14 in EtOH is irradiated under UV light for 2 hours at room temperature. Then, the supernatant 
solution is transferred to a flask and the solvent is evaporated. Side chain protecting groups are removed by 
adding to the cleaved compound a cocktail with TFA:TIS:H2O (95:2.5:2.5) and shaking for 3 hours. The 
solvent is removed under reduced pressure and the obtained residue purified by centrifugation in cold 
MTBE to get the desired final compound 11.6.15. 
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Side-chain deprotected AcHNARKLQG-C12, AcHNARKLQG-HN-GABA-HN-C3-steroid-C24-‘ABA’-
CONH2 11.6.15 C96H163N27O29. 
   
 
 
 
 
Figure 11.6.15: RPHPLC analysis using Jupiter C4 300 Å; gradient 0 to 100% increase of B (versus A) in 15 min: tret 
= 15.5 min. 
 
 
 
 
 
 
 
 
 
Figure 11.6.16: MALDI of crude compound: calcd. EM 1998.26, MW 1999.49; Found m/z (% rel. int.) 2000.02 [M 
+ H]+. 
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CHAPTER 11.7 
11.7.1 Synthesis of scaffold for DNA cleavage 
Benzyl 3α, 12α-dihydroxy-5β-cholan-24-oate (11.7.2). For synthesis, refer to 11.2.1. 
 
 
Synthesis of intermediate 11.7.3. Compound 11.7.2 (300 mg, 0.622 mmol) was dissolved in 2 mL dry 
DCM. Then a solution of Boc-GABA-OH (379.5 mg, 1.86 mmol), DCC (385.2 mg, 1.86 mmol) and DMAP 
(304.1 mg, 2.49 mmol) in dry DCM (3 mL) was added. The reaction mixture was stirred for 16h at room 
temperature. The precipitate formed was filtered off and the solvent was evaporated under vacuo. The 
residue was purified by column chromatography (silica gel DCM/MeOH 96:4; Rf: 0.40) to give compound 
11.7.3 as a yellow oil (421.3 mg, 90% yield). 1H-NMR (300 MHz, CD2Cl2); δ 7.38 − 7.36 (m, 5 H), 5.15 
(m, 3H), 4.65 (br, m, 1 H), 3.15 (m, 4H), 1.45 (s, 18H), 0.85 (s, 3 H), 0.75 (d, J = 6.40 Hz, 3 H), 0.65 (s, 3 
H). 
 
Synthesis of intermediate 11.7.4. Compound 11.7.3 (300 mg, 0.407 mmol) was dissolved in 5 mL DCM. 
1mL TFA was added to the solution and stirred for 2h. After completion, the solvent was evaporated in 
vacuo and a transparent oil was obtained (262.9 mg, 99% yield). 1H-NMR (300 MHz, CD2Cl2); δ 7.38 − 
7.36 (m, 5 H), 5.15 (m, 3H), 4.65 (br, m, 1 H), 3.45 (m, 4H), 0.85 (s, 3 H), 0.75 (d, J = 6.40 Hz, 3 H), 0.65 
(s, 3 H). 
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Synthesis of intermediate 11.7.5. Compound 11.7.4 (250 mg, 0.383 mmol) was dissolved in 6 mL dry 
toluene. Maleic anhydride (268.52 mg, 1.532 mmol) was added to the solution and the mixture stirred at 
80°C for 24h. The solvent was evaporated and the crude compound purified by column chromatography 
(fine silica gel EtOAc/Hexane 1:4; Rf: 0.60) to give compound 11.7.5 as a transparent oil (217.8 mg, 70% 
yield).  1H-NMR (300 MHz, CDCl3); δ 7.38 − 7.36 (m, 5 H), 6.70 (m, 4H), 5.12 (d, 1H,  J  = 13.56 Hz), 
5.07 (d, 1H,  J = 13.75 Hz), 4.65 (br, m, 1 H), 3.55 (m, 4H), 0.85 (s, 3 H), 0.75 (d, J = 6.40 Hz, 3 H), 0.65 
(s, 3 H). 13C NMR (125 MHz, CDCl3): δ = 173.71 (COOR-C24), 171.82 (4C maleimides), 171.57 (COOR-
C3), 170.45 (COOR-C12), 135.80 (C - benzyl group), 133.86 (2CH maleimides), 133.83 (2CH 
maleimides), 128.27 (2CH-benzyl ring), 127.99 (2CH- benzyl ring), 127.92 (CH-benzyl ring), 75.84 (CH 
ester), 74.09 (CH ester), 65.85 (CH2-benzyl ester), 49.03 (CH), 47.26 (CH), 44.80 (C), 41.54 (CH), 36.85 
(C), 35.40 (CH), 34.20 (CH), 34.15 (CH2), 34.11 (CH), 33.78 (CH2), 31.60 (CH2), 31.53 (CH2), 30.93 
(CH2), 30.60 (CH2), 26.90 (CH2), 26.75 (CH2), 26.65 (CH2), 26.43 (CH2), 26.15 (CH2), 25.32 (CH2), 23.86 
(CH2), 23.60 (CH2), 23.18 (CH2), 22.76 (19-CH3), 17.22 (21 – CH3), 14.71 (CH2), 12.11 (18-CH3). ES-MS 
m/z (% rel. int.) calcd. 812.4 (100), found 830.5 (100) [M+NH4+]. HR-MS (ES) m/z calcd. for C35H48N6O6 
+ NH4+ 812.4248, found 830.4607 (M + NH4+; Δ = 2.6 ppm). 
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11.7.2 NMR Spectra for steroid template molecules:  
Compound 11.7.3: 
 
Figure 11.7.1. 1H NMR spectrum of compound 11.7.3. 
 
Compound 11.7.4: 
 
 
 
Figure 11.7.2. 1H NMR spectrum of compound 11.7.4. 
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Compound 11.7.5: 
 
Figure 11.7.3. 1H NMR spectrum of compound 11.7.5. 
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Figure 11.7.4. 13C NMR spectrum of compound 11.7.5. 
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CHAPTER 11.8 
11.8.1 Synthesis of synthetic receptor for EDCs 
 
Coupling of first amino acid  
 
 
 
2-chlorotrityl chloride resin 11.8.1 (0.23 g, 1.55 mmol/g) were swollen in dichloromethane (dry, 10 mL/g) 
prior to the loading of the first amino acid. Fmoc-Glu(tBu)-OH (0.30 g, 0.71 mmol) or Fmoc-Arg(Pbf)-OH 
(0.46 g, 0.71 mmol) were dissolved in dry DCM with N,N’-diisopropylethylamine (DIPEA) (0.74 mL, 4.28 
mmol) and the reactions were shaken for 3 h. The resins were then washed with 3 x DCM, 3 x DMF, 3 x 
DCM and dried under vacuum for 2 h. The loading was calculated to be 0.55 mmol/g, consistent with a 
coupling yield of 71%. The resins were then capped with methanol/DIPEA/DCM = 2:1:17 by shaking for 
2 h. 
 
Fmoc deprotection for the first amino acid 
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The resins 11.8.2 and 11.8.3 were swollen in DMF prior to Fmoc deprotection. A solution of 20% piperidine 
in DMF was added to the resins and the mixtures were shaken for 2 x 30 min. The solutions were then 
washed with 3 x DMF, 3 x methanol, 3 x DMF.   
 
Coupling of the scaffold 
 
 
 
At a suspension of resins 11.8.4 and 11.8.5 in DMF were added the dipodal scaffold (0.23 g, 0.37 mmol, 
0.5 M), PyBOP (0.19 mg, 0.37 mmol, 0.5 M) and DIEA (0.13 mL, 0.74 mmol, 2 M). The mixtures were 
shaken at room temperature for 24 h, after which the resins were washed with 3 x DMF, 3 x methanol, 3 x 
DMF.   
 
Alloc deprotection 
 
 
 
Resins 11.8.6 and 11.8.7 (0.22 g, 0.55 mmol/g) were swollen and thoroughly washed with DCM under a 
stream of argon. The resins were suspended in DCM (6.7 mL) then were loaded the scavenger PhSiH3 (0.46 
mL, 3.7 mmol) and the catalyst Pd(PPh3)4 (0.01 g, 0.01 mmol). Yellow/orange mixtures were flushed with 
argon, shielded from light and shaked at room temperature for 1 h under anhydrous conditions, after which 
the resins were washed with DCM and the reactions were repeated twice. At the end of the Alloc removal 
the resins were washed with 3 x DMF, 3 x methanol, 3 x DMF.   
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Coupling of Fmoc-Gly-OH and 4-pentynoic acid 
 
 
 
To a suspension of the Alloc deprotected resin 11.8.8 (0.22 g, 0.55 mmol/g) in DMF were added Fmoc-
Gly-OH (0.18 g, 0.62 mmol, 0.5 M), PyBOP (0.32 g, 0.62 mmol, 0.5 M) and DIEA (0.21 mL, 1.2 mmol, 2 
M). The mixture was shaken at room temperature for 3 h. 
 
 
  
To resin 11.8.9 (0.095 g, 0.96 mmol/g) in DMF were added 4-pentynoic acid (0.035 g, 0.353 mmol, 0.5 
M), PyBOP (0.184 g, 0.353 mmol, 0.5 M) and DIEA (0.123 mL, 0.71 mmol, 2 M). The mixture was shaken 
at room temperature for 2 h. A small amount of resin 11.8.11 was cleaved in mild condition for LC-MS 
analysis: tR 14.26 min; exact mass calculated: 813.51; found m/z 814.40 [M + H]+ and 714.40 [M - Boc]+. 
 
 
 
Figure 11.8.1: HPLC trace from LC-MS of compound 11.8.11 (0-100% ACN in 15 min on Luna C18 250 x 4.6 mm, 
5 µm at 35°C). 
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Figure 11.8.2: ESI-MS from LC-MS at t = 14.074 min for crude compound 11.8.11. E.M calcd. for C45H71N3O10 = 
813.51 and mass found 814.4. 
 
Fmoc deprotection 
 
 
 
Resin 11.8.10 (0.22 g, 0.55 mmol/g) was fmoc deprotected with 20% piperidine in NMP 2 x 20 min and 
then it was subjected to diazotransfer reaction. 
 
Diazotransfer reaction 
 
 
 
To the resin 11.8.2 (0.22 g, 0.55 mmol/g) were added sodium bicarbonate (0.041 g, 0.49 mmol), copper (II) 
sulfate pentahydrate (1 mg, 4 µmol), freshly prepared trifyl azide (2 mL) and MeOH (2 mL). The mixture 
was shaken at room temperature for 24 h. A small amount of resin 11.8.13 was cleaved in mild condition 
for LC-MS analysis. tR 14.91 min; exact mass calculated: 1039.58; found m/z 1040.50 [M+H]+ and 470.8 
[M-Boc+2H+]/2. 
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Figure 11.8.3: HPLC trace from LC-MS of compound 11.8.13 (0-100% ACN in 15 min on Luna C18 250 x 4.6 
mm, 5 µm at 35°C). 
 
 
 
Figure 11.8.4: ESI-MS from LC-MS at t = 14.074 min for crude compound 11.8.13. E.M calcd. for C52H81N9O11S = 
1039,58 and mass found 1040.5 [M+H]+ and 470.8 [M-Boc+2H+]/2. 
 
Cleavage of alkyne and azide-containing resins 
 
 
 
Resins 11.8.11 and 11.8.13 were treated three times with AcOH: TFE: DCM (1: 1: 3) at room temperature 
for 2 h and lyophilized obtaining yellowish powders 11.8.14 and 11.8.15 (86.3% and 71.2% yield).  
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CuAAC conjugation 
 
 
 
Alkyne component 11.8.14 (26.8 mg, 0.033 mmol) in 75 µL DMF was added to a cone-bottom flask. Then, 
CuSO4·5H2O (5.5 mg, 0.022 mmol) in 90 µL DMF, sodium ascorbate (6.5 mg, 0.033 mmol) in 90 µL H2O 
and TBTA (23.35mg, 0.044 mmol) in 90µL DMF were added to the alkyne in solution, and the mixture 
was stirred for 10 min. The azide component 11.8.15 (11.1 mg, 0.011 mmol) in 75 µL DMF was finally 
added and the reaction mixture stirred for 24h at room temperature. Then the solvent was evaporated in 
vacuo. The residue was diluted in EtOAc and extracted with a saturated solution of EDTA, citric acid 1M, 
and twice with brine. The organic phase was dried under MgSO4, filtered and evaporated. 
 
 
 
Figure 11.8.6: RP-HPLC (0-100% ACN in 15 min on Luna C18, 100 Å) of reaction mixture after 24 h. Compound 
11.8.16 eluting at 14.9 min. 
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Figure 11.8.3: HPLC trace from LC-MS of pure compound 11.8.16 (0-100% ACN in 15 min on Luna C18 250 x 
4.6 mm, 5 µm at 35°C). 
 
 
 
 
Figure 11.8.4: ESI-MS from LC-MS at t = 14.385 min for crude compound 11.8.16. E.M calcd. for C97H153N13O20S 
= 1853.39 and mass found 928.0 [M/2+H]+. 
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Figure 11.8.15: MALDI of crude compound 11.8.16: calcd. EM 1852.11, MW 1853.39; Found m/z (% rel. int.) 
1854.15 [M + H]+. 
 
Deprotection 
 
 
 
The side chains were deprotected by treatment with TFA: TIS: H2O (95: 2.5: 2.5) at room temperature for 
2h. Purification was performed by RP-HPLC. The obtained material 11.8.17 was analyzed by LC-MS: tR 
11.10 min; exact mass calculated: 1344.84; found m/z 1343.80 [M-H] and 671.40 [M-2H]/2. HRMS (ESI) 
for C70H114N13O13 +: calculated 1344.8654, found 1345.8474.  
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Figure 11.8.3: HPLC trace from LC-MS of pure compound 11.8.17 (0-100% ACN in 15 min on Luna C18 250 x 
4.6 mm, 5 µm at 35°C). 
 
 
Figure 11.8.4: ESI-MS from LC-MS at t = 11.250 min for crude compound 11.8.17. E.M calcd. for C70H112N12O14 = 
1344.8 and mass found 671.2 [M/2+H]+. 
 
 
Figure 11.8.15: MALDI of crude compound 11.8.17: calcd. EM 1344.8, MW 1345.7; Found m/z (% rel. int.) 1345.94 
[M + H]+. 
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Finally the product 11.8.17 was lyophilized overnight with NaHCO3/Na2CO3 to obtain the product 11.8.18. 
This lyophilization guaranteed the formation of the correctly charged product for NMR studies. 
 
 
 
11.8.2 Development of water-soluble NHC-Cu Catalysts: Applications in 
Click Chemistry, Bioconjugation and Mechanistic Analysis 
General information 
MALDI-TOF-MS spectra were acquired with a high performance nitrogen laser (337 nm), using the 
positive and reflector mode with delayed extraction. All measurements were calibrated against MePEOH 
(Mn ≈ 2000, PD = 1.06), spotted from a MeOH (2 mg/mL) solution. Following matrix solutions were 
utilized (made in microtubes, stored in freezer, carefully defrosted and homogenized upon use): DHB: 2,5-
dihydroxybenzoic acid (98.0 % pure, 10 mg) + CH3CN (500 μL) + H2O (470 μL) + TFAaq (30 μL, 3 %); α-
CHCA: α-cyano-4-hydroxycinnamic acid (99 % pure, 10 mg) + CH3CN (500 μL) + H2O (400 μL) + TFAaq 
(100 μL, 3 %). 
Peptide synthesis: 
Immobilization of Fmoc-Pra-OH on 2-chlorotrityl chloride resin 
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To a suspension of 2-chlorotrutyl chloride resin 11.8.1 (0.150 g, 1.55 mmol/g) in dry DCM (10 mL/g resin), 
were added Fmoc-Pra-OH (Fmoc-Propargylglycine) (48 mg, 0.288 mmol) and DIPEA (0.1 mL, 0.576 
mmol). The mixture was shaken at room temperature for 3 h. After the reaction, the resin was washed with 
DCM and Et2O. Fmoc determination was performed to calculate the yield. The loading was calculated to 
be 0.56 mmol/g, indicating a coupling yield of 90%. The resin was then capped with MeOH/DIPEA in 
DCM (3 mL) 3 times for 2 min. 
Fmoc deprotection and coupling of Fmoc-Gly-OH: 
 
NHFmoc deprotection of compound 11.8.19. After an initial DMF washing step, resin 11.8.19 (0.125 
mmol) was successively treated twice for 30 min with a piperidine solution in DMF (40 % v/v, 3 mL) at 
ambient temperature, applying intermediate filtration under reduced pressure and washing with DMF, while 
the final resin is additionally washed with CH3CN and DCM. 
After Fmoc deprotection, Fmoc-Gly-OH (0.150 g, 0.502 mmol, 0.5 M), PyBOP (0.26 g, 0.502 mmol, 0.5 
M) and DIPEA (0.087 mL, 0.502 mmol, 2 M) were added to a suspension of resin in dry DMF (3 mL). The 
mixture was shaken at room temperature for 3 h. After the reaction, the resin was washed again with 
DMF/MeOH/DCM/Et2O/DMF successively.   
Automated synthesis of linear peptide 
 
Before automated peptide synthesis, resin 11.8.20 was manually NHFmoc-deprotected using the procedure 
described above. 
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Fmoc deprotected resin (0.125 mmol) was subjected to automated synthesis where solutions of Fmoc-Nσ-
protected amino acids (0.5 M in NMP) were prepared. Each coupling reaction was repeated twice for 40 
min (amino acids 0.625 mmol; HBTU 0.625 mmol in DMF, 0.5 M; DIPEA 0.625 mmol 2 M) and followed 
by Fmoc deprotection with 20% piperidine in NMP. The N-terminus was capped manually with 4-
acetamidobenzoic acid (1.25 mmol, 0.5 M), PyBOP (1.25 mmol, 0.5 M), DIPEA (2.50 mmol, 2 M) in dry 
DMF. The peptide was then cleaved from the resin and deprotected with a cocktail of TFA:TIS:water (95: 
2.5: 2.5). After precipitation in cold ether, the peptides was analyzed by RP-HPLC and MALDI. 
 
 
 
 
 
Figure 11.8.6: RP-HPLC Chromatogram of crude compound 11.8.22 (C4, 300Å column using a gradient from 0 to 
100 % CH3CN in 15 minutes). 
 
 
Figure 11.8.7: MALDI-TOF Spectrum of crude compound 11.8.22. M = 1584.88. Found [M+H]+ = 1585.15. 
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Figure 11.8.8: RP-HPLC Chromatogram of crude compound 11.8.21. (C4, 300Å column using a gradient from 0 to 
100 % CH3CN in 15 minutes). 
 
 
 
 
 
 
 
 
 
 
 
Figure 11.8.9: MS(ESI) Spectrum of crude compound 11.8.21. M = 2949.29. Found [M+4H]+/4 = 738.7; [M+3H]+/3 
= 984.3; [M+2H]+/2 = 1476.8. 
Bioconjugation via CuAAC 
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12mer GCN4 peptide bearing an alkyne functionality 11.8.22 (3.86·10-3 mmol) was dissolved in 1 mL 
deoxygenated water. The solution was transferred to a reaction vial under argon and the catalyst (4.006·10-
3 mmol) was added under stirring. Then, a solution of benzylazide in DCM (0.5 M, 2.12·10-2 mmol) was 
added. An extra 2.26 mL of deoxygenated water was added followed by 0.670 mL of HFIP. The reaction 
mixture is stirred overnight at room temperature. Analysis and purification of the final peptide are done on 
reverse-phase C4 HPLC. 
 
Figure 11.8.10: RP-HPLC Chromatogram of compound 11.8.23. (C4, 300Å column using a gradient from 0 to 100 
% CH3CN in 15 minutes). 
 
 
 
Figure 11.8.11. MALDI-TOF Spectrum of compound 11.8.23. M = 1686.93. Found [M+H]+ = 1687.8; [M+K]+ = 
1725.8; [M+Cu] = 1749.7. 
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23mer GCN4 peptide bearing an alkyne functionality 11.8.21 (8.477·10-4 mmol) was dissolved in 0.250 
mL deoxygenated water. The solution was transferred to a reaction vial under argon and the catalyst 
(9.325·10-4 mmol) was added under stirring. Then, a solution of benzylazide in DCM (0.5 M, 4.66·10-3 
mmol) was added. An extra 0.250 mL of deoxygenated water was added followed by 50 µL of HFIP. The 
reaction mixture is stirred overnight at room temperature. Analysis and purification of the final peptide are 
done on reverse-phase C18 HPLC. 
 
 
 
 
 
 
 
Figure 11.8.12: RP-HPLC Chromatogram of compound 11.8.24. (C4, 300Å column using a gradient from 0 to 100 
% ACN in 15 minutes). 
 
Figure 11.8.13: MALDI-TOF Spectrum of compound 11.8.24. M = 3080.67. Found [M+H]+ = 3081.58. 
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Immobilization of Fmoc-Aha-OH on 2-chlorotrityl resin 
 
To a suspension of resin 11.8.1 (0.150 g, 1.55 mmol/g) in dry DCM (10 mL/g resin), were added Fmoc-
Aha-OH (Fmoc-azidohomoalanine) (51 mg, 0.140 mmol) and DIPEA (0.050 mL, 0.279 mmol). The 
mixture was shaken at room temperature for 3 h. The loading was calculated to be 0.65 mmol/g, indicating 
a coupling yield of 91%. The resin was then capped with MeOH/DIPEA in DCM 3 times for 2 min. 
Fmoc deprotection and coupling of Fmoc-Gly-OH: 
 
NHFmoc deprotection of construct 11.8.25. After an initial DMF washing step, resin 11.8.25 (0.127 mmol) 
was successively treated twice for 30 min with a piperidine solution in DMF (40 % v/v, 3 mL) at ambient 
temperature, applying intermediate filtration under reduced pressure and washing with DMF, while the 
final resin is additionally washed with CH3CN and DCM. 
Fmoc deprotected resin (0.127 mmol). Fmoc-Gly-OH (0.151 g, 0.508 mmol, 0.5 M), PyBOP (0.264 mg, 
0.508 mmol, 0.5 M) and DIPEA (0.088 mL, 0.508 mmol, 2 M) were added to a suspension of resin in dry 
DMF (3 mL). The mixture was shaken at room temperature for 3 h.  
Automated synthesis of linear peptide 
 
 
Before automated peptide synthesis, the resin 11.8.26 was manually NHFmoc-deprotected using the 
procedure described in. 
The resin 11.8.26 (0.127 mmol) was subjected to automated synthesis where solutions of Fmoc-Nσ-
protected amino acids (0.5 M in NMP) were prepared. Each reaction coupling was repeated twice for 40 
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min long (amino acids 0.635 mmol; HBTU 0.635 mmol in DMF, 0.5 M; DIPEA 0.635 mmol 2 M) and 
followed by Fmoc deprotection with 20% piperidine in NMP. The N-terminus was capped manually with 
4-acetamidobenzoic acid (1.27 mmol), PyBOP (1.27 mmol), DIPEA (2.54 mmol) in dry DMF (3 mL) for 
4 hours. The peptide was then cleaved for the resin and deprotected with a cocktail of TFA:TIS:water (95: 
2.5: 2.5). After precipitation in cold ether, the peptide was analyzed by LC-MS(ESI) and MALDI. 
 
 
 
 
 
 
Figure 11.8.14: RP-HPLC Chromatogram of crude compound 11.8.27. (C4, 300 Å column using a gradient from 0 
to 100 % CH3CN in 15 minutes). 
 
 
 
Figure 11.8.15: MALDI-TOF Spectrum of crude compound 11.8.27. M = 1584.88. Found [M+H]+ = 1585.48. 
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Bioconjugation via CuAAC 
 
12mer GCN4 peptide bearing an azide functionality 11.8.27 (3.86·10-3 mmol) was dissolved in 1 mL 
deoxygenated water. The solution was transferred to a reaction vial under argon and the catalyst (4.006·10-
3 mmol) was added under stirring. Then, a solution of benzylazide in DCM (0.5 M, 2.12·10-2 mmol) was 
added. An extra 2.26 mL of deoxygenated water was added followed by 0.670 mL of HFIP. The reaction 
mixture is stirred overnight at room temperature. Analysis and purification of the final peptide are done on 
reverse-phase C4 HPLC. 
 
Figure 11.8.16: RP-HPLC Chromatogram of crude compound 11.8.28. (C4, 300Å column using a gradient from 0 to 
100 % CH3CN in 15 minutes). Presence of compound 11.8.27 at 11.270 min shows incompletion of the 
reaction. 
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Figure 11.8.17: MALDI-TOF Spectrum of compound 11.8.28. M = 1686.93. Found [M+H]+ = 1687.51. Presence of 
starting compound 11.8.27.  M = 1584.88. Found [M+H]+ = 1585.51. 
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Water-soluble NHC-Cu catalysts: applications in
click chemistry, bioconjugation and mechanistic
analysis†
Heriberto Díaz Velázquez,a,b Yara Ruiz García,c Matthias Vandichel,d
Annemieke Madderc and Francis Verpoort*a,b,e
Copper(I)-catalyzed 1,3-dipolar cycloaddition of azides and terminal alkynes (CuAAC), better known as
“click” reaction, has triggered the use of 1,2,3-triazoles in bioconjugation, drug discovery, materials
science and combinatorial chemistry. Here we report a new series of water-soluble catalysts based on
N-heterocyclic carbene (NHC)-Cu complexes which are additionally functionalized with a sulfonate
group. The complexes show superior activity towards CuAAC reactions and display a high versatility,
enabling the production of triazoles with diﬀerent substitution patterns. Additionally, successful appli-
cation of these complexes in bioconjugation using unprotected peptides acting as DNA binding domains
was achieved for the ﬁrst time. Mechanistic insight into the reaction mechanism is obtained by means of
state-of-the-art ﬁrst principles calculations.
Introduction
Although several catalysts have been developed for the Copper
catalyzed Alkyne–Azide Cycloaddition reactions (CuAAC, better
known as click reaction), in most cases they need the presence
of co-catalysts such as auxiliary ligands, bases – mainly
amines –, and reducing or oxidizing agents depending on the
Cu source used, in order to enhance their catalytic activity,
although in recent years single Cu salts have also been suc-
cessful.1 Generally high Cu loading must be applied to ensure
good performance of the catalyst.2 Several Cu(I) complexes
holding N-heterocyclic carbene (NHC) ligands are reported as
catalysts for the Huisgen cycloaddition reaction; however, the
catalysis is carried out at elevated temperatures and in the
presence of organic solvents, under two-phase systems (when
both reactants are not soluble) and only the 1,4-disubstituted
triazoles are generated.3,4 Moreover, their activity in the solu-
tion phase is significantly lower than the other catalytic
systems.5 Here we report a unique Cu(I) based catalyst that
enables the synthesis of triazoles with diﬀerent substitution
patterns, e.g. 1-, 4-, 1,4- or 1,4,5-substituted triazoles and at the
same time, able to generate triazoles from acetylene in water,
and able to produce tosyl acetamides in aqueous media
(Fig. 1).
Fig. 1 (A) Synthesis of catalysts 5–8; (B) standard click reaction moni-
tored by 1H-NMR using catalysts 5 and 7; (C) triazoles synthesized in this
work.
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Until now, no such catalyst has been reported in the litera-
ture. More specifically, we report on the synthesis and appli-
cation of new water-soluble (NHC)2Cu(I) complexes (5, 6 and 7,
8, Fig. 1A) in click chemistry in water, neat conditions and
organic solvents or mixtures, acetylene conversion into tria-
zoles (1-, 4-, 1,4- or 1,4,5-substituted triazoles, Fig. 1C) and
acetamides along with the ease of immobilization and a
detailed mechanistic analysis of the transition states involved
in the catalytic process. In the last decade, bioconjugation has
become a common tool for chemists and biochemists as a
result of the increase in peptide and protein research and
development. This covalent functionalization of these bio-
macromolecules under physiological conditions gives rise to
new areas of research such as drug discovery, high-throughput
screening and in vivo testing. Therefore, many ligation metho-
dologies have been studied and optimized.6–8 The develop-
ment of click chemistry has caused an emerged interest in the
functionalization of peptides with alkynes and azides, resulting
in a broad variety of building blocks such as unnatural amino-
acids, currently commercially available. In practice, the appli-
cation of CuAAC in peptide chemistry requires extra eﬀorts for
the optimization of the reaction conditions.8 Traces of O2 can be
reduced by CuI and sodium ascorbate into H2O2, a reactive
oxygen species that can induce degradation of amino acids and
cleavage of the polypeptide chain.9–12 Thus, a catalytic system
able to perform click reactions in biomacromolecules under
reductant-free aqueous conditions will lead to a major step
forward in bioconjugation chemistry. Furthermore, bioconjuga-
tion imposes specific requests, such as exquisite chemoselectivity,
biocompatibility, and the ability to work at low temperature still
enabling fast transformations. To date the CuAAC reaction in the
absence of an accelerating ligand is simply too slow.13
In this context, we have studied the performance of our water-
soluble NHC-Cu(I) catalysts for CuAAC reactions with unprotected
peptides under aqueous conditions. We have chosen the DNA
binding domain of the transcription factor protein GCN4, belong-
ing to the bZIP leucine zipper family as a substrate for the reac-
tion.14 Indeed, modification of the GCN4 binding domain in the
design of transcription factor models has been of particular inter-
est for gene therapy.15 Surprisingly, there are no studies so far on
the application of click chemistry on the modified GCN4 binding
domain for conjugation purposes. Here, we report the successful
functionalization of the peptide comprising the basic region DNA
binding domain with an organic azide via click chemistry using
the sulfonated NHC-Cu(I) catalysts.
Results and discussion
Our initial experiments consisted of the suitability tests for the
N-heterocyclic carbene (NHC) ligand precursors on Cu using a
Cu(I) source. We envisaged that according to the literature,4
our sulfonate-functionalized ligands should behave in a
similar fashion as non-functionalized ligands. However the
new compounds demonstrate an excellent behavior for click
reactions in water, neat conditions and organic solvents or
mixtures, for bioconjugation via CuAAC and for acetylene con-
version into triazoles and even acetamides.
Synthesis of catalysts
For the initial step in the preparation of catalysts, NHC-ligand
precursors 1–4 were synthesized (Fig. 1A). Among these, struc-
tures 1 and 2 have no precedent reports in the literature.
Ligand precursors 1–4 were originally considered for a single
mono-coordination at a 1 : 1 ratio using CuCl as the source of
CuI. However, mass spectroscopy proved that the final product
was actually a mixture of mono- and bis-coordinated NHC-Cu
complexes. Isolation of these complexes was not feasible and
therefore we were prompted to find a more convenient Cu(I)
source. From literature reports, it was clear that some Cu(I)
complexes with NHC ligands demonstrated a good activity of
which those having PF6
− as a counterion displaying activities
more than 3 times higher than the analogous complex bearing
BF4
− as a counterion.4 Consequently, we were encouraged to
use PF6
− as the counterion to improve the stability without
aﬀecting the catalyst activity. A synthesis protocol similar to
that described in the literature was followed, using KOt-Bu
as base and tetrahydrofuran (THF) as the solvent. Filtration
and precipitation with ether resulted in a series of catalysts
5–8 depicted in Fig. 1A. [Cu(CH3CN)4]PF6 was used as the
source of CuI for this purpose. Characterization of complexes
5–8 by 13C-Nuclear Magnetic Resonance (NMR) spectroscopy
resulted in the typical values for the C1 carbene signal for satu-
rated NHC-Cu complexes, 200.65 ppm and 200.74 ppm for 5
and 6, respectively, while for the unsaturated NHC-Cu com-
plexes, the values of 176.38 and 176.41 ppm were observed for
7 and 8, respectively. Mass spectroscopic results confirmed the
identity of the bis-coordinated complexes using these ligands.
The newly synthesized complexes exhibited solubility in chlori-
nated solvents, alcohols, dimethyl sulfoxide (DMSO), dimethyl-
formamide (DMF) and water. Their high stability to air and
heat, allows storage of the compounds under an Ar atmos-
phere for several weeks without loss of activity.
Catalytic activity
Catalytic experiments were carried out using the standard sub-
strates benzyl azide and phenylacetylene under neat conditions.
ESI Table S1† shows the yields obtained with catalysts 5–8
proving that the catalysts bearing saturated NHC ligands are
better performing than those holding unsaturated NHC ligands
and also showing that catalyst 5 is highly competitive with the
most active complex [(ICy)2Cu]PF6 reported by Nolan.
4 Although
certain NHC-Cu(I) complexes seem to be competitive with cata-
lyst 5,3,4 the special hydrophilicity of complexes 5–8 enables the
extension of their scope towards diﬀerent reaction conditions
whereas those described in literature might hardly achieve good
performance. In order to make a more detailed comparison
between the newly synthesized catalysts, 5 and 7 were chosen
for a reaction monitoring by 1H-NMR for the standard reaction
depicted in Fig. 2. That saturated NHC-Cu complexes are better
performing than those holding unsaturated NHC ligands is
illustrated in Fig. 2 in which 5 clearly shows a higher reactivity
Paper Organic & Biomolecular Chemistry
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compared with 7 (25% conversion after the induction period of
5 min for catalyst 5 and no conversion for 7 at the same period)
and a rate enhancement in the range of 3.5–4.0. The reason for
this higher activity may reside in the higher σ-donating ability
of the saturated NHC ligands; a similar eﬀect causing a higher
activity for NHC-Ru complexes was observed in the olefin meta-
thesis reaction.16–20 In view of the higher reactivity of 5 bearing
sulfonated NHC ligands, these were further explored for the syn-
thesis of triazoles with various substitution patterns.
Synthesis of triazoles
One of the major catalytic improvements made in the new
complexes was the possibility to employ them for the synthesis
of a variety of triazoles and the versatility of conditions. This
capability is distributed from neat over solvent mixtures to
in situ conditions. For the production of 1,4-substituted tria-
zoles under neat conditions (ESI Table S2†) the products were
pure enough for characterization by NMR spectroscopy. These
varieties of triazoles were also produced in situ, starting from
the alkyl/aryl halide and sodium azide, where the use of
DMSO/water mixture was critical to achieve excellent reaction
yields (ESI Table S3†). Although Ru-catalysts are more feasible
for click reactions of internal alkynes the newly developed Cu-
catalysts in this work were also capable of generating 1,4,5-sub-
stituted triazoles (ESI Table S4†). Due to its high-energy con-
sumption and the use of multistep procedures,21–23 as well as
the employment of toxic solvents,25,26 the production of 4- sub-
stituted-1,2,3-triazoles has represented a synthetic challenge.
We found out the feasibility to produce 4-substituted-1,2,3-tria-
zoles from non-activated terminal alkynes using mixtures of
DMSO/AcOH and NaN3 (ESI Table S7†), representing an
improvement of the few catalytic protocols of this kind.22–24
However, the most outstanding improvement of this work was
by far the synthesis of 1-substituted triazoles from acetylene
gas completely in water and in water–DMSO mixtures (Fig. 3A),
alternative to those procedures involving organic solvents and
higher catalyst loadings.27,28 Finally, the reaction of tosyl azide
and acetylene gas in water–DMSO mixtures yielded tosyl-acet-
amide (Fig. 3B), as previously reported,29 opening the possi-
bility of using acetylene gas as an eﬃcient source of acetamide
bonds in organic and biological chemistry.30 All these achieve-
ments in catalytic activity were attained using a maximum of
5 mol% of the catalyst and under general aqueous conditions,
which embodies an eco-friendly series of catalytic protocols.
Bioconjugation experiments
To further expand and illustrate the scope and potential of the
developed catalysts, bioconjugation experiments with alkyne
and/or azide tagged peptides were carried out. Hereto, two
peptides, one 10 mer and one 23 mer, comprising part of the
N-terminal basic region of the transcription factor protein
GCN4, were synthesized on 2-chlorotrityl chloride polystyrene
resin. Propargyl glycine was incorporated as the first, C-termi-
nal amino acid residue (Fig. 4) to provide for the alkyne func-
tionality for further click reaction with benzylazide. A click
reaction was carried out at the ambient temperature in a
deoxygenated mixture of water and hexafluoroisopropanol to
disrupt H-bonding interactions within the peptide using 1.5
equivalents of catalyst (6 for modification of 10-mer GCN4 and
7 for 23-mer GCN4 due to its higher stability) under anaerobic
conditions overnight. The resulting modified peptides were
purified by High Performance Liquid Chromatography (HPLC)
and further characterized by Electrospray Ionization
Liquid Chromatography connected to a Mass Spectrometer
(LC-MS-ESI) and MALDI-TOF. Generation of the Cu-acetylide
intermediate in such an environment is highly challenging,
therefore a slight excess of catalyst 6 is needed. In the current
context, it is further worth noting that both sequences are rich
in arginine residues, of which the guanidinium side chain can
easily coordinate with copper and inhibit the reaction.
These experiments underscore the potential for application
of our water-soluble (NHC)2Cu(I) catalysts 6 and 7 in the
functionalization of deprotected peptides applying the CuAAC
strategy (see ESI†).
Heterogeneous click catalysis by an ionically immobilized
(NHC)2-Cu catalyst
Further encouraged to take advantage of the ionic functional-
ity we used this feature to ionically immobilize these com-
Fig. 2 Plot of the reaction yield of a standard click reaction (Fig. 1B)
monitored by 1H-NMR using catalysts 5 and 7.
Fig. 3 (A) Use of acetylene gas in click reactions in water; (B) tosyl acet-
amide formation in aqueous media.
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plexes on an anion exchange resin. For this purpose we used
the crosslinked polystyrene-co-divinylbenzene based anion
exchanger Amberlyte® IRA 402, which holds benzyl-trimethyl
ammonium groups. After two washing cycles with water, an
immobilized NHC-Cu(I) catalyst 6-IRA 402, shown in Fig. 4,
was obtained. Several hours were needed for the total ion
exchange, which was visually detected by the colour change of
the initial solution. At the end of the reaction, the solution
became clear from being initially brownish, the resin
embedded with the catalyst changed from its typical yellowish
to brownish colour (ESI Picture S1†). The analysis of the water
phase by XRF did not show any trace of Cu(I) ions after the
immobilization, which confirmed the total anchoring of the
Cu(NHC) catalyst on the resin.
The new heterogeneous catalyst 6-IRA 402 was applied for
the three-component click reaction of benzyl azide (deriving
from benzyl bromide and sodium azide) and phenylacetylene.
The reaction carried out under mechanical stirring showed low
conversion under standard conditions, probably due to the
poor contact between the reactant and the heterogeneous cata-
lyst. However, when applying ultrasound instead of mechan-
ical stirring, the reaction was significantly accelerated,
allowing full conversion after 5 h (see Fig. 4). This prompted
us to reuse the immobilized catalyst by extracting the newly
formed product and adding fresh substrates while avoiding
contact of the heterogeneous catalyst with the environment.
The capability of this heterogeneous catalyst to be reused
allowing high yields was illustrated for a maximum of 4 cataly-
tic cycles. After the fourth cycle, the yield decreases dramati-
cally, possibly due to the leaching of the Cu(I) species, which
was confirmed by XRF experiments of the organic phase (see
ESI Graph S1†).
To our delight, the heterogeneous catalyst 6-IRA 402 was
able to perform click reactions using acetylene gas as the
source of alkyne. Again, the use of ultrasound was needed to
achieve high conversion in a short time. This provides high
versatility of these catalytic systems to be used on industrial
scale (Fig. 5).
Mechanistic analysis
In order to obtain a full mechanistic understanding of the
catalyst, we decided to perform state-of-the-art first principles
calculations on the coupling reaction between benzylazide and
phenylacetylene with two catalysts 6 and 8 (Fig. 1), bearing
respectively saturated and unsaturated NHC ligands. The goal
of the calculations is twofold: (1) providing a plausible reaction
mechanism of CuAAC catalyzed reactions by these new water
soluble Cu-NHC complexes and (2) investigating the electronic
eﬀect of the carbon–carbon backbone of the NHC-ligand on
the click reaction. Full catalyst models of species 6 and 8
(Fig. 1) were modeled at the B3LYP/6-311++g(3df,2p)-D3//
B3LYP/6-31+g(d) level of theory (details can be found in ESI†)
and a free energy diagram was constructed along the proposed
mechanistic cycle.
For the coupling between these molecules, taking place on
bi-ligand complexes (Fig. 1), there are steric limitations and
therefore the computations are restricted to mono-ligand
versions of catalysts 6 and 8. Under experimental conditions,
one can expect that mono-ligand complexes (LCuPF6) as well
as bi-ligand complexes (L2CuPF6) are available, which is the
case if there exists an equilibrium between them. The two
possibilities to generate mono-ligand complexes are given in
Fig. 6A. In the presence of phenylacetylene, the bi-ligand
complex can also react towards a monoligand complex LCu-
acetylide and L·HPF6, as was verified by Diez-Gonzalez et al.
3 If
such a reaction occurs, LCu-acetylide can catalyze the CuAAC
reaction. Remark that dependent on the counterion (in our
case PF6
−), we can expect diﬀerent crystallization behavior of
Fig. 4 The transcription factor protein GCN4, belonging to the bZIP leucine zipper family and the derived model peptide comprising the DNA
binding domain. Functionalization of a peptide with an alkyne allows cycloaddition-based modiﬁcation with a non-peptide azide moiety.
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one of the ligand, and correspondingly a diﬀerent amount of
active LCu-acetylide complexes (Fig. 6A). However, monoli-
gated complexes can also be generated without acetylene,
through the equilibrium reaction between L2CuPF6 and
LCuPF6, in which a ligand is released (Fig. 6A). This com-
pound can as well react with phenylacetylene forming a
LH+CuPF6-acetylide, in which the sulfate group of the ligand
has taken up the acidic proton of phenylacetylene. From the
free energy diﬀerences displayed in Fig. 6A (respectively 289.9
and 163.0 kJ mol−1 for the saturated NHC-complex), we can
assume that a reaction of the bi-ligand complex with phenyl-
acetylene is the easiest route to a mono-ligand complex. In
the following, catalytic cycles with L-Cu-acetylide as an
intermediate will further be discussed, while catalytic cycles
with LH+CuPF6-acetylide as an intermediate are described in
ESI.†
The Cu(I)-acetylide complex was also observed by Nolte
et al., who postulated – based on experimental findings – a six-
step catalytic cycle for a standard click reaction on Cu.5 Our
modeled catalytic cycles contain much similarity with their
scheme; however, we have chosen to display only the two most
important intermediate complexes in our scheme (Fig. 6B)
neglecting the shallow intermediates. For example, we observed
that the Cu-triazole product is formed immediately according to
the intrinsic reaction coordinate (IRC) scan from TS-1 (Fig. 6B
(left) and 6D). The Cu-triazole can then be protonated by a co-
adsorbed phenylacetylene (TS-2, Fig. 6B (left) and 6D), generat-
ing the 1,4-triazole product and the active Cu(I)-acetylide
complex. For complex 6, the coupling reaction has a free energy
barrier of 113.0 kJ mol−1 and the proton transfer reaction a free
energy barrier of 128.5 kJ mol−1 (Fig. 6B). It can however not be
excluded that more stable pathways can be found computation-
ally, in which the ligand groups interact diﬀerently with the
reactants. If the reaction proceeds without the catalyst, the
observed reaction barrier towards 1-benzyl-4-phenyl-1,2,3-tria-
zole amounts to 132.9 kJ mol−1, which is still higher than the
highest barrier in the catalytic scheme (cf. Fig. 6C and B, left).
Moreover, the Cu-NHC catalyst selectively generates only the
1,4-triazole product, while thermal reactions without the catalyst
produce a racemic mixture (3) of the two possible triazoles.
Furthermore, just as in the experiments under neat con-
ditions, the saturated NHC-complexes were found to be lower
activated than the unsaturated ones. Based on the diﬀerences
in the activation barrier for the rate determining step, we can
have an indication for the rate acceleration of the saturated
catalyst versus the unsaturated catalyst. Based on the
coupling step (TS-1), this would be around 5.4 times faster,
while based on the hydrogen transfer step (TS-2), this would be
approximately 3.6 times faster at 298 K. In the first instance,
this seems to be in good agreement with the experimentally
observed rate acceleration of about 4 between catalysts 5 and 7
(Fig. 2). As these catalysts have only one CH2-group less com-
pared to catalysts 6 and 8, the diﬀerence in the rate between
catalysts 6 and 8 will be similar, and thus, is in rather good
agreement with the computationally predicted acceleration. For
this catalytic cycle (Fig. 6B, left), the influence of water solvation
was studied in parallel (Fig. 6B, right). With implicit solvation
for water, the activation barriers are remarkably higher (for the
computational methodology, see ESI†). Note as well that the
diﬀerences in the rate between the saturated and the unsatu-
rated complexes become smaller with water as the solvent,
leading right to acceleration factors of around 2. From an
experimental point of view, it would also be interesting to deter-
mine the various rate acceleration factors between complexes 5
and 7 in many solvents, yet this clearly falls beyond the scope of
this initial communication on these new water-soluble Cu-NHC-
catalysts. However, for future research, this might validate the
proposed catalytic cycles.
The free energy contributions between the diﬀerent states
of the catalytic cycle can be split into enthalpy and entropy
Fig. 5 Synthesis and application in heterogeneous click reactions of an ionically immobilized (NHC)2Cu(I) catalyst.
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contributions (ESI Table S7†). The click reaction is very exergo-
nic with reaction free energy diﬀerences around −305 kJ
mol−1. To quantify the relative rates between catalysts 6 and 8,
one can look at the diﬀerence in activation free energy for the
global barrier. Therefore, a reduced catalytic cycle is con-
structed with only the major states (right part, Fig. 6A), omit-
ting the (de)protonation transition states. Right now, the
largest free energy barrier of both catalytic cycles can easily be
compared. The global free energy barrier from F amounts to
141.6 kJ mol−1 and 145.7 kJ mol−1, for catalysts 6 and 8,
respectively. This gives a rate acceleration of 5.3 between both
complexes, which is in agreement with the experimentally
observed rate acceleration of 4 between catalysts 5 and 7
(Fig. 2). As these catalysts have only one CH2 group less com-
pared to catalysts 6 and 8, the diﬀerence in the rate between
catalysts 6 and 8 will be similar, and thus, is in very good
agreement with the computationally predicted acceleration.
Without a catalyst the free energy barrier would be 132.9 kJ
mol−1, which is larger than the barrier measured
from complex A (90.9 and 95.8 kJ mol−1, ESI Table S8†)
but still lower than the barrier from complex F (141.6 and
145.7 kJ mol−1).
Fig. 6 (A) Equilibrium between bi-ligand and mono-ligand complexes; reaction free energies (298 K) are given in kJ mol−1 for the saturated (unsatu-
rated, in parentheses) catalyst in the gas phase (top, black) and water (bottom, blue). (B) Simpliﬁed catalytic cycles in which L-Cu represents the
mono-ligated Cu-NHC-complex 6 or 8, free energy barriers (top, green) and reaction free energies (bottom, black) are given in kJ mol−1 at 298 K for
the saturated (and for unsaturated catalyst in parentheses) catalyst. (C) Reactions between benzylazide and phenylacetylene without the catalyst. (D)
Visualization of the modeled transition states TS-1 and TS-2 on catalyst model 6.
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Conclusion and outlook
We have presented for the first time the synthesis of sulfonate
functionalized bis-NHC-Cu(I) complexes and their application
in click reactions for a variety of reaction conditions, illustrat-
ing the high versatility of these compounds, for the synthesis
of triazoles with diﬀerent substitution patterns. We have
further shown the use of these water-soluble complexes in bio-
conjugation experiments, attaining for the first time the
functionalization of an unprotected 25-aminoacid chain
peptide using low catalyst loading, which otherwise would
need a much higher amount of Cu(I) to achieve high eﬃciency
due to the chelating properties of certain aminoacid residues.
We could take further advantage of the ionic functionality
inserted into the NHC ligand and used this feature to ionically
immobilize these complexes on an anion exchange resin.
Moreover, both, the homogeneous and the heterogeneous cata-
lysts even performed click reactions using acetylene gas as the
alkyne source. Exploiting tosyl azide as a substrate generated
tosyl-acetamide as the sole product and thus broadens the
scope of the newly developed catalysts. Mechanistic analysis of
the Cu(I) catalysts bearing sulfonate functionalized NHC
ligands shows that the sulfonate group allows internal depro-
tonation and protonation steps of the alkyne and formed reac-
tion products, respectively. Comparison of energy barriers
quantitatively confirmed that the complexes with saturated
ligands are more active than the complexes with unsaturated
ligands toward click reactions, which is in good agreement
with the experiments.
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An immunogen synthesis strategy was designed to develop anti-deoxynivalenol (DON) monoclonal antibodies with low
cross-reactivity against structurally similar trichothecenes. A total of eight different DON immunogens were synthesised,
differing in the type and position of the linker on the DON molecule. After immunisation, antisera from mice immunised
with different DON immunogens were checked for the presence of relevant antibodies. Then, both homologous and
heterologous enzyme-linked immunosorbent assays (ELISAs) were performed for hybridoma screening. Finally, three
monoclonal antibodies against DON and its analogues were generated. In addition, monoclonal antibody 13H1 could
recognise DON and its analogues in the order of HT-2 toxin > 15-acetyldeoxynivalenol (15-ADON) > DON, with IC50
ranging from 1.14 to 2.13 µg ml–1. Another monoclonal antibody 10H10 manifested relatively close sensitivities to DON,
3-acetyldeoxynivalenol (3-ADON) and 15-ADON, with IC50 values of 22, 15 and 34 ng ml
–1, respectively. Using an
indirect ELISA format decreases the 10H10 sensitivity to 15-ADON with 92%. A third monoclonal antibody 2A9 showed
to be very speciﬁc and sensitive to 3-ADON, with IC50 of 0.38 ng ml
–1. Using both 2A9 and 10H10 monoclonal antibodies
allows determining sole DON contamination.
Keywords: deoxynivalenol; monoclonal antibodies; immunogens; ELISA; cross-reactivity
Introduction
Trichothecene mycotoxins are a group of naturally
occurring secondary metabolites produced by Fusarium
species, in particular F. graminearum and F. culmorum.
Among the 150 related trichothecenes, deoxynivalenol
(DON) (Figure 1) is of special importance as it is
formed in the ﬁeld prior to harvest and because its
occurrence cannot be completely avoided by plant pro-
duction-minimising strategies due to the high impact of
weather conditions. Especially wheat, triticale and maize
are vulnerable for Fusarium infection and subsequent
DON production (Maragos et al. 2006; Döll & Dänicke
2011).
DON can cause disease in several animal species,
especially in swine, and causes symptoms including
reduced feed consumption, abdominal distress, increased
salivation, malaise, diarrhoea, anorexia, leucopenia, hae-
morrhage, shock and death in extremely high DON
doses (Maragos & McCormick 2000; Pestka 2007).
Besides these effects, DON is also generally considered
to be a potent inhibitor of protein and DNA synthesis
and is known to be immunosuppressive (Krska et al.
2001; Danicke et al. 2006). Highly dividing cells, such
as intestinal epithelial cells known to ensure a proper
barrier function, are especially sensitive to trichothe-
cenes. Exposure to DON can lead to a decrease in
absorption of nutrients and a decrease in cell prolifera-
tion and consequently cell differentiation (Pinton et al.
2012).
Next to DON two acetylated derivatives are known to
be coproduced, namely 3-acetyldeoxynivalenol (3-
ADON) and 15-acetyldeoxynivalenol (15-ADON).
JECFA stated that the acetylated DON levels were less
than 10% of the total DON found in cereal grains, whereas
De Boevre et al. (2012) found higher 3-ADON and 15-
ADON co-contamination for several food and feed sam-
ples. In 2010 JECFA considered the toxicity of the acety-
lated derivatives equal to DON, but a recent study
suggested that higher toxicity of 15-ADON should be
taken into account. Another DON masked form detected
in cereals and beers, namely DON-3-glucoside (DON-3-
G), also shows a non-negligible contribution to the overall
DON contamination (Berthiller et al. 2009; JECFA 2011;
De Boevre et al. 2012; Pinton et al. 2012).
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Because of the economic importance of this toxin and
from a food safety perspective, a variety of analytical
techniques have been developed for the detection of
DON and related trichothecene mycotoxins in food and
feed. Most commonly used techniques include TLC, GC,
HPLC and immunological approaches such as radioimmu-
noassay and ELISA. Recently, ELISA and ELISA-based
procedures have gained acceptance as they offer the
advantage of speciﬁcity, sensitivity, simplicity and rapid-
ity, which are of importance for routine testing of myco-
toxins (Maragos & McCormick 2000; Maragos et al.
2006, 2012). The speciﬁcity and sensitivity are dependent
on the antibody used in the ELISA assay. Several anti-
bodies for DON have been reported and all show high
cross-reactivity against the acetylated derivatives 3-
ADON and 15-ADON, which reduces their speciﬁc char-
acter. Sensitivity values of antibodies, measured by the
IC50 value, range from approximately 20 to 3 ng ml
–1
(Casale et al. 1988; Mills et al. 1990; Usleber et al.
1991; Sinha et al. 1995; Maragos & McCormick 2000).
The objective of this study is to improve the speci-
ﬁcity of the ELISA assay by developing highly speciﬁc
monoclonal anti-DON antibodies. The high afﬁnity of
the monoclonal antibody to 3-ADON or 15-ADON
likely derives from the chemistry used to prepare the
immunogen. The ester linkage of 3-ADON or 15-ADON
may resemble the linkage of the DON-carrier protein
immunogen. Therefore, it was decided to use different
procedures to make linkers with varying length and
chemical structure between DON and the carrier protein
(Figure 2).
Materials and methods
Reagents
DON, 3-ADON and 15-ADON standards were obtained
from Fermentek (Jerusalem, Israel). HT-2 toxin was pur-
chased from Sigma-Aldrich (Bornem, Belgium).
Colorburst™ blue 3,3´,5,5´-tetramethylbenzidine
(TMB) substrate solution containing hydrogen peroxide
was supplied by Alerchek (Springvale, ME, USA).
Rabbit anti-mouse immunoglobulins (anti-mouse IgG sec-
ondary antibody; protein concentration of 2.5 g l–1) were
purchased from DakoCytomation (Glostrup, Denmark). N,
N´-carbonyldiimidazole, cyanuric chloride (CC), N,N´-dii-
sopropylethylamine, glutaric anhydride, 1-ethyl-3-[3-
dimethylaminopropyl] carbodiimide hydrochloride
(EDC), 1-butane boronic acid, sodium tetraborate, carbox-
ymethoxylamine hemihydrochloride (CMO), γ-aminobu-
tyric acid, sulfo-N-hydroxysuccinimide (NHS),
tetrahydrofuran (THF), acetic acid, potassium carbonate,
copper (II) sulfate, sodium ascorbate, 4,7-diphenyl-1,10-
bathophenanthroline disulfonic acid disodium salt, argi-
nine, glycine, aspartic acid, D-phenylalanine, lysine, tri-
ﬂuoroacetic acid (TFA), triisopropylsilane (TIS), methyl
tertiary butyl ether (MTBE), polyethylene glycol (bovine
serum albumin (BSA), ovalbumin (OVA), horseradish
peroxidase (HRP), rabbit anti-mouse IgG secondary anti-
body labelled with horseradish peroxidase (Sec Ab-HRP),
PBS (0.01 M, pH 7.4) tablet, carbonate-buffered saline
(CBS, 0.05 M, pH 9.6) capsule, complete and incomplete
Freund’s adjuvants, Tween 20 and skim milk powder were
obtained from Sigma-Aldrich (Bornem, Belgium). O-pro-
pargyl-hydroxylamine hydrochloride was purchased from
Focus Synthesis (San Diego, CA, USA). Imidazole-1-sul-
fonylazide hydrochloride was kindly provided by the
Laboratory of Medicinal Chemistry (Ghent, Belgium).
The Oasis HLB cartridges were obtained from Waters
(Zellik, Belgium). Chlorotrityl chloride resin was pur-
chased from Merck (Darmstadt, Germany). Deionised
water was puriﬁed by a Millipore Milli-Q system
(Brussels, Belgium). Other chemicals and solvents were
of analytical grade.
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H
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Figure 1. Chemical structure of deoxynivalenol.
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Figure 2. Three series of synthesised DON immunogens.
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Nunc-Immuno™ F96-well microplates and Nunclon™
cell culture plates were from Nalge Nunc International
(Roskilde, Denmark). Protein concentrators (9K MWCO,
20 ml) were purchased from Thermo Scientiﬁc
(Rockford, USA).
Preparation of DON immunogens
DON is a hapten due to its small size and therefore cannot
elicit an immune response. Consequently, for the synthesis
of immunogens, DON was coupled to a protein via a
linker to increase the molecular weight. In search for
speciﬁc anti-DON antibodies, different synthetic strategies
were followed. Firstly, DON was coupled to a carrier
protein via the C3 and/or C15 position using a linker
with a carboxyl function (Series I, Figure 2). To minimise
the chance of cross-reacting monoclonal antibodies, a
second DON series of immunogens was generated by
coupling the carrier protein via a linker on C3 and/or
C15 without a carboxyl function (Series II, Figure 2). To
reduce even further the possibility of cross-reacting mono-
clonal antibodies the linkage to the carrier protein was
introduced through reaction with the C8 carbonyl function
of DON, delivering a last series of immunogens (Series
III, Figure 2). The used carrier proteins were bovine serum
albumin (BSA) for the immunogen and ovalbumin (OVA)
or horseradish peroxidase (HRP) for the coating/competi-
tive antigen in indirect or direct enzyme-linked immuno-
sorbent assay (ELISA), respectively. The synthetic
pathways underneath are described for BSA. The basic
chemical structure of the three different series of immuno-
gens is illustrated in Figure 2.
The ﬁrst immunogen of the series I is DON-3,15-
hemiglutaryl (HG)-BSA (Figure 3A) and was formed by
the reaction of DON with glutaric anhydride in dry pyr-
idine. Concisely, to a solution of 5 mg of DON in 500 µl
of dry pyridine, 100 mg of glutaric anhydride was added
and the solution was heated at 100°C for 8 h. After
evaporation, the residue was dissolved in 7.5 ml of chloro-
form and washed three times with 5 ml of 0.1 M HCl. A
puriﬁcation step was performed using Oasis HLB® car-
tridges by a method derived from De Smet et al. (2010).
Brieﬂy, 5 µg of the crude DON-HG conjugate was dis-
solved in 1 ml of methanol–water (10:90, v/v) pH 2.3 and
loaded onto a preconditioned column. After loading, the
sorbent was dried for 15 s by applying vacuum. DON-HG
was eluted by washing the column with 1 ml of methanol–
water (55:45, v/v) followed by 1 ml of methanol. The
sorbent was dried for 15 s by applying a vacuum. After
purity determination by time-of-ﬂight (TOF) MS, an ali-
quot of 1 mg of the synthesised DON-HG (1.92 µmol)
was dissolved in 0.5 ml PBS using ultrasonication and
transferred to 30 mg BSA (0.45 µmol) in 1 ml of PBS.
Then 20 mg of EDC (0.10 µmol) was added to the above
mixture and incubated for 5 h at RT with stirring (Mills
et al. 1990; Usleber et al. 1991; Kohno et al. 2003; De
Smet et al. 2010).
To obtain DON with one HG linker, namely DON-3-
HG-BSA (Figure 3B), prior protection of the 7-OH and
15-OH groups as a cyclic boronate ester allowed one to
use similar reaction conditions as for DON-3,15-HG-BSA
(Casale et al. 1988). Additionally in the ﬁrst series of
immunogens, a common DON-BSA carbamate conjugate
(Figure 3C and 3D) was synthesised by the N,N´-carbo-
nyldiimidazole (CDI) coupling reaction, adopted from the
published literature (Xiao et al. 1995; Maragos &
McCormick 2000).
Within-series II, DON-CC-BSA (Figure 3E and 3F)
was synthesised by ﬁrst dissolving 1 mg of DON
(3.374 × 10−3 mmol) in 480 µl of cold acetonitrile. A
solution of 620 µg of cyanuric chloride (3.362 × 10−3 mmol)
in 1.24 ml of acetonitrile was prepared and cooled until –
20°C. The DON solution was added over 1 h to the vigor-
ously stirred solution of cyanuric chloride. A solution of
870 µg N,N´-diisopropylethylamine in 260 µl of cold acet-
one was added to the solution of DON and cyanuric chlor-
ide and mixed for 5 h at 55–60°C followed by mixing for
16 h at RT. For coupling to BSA, a solution of 1830 µg of
BSA (0.0270 µmol) in 1090 µl of 0.1 M sodium tetraborate
(pH 9.2) was prepared. The solution was cooled to 4°C and
3.5 mg of DON, a 10-fold molar excess with respect to the
available amino groups was added and the resulting mixture
was stirred for 1 h at 4°C (Abuchowski et al. 1977;
Abuknesha & Grifﬁth 2005).
In an effort to reduce the cross-reactivity against
3-ADON and 15-ADON, we decided to use the C8
carbonyl function of DON to attach an appropriate lin-
ker via an oxime moiety (Series III). Hereto a carbox-
ymethyloxime (CMO) strategy was applied (Figure 3G)
(Burkin et al. 2000). To investigate the effect of the
length of the linker between DON and the protein and
with the aim of lowering the immune response against
the linker itself, we also introduced a carboxypropyl
imine (CPI) linker at the C8 position of DON (Figure
3H). For this purpose, 0.5 mg of DON (1.7 µmol) was
reacted with 750 µg of CMO (7 µmol) in 500 µl of dry
pyridine for the DON-CMO synthesis and with 1.6 mg
of γ-aminobutyric acid (15.5 µmol) in 1 ml dimethyl-
formamide (DMF) for the DON-CPI synthesis. After
overnight reaction at RT, the reaction mixture was con-
centrated and the residue redissolved in 200 µl of water/
DMSO (1:1.5, v/v). Next, 2 mg of sulfo-NHS and 4 mg
of EDC were added together with 1.775 mg of BSA and
the volume was adjusted to 1 ml by further dilution with
water. The reactions were performed for 2 h at RT
followed by washing and puriﬁcation as described for
previous immunogen synthesis.
Finally, click chemistry was adopted for linking C8 of
DON without a carboxyl function. Following a modiﬁed
procedure of Ikuina et al. (2003), DON was condensed to
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Figure 3. Overview of the deoxynivalenol immunogens (only the amino group of the protein is presented): A, DON-3,15-HG protein;
B, DON-3-HG protein; C, DON-3 protein; D, DON-15 protein; E, DON-3-CC protein; F, DON-15-CC protein; G, DON-CMO protein;
H, DON-CPI protein; I, DON-oxime; J, DON-azido protein; K, DON-cyclic peptide protein.
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O-propargy-hydroxylamine hydrochloride (Figure 3I).
Brieﬂy, 2 mg of DON (6.76 µmol) was reacted with
1.81 mg of O-propargyl-hydroxylamine hydrochloride
(25.52 µmol) in the presence of THF/acetic acid (1:1, v/
v) at 40°C. After 2 h, an additional 170 µg of O-propar-
gyl-hydroxylamine hydrochloride was added and the mix-
ture was stirred for another 4.5 h to obtain DON-oxime.
For the synthesis of azido-BSA, 10.686 mg of BSA
(0.16 µmol) was dissolved in water together with 4 mg
of potassium carbonate and 0.5 mg of copper (II) sulfate.
Then, 1 mg of imidazole-1-sulfonylazide hydrochloride
(4.79 µmol) was added and the reaction was agitated
overnight. For the click reaction, 0.5 mg of DON-oxime
(1.43 µmol) was transferred to an aqueous solution of
azido-BSA (1.42 mg) containing 25 µg copper (II) sulfate
(10 mM), 20 µg sodium ascorbate (10 mM) and 54 µg
4,7-diphenyl-1,10-bathophenanthroline disulfonic acid
disodium salt (10 mM). The reaction went on for 14 h at
RT (Figure 3J) (Ikuina et al. 2003; Van Dongen et al.
2009; Horak et al. 2010).
The click chemistry immunogen product was further
expanded by the introduction of a N-azido cyclic peptide
(630.3 g mol–1) (Figure 3K). The cyclic peptide increases
the distance between DON and BSA and renders the DON
molecule more available for the immune system. Through
solid-phase peptide synthesis using 2-chlorotrityl chloride
resin and a Fmoc/tBu protection scheme, the amino acids
glycine, aspartic acid, D-phenylalanine, lysine and argi-
nine were successively coupled to each other. After mild
acid cleavage of the peptide from the resin, cyclisation of
the peptide was performed followed by treatment with
TFA–TIS–H2O (95:2.5:2.5, v/v/v) to remove the protect-
ing groups in solution. The peptide was then precipitated
in MTBE–hexane (1:1, v/v) and redissolved in methanol
for a diazo transfer. For the click chemistry, 1 mg of DON-
oxime (2.84 µmol) was reacted with 1.78 mg of cyclic
peptide (2.84 µmol) under the previously mentioned con-
ditions. Under CDI reaction conditions, the obtained
DON-cyclic peptide (2.84 µmol) was coupled to 3.9 mg
of BSA in water–DMSO (1/5, v/v) for 3 h at RT (Dai et al.
2000; Dijkgraaf et al. 2007).
All DON immunogens were dialysed against 4 L PBS
to remove low molecular weight substances and concen-
trated using Pierce Concentrator columns 20 ml/9K
MWCO.
Characterisation of immunogens
The successful synthesis of the DON-3,15-HG-linker was
conﬁrmed by mass spectrometry LCT Premier XETM TOF
(Waters, Milford, MA, USA) equipped with a standard elec-
trospray ionisation and modular LockSpray TM interface in
the positive and negative electrospray ionisation (ESI+/–)
mode. The puriﬁed DON-3,15-HG mixture was infused in
acetonitrile–water (1:1, v/v) at 10 µl min–1. The purity of the
ﬁnal product was assessed by HPLC and photo diode array
(PDA) detection (190–400 nm) using a Phenomenex Luna
2.5 mm C18 (2)-HST column. A mobile phase consisting of
eluents A (water, 0.1% formic acid) and B (acetonitrile, 0.1%
formic acid) was used at a ﬂow rate of 0.4 ml min–1. A linear
gradient of 10–100% solvent B was applied over 9 min.
Other mass measurements of DON-linker syntheses were
performed by direct injection of the reaction product into
the Quattro Premier XE mass spectrometer (Waters, Milford,
MA, USA) using the ESI+/–mode.Masslynx version 4.1 was
used for data acquisition.
After coupling to the protein, the immunogen concen-
tration was determined based on the amount of protein
coupled by the use of the NanoDrop 2000c (Thermo
Scientiﬁc, Rockford, USA) and the immunogen was char-
acterised by the use of indirect competitive ELISA. All
incubations except for the ﬁrst coating step were carried
out at 37°C. After each incubation, the plates were washed
three times (300 µl/well) with PBST (PBS containing
0.05% Tween 20). High-binding Nunc-ImmunoTM F96-
well microplates were coated with 10 µg ml–1 of the
synthesised conjugate in CBS (100 µl/well). After incuba-
tion at 4°C overnight, the plates were blocked with 2%
skimmed milk in PBS (300 μl/well) for 30 min. Standard
solutions of DON and PBS control were added (50 μl/
well), followed by adding 50 μl/well of diluted DON
monoclonal antibodies (clone 4 or 22) in PBS kindly
provided by C. Maragos (USDA). After shaking and incu-
bation for 1 h, 100 μl/well of Sec Ab-HRP was added and
incubated for another 1 h. Then, 100 μl/well of TMB
substrate solution was added. The reaction was stopped
after 15 min with 2 M sulphuric acid (50 μl/well), and the
absorbance at 450 nm was measured by a Bio-Rad 550
microplate reader (Richmond, CA, USA).
Immunisations
To obtain antibody-producing B-lymphocytes against
DON, 6–8-week-old Balb/C female mice (ethical approval
according to ethical commission for animals (ECD) 10/08)
were subjected to an injection with the different DON
immunogens emulsiﬁed with complete or incomplete
Freund’s adjuvant. For each group of mice, 100 µg of
the DON immunogen was administered. Once the mice
had reached a sufﬁcient titre, cell fusion of mouse spleen
cells and myeloma cells (NSO cells) was performed.
Polyethylene glycol (PEG) 1500 was added as fusing
reagent and hypoxanthine, aminopterine and thymidine
(HAT) for the selection of the fused cells. The cells were
distributed into 96-well culture plates and cultured in a
humidiﬁed, 37°C, 5% CO2 incubator. Culture supernatant
was screened by indirect ELISA to determine the positive
hybridomas producing antibody against DON. These
hybridomas were further screened for the production of
the target antibody and subcloned by limiting dilution.
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Characterisation of monoclonal antibodies
Checkerboard assays, in which antibodies were titrated
against various amounts of coating antigens, were con-
ducted to select appropriate working concentrations for
evaluation of assay sensitivities to DON. Standard compe-
titive curves were obtained by plotting relative absorbance
(ratio of absorbance measured at the standard concentra-
tion and zero concentration: B/B0 × 100%) against the
logarithm of analyte concentration. IC50 values (i.e., ana-
lyte concentrations at which the maximum absorbances
were inhibited by 50%) were determined to assess the
assay sensitivity. To evaluate the speciﬁcity or assay selec-
tivity of the antibody, a set of DON analogues were
utilised to perform cross-reactivity studies. The IC50 of
each tested compound was based on its corresponding
competitive curve. Cross-reactivity (CR) values were cal-
culated according to the following equation: CR
(%) = [IC50 (DON)/IC50 (analogue)] × 100%, where CR
values were calculated using IC50 values with units of
µg ml–1.
Results and discussion
Characterisation of immunogens
When the desired synthesis products were obtained based
on the exact mass measurements performed by direct
injection into the Quattro Premier XE mass spectrometer
or the LCT Premier XETM TOF mass spectrometer,
further coupling to BSA and OVA or HRP was performed.
The synthesised immunogens were characterised by com-
petitive ELISA using reference DON monoclonal antibo-
dies (clone 4 or 22, USDA). If the B0 value was equal to
or higher than 1 and decreasing B values were obtained
when using increasing standard DON concentrations, the
testing conjugates were conﬁrmed and used for immunisa-
tion or further ELISA experiments.
Determination of antisera titres by using indirect ELISA
Antisera titres were determined by an indirect homologous
ELISA using the immunising haptens coupled to OVA
instead of BSA as coating antigen (Guo et al. 2014). By
using the same format, the cross-reactivity against OVA
was determined as well. The best antisera titres were
obtained for the mice injected with DON-BSA and
DON-CC-BSA. For DON-3,15-HG-BSA, high antisera
titres were found, but the cross-reactivity against OVA
was high. It was concluded that antibodies were probably
formed against the protein instead of the target DON. This
could be explained by the presence of two linkers on the
DON molecule, which makes it less free for activation of
the immune system of the mouse. For DON-CMO-BSA,
DON-CPI-BSA, DON-azido-BSA and DON-cyclic pep-
tide-BSA, a relatively lower titre, but no cross-reactivity
against OVA was determined. When the ELISA response
reached a plateau phase using a high serum dilution, the
mice were sacriﬁced by cervical dislocation.
Hybridoma selection and subcloning
By screening and subcloning of the hybridomas, ﬁnally, a
total of three different anti-DON monoclonal antibodies
were obtained. Corresponding to the derived antisera
titres, one DON-CC-BSA mouse produced the 13H1
monoclonal antibody, while the 10H10 and 2A9 mono-
clonal antibodies were produced by two different DON-
BSA mice. Previous statement about the immunogenic
importance of the C8 carbonyl function in the DON mole-
cule was conﬁrmed as no anti-DON monoclonal antibo-
dies were derived using immunogens with a linker
coupled to the C8 carbonyl function (Usleber et al. 1991).
Characterisation of monoclonal antibodies
The characterisation of monoclonal antibodies 13H1 and
10H10 by direct ELISA is described in detail by Guo et al.
(2014). The 13H1 and 10H10 monoclonal antibody showed
sensitivity values of 2.13 and 0.022 µgml–1, respectively. For
the 13H1 monoclonal antibody the highest cross-reactivity
was observed for 15-ADON (CR = 131%) and HT-2 toxin
(CR = 187%). Monoclonal antibody 10H10 showed the
highest cross-reactivity for 3-ADON (CR = 147%) and 15-
ADON (CR = 65%). Characterisation of 10H10 was also
repeated by indirect competitive ELISA using DON-OVA
(4 µg ml–1) and DON-CC-OVA (4 µg ml–1) coating and
DON, 3-ADON and 15-ADON for competition. This com-
parison between direct and indirect ELISA is illustrated in
Table 1. The sensitivity of the antibody towards DON and 3-
ADON measured by indirect ELISA is approximately half
(DON-OVA coating) and 1/5 (DON-CC-OVA coating) of the
value measured by direct ELISA. For 15-ADON, the sensi-
tivity decreased at least ten times when using indirect ELISA.
When looking to the CRmolar values for direct ELISA and
indirect ELISA with DON-OVA coating, the same cross-
reactivity is seen for 3-ADON, but the cross-reactivity
towards 15-ADON lowered 6.7 times when using indirect
ELISA. It can even be concluded that the 10H10 antibody
shows only cross-reactivity to 3-ADON when using indirect
ELISA with DON-OVA coating. When using an indirect
ELISA format with DON-CC-OVA coating, the cross-reac-
tivity against 3-ADON increased three times and the cross-
reactivity against 15-ADON decreased four times compared
to the direct ELISA format. So, the characterisation of the
monoclonal antibody depends on the type of ELISA and the
coating antigen used.
Characterisation of monoclonal antibody 2A9 was
performed using direct ELISA and the standard curve
using 3-ADON standard for competition is shown in
Figure 4. The curve represents the relative absorbance
6 M. Sanders et al.
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values (B/B0) of the ELISA experiment performed on 3
consecutive days. A very sensitive anti-3-ADON antibody
was developed with an IC50 value of 0.38 ng ml
–1. Setting
the monoclonal antibody activity for 3-ADON as 100%,
the cross-reactivity values for DON, 15-ADON and DON-
3-G (Table 2) were determined as 0.188%, 0.088% and
1.498% and can be considered as negligible. In compar-
ison with other previously reported monoclonal antibodies
for 3-ADON, the newly developed clone 2A9 is likely the
most sensitive and speciﬁc antibody to 3-ADON (Casale
et al. 1988; Maragos & McCormick 2000; Maragos et al.
2006; Baumgartner et al. 2010).
Conclusions
By using a three-series synthesis strategy for the develop-
ment of speciﬁc monoclonal antibodies against DON,
previous statements were conﬁrmed and new conclusions
could be made. The place of the linker on the DON
molecule is of importance for the immunogenic response.
When a linker is positioned on the C3 or C15 of DON for
the synthesis of an immunogen, the produced antibody
shows higher cross-reactivity against 3-ADON or 15-
ADON, respectively. When coupling a linker to the car-
bonyl C8 of DON, no high anti-DON immune response
was observed. This emphasises the immunogenic impor-
tance of the C8 carbonyl function. The size of the linker
does not seem to inﬂuence the immunogenicity of the
injected conjugate. The kind of linker has an inﬂuence
on the electronic conﬁguration of the DON molecule and
therefore on the antigenic determinant of DON which is
available for the immune system of the mouse.
Three different monoclonal antibodies were devel-
oped. One of them (2A9) can be called an anti-3-ADON
monoclonal antibody, because of its very sensitive and
speciﬁc characteristics towards 3-ADON. The second
10H10 monoclonal antibody is a broad speciﬁc antibody
against DON and its acetylated derivatives 3-ADON and
Table 1. Comparison between direct and indirect ELISA for 10H10 antibody characterisation.
IC50 (µg ml
–1) CR (%) IC50 molar (nmol ml
–1) CR molar (%)
Direct ELISA DON 0.022 100 0.074 100
3-ADON 0.015 147 0.044 167
15-ADON 0.034 65 0.101 74
Indirect ELISA DON-OVA DON 0.040 100 0.135 100
3-ADON 0.028 142 0.083 162
15-ADON 0.421 9 1.250 11
DON-CC-OVA DON 0.113 100 0.383 100
3-ADON 0.024 480 0.070 547
15-ADON 0.637 18 1.885 20
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Figure 4. Standard curve of clone 2A9 for 3-ADON by direct
competitive ELISA (n = 3).
Table 2. Comparison of cross-reactivity results between clone 2A9 and other DON-MAbs.a
Clone 2A9 direct ELISA Mab 1–6.2.6 (1) indirect ELISA
USDA Clone 22 (4)
direct ELISA
Compound IC50 (ng ml
–1) CR (%) IC50 (ng ml
–1) CR (%) IC50 (ng ml
–1) CR (%)
3-ADON 0.38 100 1.70 100 2.88 100
DON 202.14 0.188 15.80 10.7 18.20 15.8
15-ADON 431.79 0.088 68.90 2.4 558.00 0.52
DON-3-G 25.36 1.498 n.a. − n.a. −
Notes: aHerein, CR (%) = [IC50 (3-ADON)/IC50 (analogue)] × 100%.
For comparison, the results from reference (4) by Maragos & McCormick (2000) were competitive direct ELISA for clone 22; the results from reference
(1) by Maragos et al. (2006) were competitive indirect ELISA for Mab 1–6.2.6.
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15-ADON when using it in a direct ELISA format. By
using an indirect ELISA format with DON-OVA or DON-
CC-OVA coating, the selectivity of this antibody changes
resulting in only cross-reactivity against 3-ADON. When
combining the 2A9 and 10H10 antibodies in an indirect
ELISA format, it is possible to measure the sole DON
contamination.
Therefore, we conclude that it is possible to produce
speciﬁc antibodies against trichothecene mycotoxins such
as 3-ADON by synthesising the proper immunogen with
the suitable linker and screening the hybridomas carefully.
By changing the ELISA format and/or coating antigen, it
is possible to inﬂuence the selectivity and cross-reactivity
of the monoclonal antibody.
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DNA Recognition DOI: 10.1002/anie.200((will be filled in by the editorial staff)) 
Sequence-Selective DNA Recognition and Enhanced Cellular 
Uptake by Peptide-Steroid Conjugates prepared through CuAAC 
Yara Ruiz García[a], Abhishek Iyer[a], Dorien Van Lysebetten[a], Vladimir Pabón Martínez[c], Benoit 
Louage[b], Bruno De Geest[b], Edvard Smith[c] and Annemieke Madder*[a] 
Abstract: Several GCN4 Leucine Zipper Transcription Factor (TF) 
models have already been designed and synthesized. However, the 
synthetic routes for these constructs are tedious and difficult. Therefore 
there was need to find a convergent strategy to synthesize these 
constructs which could allow versatility without adding to the complexity 
of the synthesis. Through this work we have performed a substitution 
of the Leucine zipper domain of the protein by different derivatives of 
deoxycholic acid which have enabled us to synthesize mimics of the 
GCN4 TF using a one-step “click” reaction. In addition to achieving 
sequence specific dsDNA binding, we have investigated the potential 
of these compounds to enter cells through confocal microscopy and 
flow cytometry which have not yet been performed before for steroid-
long peptide conjugated constructs nor for artificial DNA binders. We 
thus present a unique synthetic model of the bZIP TF which features 
sequence specific dsDNA binding properties as well as enhanced cell-
uptake through active diffusion. Given the unique properties of 
deoxycholic acid and convergent nature of the synthesis, we believe 
this work is a keystone in the discovery of an ideal mimic for this TF. 
 
Gene expression at the transcriptional level is mainly regulated by 
proteins that bind DNA in a sequence-specific manner. These 
proteins, known as transcription factors, are responsible for 
controlling the transfer of genetic information from DNA to mRNA. 
Numerous genetic diseases find their origin in the anomalous 
regulation of gene expression during transcription. TFs are 
involved in the development of biological functions in the cell. More 
specifically, oncoproteins are transcription factors responsible for 
cell-growth proliferation and tumor formation. As a consequence of 
the specificity of these oncoproteins in the DNA sequence 
recognition during transcription, several approaches have been 
explored to develop inhibitors or modifiers of gene expression that 
Figure 1. Artificial DNA binder design. 
 
can prevent specific genes from being transcribed. This could 
ultimately result in interesting biomedical applications such as 
design of genome interfering agents or diagnostics. In addition, the 
lack of a general recognition code for the interaction between 
amino acid sequences within a protein and its specific DNA-binding 
site has promoted the study of the structure of TFs and its 
interaction with the DNA. We here present our efforts on mimicking 
the GCN4 bZIP TF by a synthetic approach. The broad range of 
chemical tools allowed us to simplify the structure of the protein 
and to explore factors that influence DNA recognition in DNA 
binder models. This coupled with cell uptake studies is a first 
attempt to understand how mimics of a protein behave in cellulo. 
Our target has been to develop new types of site-specific DNA 
binders which can recognize dsDNA by specific binding in the 
major groove and show enhanced cellular uptake by exploiting the 
unique properties of the steroid moiety. We have been inspired by 
the leucine zipper motifs (bZIP and b-HLH-ZIP), in which the basic 
DNA recognition region binds to the major groove as a dimer, 
inserting two α-helices held in the correct position by a dimerization 
domain[1]. The main residues of the protein involved in the DNA 
recognition comprise of the amino acids 226-248 of the basic 
region of the GCN4 protein. Previous models of such transcription 
factors have been synthesized by different research groups 
proposing different dimerization domains. The pioneer mimic was 
developed by the group of Kim[2], in which the dimerization domain 
was substituted by a simple disulfide bond. Following this 
successful idea, Morii, Schepartz, and Mascareñas have enforced 
the proof-of-concept by using other dimerizing moieties[3–7]. In 
order to mimic the DNA binding potential of this natural construct, 
we envisaged that the attachment of the basic region peptides to a 
rigid scaffold, a derivative of deoxycholic acid in this case, can 
allow selective recognition of DNA. Our previous work on Myc-Max 
b-HLH-ZIP and GCN4-bZIP proteins showed that these constructs 
have the potential to bind DNA. We illustrate the importance of the 
dimerizing unit for efficient recognition[8]. The specific choice of the 
steroid scaffold was inspired by the fact that it is cheap, 
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commercially available, versatile and easy to modify synthetically. 
n addition, its known ability to enhance proteolytic stability of the 
attached peptides[9–11], amphiphilicity[12] , conformational properties 
ensuring correct positioning of the two appended chains[13] and 
potential to increase cellular uptake and bioavailability[14] make it 
the perfect dimerizer for this study. 
Based on the conclusions of our previous design, we considered 
the incorporation of a spacer between the peptide and the scaffold 
in order to provide the final conjugate with enough flexibility to 
adopt an optimal conformation for specific interaction with the 
major groove of the target DNA sequence. Moreover, by using of a 
series of different spacers between the scaffold and the peptide 
chains we believe to have gained knowledge regarding the factors 
that can influence DNA binding when synthesizing artificial 
constructs. 
In order to synthesize these constructs in an effective way, we 
followed a convergent approach involving the CuAAC reaction to 
conjugate the recognition domains to a functionalized steroid 
scaffold. The geometric, steric and electronic properties of the 
1,2,3-triazole resemble a trans-amide bond, while also affording 
resistance to enzymatic degradation[15–18], hydrolysis and 
oxidation, rendering it an attractive heterocyclic moiety to replace 
physiologically labile linkers in biologically active compounds. In 
addition, successful replacement of two amino acids in α-helical 
peptides by a triazole unit has been shown to not significantly 
influence the secondary peptide structure[15]. To date the triazole 
linkage has scarcely been used for peptide-steroid conjugation and 
only to assemble short apolar tripeptides onto bile acid scaffolds[19], 
despite the increasing interest of these type of conjugates in 
diverse applications such as HIV inhibitors[20,21] and immunogens 
for vaccine development[22].  To our knowledge, deprotected, polar 
peptides have not been assembled on bile acid scaffolds in this 
manner due to the highly challenging nature of the conjugation. In 
current work we have optimized the conditions for the CuAAC 
mediated conjugation of longer, unprotected and functionalized 
peptides which could be used in the future as a general strategy 
for the assembly of peptides on a bile acid scaffold. 
For this purpose, we have designed and synthesized four different 
scaffolds for peptide dimerization of the GCN4 basic region. 
Deoxycholic acid being the common nucleus in the different 
scaffolds, they differ with respect to the spacers between the 
peptide and the steroid skeleton, which have different lengths, 
rigidities and functionalities. Deoxycholic acid was modified at the 
alcohol positions by attachment of different linkers. The linkers 
chosen for the study were: pentynoic acid, azido glycine, 4-
azidomethyl-benzoic acid and (N-Propynoylamino)-p-toluic acid 
(PATA). The PATA linker has been specifically developed for 
bioconjugation purposes as an active alkyne for preparation of 
peptide-oligonucleotide conjugates via CuAAC[23]. Funtionalization 
of the steroid nucleus was performed by Steglich esterification, 
affording final scaffolds (1, 2 & 4). In case of PATA as linker (3), 
the diamino derivative of deoxycholic acid proved necessary for the 
coupling of the linker, as esterification gave rise to byproducts due 
to the high reactivity of the alkyne. 
The GCN4 basic DNA binding region consists of 23 amino acids 
that specifically recognize the ATF/CREB-binding site (5’-ATGA 
C/G TCAT-3’). In order to append the peptides to the bile acid 
scaffolds, peptides were modified at the C-terminus with unnatural 
amino acids bearing an alkyne or an azide. Peptides 5 and 6 were 
synthesized in an automated fashion using Fmoc/tBu SPPS. 
The alkyne and azide functionalized GCN4 basic region peptides, 
5 and 6 were then attached to the central steroid core, affording 
four different transcription factor models. Cycloaddition of the 
peptides to the scaffold via CuAAC was performed in a mixture of 
DMSO/H2O, in order to decrease the aggregation of the peptide 
due to the high polarity of DMSO. Given the hydrophilic nature of 
the deprotected peptide and the hydrophobic nature of the scaffold, 
the DMSO/H2O combination was found to be optimal for the 
CuAAC reaction. Moreover, it is known that polar solvents prevent 
aggregation of copper species. As a catalyst, Cu(CH3CN)4PF6 
gave the best results. A high excess of catalyst was needed 
presumably due to the complexation of copper with the side chains 
of the peptide, containing multiple nitrogen containing 
functionalities including the amine of lysine and the guanidinium 
group of arginine. Unexpectedly, an excess of scaffold was 
required for the completion of the reaction, the dipodal construct 
still being favored over the monopodal one under these conditions. 
The use of reductants or additives proved not necessary. The 
reaction was complete after 3 hours at room temperature under 
argon. Apart from the above mentioned advantages of triazoles, 
the reaction conditions are compatible with the presence of all 
unprotected amino acids in the sequence.  
Purification of final constructs after completion of the reaction was 
possible via RP-HPLC, affording compounds 7, 8, 9 and 10 in high 
purity for DNA binding studies. 
 
 
 
Figure 2. Deoxycholic acid derivatives for the substitution of the dimerization 
domain with the corresponding peptides. 
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Figure 3. Binding reactions were carried out in the presence of the indicated 
peptide with <1 nM labeled CRE in a binding mixture (20 pL) containing 20 mM 
Tris-HCI (pH 7.5). 4 mM KCI, 2 mM MgCl2, 1 mM EDTA, 20 pM poly(d1-dC), and 
6% sucrose. The binding mixtures were incubated at 4 "C for 30 min, and an 
aliquot (5 μL) of each binding mixture was directly loaded onto 8% nondenaturing 
acrylamide gel (29:1 acrylamide/bis-acrylamide), run in 1/5 TBE buffer (20 mM 
Tris, 20 mM boric acid, and 0.4 mM EDTA) at 4°C, and analyzed by UV 
irradiation. 
 
A series of experiments were set up to better understand the cell 
uptake capacity of the various synthetic constructs.  For this 
purpose the best DNA binding cholic acid based mimic 14 of the 
GCN4 protein was resynthesized incorporating a fluorescein tag. 
The properties of this construct were compared to the unmodified 
GCN4 peptide dimer 11. The toxicity, quantification of uptake and 
localisation in the cell of these constructs were studied using 
RAW264.7 mouse macrophages. 
Fig. 4: I. Confocal microscopy images of the uptake of (A) 14 at 4 °C, (B) 14 at 
37°C, (C) 12 at 4 °C, and (D) 12 at 37 °C at 0.25 µM. Upper panel shows 
accumulated images of DNA (blue), cell membrane (red) and fluorescein (green). 
Lower panel shows fluorescein image. (Scale bar = 20 µm). 
II. Mean fluorescence (left) and peptide positive cells (middle) of the synthesized 
compounds 12 and 14 at 4 °C and 37°C at 0.25 µM. Mean fluorescence of 
compounds 12 and 14 at 0.25 µM and 1 µM. 
III. Confocal microscopy images (left) of the uptake of 11 at (A) 4 °C and (B) 
37 °C. Upper panel shows accumulated images of DNA (blue), cell membrane 
(red) and fluorescein (green). Lower panel shows fluorescein image. (Scale bar 
= 20 µm). Mean fluorescence (right) of compounds 11 and 13 at 0.25 µM and 1 
µM 
 
Although it was shown that all compounds are taken up at 37 °C 
(figure 4.I), there is clearly an enhanced uptake when deoxycholic 
acid is used as a scaffold as seen from the mean fluorescence 
values (figure 4.II). The Monopodal Cholic acid derivative 13, 
although non-DNA binding and more hydrophobic, has enhanced 
uptake like its dimeric counterpart. However, we see a decreased 
uptake when the concentration is increased to 1 µM. This could be 
attributed to the denaturant like properties of the cholic acidThe 
most interesting results were obtained when comparing the 
localisation of the DNA binding Cholic acid Dimer 14 at 4°C and 
37°C (figure 4.IA & 4.IB). At 4°C, where endocytosis is shut down, 
only insertion in the cell membrane was observed. Accumulation in 
and around the cell membrane resulted in a high mean 
fluorescence value and high percentage of  peptide positive cells 
(figure 4.II left and middle). However, at 37°C, whereby both 
passive and active uptake is possible, the uptake is considerably 
higher. This indicates that the deoxycholic acid coupled peptides 
are mainly internalized via active transport at 37°C. However, since 
we have observed uptake at 4°C for 14 we can conclude that more 
than one uptake mechanism is involved. The most likely 
explanation is that the peptides follow an endocytotic pathway 
whereas the steroid-peptide conjugate performs a direct 
translocation/transduction type mechanism at 4°C. 
As a conclusion, we have illustrated here an optimized CuAAC 
strategy to conjugate relatively long, deprotected peptides to bile 
acid scaffolds in a convergent manner. From the four models of the 
GCN4 bZIP transcription factor presented, the one with a longer 
and more flexible linker proves to be the best synthetic DNA binder. 
This can be attributed to the fact that the longer linker allows the 
construct to grip the major groove of the DNA like a pair of tweezers 
which is not possible in the case of the less flexible linkers. The 
binding affinity of 7 is comparable with the earlier described models 
of GCN4 TFs, however, the synthetic route towards current 
constructs is considerably simplified. In addition, compound 7 
shows a clearly enhanced cell uptake when tested against 
RAW264.7 mouse macrophages illustrating the particular 
properties of the steroid nucleus which allow uptake at low 
concentrations thus affording low cytotoxicity. A steroid in this case 
is used to increase the uptake of the GCN4 Cell Penetrating 
Peptide. Thus, the four models of the GCN4 bZIP TF presented 
here allowed us to detect the parameters that affect dsDNA 
recognition in synthetic constructs and enable enhanced cell 
uptake due to the uniqueness of the peptidosteroid conjugates 
synthesized.  
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ABSTRACT: Synthetic models of bZIP transcription factors have 
been developed with the capability of specific DNA recognition. 
Our design is based on the CuAAC mediated conjugation of basic 
region Leucine Zipper peptides to different derivatives of α, β and 
γ-cyclodextrins equipped with azide functionalities. Thorough op-
timisation of reaction conditions allowed convergent and simulta-
neous conjugation of two long unprotected cationic peptides to cy-
clodextrin-bis azide derivatives. The resulting constructs were 
shown to specifically recognize their cognate DNA sequence with 
nM affinities. In comparison with previously developed TF models 
the here described derivatives combine enhanced DNA binding ca-
pabilities with an easy and convergent synthetic route. 
The study of gene expression regulation is currently of particular 
interest due to the upcoming development of gene therapy strate-
gies. Indeed, altered expression of particular genes can cause inter-
ferences with biological processes in the cell. Therefore, selective 
up- or down-regulation of specific gene transcription could ulti-
mately result in a therapeutic platform with biomedical applica-
tions. During the past decade, biologists and medicinal chemists 
have been working together in order to target specific genes for this 
purpose1–3.  
In this context, Transcription Factors (TFs) have been studied in 
great detail for the modification of gene expression and the study 
of DNA binding affinity in the cellular environment4–7. In particu-
lar, bZIP proteins have gained attention due to the simple arrange-
ment of the protein structure consisting of a well-defined dimeriza-
tion domain and a basic binding region8. These proteins are able to 
interact with DNA in a sequence-specific manner by means of in-
serting their recognition domains, consisting of defined sequences 
of amino acids, in the DNA major groove. Simplification of such 
proteins could ultimately result in peptide-based drugs for alterna-
tive disease treatment. Moreover, due to the improvements in pep-
tide manufacturing, peptide drugs can now be produced in a 
straightforward way through synthetic methods and many tech-
niques have been developed for improved peptide stability. 
Therefore, the idea of transferring the protein properties to smaller 
systems whilst conserving the DNA recognition ability has re-
ceived considerable attention. The bZIP leucine zipper TF binds 
dsDNA as a dimer, presented as uninterrupted α-helices that grip 
the major groove and interact with the DNA through basic residues. 
The main residues involved in DNA recognition are the amino ac-
ids 226-248, located at the N-terminal basic region of the GCN4 
protein8. The optimal position and spatial arrangement of the di-
meric peptides is ensured by the leucine zipper domain. Simplified 
models of these proteins have been designed based on the substitu-
tion of the dimerization domain by a scaffold for the appendage of 
the basic region peptides in a correct geometry9. First proof of this 
concept was delivered by Kim et al.10 using a disulfide bond as con-
nector between the extended basic region of the peptides. Since 
then, several models have been developed trying to improve upon 
the pioneer one11–14. 
Figure 1: Design of cyclodextrin based DNA binders.  
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We here report on cyclodextrin based TF models where the dimer-
ization domain of the GCN4 protein is substituted by a scaffold 
which allows accurate regulation of the geometry and the mutual 
distance between the two peptide strands. This has been achieved 
by the use of α, β and γ-cyclodextrin derivatives in order to scan 
and evaluate the importance of the distance between the two an-
choring points for the dimerizing peptides (figure 1). Due to the 
rigid structure of the cyclodextrins, attachment of the basic region 
peptide of the GCN4 protein onto opposite positions of the primary 
rim of the cyclodextrins indeed allows control of the dimerization 
distance. Based on the diameters of the primary rim of α, β and γ–
cyclodextrins, which are 5.7, 7.8 and 9.5 Å respectively15, three dif-
ferent peptide-cyclodextrin conjugates have been synthesized, 
keeping in mind that the width of the major groove is 11.2 Å. For 
this purpose, we have synthesized 6I,6IV-diazido-α-cyclodextrin, 
6I,6IV-diazido-β-cyclodextrin and 6I,6V - diazido-γ-cyclodextrin, 
(Figure 2), in order to conjugate peptides which are functionalized 
with an alkyne at the C-terminus via CuAAC. 
In view of the specific geometry, steric and electronic properties, a 
1, 2, 3-triazole can be regarded as a trans-amide bond mimic16. 
Moreover, this linkage is stable under physiological conditions, 
thus representing a perfect heterocyclic moiety to replace unstable 
linkers17–19. In addition, successful replacement of dipeptide se-
quences in α-helical peptides by triazole units has been shown to 
not significantly influence the secondary peptide structure16. 
 
 
Figure 2. Molecular visualization of the cyclodextrin derivatives 
synthesized as dimerization domains. From left to right: 6I,6IV-
diazido-α-cyclodextrin 1, 6I,6IV-diazido-β-cyclodextrin 2 and 
6I,6V-diazido-γ-cyclodextrin 3.  
Peptide-cyclodextrin conjugates have been previously developed 
for a broad range of applications, such as drug release systems20,21, 
enantioselective ester hydrolysis catalysis22, and for the creation of 
new types of chemosensors23, enzyme mimics24 and self-assem-
bling materials25,26. Although CD conjugation to peptides has been 
intensively studied, we here for the first time use the cyclodextrin 
moiety as artificial dimerizing unit for mimicking protein-DNA in-
teractions.  
The syntheses of the diazido cyclodextrin derivatives 1 and 2 via 
6I,6IV-dichloro-α-cyclodextrin and 6I,6IV-diiodo-β-cyclodextrin27 
precursors, respectively, were described earlier 28. Nevertheless, we 
used 6I,6IV-dibromo-α-cyclodextrin29, 6I,6IV-dibromo-β-
cyclodextrin30 and 6I,6V-dibromo-γ-cyclodextrin31 and converted 
them in one step to compounds 1-3  (Figure 3) by reaction  with 
three-fold excess of sodium azide in DMF at 50°C. Pure com-
pounds 1-3 were isolated from the reaction mixtures by reversed-
phase column chromatography with yields of 90%, 83% and 77% 
for the α, β and γ-cyclodextrin derivatives respectively. 
Figure 3. Synthesis scheme for the conjugation of the different cy-
clodextrins 1, 2 and 3 and peptide 4 to obtain final compound 5, 6 
and 7. Residues that can chelate copper are marked in red.  
As we have previously illustrated, peptides attached directly to a 
dimerization unit are unable to adopt an adequate position for major 
groove binding32. Thus, a spacer is needed between the dimeriza-
tion scaffold and the basic region GCN4 peptide to afford some 
flexibility required for binding. In addition to that, a C-terminal 
propargylglycine residue was introduced for conjugation of the 
deprotected peptide to the azide containing cyclodextrin scaffolds. 
The GCN4 basic region consists of the following 23 amino acids: 
DPAALKRARNTEAARRSRARKLQ which specifically recog-
nize the ATF/CREB-binding site (5’-ATGA C/G TCAT-3’). The 
monomeric GCN4 sequence was synthesized using standard Fmoc 
SPPS on a Rink-amide ChemMatrix resin. After cleavage and 
deprotection, the peptide could be used for the next steps without 
intermediate purification (Figure 4). 
 
Figure 4. RP-HPLC Chromatogram at 214 nm of crude peptide 4. 
(0-100% ACN in 15 min on C4, 300 Å). 
The basic region GCN4 peptide functionalized with an alkyne at 
the C-terminus was then anchored to opposite positions at the pri-
mary rim of α, β and γ-cyclodextrin derivatives (Figure 3). The Cu-
AAC is a broadly developed strategy for the bioconjugation of pep-
tides to different building blocks due to its mildness, compatibility 
with a large variety of functional groups and the possibility of per-
forming the reaction in wide range of solvents and buffers. In order 
to prevent aggregation of the peptide during the reaction, high po-
larity media were needed. In addition, polar solvents prevent cop-
per species from aggregation. Therefore, we chose DMSO/H2O as 
a solvent mixture. It is known that sodium ascorbate can cause co-
valent modifications of lysines and arginines, and can form reactive 
oxygen species 33,34. Therefore, Cu(CH3CN)4PF6 was chosen as 
catalyst after carefully studying different reaction conditions. It is 
to be noted that a high excess of catalyst is needed which can prob-
ably be ascribed to the chelation of copper by the nitrogen contain-
ing amino acid side chains, which are intensely represented within 
this particular DNA binding peptide sequence. The reaction was 
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stopped after 3 hours at room temperature under argon. Final puri-
fication of the reaction mixture was achieved via RP-HPLC and all 
conjugates could be obtained in high purity (Figure 5).  
 
Figure 5. Structure of final compounds 5 (α), 6 (β) and 7 (γ) and 
RP-HPLC Chromatograms of purified compounds (0-100% ACN 
in 15 min on C4, 300 Å). 
After successful synthesis of the constructs, the DNA binding 
capabilities of the systems were investigated. Quantitative binding 
analysis was performed by EMSA using double stranded 32P-la-
beled CRE DNA (CRE: 5’-ATGACGTCAT-3’), which is the nat-
ural palindromic binding site of GCN4 protein. This technique al-
lows the sensitive determination of the dissociation constant (Kd) 
(figure 6). 
 
 
Figure 6. EMSA titration of the dipodal peptidocyclodextrin con-
jugates to the 5’-labeled 32P-CRE sequence (CRE: 5’-
ATGACGTCAT-3’): Concentrations: 5 nM dsDNA; First lane in 
all the gels: pyrimidine strand. Concentration of peptide in the lanes 
2-9 for gel 1 and 2 (5 and 6): 0, 0.05, 0.0625, 0.075, 0.0875, 0.1, 
0.1125 and 0.125 µM. Concentration of peptide in the lanes 2-8 for 
gel 3 (7): 0, 0.06, 0.125, 0.25, 0.5, 1, 2 µM. A Fuji FLA3000 phos-
phorimager was used for gel analysis and Multi Gauge V 3.0 soft-
ware (Fujifilm) for quantification of the electrophoretic band inten-
sities. 
 
The results show all conjugates bind to the target DNA sequence as 
evident from the appearance of an up-shifted band. In contrast no 
binding was observed when incubating the conjugates with random 
DNA sequences (see SI). Previous models developed by Morii and 
Mascareñas possess the same length of the basic region peptides 
(D226-Q248) and are therefore comparable with our systems. The 
group of Morii developed a system in which the dimerization unit 
was a complex of cyclodextrin and adamantane. Both counterparts 
were anchored to a GCN4 basic region peptide and bind only when 
dimerized. EMSA studies were performed with < 1 nM radio-
labelled CRE, obtaining a Kd < 150 nM11. More recent models de-
signed by the group of Mascareñas employed a diazobenzene moi-
ety for dimerization, with a Kd < 5 nM using < 1 nM radiolabelled 
CRE. They also reported the affinity of a disulfide-bridged GCN4 
basic region, with a Kd of <150 nM approximately for a DNA con-
centration of 50 nM35. The latest model consisted on a dual mimic 
in which dimerization arrangement and DNA selectivity was con-
trolled by selected external parameters36. The basic region peptides 
were functionalized with a cysteine and a terpyridine moiety at-
tached to the residues at the N- and C- termini of the peptide chain 
to achieve selective dimerization at both sites. Depending on the 
conditions, the disulfide-based or the metal-terpyridine complex-
based dimers were preferred, and different DNA sequences could 
be targeted. By dimerizing the peptide in the presence of Ni2+, the 
construct was bound to the CRE sequence with a Kd of 299±26 nM, 
using a DNA concentration of 100 nM, ~100 pM labeled with 32P. 
For these 3 last models, it should be noted that the nonionic deter-
gent (NP-40) and BSA were used during EMSA, known to decrease 
aggregation of peptides and proteins and therefore favor the inter-
action with the DNA37,38.  In our case, the obtained Kd values for 
compounds 5, 6 and 7 were 50 ± 20, 30 ± 20 and 100 ± 60 nM 
respectively. A rough comparison thus indicates that our new con-
structs, apart from being synthesized in a straightforward and con-
vergent manner, display comparable binding properties to those de-
scribed in literature. The obtained values are further within the 
same order of magnitude as those calculated for the binding of bac-
terially expressed GCN4 and synthetic versions thereof. For in-
stance, a dimer comprising of a 56mer GCN4 basic region (residues 
226-281) also binds CRE in the nanomolar range (Kd ~12 nM)39–
41. No data for the dissociation constant of the natural protein have 
been reported so far.  
In order to better explain the results obtained from the binding pat-
tern on the gels and the determination of the Kd values, we per-
formed a molecular visualization of the dimerization interface of 
the bZIP GCN4 TF obtained by discarding the leucine zipper do-
main from the crystal structure of the natural protein (figure 7, D). 
The distance between the C-termini of the basic regions is shown 
in figure 7 at different perspectives of the protein-DNA interface, 
and is found to be 15.052 Å. The Kd values showed that derivative 
6 was the one with the best binding capability to the CRE sequence. 
Therefore, we consider that beta CD is the dimerizer which allows 
optimal anchoring of the peptides on the major groove of the DNA. 
In the protein the C-termini are placed at a distance of approxi-
mately 15 Å. In case of our constructs, although the diameter of the 
primary rim of the cyclodextrins is known (figure 7, left), due to 
the flexibility of the linker, the exact distance between the C-ter-
mini of the peptides on 5, 6 and 7 could not be predicted accurately. 
However, we observed that increasing or decreasing the distance 
between the attachment points of the peptides by the use of differ-
ent CD scaffolds results in a deviation of the optimum geometry of 
the system. This is reflected in terms of decreased binding affinity 
and lower Kds. It should also be noted that these results are specific 
for the basic region GCN4 peptide sequence and the given spacers. 
In case these parameters are varied, different conclusions are ex-
pected. 
 
Figure 7. 3D structure of α, β and γ-cyclodextrin and primary rim 
diameter distance (A, B and C respectively) and crystal structure of 
the GCN4 basic region peptides appended to the major groove of 
the DNA from different perspectives. Distance between C-termini 
indicated in angstroms (PDB: 1YSA) (D). 
 
In conclusion, three peptide-cyclodextrin conjugates for sequence-
selective DNA recognition were obtained. This was achieved by 
the use of α, β and γ-cyclodextrin diazido derivatives as scaffolds 
for the appendage of the peptides by CuAAC. We have successfully 
synthesized and fully characterized 6I,6IV-diazido-α-cyclodextrin 
(1), 6I,6IV-diazido-β-cyclodextrin (2) and 6I, 6V-diazido-γ-cy-
clodextrin (3). Though examples exist of CuAAC reactions with 
CD derivatives 25,42, to the best of our knowledge long, deprotected 
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peptides have so far not been conjugated to cyclodextrins via Cu-
AAC. We here present optimized conditions for the anchoring of 
such long peptides to cyclodextrin units via click chemistry. 
Our results indicate the usefulness of an optimized dimerization 
configuration between both peptides in artificial TF models. In-
deed, it was shown that the distance between the anchoring points 
has a notable influence on DNA binding. Successful models can be 
obtained by trying to approach the exact features of the protein at 
the interface between the dimerization and the basic region do-
mains of the bZIP TF to achieve DNA binding comparable to that 
of the natural TF.  
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Specific Recognition of a Non-palindromic dsDNA 
Sequence by a Heterodimeric Transcription Factor 
Mimic 
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Madder*a 
 
We have designed and synthesized the first mimic of the c-
Myc/Max-bHLH-ZIP transcription factor able to selectively 
recognize the dsDNA sequence 5’-CACGTG-3’ and 
complement on the major groove of DNA. Our design is based 
on our previouspeptide-steroid conjugates which are proven to 
be effective as DNA binders and afford enhanced 
bioavailability and cell-permeability. 
In the last decades, the development in the areas of 
biotechnology and chemical biology has opened up new 
prospects in anti-cancer research. Among other promising 
approaches that have recently gained attention, the inhibition of 
oncogenes and/or the reactivation of tumor suppressor genes by 
transcription factors (TFs) are of particular interest. These TFs 
are responsible for maintenance and progress of tumor growth1,2 
and can be regarded as desirable targets in gene therapeutic 
strategies.  
One of the major families of transcription factors related to 
human cancer and consequently targeted for cancer therapy is the 
Myc/Max/Mad basic (Helix-Loop-Helix) zipper transcription 
factor (bHLH-ZIP TF) network. These oncoproteins are 
heterodimers composed of proteins from the Myc, Max and Mad 
families3–5. The c-Myc-Max heterodimer binds DNA in a 
sequence-specific manner and its function is the transcription 
from promoters containing the E-box sequence 5’-CACGTG-
3’6. The disregulation of the c-Myc gene causes its 
overexpression that is related to the progression of diseases such 
as Burkitt’s lymphoma, cancer in infancy as neuroblastomas and 
lung, breast and colon carcinomas7,8. 
The crystal structure of cMyc-Max bHLH-ZIP transcription 
factor as an oncoprotein has been studied in detail. Eukaryotic 
bZIP and bHLH-ZIP TF motifs have one of the simplest protein 
structures capable of sequence-specific DNA recognition on the 
major groove. The structural motif of bHLH-ZIP is similar to the 
bZIP one. Both are characterized by a dimerization domain, 
which is a prerequisite for DNA binding and a DNA recognition 
domain known as the basic region that contains the α-helical 
peptides responsible for the specific DNA binding. However, the 
main difference is the interface between the two domains. In the 
case of bZIP proteins the α helices are continuous, while in the 
case of bHLH-ZIP proteins they are interrupted by a loop making 
the design and synthesis of the mimics of the bHLH-ZIP protein 
considerably more complicated (figure X). The Helix-Loop-
Helix motif does not contribute significantly to DNA binding or 
to dimerization and is known to tolerate variations in size9,10.  
Figure X. Experimentally-determined structures of cMyc/Max 
bHLH-ZIP (left) and GCN4 bZIP (right) Transcription Factors. 
 
Due to the relevant role of this oncoprotein in cancer 
development, Kent et al11 developed the first approach directed 
towards the total synthesis of a non-covalently-linked 
heterodimeric bHLH-ZIP protein mimic by convergent chemical 
ligation of unprotected peptide segments. However, progress in 
the synthesis of the simplified heterodimeric bHLH-ZIP TF 
models has only been investigated by the OBCR group, by the 
substitution of the dimerization domain via a steroid-based 
moiety12 (Figure X). On the other hand, several artificial models 
of bZIP transcription factors have been developed by various 
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groups13–18, by substituting the dimerization domain for a 
synthetically accessible linker to which the basic regions were 
attached. 
Figure X. Illustration of the first mimic of bHLH-ZIP TF by Kent 
(left) and our cMyc/Max bHLH-ZIP TF models (right). 
 
Steroidal building blocks have been extensively studied in drug 
design due to their amphiphilic nature, bioavailability and 
tendency to enhance peptide biostability19–22. In addition, due to 
their rigid core, the right dimensions for major groove binding 
increase the helicity of the appended peptides and they can 
substitute the leucine zipper domain as an anchoring point for the 
basic region of bHLH ZIP TF. Consequently, peptidosteroid 
tweezers are perfect alternatives to current chemotherapeutics, 
leading to a new type of sequence-specific DNA binder with less 
toxic side effects by preventing the interaction of a TF with its 
promoter.  
In our group, the previously synthesized artificial peptidosteroid-
based mimic of this oncoprotein lead to unsuccessful DNA 
binding due to the lack of an α-helix conformation in the 
peptides. This lack of α-helicity resulted in the displacement of 
the side chains of the peptide with respect to the DNA, disrupting 
the specific interactions involved in the peptide-DNA complex 
12. As reported in the article, the direct conjugation of the basic 
region to the scaffold impedes the correct dimerization of the 
peptides due to the rigidity and sterical encumbrance imposed by 
the nucleus of the steroid scaffold. This was illustrated by the 
high resolution of the protein structure by Burley et al3(PDB-ID: 
1NKP). As a conclusion, we proposed the need for a spacer 
between the dimerization moiety in addition to having an 
elongated DNA recognition domain in our artificial DNA binder. 
This would then make the mimic a better structural fit in 
comparison to the natural protein. We considered the elongation 
of the basic region peptides at the C-terminus corresponding to 
at least four amino acids or approximately one helical turn which 
should be added to the 17-residue c-Myc/Max peptides. A linker 
was incorporated on the final peptide-steroid conjugate in order 
to provide the peptides with the autonomy needed to be inserted 
to the major groove of the DNA in the optimal configuration. 
Glycine was coupled as second residue to increase the space 
between the scaffold and the peptide as reported in previous 
models of bZIP TF. Moreover, a convergent approach was 
applied for the appendage of the peptides onto the scaffold, as a 
more efficient way to synthesize supramolecular peptide 
conjugates. Based on our previous results, we hereby report the 
synthesis of an optimized model of bHLH ZIP transcription 
factor that binds specifically to the non-palindromic target DNA 
sequence. 
In order to dimerize the peptides c-Myc and Max onto the 
scaffold, an orthogonally-functionalized deoxycholic acid 
scaffold derivative was synthesized to allow the convergent 
incorporation of the basic region peptides of c-Myc and Max 
oncoproteins. The design and synthesis of a deoxycholic acid 
derivative scaffold for peptide heterodimerization of the 
Myc/Max basic region was possible due to the concave structure 
of the steroid nucleus. This allowed the two alcohol 
functionalities to be selectively esterified to allowing convergent 
conjugation of two different peptide sequences24. The selective 
esterification at C3 with pentynoic acid was carried out using 
catalytic amount of DMAP and EDC·HCl as coupling reagent. 
Subsequent functionalization of the alcohol at C12 with Boc 
protected gamma-aminobutyric acid was performed with EDC 
and excess of DMAP to lead the reaction to completion. Finally, 
Boc deprotection and conversion of the obtained amine to 
maleimide resulted in the hetero-functionalized scaffold. As 
reported previously, an aliphatic linker is needed for DNA 
binding in the area of transcription factor mimics23. The spacers 
between the peptides and the scaffold should provide sufficient 
length and flexibility to the mimic to accommodate the peptides 
into the DNA major groove in the right conformation. Therefore, 
we chose 4-maleimido-butyric acid and pentynoic acid as linkers 
to allow the flexibility needed for DNA recognition at the major 
groove. 
 
The Click and cysteine maleimide conjugation strategies were 
chosen for peptide conjugation due to their generality and 
orthogonality. For this purpose, the c-Myc and Max peptides 
sequences were modified at the C-terminus with a cysteine and 
azido-homoalanine (Aha) respectively. The Myc/Max basic 
regions consist of a sequence of 16 aminoacids that specifically 
recognize the E-box DNA sequence (5’- AGCACGTGCT -3’). 
The monomeric Myc and Max sequences, were synthesized 
using Fmoc-/tBu-SPPS on Rink-amide ChemMatrix resin. The 
Myc/Max basic regions, functionalized with a cysteine and an 
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azide, were conjugated to the central steroid scaffold resulting in 
the heterodimeric TF mimic. First, the conjugation at the C12 
position was performed via thiol-maleimide conjugation through 
1, 4 Michael addition to a cysteine-contained peptide resulting in 
a succinimidyl thioether moiety. The second conjugation was 
performed via CuAAC at C3 position of the alkyne-
functionalized scaffold forming a triazole. The click conjugation 
was compatible with the presence of the peptide chain at C12.  
The conjugation strategy is based on our previous results for the 
conjugation of peptides to steroid scaffolds in which we explored 
the CuAAC for the attachment of long deprotected peptides to 
hydrophobic cores. Our successful results made click chemistry 
the best choice for functionalization of the challenged C3 
position due to the steric constraint imposed by the deprotected 
peptide at C12 position as a result of hydrogen-bond and 
electrostatic interactions with the free peptide in solution and the 
masking of the exposure of the alkyne for the conjugation to the 
azide in the peptide. Moreover, the results show that our CuAAC 
protocol is compatible with different peptide sequences. Both, 
the succinimidyl thioether and triazole moieties are generally 
accepted as stable linkages under physiological conditions. 
 
 
Figure X. RP-HPLC Chromatogram of purified compound X. 
DNA RECOGNITION 
The heterodimeric c-Myc/Max peptidosteroid conjugate X after 
purification was subjected to EMSA study with 32P-radiolabelled 
DNA, in order to test the recognition capability to the E-box 
sequence (5’ –CA CGT G – 3’). Therefore, the symmetric 
sequence (5’ – CTA CTA GCA CGT GCT AGT AG – 3’) was 
annealed to form the DNA-duplex subjected to complex 
formation with the peptides. The results of the experiment clearly 
reflect the formation of dsDNA-dimeric peptide construct due to 
the presence of an upper band with lower mobility. The presence 
of two bands at the dsDNA lane is consequence of the incomplete 
annealing of both DNA sequences. The lowest band corresponds 
to the ssDNA while the upshifted band is the dsDNA (figure X-
gel from Vladimir). The dissociation constant of the complex 
formation is … nM.  
 To conclude, the potential of a reduced-size bHLH-ZIP 
cMyc/Max TF to recognize its dsDNA binding sequence was 
tested. The results show that an optimized and miniaturized 
version of the protein contains the necessary features to form a 
complex with dsDNA in a sequence-specific manner (figure X). 
In addition, we show the possibility of selective functionalization 
of steroid-based scaffolds to synthesize heterodimeric peptide-
based conjugates, broadening the application of current 
methodology to other families of TF, such as bZIP Fos/Jun TF. 
In addition to the above, our design overcomes the difficulties of 
the decoration of building blocks by the well-known SPPS, since 
it is based solely on conjugation strategies in the solution phase. 
This can be considered the first model of an oncoprotein 
accessible by synthetic methods towards cancer therapy 
development. 
 
Figure X. Visualization models of our previous peptide-steroid 
conjugate and the optimized one reported in this article with its 
binding sequence from different perspectives. 
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Untapped Opportunities of Resin-to-Resin Transfer Reactions (RRTR) for 
the Convergent Assembly of Multivalent Peptide Conjugates** 
Yara Ruiz García, Dieter Verzele and Annemieke Madder* 
Over the past decade, bioconjugation strategies has been 
increasingly developed in the fields of bioorganic chemistry 
and chemical biology, along with the rise of the 
bioorthogonal chemistry concept.[1,2] Developments include 
tandem, one-pot or solid-phase chemical ligations 
(SPCL),[3,4] and methodologies are currently as sophisticated 
as, for example, dual kinetically controlled ligations (KCL) 
for the assembly of peptides.[5] The predominance of Kent et 
al.’s native chemical ligation (NCL) method[6,7] confirms the 
desire for native amide bonds, given their omnipresence in 
life and nature, with recent focus towards conceptual 
advances in amidation strategies.[8] 
Despite the merits of these methods, several issues persist 
and should not be trivialized. Difficulties often arise during 
handling of the precursor peptide segments, as agreed by 
important peers in this area[9] and encountered in our daily 
practice, despite ongoing efforts reported in literature to 
overcome these issues.[10] With the need for specific reactive 
handles, synthesis of multivalent designs by ligation methods 
furthermore requires significant strategic scheduling to obtain a 
desired assembly. Therefore, we felt a need to return to simplicity 
from a practical perspective focussing on the solid-phase resin as 
keystone of peptide synthesis. We here wish to describe so-called 
resin-to-resin transfer reactions (RRTRs) to facilitate convergent 
peptide assembly and rejuvenate this literature oddity beyond its 
current obsolete status. We have successfully designed and 
synthesized heterodipodal peptidosteroid tweezer-type construct, 
providing a proof-of-concept of our new strategy. 
With the sole precedent by DeGrado et al.[11] dealing with the 
synthesis of linear oligopeptides, we found the possibility of applying 
the original RRTR methodology on peptide-based conjugates, an 
emerging area in supramolecular chemistry and multivalency..[12–14] 
Since the first examples of a three-phase reaction applied in organic 
chemistry, named as Wolf-and-Lamb and Shadchan chemistry[15–23] 
and in organometallics[24–27], the methodology of RRTR have lost 
attention, although it could regain relevance in a contemporary 
context considering the revived interest in the efficiency of 
(tandem/one-pot) multi- and interpolymer transformations for high-
throughput and flow chemistry[28,29].  
 
Figure 1. Triphasic Resin-to-Resin Transfer Reaction (RRTR) for the 
assembly of multivalent peptide conjugates, combining Ellman’s 
Safety-Catch (SC) linker and Holmes’ Photocleavable Linker (PL) with 
a chaperone that mediates solution-phase transfer by acting as both 
nucleophilic cleavage agent and activated carboxyl leaving group for in 
situ amidation. Practical simplicity by just mixing resins, collecting the 
solution which contains the desired conjugate. For monitoring and 
isolation............................................................................................... 
As presented in Figure 1, resin-to-resin transfer reactions are 
characterized as triphasic systems involving two solid-phases and a 
shared solution phase, with transfer between and reaction at both 
resins as the name implies. In present prototype, we expected a 
successful match between Ellman’s 4-sulfamylbutyryl safety-catch 
linker[30–32] at the so-called donor resin and Holmes’ photolinker 
moiety[33] at the acceptor resin. Susceptible to nucleophiles upon 
activation after peptide elongation, the former resin donates a 
protected segment to an accepting scaffold moiety via the shared 
solution phase, mediated by a chaperone agent. This chaperone acts 
as both nucleophile and acyl leaving group with balanced reactivity 
towards the peptide C-terminus. In situ amidation occurs during 
interbead exchange by shuttling a (side-chain protected) peptide from 
the donor resin to a scaffold at acceptor resin in a one-pot triphasic 
fasion. As such, conjugates are efficiently formed requiring only 
solid-phase manipulations and no need for prior peptide cleavage 
needed nor delicate handling of peptide fragments. Excesses of 
solution-phase species are easily and readily removed after reaction 
by simple filtration and washing of the resin mixture. Intermediate 
monitoring and final recovery/isolation is performed likewise by 
simple filtration upon clean and mild UV irradiation of (sampled) 
resin[34]. 
Protected peptide
Scaffold
CHAPERONE
agent
Ellman’s Safety-Catch Linker ≡
Holmes’ Photocleavable Linker ≡
One-Pot
ScaffoldProtected peptide
Upon washing
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As detailed in Figure 2 (A), our proof-of-concept design 
comprised of a bile acid based steroid scaffold as accepting template 
[35] and GCN4 transcription factor derived model peptides shuttled 
from the donor resin. The employed GCN4 model peptides feature a 
representative variety of residues and protecting groups. To allow 
HPLC monitoring of reactions involving essentially UV-inactive 
intermediates, an aminomethyl benzoic acid moiety featuring a 
combination of adequate UV-sensitivity and sufficient reactivity (in 
comparison with its more UV-active p-aminobenzoic acid 
counterpart which is less prone to further amide couplings at the 
aniline), was installed between the cleavable linker to the solid 
support and the available C24 position of the bile acid moiety. Figure 
2 (B) and (C) illustrate the clean conversion of acceptor resin xx into 
the C12 peptidosteroid intermediate xx, through reaction with donor 
resin xx. The Tentagel acceptor resin ensures sufficient swelling in 
NMP for penetration of the liberated (protected) oligopeptides from 
the polystyrene donor resin in current prototype. The donor peptide is 
situated on a preloaded Gly-Safety-Catch (donor) resin and needs to 
be activated in a suitable fashion for release and transfer onto the 
acceptor resin. Optimal conditions for activation and release were 
identified using NaSPh and HOBt as chaperone. Addition of DIPEA 
was shown to be essential for deprotonation of the accepting amine 
and thus ensure its nucleophilicity.  
The reasonable excess of donor peptide is easily removed by 
filtration, which facilitates the purification process in contrast to other 
convergent, solution-phase schemes. In addition, the final compound 
is completely isolated from remaining resin excess. The use of a 
Safety-Catch linker, remaining on the donor resin after RRTR 
reaction, provides the benefit of inertness during subsequent steps, 
monitoring and final isolation, and allows standard colour testing for 
rapid verification next to photolytic cleavage without affecting the 
final product. Our methodology further offers the possibility to handle 
minute quantities of precious intermediates as they are immobilized 
on the resin during the entire reaction time and thus easily manageable 
without the need of cleavage for further steps.  
Deoxycholid acid derived orthogonally protected amine was 
attached to a solid support, already containing a photolabile linker and 
a tag. Subsequent conjugation to the deprotected amine at C12 with a 
protected hexapeptide on solid support delivered the first proof-of-
concept of our methodology. Then, Alloc deprotection of amine at the 
C3 position was carried out with our optimized  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
conditions. The sterically hindered amine at C3 presents difficulties 
for conjugation due to the steric constraint imposed by the peptide 
attached at C12 position. We observed that the attachment of a  
Figure 2. First RRTR to C12 bile acid position. (A) Synthetic conditions. 
(B) RPHPLC of starting acceptor after photocleavage. (C) RPHPLC 
after photocleavage showing complete conversion to (side-chain 
protected) monomeric C12-peptidosteroid conjugate xx. (cleavage as 
C24-carboxyamides, compound number interchangeably, equivalents 
relative to acceptor resin) (RPHPLC conditions: Jupiter C4 300 Å; 
gradient 0 to 100% increase of B (versus A) in 15 min). 
spacer was necessary prior RRTR to C3. Consequently, a GABA 
moiety was installed prior to RRTR to alleviate steric constraints.  
In the context of our research towards conformationally defined 
multipodal peptide architectures based on bile acid derivatives as 
anchoring scaffolds, both for receptor/loop design and for zipper-type 
transcription factor models, we have considered the newly developed 
convergent strategy for the construction of library formats in these 
areas, accelerating the trial-and-error optimization of binding[36–40]. 
The steroid scaffold is considered a demanding/challenging building 
block for decoration due to sterical reasons, as such underscoring the 
robustness of the optimized conditions. We here present the synthesis 
of steroid-peptide based conjugates via RRTR. We tested our 
methodology on a truncated arbitrary model derived from the GCN4 
leucine zipper homodimer[41].    
For the optimization of conjugation at C3, a variety of chaperone 
agents were tested for this more challenging position: HOBt, HOAt, 
HOSu and Oxyma Pure (ethyl 2-cyano-2-(hydroxyimino) acetate)[42]. 
Again in line with DeGrado precedent, either HOBt or HOSu 
performed equally well, plus HOSu was a good choice considering 
commercial scarcity of explosive benzotriazole-based reagents. A 
similar excess of donor xx was reasonable considering the resin 
accumulation during the reaction, which can inhibit the cleavage of 
the peptide from the resin and the posterior conjugation to the 
acceptor resin. A larger excess of DIPEA was needed, due to the 
sterically hindered position of the amine at the C3 and the resin 
accumulation. Monitoring of the intermediate compounds was carried 
out by RPHPLC. In addition, protected peptidosteroid conjugates 
could be successfully analyzed on a Jupiter C4 300Å column for 
polarity reasons of such hydrophobic compounds. After side-chain 
deprotection, desired final compound could be analyzed in good 
integrity, with both RPHPLC and MALDI.  
(A)
(B) (C)
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As demonstrated in Figure 3. As such RRTR synthesis of dimeric 
13-mer, a length often starting to pose difficulties as such during 
SPPS due to aggregation of peptide chain during synthesis and 
sterical hindrance imposed by the specific design, can be successfully 
synthesized with our convergent methodology.  
In summary, we here present an upgrade of classical condensation 
strategy, without the practical encumbrances often associated with 
synthesizing, isolating, purifying, and handling of the separate 
peptide fragments to be conjugated. We have achieved the synthesis 
of a supramolecular, multivalent (bio)conjugate with precise 
geometrical and appendage composition, through a fully and genuine 
solid-supported methodology. Moreover, protected peptide fragment 
manipulations are troublesome due to solubility issues. Our 
convergent methodology combines the orthogonality of the Ellman’s 
safety-catch linker with the use of Holmes’ photolinker to obtain 
multipolymeric schemes with notable advantages over the last 
Convergent Solid Phase Peptide Synthesis and can be proposed as an 
alternative to the former Native Chemical Ligation in peptide 
assembly in which common schemes and decoration efforts fail. 
Consequetly, it is proposed as a shortcut towards synthesis of larger 
and more complex polypeptides and architectures. Furthermore, it 
compensates for no time-consuming purification.  
As main features of our procedure, there are no intermediates in 
solution as is typical for other ligations and excesses are easily 
removed. Therefore, handling of intermediate peptidosteroid 
conjugates is not necessary, avoiding low yields and shortening the 
synthetic route. The proof-of-concept we present here, is delivered 
using a scaffold featuring a combination of characteristics that 
include sterical hindered and concave positions, in a close proximity, 
that could possibly cause problems such as incomplete couplings with 
other ligation methodologies. Furthermore, strategic integration of 
Fmoc, Boc, and Alloc chemistries, combined with nucleophile 
susceptible Safety-Catch and photolabile cleavage, allowed the 
obtaining of a practical solid- phase procedure beyond the capabilities 
of separate approaches. 
 
 
 
 
 
 
 
 
 
Figure 3. Second RRTR to C3-position upon Alloc deprotection and 
GABA introduction, to yield the desired dimeric peptidosteroid upon 
final deprotection and cleavage. (A) RPHPLC of (side-chain 
protected) C3-GABA derived acceptor intermediate xx. (B) RPHPLC 
showing complete C3-RRTR conversion towards side-chain 
protected C12-C3 dimeric peptidosteroid. (C) RPHPLC and (D) 
MALDI of desired dimeric peptidosteroid upon final cleavage and 
side-chain deprotection. (cleavage as C24-carboxyamides, compound 
number interchangeably, equivalents relative to acceptor resin) 
(RPHPLC with Jupiter C4 300 Å; gradient 0 to 100% increase of B 
(versus A) in 15 min and MALDI recorded in the positive and 
reflection mode) 
 
As mentioned above, advanced orthogonality, simple but fine-
tuned, and entirely solid-phase procedure characterized our 
methodology.  Moreover, our design can be adapted for other 
purposes, as extra decoration position in between the scaffold 
attachment point and photocleavable linker provides therein an extra 
dimension for multivalency, to be combined with further RRTR 
procedures as described herein. Our current research, facing the 
context of modern (SP)CL and illustrating a contemporary field of 
multivalent peptide architectures as supramolecular devices, we here 
wish to disclose our first successes in that direction, with potential 
broad utility in other designs, easily executed and implemented. In 
conclusion, we describe the first use of resin-to-resin for multivalent 
decoration to get conjugates, thereby presenting a proof-of-concept 
for the untapped opportunities of this methodology towards a wide 
range of applications in a contemporary context. Our strategy can be 
useful for solid-phase conjugations amenable to library formats; 
applicable in areas as diverse as protein models, receptor enzyme 
design, chemical biology and classical medicinal chemistry, and 
compatible in microwave and flow chemistry [cross-ref Ley + 2012 
papers: Noël Angewandte], consequently, rejuvenating the 
fashionable interest in such systems. 
2000.0202
2021.9564
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Experimental Section 
Typical procedure for RRTR (illustrated for Cx decoration of xx): text 
text text text text. 
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Stapling monomeric GCN4 peptides allows for DNA 
binding and enhanced cellular uptake† 
Abhishek Iyer[a], Dorien Van Lysebetten[a], Yara Ruiz García[a], Benoit Louage[b], 
Bruno De Geest[b], and Annemieke Madder*[a]
The basic DNA recognition region of the GCN4 protein 
comprising 23 amino acids has been modified to contain two 
optimally positioned cysteines which have been linked using 
cross-linkers of suitable lengths. This results in stapled 
peptides each with a stabilized α-helical conformation and 
concurrent enhancement of DNA binding and cellular uptake. 
Transcription factors are usually classified according to the fold of 
their DNA-binding domains and grouped into a small number of 
families, like the bZIP, bHLH, homeodomain, HTH, and zinc fingers 
which have already been studied in detail1. Most transcription factors 
are large proteins possessing complex secondary structures rendering 
it difficult to design smaller synthetically accessible versions thereof 
retaining the DNA binding capacity. The GCN4 leucine zipper is 
however a relatively easy protein to mimic due to its well-defined 
dimerization domain and basic recognition region. Construction of 
smaller dimeric mimics of this transcription factor, although feasible, 
have proven to be synthetically challenging2,3.  
Previous attempts at more thorough structural minimisation and 
reduction of complexity using the monomeric GCN4 peptide has 
shown that DNA binding is greatly reduced due to loss of secondary 
structure4. Indeed, since the basic region of the GCN4 transcription 
factor cannot adopt a helical fold  in solution by itself nor bind to 
DNA5 due to entropic reasons,6 an external factor for forcing the 
peptide into a helical conformation is needed. It has already been 
shown that dimerization can enhance DNA binding. For this 
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reason, unlike the existing synthetic bZip peptides in which DNA 
binding is induced via  dimerisation,7, 2 we here aim to stabilize a 
single α helix via peptide stapling, reasoning that enhancing the 
helicity within the monomer should sufficiently stabilize the 
conformation to allow DNA binding4. 
Stapled peptides have been used extensively for improving 
helicity8, increasing cell-penetration9,10, proteolytic stability and 
enhancing peptide-protein interactions (PPIs)11. In all the above 
mentioned cases stapled peptides have proven to be an effective 
methodology12. However, the use of stapled peptides for enhancing 
DNA binding has remained largely unexplored. In this work we have 
examined the DNA binding induced by stapling using the monomeric 
GCN4 transcription factor as a model peptide, by comparing the i, i+4 
and i, i+7 stapling methods and varying the positions of the staple 
along the helix. The cellular uptake of the constructs was also 
investigated using fluorescently labelled versions of the peptide. 
Initial studies were dedicated to selecting the most suitable 
method for peptide stapling among the ones reported in literature. The 
idea was to adopt a method as general as possible to be potentially 
applicable to any DNA binding peptide to increase its helicity. To 
ensure easy and cost-effective modification the use of unnatural 
amino acids was avoided. In case of the very well-known hydrocarbon 
stapling, coupling of the non-natural amino acids as well as peptide 
folding on resin can be a problem13. The commercial availability 
and/or easy synthesis of cross-linking moieties, mild reactions 
conditions and easy scalability due to synthesis in solution, were the 
reasons for choosing cysteine cross-linking for current study12. 
A detailed analysis of the essential contacts for DNA binding as 
derived from the reported crystal structure was described earlier by 
Ellenberger and Keller.14, 15 Based on this study, amino acids indicated 
as not involved in DNA contacts were identified and systematically 
replaced by Cys according to an i,i+4 or i,i+7 format. Molecular 
modelling aided visualisation based on the pdb file 1YSA was used to 
ensure that the introduced linkers point away from the DNA and not 
towards it thereby avoiding any steric repulsion which may arise due 
to peptide stapling. In this way three different peptides, comprising 
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the D226 – Q248 sequence from the DNA binding basic region of 
GCN4, containing a double Cys substitution (at positions 237/244 for 
1, 229/233 for 2 and 233/237 for 3) were synthesized on solid support, 
cleaved and subsequently treated with various linkers yielding a series 
of five stapled peptides as shown in Figure 1. 
Fig.1: Synthetic stapled peptides 1a-c, 2d, 3d for DNA binding and 
unmodified basic region peptide 4. The peptides are N-terminally 
capped with a p-acetylamino benzoic acid (ABA) moiety to ensure 
UV-based detection and analysis in the case of DNA binding. For cell 
uptake studies the ABA moiety was replaced by fluorescein. 
The stapled peptides and the unmodified WT basic region 
peptide were successfully synthesized. The cross-linkers a, c & d are 
commercially available. The stapling moiety b has not been used thus 
far for peptide stapling and was designed and synthesized as a more 
polar alternative to the biphenyl and bipyridine cross-linkers.  
Next, the DNA binding capacity of all peptides was evaluated 
through EMSA titration of various peptide concentrations to the 
cognate CRE DNA sequence 5’ – CGG ATG ACG TCA TTT TTT 
TTC – 3’ (Figure 2). 
Fig. 2: EMSA titrations for peptides 1a-c, 2d & 3d.  Loading mixture 
comprises 5 µL from a mixture of 10 µL mQ, 4 µL sucrose, 2 µL 
loading buffer, 2 µL DNA, 2 µL peptide resulting in a total DNA 
concentration of 167 nM.  The loading buffer consists of 20 µL Tris 1 
M, pH = 7.6, 20 µL KCl 0.2 M, 20 µL MgCl2 0.1 M, 40 µL EDTA 
0.025 M. Peptide concentrations from left to right (in µM) are 
indicated below each gel. 
The WT peptide 4 does not bind DNA under the given EMSA 
conditions. For all the synthetic constructs 1a-c, 2d & 3d we see 
enhanced DNA binding as compared to peptide 4. In the case of 
peptides 1a-c binding is only observed at higher concentrations of 
peptide as compared to 2d and 3d. The more hydrophobic nature of 
the biphenyl cross-linker, makes peptide 1a more susceptible to 
aggregation as can be seen from the complete disappearance of the 
bands in the last lane. On the other hand, peptides 1b and 1c are less 
prone to aggregation but do not bind as well as 1a. Unlike peptides 
1a-c, the DNA binding pattern in gel 2d is different.  We propose that 
the appearance of two bands related to DNA-peptide complex 
formation is due to the presence of two binding sites in the CRE 
sequence (…GTCAT…). It can be noticed that after full occupation 
of one binding site by the peptide, remaining non-bound peptide can 
interact with the second binding site. The binding pattern of peptide 4 
is unique and only visible in the case of the two sequences that bind 
at a lower concentration range. It can further be noticed that peptide 5 
shows a similar binding pattern as peptide 4 but suffers from non-
specific interactions to a small extent. Non-specific interactions cause 
aggregation, bands getting blurred or disappearance of all bands. 
From the few examples about DNA binding stapled peptides that 
do exist in literature4,16 and from our own data we believe the major 
challenge in case of DNA binding peptides is that increasing the 
helicity has to be complemented with a degree of flexibility in order 
to account for the conformational change which occurs when the 
peptide binds to DNA. Since this conformational change is more 
significant in the case of DNA binding peptides as compared to PPIs, 
merely locking the conformation of the peptide into a helix may not 
be sufficient to achieve enhanced DNA binding. On the other hand, 
peptide stapling by providing an N or C terminal helix stabilization 
can give better results in the case of DNA binding peptides as can be 
seen from the binding pattern of peptides 2d & 3d. This, of course, 
may result in a less helical conformation of the peptide without the 
presence of DNA but allows it to adjust its conformation into a 
structure whereby it can maximize the contact between the positively 
charged side chain interactions mainly involving the Lys and Arg 
residues with the negatively charged backbone of the DNA without a 
high entropic penalty. We believe peptide 2d fits this criteria and 
hence is the best DNA binder from the constructs synthesized. 
Moreover, it is able to bind in a dimeric fashion without having been 
artificially dimerized. We thus observe for the first time dimeric DNA 
binding with a monomeric GCN4 derived basic region peptide.  
It has been postulated that stabilization of the secondary structure 
via peptide stapling can enhance cell uptake17. Peptides with 
hydrocarbon staples in particular have shown considerable increase in 
uptake as compared to their non-stapled counterparts10,18. The 
fluorescently labelled peptides Ia-c & IId were tested in a cellular 
environment using RAW 264.7 mouse macrophages. Confocal 
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microscopy confirmed that cell penetration is achieved at a 
concentration as low as 0.25 µM for all peptides at 37°C, including 
native GCN4 sequence IV, as seen from figure 3A-E. The cell 
penetrating properties even at low concentrations combined with the 
low cytotoxicity values observed in the MTT-assay (see SI) make 
these a valuable set of CPPs. 
Incubation at 4 °C provides insight into the mode of uptake as 
endocytic pathways are shut down at this temperature. Comparison of 
the data obtained at 4 °C and 37 °C with flow cytometry (figure 5) 
confocal microscopy (see SI) showed that active uptake is the main 
internalization pathway as the uptake drops at 4 °C. 
 
Fig. 3: Confocal microscopy images of the uptake of peptides (A) Ia, 
(B) Ib, (C) Ic, (D) IIId, and (E) IV at 37 °C. The upper panel shows 
accumulated images of DNA (blue), cell membrane (red) and 
fluorescein (green).  The lower panel shows the fluorescein image. 
(Scale bar = 20 µm). 
Quantification of the uptake by flow cytometry shows a 
concentration dependent uptake (figure 5). The mean fluorescence 
emitted by the fluorescent labelled peptides in the cell increased 
considerably for an i, i+7 staple. 
Fig. 4: Mean fluorescence of fluorescently labelled peptides by 
incubation at 0.25 µM. 
In conclusion, the elegant nature of the synthesis in combination 
with the observed DNA binding and cellular uptake properties render 
these constructs of considerable and specific interest among the 
mimics of the GCN4 transcription factor reported to date. Through 
this work and due to the nature of the stapled peptides, we believe that 
a general method is now at our disposal to allow DNA binding and 
enhance cellular uptake of a given DNA binding peptide while 
avoiding tedious synthetic routes. It has been further shown that N-
terminal helix stabilization as in the case of 2d is more effective for 
enhancing DNA binding than stapling in the middle of the sequence 
or towards the C-terminus (1a-c).  For cell penetration, however, the 
more helical i, i+7 stapled peptides Ia-c have shown better uptake than 
IV. Although the two are not mutually exclusive, for future 
applications such as DNA binding in cellulo a balance will have to 
exist between a peptide’s DNA binding and cell penetration abilities. 
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